Tag | Content |
---|---|
Uniprot ID | P00533; O00688; O00732; P06268; Q14225; Q68GS5; Q92795; Q9BZS2; Q9GZX1; Q9H2C9; Q9H3C9; Q9UMD7; Q9UMD8; Q9UMG5; |
Entrez ID | 1956 |
Genbank protein ID | AAG43240.1; AAA63171.1; AAG35790.1; AAC50799.1; CAA29668.1; AAG43243.1; AAC50800.1; CAA25282.1; AAC50804.1; AAG35789.1; AAC50796.1; AAA52370.1; AAC50802.1; AAC50797.1; AAC50801.1; AAT97979.1; AAC50798.1; AAB53063.1; AAG35786.1; AAK01080.1; AAG35787.1; CAA25240.1; AAS83109.1; AAG35788.1; |
Genbank nucleotide ID | NM_201284.1; NM_005228.4; NM_201282.1; NM_201283.1; |
Ensembl protein ID | ENSP00000345973; ENSP00000275493; ENSP00000413843; ENSP00000342376; |
Ensembl nucleotide ID | ENSG00000146648 |
Gene name | Epidermal growth factor receptor |
Gene symbol | EGFR |
Organism | Homo sapiens |
NCBI taxa ID | 9606 |
Cleft type | |
Developmental stage | |
Data sources | Homology search |
Reference | |
Functional description | Receptor tyrosine kinase binding ligands of the EGF family and activating several signaling cascades to convert extracellular cues into appropriate cellular responses (PubMed:2790960, PubMed:10805725, PubMed:27153536). Known ligands include EGF, TGFA/TGF-alpha, AREG, epigen/EPGN, BTC/betacellulin, epiregulin/EREG and HBEGF/heparin-binding EGF (PubMed:2790960, PubMed:7679104, PubMed:8144591, PubMed:9419975, PubMed:15611079, PubMed:12297049, PubMed:27153536, PubMed:20837704). Ligand binding triggers receptor homo- and/or heterodimerization and autophosphorylation on key cytoplasmic residues. The phosphorylated receptor recruits adapter proteins like GRB2 which in turn activates complex downstream signaling cascades. Activates at least 4 major downstream signaling cascades including the RAS-RAF-MEK-ERK, PI3 kinase-AKT, PLCgamma-PKC and STATs modules (PubMed:27153536). May also activate the NF-kappa-B signaling cascade (PubMed:11116146). Also directly phosphorylates other proteins like RGS16, activating its GTPase activity and probably coupling the EGF receptor signaling to the G protein-coupled receptor signaling (PubMed:11602604). Also phosphorylates MUC1 and increases its interaction with SRC and CTNNB1/beta-catenin (PubMed:11483589). Positively regulates cell migration via interaction with CCDC88A/GIV which retains EGFR at the cell membrane following ligand stimulation, promoting EGFR signaling which triggers cell migration (PubMed:20462955). Plays a role in enhancing learning and memory performance (By similarity). |
Sequence | MRPSGTAGAA LLALLAALCP ASRALEEKKV CQGTSNKLTQ LGTFEDHFLS LQRMFNNCEV 60 VLGNLEITYV QRNYDLSFLK TIQEVAGYVL IALNTVERIP LENLQIIRGN MYYENSYALA 120 VLSNYDANKT GLKELPMRNL QEILHGAVRF SNNPALCNVE SIQWRDIVSS DFLSNMSMDF 180 QNHLGSCQKC DPSCPNGSCW GAGEENCQKL TKIICAQQCS GRCRGKSPSD CCHNQCAAGC 240 TGPRESDCLV CRKFRDEATC KDTCPPLMLY NPTTYQMDVN PEGKYSFGAT CVKKCPRNYV 300 VTDHGSCVRA CGADSYEMEE DGVRKCKKCE GPCRKVCNGI GIGEFKDSLS INATNIKHFK 360 NCTSISGDLH ILPVAFRGDS FTHTPPLDPQ ELDILKTVKE ITGFLLIQAW PENRTDLHAF 420 ENLEIIRGRT KQHGQFSLAV VSLNITSLGL RSLKEISDGD VIISGNKNLC YANTINWKKL 480 FGTSGQKTKI ISNRGENSCK ATGQVCHALC SPEGCWGPEP RDCVSCRNVS RGRECVDKCN 540 LLEGEPREFV ENSECIQCHP ECLPQAMNIT CTGRGPDNCI QCAHYIDGPH CVKTCPAGVM 600 GENNTLVWKY ADAGHVCHLC HPNCTYGCTG PGLEGCPTNG PKIPSIATGM VGALLLLLVV 660 ALGIGLFMRR RHIVRKRTLR RLLQERELVE PLTPSGEAPN QALLRILKET EFKKIKVLGS 720 GAFGTVYKGL WIPEGEKVKI PVAIKELREA TSPKANKEIL DEAYVMASVD NPHVCRLLGI 780 CLTSTVQLIT QLMPFGCLLD YVREHKDNIG SQYLLNWCVQ IAKGMNYLED RRLVHRDLAA 840 RNVLVKTPQH VKITDFGLAK LLGAEEKEYH AEGGKVPIKW MALESILHRI YTHQSDVWSY 900 GVTVWELMTF GSKPYDGIPA SEISSILEKG ERLPQPPICT IDVYMIMVKC WMIDADSRPK 960 FRELIIEFSK MARDPQRYLV IQGDERMHLP SPTDSNFYRA LMDEEDMDDV VDADEYLIPQ 1020 QGFFSSPSTS RTPLLSSLSA TSNNSTVACI DRNGLQSCPI KEDSFLQRYS SDPTGALTED 1080 SIDDTFLPVP EYINQSVPKR PAGSVQNPVY HNQPLNPAPS RDPHYQDPHS TAVGNPEYLN 1140 TVQPTCVNST FDSPAHWAQK GSHQISLDNP DYQQDFFPKE AKPNGIFKGS TAENAEYLRV 1200 APQSSEFIGA |
Abbreviation :
CLO : cleft lip only. CPO : cleft palate only.
CLP : cleft lip and palate. CL/P : cleft lip with/without cleft palate.
For humans: CL/P, CLO, CPO, and CLP. For mice: CLO, CLP, and CPO.
Relation | Gene symbol | Entrez ID | UniProt ID | Cleft type | Developmental stage | Species | Evidence | Details |
---|---|---|---|---|---|---|---|---|
1:1 ortholog | EGFR | 1956 | P00533 | Homo sapiens | Prediction | More>> | ||
1:1 ortholog | Egfr | 13649 | Q01279 | CPO | E14.5 | Mus musculus | Publication | More>> |
1:1 ortholog | EGFR | H2QUL1 | Pan troglodytes | Prediction | More>> | |||
1:1 ortholog | EGFR | A0A5G2QBP1 | Sus scrofa | Prediction | More>> | |||
1:1 ortholog | Egfr | G3V6K6 | Rattus norvegicus | Prediction | More>> | |||
1:1 ortholog | egfra | A0A0R4IFV9 | Danio rerio | Prediction | More>> |
ID | Variant | Type | Disease | Chromosome\Coordinate | Evidence |
---|---|---|---|---|---|
rs749433287 | p.Pro3Leu | missense variant | - | NC_000007.14:g.55019285C>T | ExAC,gnomAD |
rs773069229 | p.Pro3Ser | missense variant | - | NC_000007.14:g.55019284C>T | ExAC,TOPMed,gnomAD |
rs773069229 | p.Pro3Thr | missense variant | - | NC_000007.14:g.55019284C>A | ExAC,TOPMed,gnomAD |
rs771210838 | p.Ser4Tyr | missense variant | - | NC_000007.14:g.55019288C>A | ExAC,gnomAD |
rs771210838 | p.Ser4Phe | missense variant | - | NC_000007.14:g.55019288C>T | ExAC,gnomAD |
rs759582787 | p.Gly5Ala | missense variant | - | NC_000007.14:g.55019291G>C | ExAC,TOPMed,gnomAD |
rs774487133 | p.Gly5Arg | missense variant | - | NC_000007.14:g.55019290G>C | ExAC,gnomAD |
rs759582787 | p.Gly5Glu | missense variant | - | NC_000007.14:g.55019291G>A | ExAC,TOPMed,gnomAD |
rs767651648 | p.Thr6Ala | missense variant | - | NC_000007.14:g.55019293A>G | ExAC,TOPMed,gnomAD |
RCV000372969 | p.Thr6Ala | missense variant | Lung cancer | NC_000007.14:g.55019293A>G | ClinVar |
rs761183109 | p.Ala7Ser | missense variant | - | NC_000007.14:g.55019296G>T | ExAC,gnomAD |
rs761183109 | p.Ala7Pro | missense variant | - | NC_000007.14:g.55019296G>C | ExAC,gnomAD |
rs754259847 | p.Gly8Arg | missense variant | - | NC_000007.14:g.55019299G>C | ExAC,TOPMed,gnomAD |
rs754259847 | p.Gly8Arg | missense variant | - | NC_000007.14:g.55019299G>A | ExAC,TOPMed,gnomAD |
rs1217714114 | p.Ala10Glu | missense variant | - | NC_000007.14:g.55019306C>A | TOPMed,gnomAD |
rs567894670 | p.Ala13Val | missense variant | - | NC_000007.14:g.55019315C>T | 1000Genomes,ExAC,TOPMed,gnomAD |
rs1180577495 | p.Ala17Val | missense variant | - | NC_000007.14:g.55019327C>T | TOPMed |
rs754527029 | p.Leu18Phe | missense variant | - | NC_000007.14:g.55019329C>T | ExAC,gnomAD |
rs780865931 | p.Cys19Ser | missense variant | - | NC_000007.14:g.55019333G>C | ExAC,gnomAD |
rs1028735720 | p.Pro20Arg | missense variant | - | NC_000007.14:g.55019336C>G | TOPMed,gnomAD |
rs1028735720 | p.Pro20Gln | missense variant | - | NC_000007.14:g.55019336C>A | TOPMed,gnomAD |
rs1194702075 | p.Ala21Glu | missense variant | - | NC_000007.14:g.55019339C>A | TOPMed,gnomAD |
rs373129709 | p.Ala21Thr | missense variant | - | NC_000007.14:g.55019338G>A | ESP,ExAC,TOPMed,gnomAD |
rs1194702075 | p.Ala21Val | missense variant | - | NC_000007.14:g.55019339C>T | TOPMed,gnomAD |
rs373129709 | p.Ala21Ser | missense variant | - | NC_000007.14:g.55019338G>T | ESP,ExAC,TOPMed,gnomAD |
rs1257423707 | p.Ser22Asn | missense variant | - | NC_000007.14:g.55019342G>A | TOPMed |
rs987102148 | p.Arg23Trp | missense variant | - | NC_000007.14:g.55019344C>T | TOPMed,gnomAD |
rs911767401 | p.Ala24Thr | missense variant | - | NC_000007.14:g.55019347G>A | TOPMed,gnomAD |
rs749088691 | p.Lys28Glu | missense variant | - | NC_000007.14:g.55019359A>G | ExAC,gnomAD |
rs774551548 | p.Lys29Thr | missense variant | - | NC_000007.14:g.55019363A>C | ExAC,gnomAD |
VAR_066493 | p.Val30_Arg297del | inframe_deletion | - | - | UniProt |
rs746023542 | p.Gln32Arg | missense variant | - | NC_000007.14:g.55142292A>G | ExAC,gnomAD |
rs772311777 | p.Gly33Ser | missense variant | - | NC_000007.14:g.55142294G>A | ExAC,gnomAD |
rs144158123 | p.Thr34Arg | missense variant | - | NC_000007.14:g.55142298C>G | ESP,ExAC,TOPMed,gnomAD |
rs144158123 | p.Thr34Met | missense variant | - | NC_000007.14:g.55142298C>T | ESP,ExAC,TOPMed,gnomAD |
rs1406387936 | p.Ser35Asn | missense variant | - | NC_000007.14:g.55142301G>A | gnomAD |
NCI-TCGA novel | p.Leu38Val | missense variant | - | NC_000007.14:g.55142309C>G | NCI-TCGA |
rs375919121 | p.Thr39Met | missense variant | - | NC_000007.14:g.55142313C>T | ESP,ExAC,gnomAD |
rs1442908038 | p.Gly42Ser | missense variant | - | NC_000007.14:g.55142321G>A | gnomAD |
rs1001476056 | p.Phe44Ser | missense variant | - | NC_000007.14:g.55142328T>C | TOPMed,gnomAD |
rs1343024399 | p.Asp46Val | missense variant | - | NC_000007.14:g.55142334A>T | gnomAD |
rs1052582656 | p.Asp46Glu | missense variant | - | NC_000007.14:g.55142335T>A | gnomAD |
COSM3639716 | p.His47Tyr | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000007.14:g.55142336C>T | NCI-TCGA Cosmic |
rs1263793183 | p.Phe48Ser | missense variant | - | NC_000007.14:g.55142340T>C | gnomAD |
NCI-TCGA novel | p.Ser50Asn | missense variant | - | NC_000007.14:g.55142346G>A | NCI-TCGA |
rs759219499 | p.Arg53Lys | missense variant | - | NC_000007.14:g.55142355G>A | ExAC,gnomAD |
NCI-TCGA novel | p.Met54TyrPheSerTerUnk | frameshift | - | NC_000007.14:g.55142356_55142357insT | NCI-TCGA |
rs767259994 | p.Asn56Ser | missense variant | - | NC_000007.14:g.55142364A>G | ExAC,gnomAD |
rs760228905 | p.Glu59Lys | missense variant | - | NC_000007.14:g.55142372G>A | ExAC,TOPMed,gnomAD |
rs763572530 | p.Glu59Ala | missense variant | - | NC_000007.14:g.55142373A>C | ExAC,gnomAD |
COSM35602 | p.Leu62Arg | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000007.14:g.55142382T>G | NCI-TCGA Cosmic |
NCI-TCGA novel | p.Gly63Glu | missense variant | - | NC_000007.14:g.55142385G>A | NCI-TCGA |
COSM1451530 | p.Gly63Arg | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000007.14:g.55142384G>A | NCI-TCGA Cosmic |
rs369580836 | p.Gln71Arg | missense variant | - | NC_000007.14:g.55142409A>G | ESP,ExAC,TOPMed,gnomAD |
rs1470757416 | p.Gln71Ter | stop gained | - | NC_000007.14:g.55142408C>T | TOPMed,gnomAD |
rs369580836 | p.Gln71Pro | missense variant | - | NC_000007.14:g.55142409A>C | ESP,ExAC,TOPMed,gnomAD |
rs1269583681 | p.Asn73Lys | missense variant | - | NC_000007.14:g.55142416T>G | TOPMed |
rs778638117 | p.Leu76Ile | missense variant | - | NC_000007.14:g.55142423C>A | ExAC,gnomAD |
rs374986786 | p.Thr81Ala | missense variant | - | NC_000007.14:g.55143305A>G | ESP,ExAC,gnomAD |
rs1309796320 | p.Ile82Val | missense variant | - | NC_000007.14:g.55143308A>G | NCI-TCGA |
rs1309796320 | p.Ile82Val | missense variant | - | NC_000007.14:g.55143308A>G | gnomAD |
rs753319070 | p.Glu84Gln | missense variant | - | NC_000007.14:g.55143314G>C | ExAC,gnomAD |
rs753319070 | p.Glu84Lys | missense variant | - | NC_000007.14:g.55143314G>A | ExAC,gnomAD |
rs1282801317 | p.Glu84Asp | missense variant | - | NC_000007.14:g.55143316G>C | gnomAD |
COSM3929114 | p.Glu84Val | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000007.14:g.55143315A>T | NCI-TCGA Cosmic |
COSM3881800 | p.Val85Met | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000007.14:g.55143317G>A | NCI-TCGA Cosmic |
NCI-TCGA novel | p.Gly87Cys | missense variant | - | NC_000007.14:g.55143323G>T | NCI-TCGA |
NCI-TCGA novel | p.Gly87Asp | missense variant | - | NC_000007.14:g.55143324G>A | NCI-TCGA |
rs765137528 | p.Tyr88Cys | missense variant | - | NC_000007.14:g.55143327A>G | ExAC,gnomAD |
rs142061256 | p.Leu90His | missense variant | - | NC_000007.14:g.55143333T>A | ESP,ExAC,gnomAD |
NCI-TCGA novel | p.Leu90Ile | missense variant | - | NC_000007.14:g.55143332C>A | NCI-TCGA |
rs750399097 | p.Leu90Phe | missense variant | - | NC_000007.14:g.55143332C>T | ExAC,gnomAD |
COSM6178068 | p.Ile91Val | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000007.14:g.55143335A>G | NCI-TCGA Cosmic |
rs779879611 | p.Ala92Val | missense variant | - | NC_000007.14:g.55143339C>T | ExAC,gnomAD |
NCI-TCGA novel | p.Ala92Thr | missense variant | - | NC_000007.14:g.55143338G>A | NCI-TCGA |
rs1422504667 | p.Thr95Ile | missense variant | - | NC_000007.14:g.55143348C>T | TOPMed |
rs1260357262 | p.Val96Met | missense variant | - | NC_000007.14:g.55143350G>A | gnomAD |
rs755189573 | p.Glu97Gln | missense variant | - | NC_000007.14:g.55143353G>C | ExAC,gnomAD |
rs755189573 | p.Glu97Gln | missense variant | - | NC_000007.14:g.55143353G>C | NCI-TCGA |
rs17289589 | p.Arg98Leu | missense variant | - | NC_000007.14:g.55143357G>T | ESP,ExAC,TOPMed,gnomAD |
rs17289589 | p.Arg98Gln | missense variant | - | NC_000007.14:g.55143357G>A | NCI-TCGA,NCI-TCGA Cosmic |
rs17289589 | p.Arg98Gln | missense variant | - | NC_000007.14:g.55143357G>A | ESP,ExAC,TOPMed,gnomAD |
rs866460345 | p.Pro100Ser | missense variant | - | NC_000007.14:g.55143362C>T | NCI-TCGA Cosmic |
rs376963968 | p.Pro100His | missense variant | - | NC_000007.14:g.55143363C>A | NCI-TCGA,NCI-TCGA Cosmic |
rs866460345 | p.Pro100Ser | missense variant | - | NC_000007.14:g.55143362C>T | - |
rs376963968 | p.Pro100His | missense variant | - | NC_000007.14:g.55143363C>A | ESP |
COSM3639718 | p.Leu101Phe | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000007.14:g.55143367G>T | NCI-TCGA Cosmic |
rs141271101 | p.Gln105His | missense variant | - | NC_000007.14:g.55143379G>C | ESP,ExAC,TOPMed,gnomAD |
rs771366736 | p.Ile106Val | missense variant | - | NC_000007.14:g.55143380A>G | ExAC,gnomAD |
RCV000440142 | p.Arg108Gly | missense variant | - | NC_000007.14:g.55143386A>G | ClinVar |
rs1057519828 | p.Arg108Lys | missense variant | - | NC_000007.14:g.55143387G>A | NCI-TCGA Cosmic |
rs1057519888 | p.Arg108Gly | missense variant | - | NC_000007.14:g.55143386A>G | NCI-TCGA Cosmic |
RCV000424206 | p.Arg108Gly | missense variant | Glioblastoma | NC_000007.14:g.55143386A>G | ClinVar |
rs1057519828 | p.Arg108Lys | missense variant | - | NC_000007.14:g.55143387G>A | - |
RCV000434481 | p.Arg108Gly | missense variant | Neoplasm of brain | NC_000007.14:g.55143386A>G | ClinVar |
RCV000432019 | p.Arg108Lys | missense variant | Neoplasm of brain | NC_000007.14:g.55143387G>A | ClinVar |
rs1057519888 | p.Arg108Gly | missense variant | - | NC_000007.14:g.55143386A>G | - |
rs145113601 | p.Gly109Ala | missense variant | - | NC_000007.14:g.55143390G>C | ESP,ExAC,TOPMed,gnomAD |
rs1488843432 | p.Met111Ile | missense variant | - | NC_000007.14:g.55143397G>A | TOPMed |
rs746631025 | p.Met111Thr | missense variant | - | NC_000007.14:g.55143396T>C | ExAC,TOPMed,gnomAD |
rs1385682568 | p.Tyr113Phe | missense variant | - | NC_000007.14:g.55143402A>T | gnomAD |
rs1219568637 | p.Glu114Lys | missense variant | - | NC_000007.14:g.55143404G>A | NCI-TCGA Cosmic |
rs1219568637 | p.Glu114Lys | missense variant | - | NC_000007.14:g.55143404G>A | TOPMed |
NCI-TCGA novel | p.Asn115Lys | missense variant | - | NC_000007.14:g.55143409T>G | NCI-TCGA |
rs773596817 | p.Asn115Lys | missense variant | - | NC_000007.14:g.55143409T>A | ExAC,TOPMed,gnomAD |
rs1332428616 | p.Asn115His | missense variant | - | NC_000007.14:g.55143407A>C | gnomAD |
COSM4893368 | p.Ser116Phe | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000007.14:g.55143411C>T | NCI-TCGA Cosmic |
rs1249939049 | p.Ala118Ser | missense variant | - | NC_000007.14:g.55143416G>T | gnomAD |
rs1247204001 | p.Ala118Gly | missense variant | - | NC_000007.14:g.55143417C>G | gnomAD |
NCI-TCGA novel | p.Val121Phe | missense variant | - | NC_000007.14:g.55143425G>T | NCI-TCGA |
rs1229095978 | p.Ser123Phe | missense variant | - | NC_000007.14:g.55143432C>T | TOPMed |
rs1229095978 | p.Ser123Phe | missense variant | - | NC_000007.14:g.55143432C>T | NCI-TCGA |
rs1295285127 | p.Tyr125Cys | missense variant | - | NC_000007.14:g.55143438A>G | TOPMed |
NCI-TCGA novel | p.Ala127Glu | missense variant | - | NC_000007.14:g.55143444C>A | NCI-TCGA |
rs377444977 | p.Ala127Thr | missense variant | - | NC_000007.14:g.55143443G>A | ESP,ExAC,TOPMed,gnomAD |
rs1485906237 | p.Ala127Val | missense variant | - | NC_000007.14:g.55143444C>T | gnomAD |
rs762889647 | p.Lys129Thr | missense variant | - | NC_000007.14:g.55143450A>C | ExAC,gnomAD |
rs1485016142 | p.Gly131Arg | missense variant | - | NC_000007.14:g.55143455G>A | TOPMed,gnomAD |
NCI-TCGA novel | p.Glu134Gly | missense variant | - | NC_000007.14:g.55143465A>G | NCI-TCGA |
rs751337426 | p.Glu134Lys | missense variant | - | NC_000007.14:g.55143464G>A | ExAC,gnomAD |
rs754854319 | p.Met137Val | missense variant | - | NC_000007.14:g.55143473A>G | ExAC,TOPMed,gnomAD |
rs1437762652 | p.Arg138Lys | missense variant | - | NC_000007.14:g.55143477G>A | gnomAD |
COSM1090858 | p.Leu140Val | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000007.14:g.55143482T>G | NCI-TCGA Cosmic |
rs767608234 | p.Gln141His | missense variant | - | NC_000007.14:g.55143487G>T | ExAC,gnomAD |
rs780476417 | p.His145Arg | missense variant | - | NC_000007.14:g.55146615A>G | ExAC,TOPMed,gnomAD |
rs1198703773 | p.His145Asn | missense variant | - | NC_000007.14:g.55146614C>A | TOPMed |
rs532655845 | p.Ala147Pro | missense variant | - | NC_000007.14:g.55146620G>C | 1000Genomes,ExAC,TOPMed,gnomAD |
rs532655845 | p.Ala147Thr | missense variant | - | NC_000007.14:g.55146620G>A | 1000Genomes,ExAC,TOPMed,gnomAD |
COSM1090861 | p.Val148Met | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000007.14:g.55146623G>A | NCI-TCGA Cosmic |
rs774146556 | p.Arg149Trp | missense variant | - | NC_000007.14:g.55146626C>T | ExAC,TOPMed,gnomAD |
rs759532524 | p.Arg149Gln | missense variant | - | NC_000007.14:g.55146627G>A | ExAC,TOPMed,gnomAD |
rs1398462122 | p.Phe150Leu | missense variant | - | NC_000007.14:g.55146629T>C | TOPMed |
rs551591429 | p.Asn152Ser | missense variant | - | NC_000007.14:g.55146636A>G | 1000Genomes,ExAC,gnomAD |
NCI-TCGA novel | p.Pro154His | missense variant | - | NC_000007.14:g.55146642C>A | NCI-TCGA |
rs919891568 | p.Ala155Ser | missense variant | - | NC_000007.14:g.55146644G>T | TOPMed |
rs937907395 | p.Asn158Asp | missense variant | - | NC_000007.14:g.55146653A>G | TOPMed |
NCI-TCGA novel | p.Val159Met | missense variant | - | NC_000007.14:g.55146656G>A | NCI-TCGA |
NCI-TCGA novel | p.Gln163Arg | missense variant | - | NC_000007.14:g.55146669A>G | NCI-TCGA |
rs587778252 | p.Arg165Trp | missense variant | - | NC_000007.14:g.55146674C>T | ExAC,TOPMed,gnomAD |
rs761795138 | p.Arg165Gln | missense variant | - | NC_000007.14:g.55146675G>A | ExAC,TOPMed,gnomAD |
RCV000120701 | p.Arg165Trp | missense variant | - | NC_000007.14:g.55146674C>T | ClinVar |
rs765416003 | p.Ile167Thr | missense variant | - | NC_000007.14:g.55146681T>C | ExAC,TOPMed,gnomAD |
rs530692924 | p.Val168Leu | missense variant | - | NC_000007.14:g.55146683G>C | 1000Genomes,ExAC,gnomAD |
rs758945260 | p.Ser170Asn | missense variant | - | NC_000007.14:g.55146690G>A | ExAC,gnomAD |
rs758945260 | p.Ser170Ile | missense variant | - | NC_000007.14:g.55146690G>T | ExAC,gnomAD |
rs17289686 | p.Asp171Glu | missense variant | - | NC_000007.14:g.55146694C>A | 1000Genomes,ESP,ExAC,TOPMed,gnomAD |
NCI-TCGA novel | p.Met176Ile | missense variant | - | NC_000007.14:g.55146709G>C | NCI-TCGA |
rs770290445 | p.Ser177Trp | missense variant | - | NC_000007.14:g.55146711C>G | ExAC,TOPMed,gnomAD |
rs770290445 | p.Ser177Leu | missense variant | - | NC_000007.14:g.55146711C>T | ExAC,TOPMed,gnomAD |
NCI-TCGA novel | p.Ser177Pro | missense variant | - | NC_000007.14:g.55146710T>C | NCI-TCGA |
rs1219334377 | p.Met178Val | missense variant | - | NC_000007.14:g.55146713A>G | gnomAD |
rs745755245 | p.Met178Ile | missense variant | - | NC_000007.14:g.55146715G>A | ExAC,gnomAD |
rs772071414 | p.His183Asp | missense variant | - | NC_000007.14:g.55146728C>G | ExAC,gnomAD |
rs772071414 | p.His183Asn | missense variant | - | NC_000007.14:g.55146728C>A | ExAC,gnomAD |
rs1224862076 | p.Leu184Val | missense variant | - | NC_000007.14:g.55146731C>G | TOPMed,gnomAD |
rs921852102 | p.Leu184Pro | missense variant | - | NC_000007.14:g.55146732T>C | TOPMed |
rs921852102 | p.Leu184Gln | missense variant | - | NC_000007.14:g.55146732T>A | TOPMed |
NCI-TCGA novel | p.Cys187Tyr | missense variant | - | NC_000007.14:g.55151294G>A | NCI-TCGA |
NCI-TCGA novel | p.Asp191Asn | missense variant | - | NC_000007.14:g.55151305G>A | NCI-TCGA |
rs770074413 | p.Pro192Thr | missense variant | - | NC_000007.14:g.55151308C>A | ExAC,TOPMed,gnomAD |
NCI-TCGA novel | p.Pro192Ser | missense variant | - | NC_000007.14:g.55151308C>T | NCI-TCGA |
NCI-TCGA novel | p.Pro192Arg | missense variant | - | NC_000007.14:g.55151309C>G | NCI-TCGA |
rs766507267 | p.Asn196Ser | missense variant | - | NC_000007.14:g.55151321A>G | ExAC,TOPMed,gnomAD |
rs1335854310 | p.Ser198Asn | missense variant | - | NC_000007.14:g.55151327G>A | gnomAD |
COSM1090865 | p.Ser198Arg | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000007.14:g.55151328C>A | NCI-TCGA Cosmic |
rs767829342 | p.Glu204Lys | missense variant | - | NC_000007.14:g.55151344G>A | ExAC,gnomAD |
rs779156097 | p.Thr211Ser | missense variant | - | NC_000007.14:g.55152549C>G | ExAC,gnomAD |
rs750423932 | p.Lys212Gln | missense variant | - | NC_000007.14:g.55152551A>C | ExAC,gnomAD |
rs1372330611 | p.Ala216Gly | missense variant | - | NC_000007.14:g.55152564C>G | gnomAD |
rs1190573231 | p.Ala216Thr | missense variant | - | NC_000007.14:g.55152563G>A | gnomAD |
rs776050604 | p.Gln218His | missense variant | - | NC_000007.14:g.55152571G>T | ExAC,gnomAD |
rs761098433 | p.Ser220Pro | missense variant | - | NC_000007.14:g.55152575T>C | ExAC,gnomAD |
rs776886714 | p.Gly221Arg | missense variant | - | NC_000007.14:g.55152578G>A | ExAC,gnomAD |
rs776886714 | p.Gly221Trp | missense variant | - | NC_000007.14:g.55152578G>T | ExAC,gnomAD |
rs751295137 | p.Arg222His | missense variant | - | NC_000007.14:g.55152582G>A | ExAC,TOPMed,gnomAD |
NCI-TCGA novel | p.Arg222Leu | missense variant | - | NC_000007.14:g.55152582G>T | NCI-TCGA |
COSM191968 | p.Arg222Cys | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000007.14:g.55152581C>T | NCI-TCGA Cosmic |
rs759106015 | p.Arg224His | missense variant | - | NC_000007.14:g.55152588G>A | ExAC,TOPMed,gnomAD |
rs759106015 | p.Arg224His | missense variant | - | NC_000007.14:g.55152588G>A | NCI-TCGA |
rs1046438724 | p.Ser227Phe | missense variant | - | NC_000007.14:g.55152597C>T | NCI-TCGA Cosmic |
rs1046438724 | p.Ser227Phe | missense variant | - | NC_000007.14:g.55152597C>T | TOPMed,gnomAD |
rs766952405 | p.Ser227Pro | missense variant | - | NC_000007.14:g.55152596T>C | ExAC,gnomAD |
rs752616839 | p.Pro228His | missense variant | - | NC_000007.14:g.55152600C>A | ExAC,gnomAD |
COSM5872872 | p.Pro228Leu | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000007.14:g.55152600C>T | NCI-TCGA Cosmic |
rs1357816760 | p.Ser229Arg | missense variant | - | NC_000007.14:g.55152604T>A | gnomAD |
rs1247276424 | p.Ser229Gly | missense variant | - | NC_000007.14:g.55152602A>G | gnomAD |
rs1291943679 | p.Ser229Asn | missense variant | - | NC_000007.14:g.55152603G>A | gnomAD |
COSM3412174 | p.Ser229Cys | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000007.14:g.55152602A>T | NCI-TCGA Cosmic |
rs1203062307 | p.Asp230Ala | missense variant | - | NC_000007.14:g.55152606A>C | gnomAD |
rs756040606 | p.Cys231Gly | missense variant | - | NC_000007.14:g.55152608T>G | ExAC |
rs777575581 | p.Cys231Ser | missense variant | - | NC_000007.14:g.55152609G>C | ExAC,gnomAD |
COSM3639727 | p.Asn234Ser | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000007.14:g.55152618A>G | NCI-TCGA Cosmic |
NCI-TCGA novel | p.Ala237Asp | missense variant | - | NC_000007.14:g.55152627C>A | NCI-TCGA |
rs1447176163 | p.Gly239Ala | missense variant | - | NC_000007.14:g.55152633G>C | TOPMed,gnomAD |
NCI-TCGA novel | p.Gly239Ser | missense variant | - | NC_000007.14:g.55152632G>A | NCI-TCGA |
COSM3412176 | p.Cys240Tyr | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000007.14:g.55152636G>A | NCI-TCGA Cosmic |
rs370744986 | p.Thr241Ile | missense variant | - | NC_000007.14:g.55152639C>T | ESP,TOPMed,gnomAD |
rs554981236 | p.Arg244Gly | missense variant | - | NC_000007.14:g.55152647C>G | 1000Genomes,ExAC,TOPMed,gnomAD |
rs200664836 | p.Arg244Gln | missense variant | - | NC_000007.14:g.55152648G>A | 1000Genomes,ExAC,TOPMed,gnomAD |
rs554981236 | p.Arg244Trp | missense variant | - | NC_000007.14:g.55152647C>T | 1000Genomes,ExAC,TOPMed,gnomAD |
rs780001754 | p.Asp247Asn | missense variant | - | NC_000007.14:g.55152656G>A | ExAC,TOPMed,gnomAD |
rs780001754 | p.Asp247His | missense variant | - | NC_000007.14:g.55152656G>C | ExAC,TOPMed,gnomAD |
rs765893589 | p.Leu249Pro | missense variant | - | NC_000007.14:g.55152663T>C | ExAC,gnomAD |
rs775252718 | p.Arg252Gly | missense variant | - | NC_000007.14:g.55154017C>G | ExAC,gnomAD |
rs760101437 | p.Arg252His | missense variant | - | NC_000007.14:g.55154018G>A | ExAC,gnomAD |
rs760101437 | p.Arg252His | missense variant | - | NC_000007.14:g.55154018G>A | NCI-TCGA,NCI-TCGA Cosmic |
COSM1559807 | p.Arg252Cys | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000007.14:g.55154017C>T | NCI-TCGA Cosmic |
COSM3412178 | p.Arg252Pro | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000007.14:g.55154018G>C | NCI-TCGA Cosmic |
rs374084791 | p.Lys253Arg | missense variant | - | NC_000007.14:g.55154021A>G | 1000Genomes,ExAC,TOPMed,gnomAD |
NCI-TCGA novel | p.Phe254Ile | missense variant | - | NC_000007.14:g.55154023T>A | NCI-TCGA |
rs372202099 | p.Arg255Gln | missense variant | - | NC_000007.14:g.55154027G>A | ESP,ExAC,TOPMed,gnomAD |
rs776490661 | p.Arg255Ter | stop gained | - | NC_000007.14:g.55154026C>T | ExAC,gnomAD |
COSM3412180 | p.Asp256Tyr | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000007.14:g.55154029G>T | NCI-TCGA Cosmic |
COSM1451549 | p.Asp256Gly | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000007.14:g.55154030A>G | NCI-TCGA Cosmic |
rs138847501 | p.Glu257Lys | missense variant | - | NC_000007.14:g.55154032G>A | ESP,ExAC,TOPMed,gnomAD |
rs138847501 | p.Glu257Lys | missense variant | - | NC_000007.14:g.55154032G>A | NCI-TCGA |
rs766478921 | p.Thr259Met | missense variant | - | NC_000007.14:g.55154039C>T | NCI-TCGA |
rs766478921 | p.Thr259Met | missense variant | - | NC_000007.14:g.55154039C>T | ExAC,gnomAD |
rs1396651256 | p.Thr259Pro | missense variant | - | NC_000007.14:g.55154038A>C | gnomAD |
COSM1330578 | p.Lys261Asn | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000007.14:g.55154046G>T | NCI-TCGA Cosmic |
rs1057519829 | p.Thr263Pro | missense variant | - | NC_000007.14:g.55154050A>C | gnomAD |
rs1057519829 | p.Thr263Pro | missense variant | - | NC_000007.14:g.55154050A>C | NCI-TCGA Cosmic |
NCI-TCGA novel | p.Thr263Ile | missense variant | - | NC_000007.14:g.55154051C>T | NCI-TCGA |
RCV000444169 | p.Thr263Pro | missense variant | Neoplasm of brain | NC_000007.14:g.55154050A>C | ClinVar |
rs1057519829 | p.Thr263Ala | missense variant | - | NC_000007.14:g.55154050A>G | gnomAD |
COSM3639729 | p.Cys264Tyr | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000007.14:g.55154054G>A | NCI-TCGA Cosmic |
rs748627278 | p.Pro265His | missense variant | - | NC_000007.14:g.55154057C>A | ExAC,TOPMed,gnomAD |
rs17336639 | p.Pro266Gln | missense variant | - | NC_000007.14:g.55154060C>A | ESP,ExAC,TOPMed,gnomAD |
rs17336639 | p.Pro266Arg | missense variant | - | NC_000007.14:g.55154060C>G | ESP,ExAC,TOPMed,gnomAD |
COSM5872876 | p.Pro266HisPheSerTerUnkUnk | frameshift | Variant assessed as Somatic; HIGH impact. | NC_000007.14:g.55154055C>- | NCI-TCGA Cosmic |
rs1483973439 | p.Met268Thr | missense variant | - | NC_000007.14:g.55154066T>C | gnomAD |
rs1220356597 | p.Leu269Phe | missense variant | - | NC_000007.14:g.55154068C>T | gnomAD |
COSM3412184 | p.Tyr270Cys | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000007.14:g.55154072A>G | NCI-TCGA Cosmic |
NCI-TCGA novel | p.Pro272Leu | missense variant | - | NC_000007.14:g.55154078C>T | NCI-TCGA |
rs1268199326 | p.Pro272His | missense variant | - | NC_000007.14:g.55154078C>A | gnomAD |
rs966001143 | p.Thr274Met | missense variant | - | NC_000007.14:g.55154084C>T | TOPMed |
rs1412517681 | p.Thr274Ala | missense variant | - | NC_000007.14:g.55154083A>G | TOPMed |
rs771396903 | p.Gln276Arg | missense variant | - | NC_000007.14:g.55154090A>G | ExAC,TOPMed,gnomAD |
NCI-TCGA novel | p.Gln276Leu | missense variant | - | NC_000007.14:g.55154090A>T | NCI-TCGA |
rs1215369904 | p.Met277Thr | missense variant | - | NC_000007.14:g.55154093T>C | TOPMed |
NCI-TCGA novel | p.Asp278Gly | missense variant | - | NC_000007.14:g.55154096A>G | NCI-TCGA |
rs918710688 | p.Pro281Arg | missense variant | - | NC_000007.14:g.55154105C>G | TOPMed,gnomAD |
rs199796955 | p.Glu282Lys | missense variant | - | NC_000007.14:g.55154107G>A | NCI-TCGA |
rs199796955 | p.Glu282Lys | missense variant | - | NC_000007.14:g.55154107G>A | ESP,ExAC,TOPMed,gnomAD |
rs776146284 | p.Tyr285His | missense variant | - | NC_000007.14:g.55154116T>C | ExAC,gnomAD |
RCV000442544 | p.Ala289Asn | missense variant | Neoplasm of brain | NC_000007.14:g.55154128_55154129delinsAA | ClinVar |
RCV000417429 | p.Ala289Ile | missense variant | Neoplasm of brain | NC_000007.14:g.55154128_55154129delinsAT | ClinVar |
RCV000437629 | p.Ala289Asn | missense variant | Squamous cell carcinoma of the head and neck (HNSCC) | NC_000007.14:g.55154128_55154129delinsAA | ClinVar |
rs149840192 | p.Ala289Val | missense variant | - | NC_000007.14:g.55154129C>T | - |
RCV000422848 | p.Ala289Thr | missense variant | Squamous cell carcinoma of the head and neck (HNSCC) | NC_000007.14:g.55154128G>A | ClinVar |
RCV000423404 | p.Ala289Val | missense variant | Glioblastoma | NC_000007.14:g.55154129C>T | ClinVar |
RCV000433672 | p.Ala289Thr | missense variant | Neoplasm of brain | NC_000007.14:g.55154128G>A | ClinVar |
RCV000443246 | p.Ala289Thr | missense variant | Glioblastoma | NC_000007.14:g.55154128G>A | ClinVar |
NCI-TCGA novel | p.Ala289ArgPheSerTerUnk | frameshift | - | NC_000007.14:g.55154126_55154138GTGCCACCTGCGT>- | NCI-TCGA |
RCV000429429 | p.Ala289Ile | missense variant | Squamous cell carcinoma of the head and neck (HNSCC) | NC_000007.14:g.55154128_55154129delinsAT | ClinVar |
RCV000443311 | p.Ala289Asp | missense variant | Squamous cell carcinoma of the head and neck (HNSCC) | NC_000007.14:g.55154129C>A | ClinVar |
RCV000423749 | p.Ala289Val | missense variant | Neoplasm of brain | NC_000007.14:g.55154129C>T | ClinVar |
rs769696078 | p.Ala289Thr | missense variant | - | NC_000007.14:g.55154128G>A | NCI-TCGA,NCI-TCGA Cosmic |
rs149840192 | p.Ala289Asp | missense variant | - | NC_000007.14:g.55154129C>A | NCI-TCGA Cosmic |
rs149840192 | p.Ala289Val | missense variant | - | NC_000007.14:g.55154129C>T | NCI-TCGA,NCI-TCGA Cosmic |
RCV000439402 | p.Ala289Val | missense variant | Squamous cell carcinoma of the head and neck (HNSCC) | NC_000007.14:g.55154129C>T | ClinVar |
RCV000434840 | p.Ala289Asp | missense variant | Glioblastoma | NC_000007.14:g.55154129C>A | ClinVar |
RCV000427425 | p.Ala289Asp | missense variant | Neoplasm of brain | NC_000007.14:g.55154129C>A | ClinVar |
RCV000435251 | p.Ala289Ile | missense variant | Glioblastoma | NC_000007.14:g.55154128_55154129delinsAT | ClinVar |
RCV000424975 | p.Ala289Asn | missense variant | Glioblastoma | NC_000007.14:g.55154128_55154129delinsAA | ClinVar |
rs769696078 | p.Ala289Thr | missense variant | - | NC_000007.14:g.55154128G>A | ExAC,gnomAD |
rs149840192 | p.Ala289Asp | missense variant | - | NC_000007.14:g.55154129C>A | - |
rs1020654485 | p.Thr290Ile | missense variant | - | NC_000007.14:g.55154132C>T | TOPMed,gnomAD |
rs1220574404 | p.Cys291Phe | missense variant | - | NC_000007.14:g.55154135G>T | TOPMed |
rs762649354 | p.Val292Ala | missense variant | - | NC_000007.14:g.55154138T>C | ExAC |
rs150549265 | p.Val292Met | missense variant | - | NC_000007.14:g.55154137G>A | ESP,TOPMed,gnomAD |
rs150549265 | p.Val292Met | missense variant | - | NC_000007.14:g.55154137G>A | NCI-TCGA |
rs751667358 | p.Arg297Cys | missense variant | - | NC_000007.14:g.55154152C>T | ExAC,gnomAD |
COSM6178064 | p.Val300Met | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000007.14:g.55155838G>A | NCI-TCGA Cosmic |
rs779094647 | p.Val301Leu | missense variant | - | NC_000007.14:g.55155841G>T | ExAC,gnomAD |
COSM297803 | p.Asp303His | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000007.14:g.55155847G>C | NCI-TCGA Cosmic |
COSM3923810 | p.Asp303Asn | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000007.14:g.55155847G>A | NCI-TCGA Cosmic |
rs1277911361 | p.His304Arg | missense variant | - | NC_000007.14:g.55155851A>G | gnomAD |
rs182002674 | p.His304Gln | missense variant | - | NC_000007.14:g.55155852C>A | 1000Genomes,ExAC,TOPMed,gnomAD |
COSM2149971 | p.His304Tyr | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000007.14:g.55155850C>T | NCI-TCGA Cosmic |
rs1278838499 | p.Gly305Cys | missense variant | - | NC_000007.14:g.55155853G>T | TOPMed |
rs1321610304 | p.Cys307Arg | missense variant | - | NC_000007.14:g.55155859T>C | gnomAD |
rs749132706 | p.Val308Ile | missense variant | - | NC_000007.14:g.55155862G>A | ExAC,TOPMed,gnomAD |
rs1444692842 | p.Arg309Gly | missense variant | - | NC_000007.14:g.55155865C>G | gnomAD |
COSM274945 | p.Arg309Gln | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000007.14:g.55155866G>A | NCI-TCGA Cosmic |
COSM3929116 | p.Gly312Trp | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000007.14:g.55155874G>T | NCI-TCGA Cosmic |
rs770879879 | p.Gly312Ala | missense variant | - | NC_000007.14:g.55155875G>C | ExAC,gnomAD |
rs149321481 | p.Ala313Val | missense variant | - | NC_000007.14:g.55155878C>T | ESP,ExAC,TOPMed,gnomAD |
rs552062864 | p.Asp314Asn | missense variant | - | NC_000007.14:g.55155880G>A | 1000Genomes |
rs552062864 | p.Asp314Asn | missense variant | - | NC_000007.14:g.55155880G>A | NCI-TCGA |
COSM3833026 | p.Asp314Gly | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000007.14:g.55155881A>G | NCI-TCGA Cosmic |
rs745658347 | p.Ser315Asn | missense variant | - | NC_000007.14:g.55155884G>A | ExAC,gnomAD |
rs1484032303 | p.Tyr316Cys | missense variant | - | NC_000007.14:g.55155887A>G | gnomAD |
COSM3929118 | p.Glu317Lys | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000007.14:g.55155889G>A | NCI-TCGA Cosmic |
rs775800262 | p.Met318Ile | missense variant | - | NC_000007.14:g.55155894G>T | ExAC,gnomAD |
COSM3639733 | p.Glu319Lys | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000007.14:g.55155895G>A | NCI-TCGA Cosmic |
rs1175454134 | p.Glu319Ter | stop gained | - | NC_000007.14:g.55155895G>T | gnomAD |
rs764038041 | p.Asp321Glu | missense variant | - | NC_000007.14:g.55155903C>A | ExAC,TOPMed,gnomAD |
COSM3929120 | p.Asp321Tyr | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000007.14:g.55155901G>T | NCI-TCGA Cosmic |
rs776791214 | p.Gly322Ser | missense variant | - | NC_000007.14:g.55155904G>A | ExAC,gnomAD |
rs367680488 | p.Val323Ala | missense variant | - | NC_000007.14:g.55155908T>C | ESP,ExAC,TOPMed,gnomAD |
rs761844164 | p.Val323Ile | missense variant | - | NC_000007.14:g.55155907G>A | ExAC,TOPMed,gnomAD |
rs761844164 | p.Val323Ile | missense variant | - | NC_000007.14:g.55155907G>A | NCI-TCGA,NCI-TCGA Cosmic |
rs758748662 | p.Arg324His | missense variant | - | NC_000007.14:g.55155911G>A | ExAC,gnomAD |
rs758748662 | p.Arg324His | missense variant | - | NC_000007.14:g.55155911G>A | NCI-TCGA,NCI-TCGA Cosmic |
COSM1736054 | p.Arg324Leu | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000007.14:g.55155911G>T | NCI-TCGA Cosmic |
rs1343888047 | p.Arg324Cys | missense variant | - | NC_000007.14:g.55155910C>T | gnomAD |
rs766740458 | p.Lys325Gln | missense variant | - | NC_000007.14:g.55155913A>C | ExAC,gnomAD |
rs886037891 | p.Cys326Phe | missense variant | - | NC_000007.14:g.55155917G>T | - |
RCV000256393 | p.Cys326Phe | missense variant | Cowden syndrome 1 (CWS1) | NC_000007.14:g.55155917G>T | ClinVar |
rs144460286 | p.Lys328Gln | missense variant | - | NC_000007.14:g.55155922A>C | ESP,ExAC,gnomAD |
rs777342222 | p.Cys329Arg | missense variant | - | NC_000007.14:g.55155925T>C | ExAC,gnomAD |
NCI-TCGA novel | p.Cys329Tyr | missense variant | - | NC_000007.14:g.55155926G>A | NCI-TCGA |
rs139429793 | p.Glu330Lys | missense variant | - | NC_000007.14:g.55155928G>A | ESP,ExAC,TOPMed,gnomAD |
rs778901010 | p.Glu330Val | missense variant | - | NC_000007.14:g.55155929A>T | ExAC,gnomAD |
RCV000677876 | p.Glu330Lys | missense variant | Lung adenocarcinoma | NC_000007.14:g.55155928G>A | ClinVar |
rs778901010 | p.Glu330Gly | missense variant | - | NC_000007.14:g.55155929A>G | ExAC,gnomAD |
NCI-TCGA novel | p.Cys333ProPheSerTerUnk | frameshift | - | NC_000007.14:g.55155937_55155938TG>- | NCI-TCGA |
COSM2156010 | p.Arg334Cys | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000007.14:g.55155940C>T | NCI-TCGA Cosmic |
rs771929085 | p.Arg334His | missense variant | - | NC_000007.14:g.55155941G>A | ExAC,gnomAD |
rs1381010963 | p.Ile342Thr | missense variant | - | NC_000007.14:g.55156551T>C | TOPMed |
rs1284204782 | p.Ile342Leu | missense variant | - | NC_000007.14:g.55156550A>C | TOPMed,gnomAD |
rs771398183 | p.Gly343Val | missense variant | - | NC_000007.14:g.55156554G>T | ExAC,TOPMed |
rs371234907 | p.Ser348Leu | missense variant | - | NC_000007.14:g.55156569C>T | ESP,TOPMed |
rs767790289 | p.Ile351Val | missense variant | - | NC_000007.14:g.55156577A>G | NCI-TCGA,NCI-TCGA Cosmic |
rs767790289 | p.Ile351Val | missense variant | - | NC_000007.14:g.55156577A>G | ExAC,TOPMed,gnomAD |
rs753466844 | p.Thr354Met | missense variant | - | NC_000007.14:g.55156587C>T | ExAC,gnomAD |
NCI-TCGA novel | p.Thr354LysPheSerTerUnkUnk | frameshift | - | NC_000007.14:g.55156586_55156605ACGAATATTAAACACTTCAA>- | NCI-TCGA |
rs1423110562 | p.Lys357Ile | missense variant | - | NC_000007.14:g.55156596A>T | gnomAD |
NCI-TCGA novel | p.Phe359Leu | missense variant | - | NC_000007.14:g.55156603C>A | NCI-TCGA |
NCI-TCGA novel | p.Lys360IlePheSerTerUnkUnk | frameshift | - | NC_000007.14:g.55156604_55156605insT | NCI-TCGA |
rs1164954595 | p.Thr363Ile | missense variant | - | NC_000007.14:g.55156614C>T | - |
rs1164954595 | p.Thr363Ile | missense variant | - | NC_000007.14:g.55156614C>T | NCI-TCGA Cosmic |
COSM3923812 | p.Ser364Phe | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000007.14:g.55156617C>T | NCI-TCGA Cosmic |
rs758017949 | p.Asp368Val | missense variant | - | NC_000007.14:g.55156629A>T | ExAC,gnomAD |
rs749927550 | p.Asp368His | missense variant | - | NC_000007.14:g.55156628G>C | ExAC,gnomAD |
NCI-TCGA novel | p.Asp368Asn | missense variant | - | NC_000007.14:g.55156628G>A | NCI-TCGA |
rs780131926 | p.Leu369Ile | missense variant | - | NC_000007.14:g.55156631C>A | ExAC,TOPMed,gnomAD |
rs1405999227 | p.Ile371Val | missense variant | - | NC_000007.14:g.55156637A>G | gnomAD |
NCI-TCGA novel | p.Pro373Gln | missense variant | - | NC_000007.14:g.55156644C>A | NCI-TCGA |
NCI-TCGA novel | p.Pro373Ser | missense variant | - | NC_000007.14:g.55156643C>T | NCI-TCGA |
NCI-TCGA novel | p.Ala375Val | missense variant | - | NC_000007.14:g.55156650C>T | NCI-TCGA |
rs1341708803 | p.Phe376Leu | missense variant | - | NC_000007.14:g.55156652T>C | gnomAD |
NCI-TCGA novel | p.Arg377Lys | missense variant | - | NC_000007.14:g.55156656G>A | NCI-TCGA |
COSM6110421 | p.Arg377Ser | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000007.14:g.55156657G>T | NCI-TCGA Cosmic |
NCI-TCGA novel | p.Asp379Asn | missense variant | - | NC_000007.14:g.55156760G>A | NCI-TCGA |
NCI-TCGA novel | p.Ser380Phe | missense variant | - | NC_000007.14:g.55156764C>T | NCI-TCGA |
rs1169461493 | p.His383Arg | missense variant | - | NC_000007.14:g.55156773A>G | TOPMed |
rs755972013 | p.His383Asn | missense variant | - | NC_000007.14:g.55156772C>A | ExAC,gnomAD |
COSM1313184 | p.Thr384Ser | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000007.14:g.55156776C>G | NCI-TCGA Cosmic |
COSM6178060 | p.Leu387Met | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000007.14:g.55156784C>A | NCI-TCGA Cosmic |
NCI-TCGA novel | p.Pro389Ser | missense variant | - | NC_000007.14:g.55156790C>T | NCI-TCGA |
NCI-TCGA novel | p.Gln390Arg | missense variant | - | NC_000007.14:g.55156794A>G | NCI-TCGA |
COSM3639735 | p.Gln390Lys | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000007.14:g.55156793C>A | NCI-TCGA Cosmic |
rs1197499057 | p.Gln390Pro | missense variant | - | NC_000007.14:g.55156794A>C | gnomAD |
rs1389500636 | p.Glu391Lys | missense variant | - | NC_000007.14:g.55156796G>A | TOPMed |
RCV000120687 | p.Asp393His | missense variant | - | NC_000007.14:g.55156802G>C | ClinVar |
rs587778246 | p.Asp393His | missense variant | - | NC_000007.14:g.55156802G>C | gnomAD |
rs1178642122 | p.Ile394Met | missense variant | - | NC_000007.14:g.55156807T>G | gnomAD |
rs757265130 | p.Val398Ile | missense variant | - | NC_000007.14:g.55156817G>A | ExAC,gnomAD |
COSM1698691 | p.Glu400Lys | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000007.14:g.55156823G>A | NCI-TCGA Cosmic |
rs777165081 | p.Phe404Ile | missense variant | - | NC_000007.14:g.55157665T>A | ExAC |
rs1230904747 | p.Leu406Gln | missense variant | - | NC_000007.14:g.55157672T>A | gnomAD |
rs1179620001 | p.Ile407Val | missense variant | - | NC_000007.14:g.55157674A>G | gnomAD |
COSM4916543 | p.Pro411Arg | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000007.14:g.55157687C>G | NCI-TCGA Cosmic |
rs770466526 | p.Asn413Ser | missense variant | - | NC_000007.14:g.55157693A>G | ExAC,gnomAD |
rs1424097500 | p.Arg414Met | missense variant | - | NC_000007.14:g.55157696G>T | gnomAD |
rs1274543317 | p.Thr415Lys | missense variant | - | NC_000007.14:g.55157699C>A | TOPMed |
rs758956103 | p.Asp416Glu | missense variant | - | NC_000007.14:g.55157703C>G | ExAC,gnomAD |
rs1456537863 | p.Leu417Arg | missense variant | - | NC_000007.14:g.55157705T>G | gnomAD |
rs1390766480 | p.His418Tyr | missense variant | - | NC_000007.14:g.55157707C>T | gnomAD |
NCI-TCGA novel | p.Ala419Pro | missense variant | - | NC_000007.14:g.55157710G>C | NCI-TCGA |
rs760639592 | p.Glu421Lys | missense variant | - | NC_000007.14:g.55157716G>A | ExAC,gnomAD |
rs1230287644 | p.Glu424Asp | missense variant | - | NC_000007.14:g.55157727A>T | gnomAD |
rs558565565 | p.Ile425Val | missense variant | - | NC_000007.14:g.55157728A>G | TOPMed |
RCV000144851 | p.Gly428Asp | missense variant | Inflammatory skin and bowel disease, neonatal, 2 (NISBD2) | NC_000007.14:g.55157738G>A | ClinVar |
NCI-TCGA novel | p.Gly428Ser | missense variant | - | NC_000007.14:g.55157737G>A | NCI-TCGA |
rs606231253 | p.Gly428Asp | missense variant | - | NC_000007.14:g.55157738G>A | ExAC,gnomAD |
rs765369188 | p.Thr430Asn | missense variant | - | NC_000007.14:g.55157744C>A | ExAC,gnomAD |
COSM3881818 | p.Thr430Ile | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000007.14:g.55157744C>T | NCI-TCGA Cosmic |
COSM6178056 | p.Gln432His | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000007.14:g.55157751A>T | NCI-TCGA Cosmic |
rs750713244 | p.His433Arg | missense variant | - | NC_000007.14:g.55157753A>G | ExAC,gnomAD |
rs1171743336 | p.His433Gln | missense variant | - | NC_000007.14:g.55160139T>A | gnomAD |
rs1345387967 | p.Phe436Ile | missense variant | - | NC_000007.14:g.55160146T>A | TOPMed |
COSM1090871 | p.Ser437Tyr | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000007.14:g.55160150C>A | NCI-TCGA Cosmic |
rs1166858113 | p.Val441Ile | missense variant | - | NC_000007.14:g.55160161G>A | gnomAD |
rs765091640 | p.Ser442Asn | missense variant | - | NC_000007.14:g.55160165G>A | ExAC,gnomAD |
rs1032006770 | p.Asn444Ser | missense variant | - | NC_000007.14:g.55160171A>G | TOPMed,gnomAD |
rs372990493 | p.Ile445Val | missense variant | - | NC_000007.14:g.55160173A>G | ESP,TOPMed,gnomAD |
rs1310061365 | p.Thr446Ile | missense variant | - | NC_000007.14:g.55160177C>T | gnomAD |
NCI-TCGA novel | p.Ser447Phe | missense variant | - | NC_000007.14:g.55160180C>T | NCI-TCGA |
rs763266323 | p.Leu448Phe | missense variant | - | NC_000007.14:g.55160184G>C | ExAC,TOPMed,gnomAD |
rs751667594 | p.Arg451His | missense variant | - | NC_000007.14:g.55160192G>A | ExAC,TOPMed,gnomAD |
rs751667594 | p.Arg451Leu | missense variant | - | NC_000007.14:g.55160192G>T | ExAC,TOPMed,gnomAD |
rs377567759 | p.Arg451Cys | missense variant | - | NC_000007.14:g.55160191C>T | ESP,TOPMed,gnomAD |
rs1226827460 | p.Ser452Phe | missense variant | - | NC_000007.14:g.55160195C>T | gnomAD |
rs1177337471 | p.Ile456Thr | missense variant | - | NC_000007.14:g.55160207T>C | TOPMed |
rs1340811850 | p.Ser457Asn | missense variant | - | NC_000007.14:g.55160210G>A | gnomAD |
rs146711874 | p.Asp458Glu | missense variant | - | NC_000007.14:g.55160214T>G | 1000Genomes,ExAC,TOPMed,gnomAD |
rs753269876 | p.Asp460Asn | missense variant | - | NC_000007.14:g.55160218G>A | ExAC,gnomAD |
NCI-TCGA novel | p.Asp460Glu | missense variant | - | NC_000007.14:g.55160220T>A | NCI-TCGA |
NCI-TCGA novel | p.Val461Met | missense variant | - | NC_000007.14:g.55160221G>A | NCI-TCGA |
rs1197924233 | p.Ile462Met | missense variant | - | NC_000007.14:g.55160226A>G | TOPMed,gnomAD |
rs746763556 | p.Ser464Ala | missense variant | - | NC_000007.14:g.55160230T>G | ExAC,TOPMed,gnomAD |
NCI-TCGA novel | p.Ser464GlyPheSerTerUnk | stop gained | - | NC_000007.14:g.55160229_55160230insGGCTGAGGACA | NCI-TCGA |
NCI-TCGA novel | p.Ser464Pro | missense variant | - | NC_000007.14:g.55160230T>C | NCI-TCGA |
NCI-TCGA novel | p.Ser464ArgPheSerTerUnkUnk | frameshift | - | NC_000007.14:g.55160228_55160229insCAGG | NCI-TCGA |
rs746763556 | p.Ser464Thr | missense variant | - | NC_000007.14:g.55160230T>A | ExAC,TOPMed,gnomAD |
COSM6110417 | p.Gly465Arg | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000007.14:g.55160233G>A | NCI-TCGA Cosmic |
NCI-TCGA novel | p.Leu469Val | missense variant | - | NC_000007.14:g.55160245T>G | NCI-TCGA |
rs1389684767 | p.Asn473Asp | missense variant | - | NC_000007.14:g.55160257A>G | gnomAD |
rs1221992080 | p.Ile475Val | missense variant | - | NC_000007.14:g.55160263A>G | TOPMed |
rs746521110 | p.Asn476Ser | missense variant | - | NC_000007.14:g.55160267A>G | ExAC,TOPMed,gnomAD |
rs768208443 | p.Lys479Asn | missense variant | - | NC_000007.14:g.55160277A>C | ExAC,gnomAD |
rs147732025 | p.Leu480Met | missense variant | - | NC_000007.14:g.55160278C>A | 1000Genomes,ExAC,TOPMed,gnomAD |
rs147732025 | p.Leu480Val | missense variant | - | NC_000007.14:g.55160278C>G | 1000Genomes,ExAC,TOPMed,gnomAD |
rs587778247 | p.Phe481Leu | missense variant | - | NC_000007.14:g.55160283T>G | - |
RCV000120688 | p.Phe481Leu | missense variant | - | NC_000007.14:g.55160283T>G | ClinVar |
rs982033612 | p.Gly485Ala | missense variant | - | NC_000007.14:g.55160294G>C | TOPMed,gnomAD |
rs769434273 | p.Gly485Cys | missense variant | - | NC_000007.14:g.55160293G>T | ExAC,TOPMed,gnomAD |
rs769434273 | p.Gly485Ser | missense variant | - | NC_000007.14:g.55160293G>A | ExAC,TOPMed,gnomAD |
COSM6178052 | p.Gln486Ter | stop gained | Variant assessed as Somatic; HIGH impact. | NC_000007.14:g.55160296C>T | NCI-TCGA Cosmic |
rs1271375100 | p.Thr488Ser | missense variant | - | NC_000007.14:g.55160303C>G | gnomAD |
RCV000429440 | p.Ser492Gly | missense variant | Neoplasm of the large intestine | NC_000007.14:g.55160314A>G | ClinVar |
rs1057519860 | p.Ser492Arg | missense variant | - | NC_000007.14:g.55160316C>A | - |
RCV000423834 | p.Ser492Arg | missense variant | Neoplasm of the large intestine | NC_000007.14:g.55160316C>A | ClinVar |
rs1057519760 | p.Ser492Gly | missense variant | - | NC_000007.14:g.55160314A>G | - |
rs766676440 | p.Gly495Asp | missense variant | - | NC_000007.14:g.55160324G>A | ExAC,gnomAD |
rs774773441 | p.Asn497Lys | missense variant | - | NC_000007.14:g.55160331C>A | ExAC,TOPMed,gnomAD |
rs927866979 | p.Ser498Thr | missense variant | - | NC_000007.14:g.55160333G>C | TOPMed |
rs1206537132 | p.Lys500Glu | missense variant | - | NC_000007.14:g.55160338A>G | gnomAD |
rs760711480 | p.Gly503Ser | missense variant | - | NC_000007.14:g.55161507G>A | ExAC,TOPMed,gnomAD |
NCI-TCGA novel | p.Gly503Val | missense variant | - | NC_000007.14:g.55161508G>T | NCI-TCGA |
rs1334180707 | p.Gln504Glu | missense variant | - | NC_000007.14:g.55161510C>G | gnomAD |
rs1188823834 | p.Gln504His | missense variant | - | NC_000007.14:g.55161512G>C | TOPMed |
NCI-TCGA novel | p.Cys506Tyr | missense variant | - | NC_000007.14:g.55161517G>A | NCI-TCGA |
rs1287531915 | p.Ala508Gly | missense variant | - | NC_000007.14:g.55161523C>G | TOPMed,gnomAD |
rs1407608935 | p.Ala508Thr | missense variant | - | NC_000007.14:g.55161522G>A | gnomAD |
rs1287531915 | p.Ala508Asp | missense variant | - | NC_000007.14:g.55161523C>A | TOPMed,gnomAD |
rs1240855741 | p.Leu509Ser | missense variant | - | NC_000007.14:g.55161526T>C | gnomAD |
rs371114444 | p.Ser511Tyr | missense variant | - | NC_000007.14:g.55161532C>A | ESP,ExAC,TOPMed,gnomAD |
rs587778248 | p.Pro512Ser | missense variant | - | NC_000007.14:g.55161534C>T | ExAC,TOPMed,gnomAD |
RCV000120689 | p.Pro512Ser | missense variant | - | NC_000007.14:g.55161534C>T | ClinVar |
rs754646330 | p.Glu513Ter | stop gained | - | NC_000007.14:g.55161537G>T | ExAC,TOPMed,gnomAD |
rs754646330 | p.Glu513Lys | missense variant | - | NC_000007.14:g.55161537G>A | ExAC,TOPMed,gnomAD |
rs1339627647 | p.Glu513Ala | missense variant | - | NC_000007.14:g.55161538A>C | TOPMed |
rs368484180 | p.Pro518Ser | missense variant | - | NC_000007.14:g.55161552C>T | ESP,ExAC,TOPMed |
rs564398642 | p.Pro518Leu | missense variant | - | NC_000007.14:g.55161553C>T | 1000Genomes,ExAC,TOPMed,gnomAD |
rs116057045 | p.Glu519Asp | missense variant | - | NC_000007.14:g.55161557G>T | 1000Genomes,ESP,ExAC,TOPMed,gnomAD |
rs749186957 | p.Glu519Gly | missense variant | - | NC_000007.14:g.55161556A>G | ExAC,gnomAD |
RCV000120690 | p.Arg521Lys | missense variant | - | NC_000007.14:g.55161562G>A | ClinVar |
rs2227983 | p.Arg521Thr | missense variant | - | NC_000007.14:g.55161562G>C | 1000Genomes,ESP,ExAC,TOPMed,gnomAD |
rs2227983 | p.Arg521Lys | missense variant | - | NC_000007.14:g.55161562G>A | 1000Genomes,ESP,ExAC,TOPMed,gnomAD |
rs2227983 | p.Arg521Met | missense variant | - | NC_000007.14:g.55161562G>T | 1000Genomes,ESP,ExAC,TOPMed,gnomAD |
rs587778249 | p.Val524Ile | missense variant | - | NC_000007.14:g.55161570G>A | ExAC,TOPMed,gnomAD |
rs587778249 | p.Val524Leu | missense variant | - | NC_000007.14:g.55161570G>C | ExAC,TOPMed,gnomAD |
RCV000120691 | p.Val524Ile | missense variant | - | NC_000007.14:g.55161570G>A | ClinVar |
NCI-TCGA novel | p.Cys526Ser | missense variant | - | NC_000007.14:g.55161577G>C | NCI-TCGA |
rs768627073 | p.Arg527Trp | missense variant | - | NC_000007.14:g.55161579C>T | ExAC,TOPMed,gnomAD |
rs150477666 | p.Arg527Gln | missense variant | - | NC_000007.14:g.55161580G>A | ESP,ExAC,TOPMed,gnomAD |
rs768627073 | p.Arg527Gly | missense variant | - | NC_000007.14:g.55161579C>G | ExAC,TOPMed,gnomAD |
RCV000120692 | p.Arg527Gln | missense variant | - | NC_000007.14:g.55161580G>A | ClinVar |
rs762336338 | p.Asn528Asp | missense variant | - | NC_000007.14:g.55161582A>G | ExAC,TOPMed,gnomAD |
rs1330512770 | p.Arg531Gln | missense variant | - | NC_000007.14:g.55161592G>A | gnomAD |
COSM3881824 | p.Arg531Ter | stop gained | Variant assessed as Somatic; HIGH impact. | NC_000007.14:g.55161591C>T | NCI-TCGA Cosmic |
rs752350337 | p.Val536Ala | missense variant | - | NC_000007.14:g.55161607T>C | ExAC,gnomAD |
rs767193132 | p.Val536Met | missense variant | - | NC_000007.14:g.55161606G>A | ExAC,TOPMed,gnomAD |
rs1038997598 | p.Asp537Asn | missense variant | - | NC_000007.14:g.55161609G>A | TOPMed |
rs1275660363 | p.Asp537Glu | missense variant | - | NC_000007.14:g.55161611C>G | gnomAD |
rs1209490447 | p.Lys538Thr | missense variant | - | NC_000007.14:g.55161613A>C | TOPMed |
rs1340266257 | p.Asn540Lys | missense variant | - | NC_000007.14:g.55161620C>A | TOPMed |
COSM1090877 | p.Leu541Ile | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000007.14:g.55161621C>A | NCI-TCGA Cosmic |
rs1208487495 | p.Leu541Phe | missense variant | - | NC_000007.14:g.55161621C>T | gnomAD |
rs755584255 | p.Gly544Ser | missense variant | - | NC_000007.14:g.55161630G>A | ExAC,gnomAD |
NCI-TCGA novel | p.Glu545Gln | missense variant | - | NC_000007.14:g.55163734G>C | NCI-TCGA |
rs778985185 | p.Glu545Lys | missense variant | - | NC_000007.14:g.55163734G>A | ExAC,TOPMed,gnomAD |
RCV000443890 | p.Pro546Ser | missense variant | Head and Neck Neoplasms | NC_000007.14:g.55163737C>T | ClinVar |
rs1057519830 | p.Pro546Ser | missense variant | - | NC_000007.14:g.55163737C>T | - |
NCI-TCGA novel | p.Pro546Gln | missense variant | - | NC_000007.14:g.55163738C>A | NCI-TCGA |
rs1427028322 | p.Arg547Gly | missense variant | - | NC_000007.14:g.55163740A>G | TOPMed |
rs1419611893 | p.Phe549Ser | missense variant | - | NC_000007.14:g.55163747T>C | gnomAD |
COSM4844514 | p.Val550Leu | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000007.14:g.55163749G>C | NCI-TCGA Cosmic |
rs940873450 | p.Glu551Val | missense variant | - | NC_000007.14:g.55163753A>T | TOPMed |
rs1162236403 | p.Asn552Ser | missense variant | - | NC_000007.14:g.55163756A>G | gnomAD |
rs779741928 | p.Glu554Gly | missense variant | - | NC_000007.14:g.55163762A>G | ExAC,gnomAD |
NCI-TCGA novel | p.Ile556Val | missense variant | - | NC_000007.14:g.55163767A>G | NCI-TCGA |
rs747203424 | p.Ile556Met | missense variant | - | NC_000007.14:g.55163769A>G | ExAC,gnomAD |
rs1488695603 | p.Gln557Ter | stop gained | - | NC_000007.14:g.55163770C>T | TOPMed |
rs748219780 | p.Pro560Ser | missense variant | - | NC_000007.14:g.55163779C>T | ExAC,TOPMed,gnomAD |
rs748219780 | p.Pro560Thr | missense variant | - | NC_000007.14:g.55163779C>A | ExAC,TOPMed,gnomAD |
rs769918274 | p.Glu561Gln | missense variant | - | NC_000007.14:g.55163782G>C | ExAC,TOPMed,gnomAD |
rs773651001 | p.Pro564Ser | missense variant | - | NC_000007.14:g.55163791C>T | ExAC,gnomAD |
rs773651001 | p.Pro564Thr | missense variant | - | NC_000007.14:g.55163791C>A | ExAC,gnomAD |
rs1258211270 | p.Gln565Arg | missense variant | - | NC_000007.14:g.55163795A>G | TOPMed |
rs771278492 | p.Met567Val | missense variant | - | NC_000007.14:g.55163800A>G | ExAC,gnomAD |
rs1228970909 | p.Asn568Lys | missense variant | - | NC_000007.14:g.55163805C>A | TOPMed |
rs774558548 | p.Thr570Ser | missense variant | - | NC_000007.14:g.55163810C>G | ExAC,gnomAD |
COSM3412190 | p.Cys571Ser | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000007.14:g.55163813G>C | NCI-TCGA Cosmic |
rs759987693 | p.Thr572Arg | missense variant | - | NC_000007.14:g.55163816C>G | ExAC,TOPMed,gnomAD |
rs1294381114 | p.Gly573Arg | missense variant | - | NC_000007.14:g.55163818G>A | TOPMed |
COSM1673192 | p.Gly573Ter | stop gained | Variant assessed as Somatic; HIGH impact. | NC_000007.14:g.55163818G>T | NCI-TCGA Cosmic |
rs760471492 | p.Arg574Trp | missense variant | - | NC_000007.14:g.55163821C>T | ExAC,TOPMed,gnomAD |
rs370810719 | p.Arg574Gln | missense variant | - | NC_000007.14:g.55163822G>A | ESP,ExAC,gnomAD |
rs760471492 | p.Arg574Trp | missense variant | - | NC_000007.14:g.55163821C>T | NCI-TCGA |
rs1249099747 | p.Gly575Glu | missense variant | - | NC_000007.14:g.55165281G>A | TOPMed,gnomAD |
rs556794990 | p.Asn578Ser | missense variant | - | NC_000007.14:g.55165290A>G | 1000Genomes,ExAC,gnomAD |
rs761585117 | p.Ile580Thr | missense variant | - | NC_000007.14:g.55165296T>C | ExAC,TOPMed,gnomAD |
rs1376117521 | p.Gln581Pro | missense variant | - | NC_000007.14:g.55165299A>C | gnomAD |
rs764787649 | p.Gln581Lys | missense variant | - | NC_000007.14:g.55165298C>A | ExAC,gnomAD |
COSM6005744 | p.Gln581Ter | stop gained | Variant assessed as Somatic; HIGH impact. | NC_000007.14:g.55165298C>T | NCI-TCGA Cosmic |
rs1306429085 | p.Cys582Arg | missense variant | - | NC_000007.14:g.55165301T>C | gnomAD |
NCI-TCGA novel | p.Ala583Ser | missense variant | - | NC_000007.14:g.55165304G>T | NCI-TCGA |
rs1447966312 | p.Ala583Val | missense variant | - | NC_000007.14:g.55165305C>T | TOPMed |
rs956386356 | p.His584Gln | missense variant | - | NC_000007.14:g.55165309C>G | TOPMed |
rs542237406 | p.Ile586Asn | missense variant | - | NC_000007.14:g.55165314T>A | 1000Genomes,ExAC,gnomAD |
rs953188147 | p.Ile586Val | missense variant | - | NC_000007.14:g.55165313A>G | TOPMed |
rs542237406 | p.Ile586Thr | missense variant | - | NC_000007.14:g.55165314T>C | 1000Genomes,ExAC,gnomAD |
rs1281578598 | p.Ile586Met | missense variant | - | NC_000007.14:g.55165315T>G | gnomAD |
rs989939484 | p.Gly588Ser | missense variant | - | NC_000007.14:g.55165319G>A | NCI-TCGA |
rs989939484 | p.Gly588Ser | missense variant | - | NC_000007.14:g.55165319G>A | TOPMed,gnomAD |
rs1235180640 | p.Pro589Ser | missense variant | - | NC_000007.14:g.55165322C>T | TOPMed |
rs751570775 | p.Pro589His | missense variant | - | NC_000007.14:g.55165323C>A | ExAC,TOPMed,gnomAD |
rs751570775 | p.Pro589Leu | missense variant | - | NC_000007.14:g.55165323C>T | ExAC,TOPMed,gnomAD |
rs751570775 | p.Pro589Leu | missense variant | - | NC_000007.14:g.55165323C>T | NCI-TCGA Cosmic |
NCI-TCGA novel | p.Cys591Ter | stop gained | - | NC_000007.14:g.55165330C>A | NCI-TCGA |
rs144943614 | p.Val592Ile | missense variant | - | NC_000007.14:g.55165331G>A | 1000Genomes,ESP,ExAC,TOPMed,gnomAD |
rs756307243 | p.Lys593Asn | missense variant | - | NC_000007.14:g.55165336G>C | ExAC,gnomAD |
rs778011429 | p.Thr594Asn | missense variant | - | NC_000007.14:g.55165338C>A | ExAC,TOPMed,gnomAD |
rs778011429 | p.Thr594Ile | missense variant | - | NC_000007.14:g.55165338C>T | ExAC,TOPMed,gnomAD |
rs778011429 | p.Thr594Ile | missense variant | - | NC_000007.14:g.55165338C>T | NCI-TCGA |
COSM2151966 | p.Pro596Arg | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000007.14:g.55165344C>G | NCI-TCGA Cosmic |
COSM3412194 | p.Pro596Ser | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000007.14:g.55165343C>T | NCI-TCGA Cosmic |
rs1477025000 | p.Pro596Leu | missense variant | - | NC_000007.14:g.55165344C>T | TOPMed,gnomAD |
rs757419349 | p.Ala597Ser | missense variant | - | NC_000007.14:g.55165346G>T | ExAC,TOPMed,gnomAD |
RCV000423114 | p.Gly598Ala | missense variant | Neoplasm of brain | NC_000007.14:g.55165350G>C | ClinVar |
RCV000429899 | p.Gly598Ala | missense variant | - | NC_000007.14:g.55165350G>C | ClinVar |
RCV000440786 | p.Gly598Ala | missense variant | Glioblastoma | NC_000007.14:g.55165350G>C | ClinVar |
rs139236063 | p.Gly598Ala | missense variant | - | NC_000007.14:g.55165350G>C | ExAC,gnomAD |
rs139236063 | p.Gly598Val | missense variant | - | NC_000007.14:g.55165350G>T | ExAC,gnomAD |
RCV000434448 | p.Gly598Val | missense variant | Neoplasm of brain | NC_000007.14:g.55165350G>T | ClinVar |
RCV000436167 | p.Gly598Val | missense variant | Glioblastoma | NC_000007.14:g.55165350G>T | ClinVar |
NCI-TCGA novel | p.Gly598Glu | missense variant | - | NC_000007.14:g.55165350G>A | NCI-TCGA |
RCV000418494 | p.Gly598Val | missense variant | - | NC_000007.14:g.55165350G>T | ClinVar |
rs139236063 | p.Gly598Ala | missense variant | - | NC_000007.14:g.55165350G>C | NCI-TCGA Cosmic |
rs139236063 | p.Gly598Val | missense variant | - | NC_000007.14:g.55165350G>T | NCI-TCGA,NCI-TCGA Cosmic |
rs1206543227 | p.Val599Asp | missense variant | - | NC_000007.14:g.55165353T>A | gnomAD |
rs746395542 | p.Met600Val | missense variant | - | NC_000007.14:g.55165355A>G | ExAC,gnomAD |
rs746395542 | p.Met600Leu | missense variant | - | NC_000007.14:g.55165355A>T | ExAC,gnomAD |
rs149375515 | p.Met600Thr | missense variant | - | NC_000007.14:g.55165356T>C | ESP,ExAC,TOPMed,gnomAD |
rs201498575 | p.Gly601Glu | missense variant | - | NC_000007.14:g.55165359G>A | 1000Genomes,TOPMed |
rs769537072 | p.Asn603Lys | missense variant | - | NC_000007.14:g.55165366C>A | ExAC,TOPMed,gnomAD |
rs913231421 | p.Asn604Ser | missense variant | - | NC_000007.14:g.55165368A>G | TOPMed |
COSM1698693 | p.Asn604Asp | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000007.14:g.55165367A>G | NCI-TCGA Cosmic |
rs1436144358 | p.Thr605Ala | missense variant | - | NC_000007.14:g.55165370A>G | gnomAD |
rs143152775 | p.Leu606Val | missense variant | - | NC_000007.14:g.55165373C>G | ESP,ExAC,TOPMed,gnomAD |
NCI-TCGA novel | p.Trp608Cys | missense variant | - | NC_000007.14:g.55165381G>C | NCI-TCGA |
rs201061916 | p.Ala611Thr | missense variant | - | NC_000007.14:g.55165388G>A | ExAC,TOPMed,gnomAD |
rs1214761095 | p.Asp612Asn | missense variant | - | NC_000007.14:g.55165391G>A | gnomAD |
rs764290273 | p.Ala613Thr | missense variant | - | NC_000007.14:g.55165394G>A | ExAC,gnomAD |
NCI-TCGA novel | p.Ala613Val | missense variant | - | NC_000007.14:g.55165395C>T | NCI-TCGA |
rs779076899 | p.Gly614Arg | missense variant | - | NC_000007.14:g.55165397G>C | ExAC,TOPMed,gnomAD |
rs750850720 | p.Gly614Asp | missense variant | - | NC_000007.14:g.55165398G>A | ExAC,TOPMed,gnomAD |
rs779076899 | p.Gly614Ser | missense variant | - | NC_000007.14:g.55165397G>A | ExAC,TOPMed,gnomAD |
rs756534868 | p.Val616Ala | missense variant | - | NC_000007.14:g.55165404T>C | ExAC |
rs150899403 | p.Cys620Tyr | missense variant | - | NC_000007.14:g.55165416G>A | - |
COSM29341 | p.Cys620Trp | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000007.14:g.55165417C>G | NCI-TCGA Cosmic |
rs150899403 | p.Cys620Tyr | missense variant | - | NC_000007.14:g.55165416G>A | NCI-TCGA,NCI-TCGA Cosmic |
COSM3639743 | p.Pro622Ser | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000007.14:g.55165421C>T | NCI-TCGA Cosmic |
rs747376358 | p.Asn623Tyr | missense variant | - | NC_000007.14:g.55165424A>T | ExAC,gnomAD |
rs28384376 | p.Cys624Phe | missense variant | - | NC_000007.14:g.55165428G>T | - |
rs28384376 | p.Cys624Phe | missense variant | - | NC_000007.14:g.55165428G>T | NCI-TCGA,NCI-TCGA Cosmic |
NCI-TCGA novel | p.Thr625Ala | missense variant | - | NC_000007.14:g.55165430A>G | NCI-TCGA |
rs753315940 | p.Gly627Arg | missense variant | - | NC_000007.14:g.55165436G>A | ExAC,gnomAD |
COSM2157152 | p.Cys628Phe | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000007.14:g.55171177G>T | NCI-TCGA Cosmic |
COSM3412200 | p.Cys628Tyr | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000007.14:g.55171177G>A | NCI-TCGA Cosmic |
rs552265738 | p.Pro631Ser | missense variant | - | NC_000007.14:g.55171185C>T | 1000Genomes,ExAC,gnomAD |
rs1157210752 | p.Leu633Phe | missense variant | - | NC_000007.14:g.55171191C>T | TOPMed |
rs765068810 | p.Glu634Lys | missense variant | - | NC_000007.14:g.55171194G>A | ExAC,TOPMed,gnomAD |
rs957617087 | p.Gly635Ser | missense variant | - | NC_000007.14:g.55171197G>A | TOPMed,gnomAD |
COSM39163 | p.Cys636Tyr | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000007.14:g.55171201G>A | NCI-TCGA Cosmic |
rs571064657 | p.Thr638Met | missense variant | - | NC_000007.14:g.55171207C>T | 1000Genomes,ExAC,gnomAD |
rs762592162 | p.Thr638Ala | missense variant | - | NC_000007.14:g.55171206A>G | ExAC,gnomAD |
rs952307505 | p.Asn639Ser | missense variant | - | NC_000007.14:g.55171210A>G | TOPMed,gnomAD |
rs200989322 | p.Gly640Trp | missense variant | - | NC_000007.14:g.55171212G>T | 1000Genomes,ExAC,gnomAD |
rs1467090960 | p.Pro641Ser | missense variant | - | NC_000007.14:g.55172984C>T | gnomAD |
rs770443325 | p.Pro644Arg | missense variant | - | NC_000007.14:g.55172994C>G | ExAC,TOPMed,gnomAD |
RCV000259941 | p.Pro644Leu | missense variant | Lung cancer | NC_000007.14:g.55172994C>T | ClinVar |
rs770443325 | p.Pro644Leu | missense variant | - | NC_000007.14:g.55172994C>T | ExAC,TOPMed,gnomAD |
rs772046081 | p.Ser645Cys | missense variant | - | NC_000007.14:g.55172997C>G | ExAC,gnomAD |
rs140516819 | p.Ile646Leu | missense variant | - | NC_000007.14:g.55172999A>C | 1000Genomes,ESP,ExAC,TOPMed,gnomAD |
rs140516819 | p.Ile646Val | missense variant | - | NC_000007.14:g.55172999A>G | 1000Genomes,ESP,ExAC,TOPMed,gnomAD |
rs1300062728 | p.Ile646Ser | missense variant | - | NC_000007.14:g.55173000T>G | TOPMed |
rs764359156 | p.Ala647Thr | missense variant | - | NC_000007.14:g.55173002G>A | ExAC,TOPMed,gnomAD |
rs776728879 | p.Thr648Ile | missense variant | - | NC_000007.14:g.55173006C>T | ExAC,gnomAD |
rs776728879 | p.Thr648Ser | missense variant | - | NC_000007.14:g.55173006C>G | ExAC,gnomAD |
NCI-TCGA novel | p.Met650Ile | missense variant | - | NC_000007.14:g.55173013G>A | NCI-TCGA |
rs758954817 | p.Val651Gly | missense variant | - | NC_000007.14:g.55173015T>G | ExAC,gnomAD |
RCV000709009 | p.Val651Met | missense variant | Hereditary cancer | NC_000007.14:g.55173014G>A | ClinVar |
rs1467640610 | p.Ala653Ser | missense variant | - | NC_000007.14:g.55173020G>T | gnomAD |
rs767037049 | p.Leu655Val | missense variant | - | NC_000007.14:g.55173026C>G | ExAC,gnomAD |
rs767037049 | p.Leu655Phe | missense variant | - | NC_000007.14:g.55173026C>T | ExAC,gnomAD |
rs755356995 | p.Val659Ala | missense variant | - | NC_000007.14:g.55173039T>C | ExAC,TOPMed |
rs201580890 | p.Val659Leu | missense variant | - | NC_000007.14:g.55173038G>C | 1000Genomes |
rs1426364365 | p.Val660Met | missense variant | - | NC_000007.14:g.55173041G>A | TOPMed,gnomAD |
rs1424043738 | p.Gly663Arg | missense variant | - | NC_000007.14:g.55173050G>A | gnomAD |
rs1393556056 | p.Ile664Thr | missense variant | - | NC_000007.14:g.55173054T>C | gnomAD |
rs756705853 | p.Ile664Phe | missense variant | - | NC_000007.14:g.55173053A>T | ExAC,gnomAD |
rs745422316 | p.Gly665Ser | missense variant | - | NC_000007.14:g.55173056G>A | ExAC,TOPMed,gnomAD |
NCI-TCGA novel | p.Gly665Asp | missense variant | - | NC_000007.14:g.55173057G>A | NCI-TCGA |
rs771988878 | p.Leu666Phe | missense variant | - | NC_000007.14:g.55173059C>T | ExAC,gnomAD |
rs771988878 | p.Leu666Val | missense variant | - | NC_000007.14:g.55173059C>G | ExAC,gnomAD |
rs746757722 | p.Met668Leu | missense variant | - | NC_000007.14:g.55173065A>C | ExAC,gnomAD |
rs746757722 | p.Met668Val | missense variant | - | NC_000007.14:g.55173065A>G | ExAC,gnomAD |
rs768336804 | p.Arg669Gln | missense variant | - | NC_000007.14:g.55173069G>A | ExAC,gnomAD |
rs1231769201 | p.Arg669Ter | stop gained | - | NC_000007.14:g.55173068C>T | gnomAD |
rs776875545 | p.Arg670Ser | missense variant | - | NC_000007.14:g.55173073G>T | ExAC,TOPMed,gnomAD |
rs1266662784 | p.Arg671His | missense variant | - | NC_000007.14:g.55173075G>A | gnomAD |
rs770193776 | p.Arg671Cys | missense variant | - | NC_000007.14:g.55173074C>T | ExAC,gnomAD |
rs1199980775 | p.Ile673Val | missense variant | - | NC_000007.14:g.55173080A>G | TOPMed |
rs17337079 | p.Val674Phe | missense variant | - | NC_000007.14:g.55173083G>T | ExAC,TOPMed,gnomAD |
rs17337079 | p.Val674Ile | missense variant | - | NC_000007.14:g.55173083G>A | ExAC,TOPMed,gnomAD |
RCV000709010 | p.Arg675Gln | missense variant | Hereditary cancer | NC_000007.14:g.55173087G>A | ClinVar |
NCI-TCGA novel | p.Arg675Trp | missense variant | - | NC_000007.14:g.55173086C>T | NCI-TCGA |
rs150423237 | p.Arg675Gln | missense variant | - | NC_000007.14:g.55173087G>A | ESP,ExAC,TOPMed,gnomAD |
rs756870976 | p.Arg677His | missense variant | - | NC_000007.14:g.55173093G>A | ExAC,TOPMed,gnomAD |
rs1417155613 | p.Arg677Cys | missense variant | - | NC_000007.14:g.55173092C>T | TOPMed,gnomAD |
rs138193597 | p.Thr678Met | missense variant | - | NC_000007.14:g.55173096C>T | ESP,ExAC,TOPMed,gnomAD |
rs1167057229 | p.Thr678Ala | missense variant | - | NC_000007.14:g.55173095A>G | gnomAD |
rs373336251 | p.Arg680Gln | missense variant | - | NC_000007.14:g.55173102G>A | ESP,ExAC,TOPMed,gnomAD |
rs369399038 | p.Arg680Trp | missense variant | - | NC_000007.14:g.55173101C>T | ESP,TOPMed,gnomAD |
NCI-TCGA novel | p.Arg681Met | missense variant | - | NC_000007.14:g.55173105G>T | NCI-TCGA |
rs1338409357 | p.Leu682Val | missense variant | - | NC_000007.14:g.55173107C>G | TOPMed,gnomAD |
rs1338409357 | p.Leu682Met | missense variant | - | NC_000007.14:g.55173107C>A | TOPMed,gnomAD |
NCI-TCGA novel | p.Leu683Met | missense variant | - | NC_000007.14:g.55173110C>A | NCI-TCGA |
rs1427460008 | p.Gln684Arg | missense variant | - | NC_000007.14:g.55173114A>G | TOPMed |
NCI-TCGA novel | p.Gln684His | missense variant | - | NC_000007.14:g.55173115G>T | NCI-TCGA |
rs1305428034 | p.Arg686Lys | missense variant | - | NC_000007.14:g.55173120G>A | gnomAD |
rs1314649810 | p.Glu687Lys | missense variant | - | NC_000007.14:g.55173122G>A | gnomAD |
rs749554270 | p.Leu688Phe | missense variant | - | NC_000007.14:g.55173921C>T | ExAC,gnomAD |
rs397517083 | p.Val689Leu | missense variant | - | NC_000007.14:g.55173924G>C | - |
RCV000038372 | p.Val689Leu | missense variant | - | NC_000007.14:g.55173924G>C | ClinVar |
rs1057519794 | p.Glu690Lys | missense variant | - | NC_000007.14:g.55173927G>A | - |
RCV000438760 | p.Glu690Lys | missense variant | Endometrial Endometrioid Adenocarcinoma, Variant with Squamous Differentiation | NC_000007.14:g.55173927G>A | ClinVar |
rs1168763004 | p.Pro691Thr | missense variant | - | NC_000007.14:g.55173930C>A | gnomAD |
COSM13179 | p.Pro694Ser | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000007.14:g.55173939C>T | NCI-TCGA Cosmic |
rs936074781 | p.Glu697Gln | missense variant | - | NC_000007.14:g.55173948G>C | TOPMed |
COSM249886 | p.Pro699Leu | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000007.14:g.55173955C>T | NCI-TCGA Cosmic |
rs1331500903 | p.Asn700Lys | missense variant | - | NC_000007.14:g.55173959C>A | gnomAD |
rs774261340 | p.Gln701Lys | missense variant | - | NC_000007.14:g.55173960C>A | ExAC,gnomAD |
rs1273890779 | p.Leu703Phe | missense variant | - | NC_000007.14:g.55173966C>T | gnomAD |
rs1220800698 | p.Ile706Met | missense variant | - | NC_000007.14:g.55173977C>G | gnomAD |
RCV000038373 | p.Ile706Thr | missense variant | - | NC_000007.14:g.55173976T>C | ClinVar |
NCI-TCGA novel | p.Ile706Leu | missense variant | - | NC_000007.14:g.55173975A>C | NCI-TCGA |
rs397517084 | p.Ile706Thr | missense variant | - | NC_000007.14:g.55173976T>C | - |
RCV000154230 | p.Glu709Lys | missense variant | - | NC_000007.14:g.55173984G>A | ClinVar |
rs397517085 | p.Glu709Ala | missense variant | - | NC_000007.14:g.55173985A>C | UniProt,dbSNP |
VAR_026084 | p.Glu709Ala | missense variant | - | NC_000007.14:g.55173985A>C | UniProt |
rs727504256 | p.Glu709Lys | missense variant | - | NC_000007.14:g.55173984G>A | ExAC,gnomAD |
rs397517085 | p.Glu709Val | missense variant | - | NC_000007.14:g.55173985A>T | - |
rs397517085 | p.Glu709Gly | missense variant | - | NC_000007.14:g.55173985A>G | - |
rs397517085 | p.Glu709Gly | missense variant | - | NC_000007.14:g.55173985A>G | UniProt,dbSNP |
VAR_069498 | p.Glu709Gly | missense variant | - | NC_000007.14:g.55173985A>G | UniProt |
RCV000206908 | p.Glu709Ala | missense variant | Lung cancer | NC_000007.14:g.55173985A>C | ClinVar |
RCV000038374 | p.Glu709Ala | missense variant | - | NC_000007.14:g.55173985A>C | ClinVar |
RCV000150615 | p.Glu709Gly | missense variant | - | NC_000007.14:g.55173985A>G | ClinVar |
RCV000154197 | p.Glu709Val | missense variant | - | NC_000007.14:g.55173985A>T | ClinVar |
rs397517086 | p.Glu709Asp | inframe deletion | - | NC_000007.14:g.55173986_55173988AAC>- | NCI-TCGA,NCI-TCGA Cosmic |
rs1317269653 | p.Thr710Ala | missense variant | - | NC_000007.14:g.55173987A>G | gnomAD |
COSM53287 | p.Glu711Lys | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000007.14:g.55173990G>A | NCI-TCGA Cosmic |
NCI-TCGA novel | p.Phe712Leu | missense variant | - | NC_000007.14:g.55173995C>G | NCI-TCGA |
RCV000268060 | p.Lys713Thr | missense variant | Lung cancer | NC_000007.14:g.55173997A>C | ClinVar |
rs373578289 | p.Lys713Arg | missense variant | - | NC_000007.14:g.55173997A>G | ESP,ExAC,TOPMed,gnomAD |
rs373578289 | p.Lys713Thr | missense variant | - | NC_000007.14:g.55173997A>C | ESP,ExAC,TOPMed,gnomAD |
rs1300698331 | p.Lys716Glu | missense variant | - | NC_000007.14:g.55174005A>G | TOPMed |
COSM116797 | p.Lys716Arg | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000007.14:g.55174006A>G | NCI-TCGA Cosmic |
RCV000418583 | p.Gly719Asp | missense variant | Non-small cell lung cancer (NSCLC) | NC_000007.14:g.55174015G>A | ClinVar |
RCV000114405 | p.Gly719Arg | missense variant | Squamous cell carcinoma of the head and neck (HNSCC) | NC_000007.14:g.55174014G>C | ClinVar |
RCV000038381 | p.Gly719Ala | missense variant | Non-small cell lung cancer (NSCLC) | NC_000007.14:g.55174015G>C | ClinVar |
RCV000420993 | p.Gly719Asp | missense variant | Squamous cell lung carcinoma | NC_000007.14:g.55174015G>A | ClinVar |
rs121913428 | p.Gly719Ala | missense variant | - | NC_000007.14:g.55174015G>C | UniProt,dbSNP |
VAR_026086 | p.Gly719Ala | missense variant | - | NC_000007.14:g.55174015G>C | UniProt |
rs28929495 | p.Gly719Arg | missense variant | - | NC_000007.14:g.55174014G>C | - |
rs28929495 | p.Gly719Cys | missense variant | - | NC_000007.14:g.55174014G>T | UniProt,dbSNP |
VAR_026087 | p.Gly719Cys | missense variant | - | NC_000007.14:g.55174014G>T | UniProt |
rs28929495 | p.Gly719Cys | missense variant | - | NC_000007.14:g.55174014G>T | - |
rs121913428 | p.Gly719Asp | missense variant | - | NC_000007.14:g.55174015G>A | UniProt,dbSNP |
VAR_026088 | p.Gly719Asp | missense variant | - | NC_000007.14:g.55174015G>A | UniProt |
RCV000439067 | p.Gly719Asp | missense variant | Lung adenocarcinoma | NC_000007.14:g.55174015G>A | ClinVar |
RCV000423860 | p.Gly719Ser | missense variant | Non-small cell lung cancer (NSCLC) | NC_000007.14:g.55174014G>A | ClinVar |
RCV000428419 | p.Gly719Asp | missense variant | Glioblastoma | NC_000007.14:g.55174015G>A | ClinVar |
RCV000433465 | p.Gly719Cys | missense variant | Lung adenocarcinoma | NC_000007.14:g.55174014G>T | ClinVar |
RCV000426731 | p.Gly719Cys | missense variant | Glioblastoma | NC_000007.14:g.55174014G>T | ClinVar |
rs28929495 | p.Gly719Ser | missense variant | - | NC_000007.14:g.55174014G>A | - |
rs28929495 | p.Gly719Ser | missense variant | - | NC_000007.14:g.55174014G>A | UniProt,dbSNP |
VAR_019297 | p.Gly719Ser | missense variant | - | NC_000007.14:g.55174014G>A | UniProt |
rs772799315 | p.Ser720Cys | missense variant | - | NC_000007.14:g.55174018C>G | ExAC,gnomAD |
NCI-TCGA novel | p.Gly721Val | missense variant | - | NC_000007.14:g.55174021G>T | NCI-TCGA |
rs762494280 | p.Ala722Val | missense variant | - | NC_000007.14:g.55174024C>T | ExAC,gnomAD |
RCV000421183 | p.Gly724Ser | missense variant | Neoplasm of the large intestine | NC_000007.14:g.55174029G>A | ClinVar |
rs1051753269 | p.Gly724Ser | missense variant | - | NC_000007.14:g.55174029G>A | TOPMed,gnomAD |
rs767505234 | p.Thr725Met | missense variant | - | NC_000007.14:g.55174033C>T | ExAC,gnomAD |
RCV000114409 | p.Val726Met | missense variant | Squamous cell carcinoma of the head and neck (HNSCC) | NC_000007.14:g.55174035G>A | ClinVar |
rs483352805 | p.Val726Met | missense variant | - | NC_000007.14:g.55174035G>A | - |
rs138240620 | p.Tyr727Cys | missense variant | - | NC_000007.14:g.55174039A>G | 1000Genomes,ESP,ExAC,TOPMed,gnomAD |
RCV000114407 | p.Leu730Val | missense variant | Squamous cell carcinoma of the head and neck (HNSCC) | NC_000007.14:g.55174725C>G | ClinVar |
rs121913434 | p.Leu730Val | missense variant | - | NC_000007.14:g.55174725C>G | - |
rs771995749 | p.Leu730Arg | missense variant | - | NC_000007.14:g.55174726T>G | ExAC,gnomAD |
rs771995749 | p.Leu730Pro | missense variant | - | NC_000007.14:g.55174726T>C | ExAC,gnomAD |
RCV000038384 | p.Trp731Ter | nonsense | - | NC_000007.14:g.55174729G>A | ClinVar |
rs121913467 | p.Trp731Ter | stop gained | - | NC_000007.14:g.55174730G>A | - |
rs397517089 | p.Trp731Leu | missense variant | - | NC_000007.14:g.55174729G>T | gnomAD |
RCV000444748 | p.Trp731Ter | nonsense | Non-small cell lung cancer (NSCLC) | NC_000007.14:g.55174730G>A | ClinVar |
rs397517089 | p.Trp731Ter | stop gained | - | NC_000007.14:g.55174729G>A | gnomAD |
RCV000441469 | p.Pro733Leu | missense variant | Esophageal Squamous Cell Carcinoma | NC_000007.14:g.55174735C>T | ClinVar |
RCV000428149 | p.Pro733Leu | missense variant | Non-small cell lung cancer (NSCLC) | NC_000007.14:g.55174735C>T | ClinVar |
rs121913446 | p.Pro733Leu | missense variant | - | NC_000007.14:g.55174735C>T | - |
RCV000424211 | p.Glu734Lys | missense variant | Non-small cell lung cancer (NSCLC) | NC_000007.14:g.55174737G>A | ClinVar |
rs121913420 | p.Glu734Lys | missense variant | - | NC_000007.14:g.55174737G>A | UniProt,dbSNP |
VAR_026090 | p.Glu734Lys | missense variant | - | NC_000007.14:g.55174737G>A | UniProt |
rs121913420 | p.Glu734Lys | missense variant | - | NC_000007.14:g.55174737G>A | - |
RCV000442962 | p.Gly735Ser | missense variant | Prostate neoplasm | NC_000007.14:g.55174740G>A | ClinVar |
rs121913430 | p.Gly735Ser | missense variant | - | NC_000007.14:g.55174740G>A | - |
RCV000434054 | p.Gly735Ser | missense variant | Non-small cell lung cancer (NSCLC) | NC_000007.14:g.55174740G>A | ClinVar |
COSM3639748 | p.Lys737Glu | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000007.14:g.55174746A>G | NCI-TCGA Cosmic |
rs1488735128 | p.Val738Ala | missense variant | - | NC_000007.14:g.55174750T>C | gnomAD |
rs780083331 | p.Lys739Asn | missense variant | - | NC_000007.14:g.55174754A>T | ExAC,gnomAD |
rs397517092 | p.Ile740Thr | missense variant | - | NC_000007.14:g.55174756T>C | - |
rs747133806 | p.Ile740Val | missense variant | - | NC_000007.14:g.55174755A>G | ExAC,gnomAD |
RCV000038387 | p.Ile740Thr | missense variant | - | NC_000007.14:g.55174756T>C | ClinVar |
COSM17570 | p.Pro741Leu | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000007.14:g.55174759C>T | NCI-TCGA Cosmic |
RCV000423407 | p.Val742Ala | missense variant | Non-small cell lung cancer (NSCLC) | NC_000007.14:g.55174762T>C | ClinVar |
rs587778250 | p.Val742Ile | missense variant | - | NC_000007.14:g.55174761G>A | ExAC,gnomAD |
RCV000120695 | p.Val742Ile | missense variant | - | NC_000007.14:g.55174761G>A | ClinVar |
rs121913466 | p.Val742Ala | missense variant | - | NC_000007.14:g.55174762T>C | - |
rs759256622 | p.Ala743Thr | missense variant | - | NC_000007.14:g.55174764G>A | ExAC,TOPMed,gnomAD |
rs1554348865 | p.Ile744Val | missense variant | - | NC_000007.14:g.55174767A>G | - |
RCV000433245 | p.Lys745Arg | missense variant | Squamous cell carcinoma of the head and neck (HNSCC) | NC_000007.14:g.55174771A>G | ClinVar |
RCV000154414 | p.Lys745Ter | frameshift | - | NC_000007.14:g.55174769_55174787del | ClinVar |
rs121913433 | p.Lys745Arg | missense variant | - | NC_000007.14:g.55174771A>G | - |
rs121913427 | p.Glu746Gln | missense variant | - | NC_000007.14:g.55174773G>C | - |
RCV000424472 | p.Glu746Lys | missense variant | Non-small cell lung cancer (NSCLC) | NC_000007.14:g.55174773G>A | ClinVar |
RCV000154381 | p.Glu746Gln | missense variant | Non-small cell lung cancer (NSCLC) | NC_000007.14:g.55174773G>C | ClinVar |
RCV000154418 | p.Glu746Ter | frameshift | - | NC_000007.14:g.55174768_55174769insAAAATTCCCGTCGCTA | ClinVar |
VAR_069499 | p.Glu746_Ser752delinsAsp | deletion_insertion | - | - | UniProt |
VAR_026092 | p.Glu746_Ala750del | inframe_deletion | - | - | UniProt |
VAR_026091 | p.Glu746del | inframe_deletion | - | - | UniProt |
VAR_069500 | p.Glu746_Thr751delinsAla | deletion_insertion | - | - | UniProt |
rs397517096 | p.Leu747Pro | missense variant | - | NC_000007.14:g.55174776_55174777delinsCC | - |
RCV000443228 | p.Leu747Ser | missense variant | Squamous cell lung carcinoma | NC_000007.14:g.55174777T>C | ClinVar |
RCV000434243 | p.Leu747Ser | missense variant | Lung cancer | NC_000007.14:g.55174777T>C | ClinVar |
RCV000038391 | p.Leu747Pro | missense variant | - | NC_000007.14:g.55174776_55174777delinsCC | ClinVar |
VAR_026093 | p.Leu747Phe | Missense | - | - | UniProt |
VAR_026094 | p.Leu747_Glu749del | inframe_deletion | - | - | UniProt |
VAR_069501 | p.Leu747_Thr751del | inframe_deletion | - | - | UniProt |
rs1338629905 | p.Arg748Ser | missense variant | - | NC_000007.14:g.55174781A>T | TOPMed |
rs1379373864 | p.Arg748Lys | missense variant | - | NC_000007.14:g.55174780G>A | gnomAD |
VAR_026095 | p.Arg748Pro | Missense | - | - | UniProt |
RCV000444877 | p.Glu749Gln | missense variant | Lung cancer | NC_000007.14:g.55174782G>C | ClinVar |
rs1057520037 | p.Glu749Gln | missense variant | - | NC_000007.14:g.55174782G>C | - |
rs1468115455 | p.Ala750Gly | missense variant | - | NC_000007.14:g.55174786C>G | TOPMed |
RCV000038395 | p.Ala750Pro | missense variant | - | NC_000007.14:g.55174785G>C | ClinVar |
RCV000154293 | p.Thr751Ter | frameshift | - | NC_000007.14:g.55174788_55174812del | ClinVar |
rs727504316 | p.Thr751Ile | missense variant | - | NC_000007.14:g.55174789C>T | ExAC,gnomAD |
NCI-TCGA novel | p.Thr751Pro | missense variant | - | NC_000007.14:g.55174788A>C | NCI-TCGA |
NCI-TCGA novel | p.Thr751AsnPheSerTerUnkUnk | frameshift | - | NC_000007.14:g.55174789C>- | NCI-TCGA |
RCV000154392 | p.Thr751Ile | missense variant | - | NC_000007.14:g.55174789C>T | ClinVar |
RCV000432149 | p.Ser752Tyr | missense variant | Non-small cell lung cancer (NSCLC) | NC_000007.14:g.55174792C>A | ClinVar |
NCI-TCGA novel | p.Ser752ProPheSerTerUnk | frameshift | - | NC_000007.14:g.55174791_55174813TCTCCGAAAGCCAACAAGGAAAT>- | NCI-TCGA |
COSM4170219 | p.Ser752Phe | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000007.14:g.55174792C>T | NCI-TCGA Cosmic |
rs1373423544 | p.Ser752Thr | missense variant | - | NC_000007.14:g.55174791T>A | gnomAD |
rs121913464 | p.Ser752Tyr | missense variant | - | NC_000007.14:g.55174792C>A | - |
VAR_026096 | p.Ser752_Ile759del | inframe_deletion | - | - | UniProt |
RCV000436542 | p.Pro753Ser | missense variant | Non-small cell lung cancer (NSCLC) | NC_000007.14:g.55174794C>T | ClinVar |
RCV000441908 | p.Pro753Ser | missense variant | Head and Neck Neoplasms | NC_000007.14:g.55174794C>T | ClinVar |
rs559717059 | p.Pro753Leu | missense variant | - | NC_000007.14:g.55174795C>T | ExAC,TOPMed,gnomAD |
rs121913231 | p.Pro753Ser | missense variant | - | NC_000007.14:g.55174794C>T | ExAC,gnomAD |
NCI-TCGA novel | p.Pro753Gln | missense variant | - | NC_000007.14:g.55174795C>A | NCI-TCGA |
RCV000038397 | p.Lys754Glu | missense variant | - | NC_000007.14:g.55174797A>G | ClinVar |
COSM1140059 | p.Lys754Ile | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000007.14:g.55174798A>T | NCI-TCGA Cosmic |
rs397517101 | p.Lys754Glu | missense variant | - | NC_000007.14:g.55174797A>G | - |
rs397517102 | p.Lys757Arg | missense variant | - | NC_000007.14:g.55174807A>G | ExAC,TOPMed,gnomAD |
RCV000677877 | p.Lys757Arg | missense variant | Lung adenocarcinoma | NC_000007.14:g.55174807A>G | ClinVar |
RCV000038398 | p.Lys757Met | missense variant | - | NC_000007.14:g.55174807A>T | ClinVar |
rs397517102 | p.Lys757Met | missense variant | - | NC_000007.14:g.55174807A>T | ExAC,TOPMed,gnomAD |
rs761470472 | p.Glu758Gly | missense variant | - | NC_000007.14:g.55174810A>G | ExAC,gnomAD |
RCV000150621 | p.Leu760Ter | frameshift | - | NC_000007.14:g.55174814_55174815insT | ClinVar |
rs121913418 | p.Asp761Tyr | missense variant | - | NC_000007.14:g.55174818G>T | gnomAD |
RCV000038400 | p.Asp761Tyr | missense variant | - | NC_000007.14:g.55174818G>T | ClinVar |
RCV000425618 | p.Asp761Asn | missense variant | Non-small cell lung cancer (NSCLC) | NC_000007.14:g.55174818G>A | ClinVar |
rs121913418 | p.Asp761Asn | missense variant | - | NC_000007.14:g.55174818G>A | gnomAD |
rs1476693500 | p.Ala763Val | missense variant | - | NC_000007.14:g.55181297C>T | gnomAD |
rs374873413 | p.Val765Leu | missense variant | - | NC_000007.14:g.55181302G>C | ESP,ExAC,TOPMed,gnomAD |
RCV000150622 | p.Val765HisHis | insertion | - | NC_000007.14:g.55181301_55181302insCATCAC | ClinVar |
rs374873413 | p.Val765Met | missense variant | - | NC_000007.14:g.55181302G>A | ESP,ExAC,TOPMed,gnomAD |
rs1323967615 | p.Met766Leu | missense variant | - | NC_000007.14:g.55181305A>T | gnomAD |
rs1322818258 | p.Met766Ile | missense variant | - | NC_000007.14:g.55181307G>A | gnomAD |
rs397517107 | p.Ala767Val | missense variant | - | NC_000007.14:g.55181309C>T | - |
RCV000038406 | p.Ala767Val | missense variant | - | NC_000007.14:g.55181309C>T | ClinVar |
RCV000038407 | p.Ser768Ile | missense variant | Non-small cell lung cancer (NSCLC) | NC_000007.14:g.55181312G>T | ClinVar |
rs756614898 | p.Ser768Gly | missense variant | - | NC_000007.14:g.55181311A>G | ExAC,TOPMed,gnomAD |
rs397517108 | p.Ser768Ile | missense variant | - | NC_000007.14:g.55181312_55181313delinsTT | - |
rs778199483 | p.Ser768Arg | missense variant | - | NC_000007.14:g.55181313C>G | ExAC,TOPMed,gnomAD |
rs121913465 | p.Ser768Ile | missense variant | - | NC_000007.14:g.55181312G>T | UniProt,dbSNP |
VAR_069502 | p.Ser768Ile | missense variant | - | NC_000007.14:g.55181312G>T | UniProt |
RCV000038408 | p.Ser768Ile | missense variant | Non-small cell lung cancer (NSCLC) | NC_000007.14:g.55181312_55181313delinsTT | ClinVar |
RCV000206947 | p.Val769Met | missense variant | Lung cancer | NC_000007.14:g.55181314G>A | ClinVar |
RCV000038410 | p.Val769Leu | missense variant | - | NC_000007.14:g.55181314G>C | ClinVar |
rs147149347 | p.Val769Met | missense variant | - | NC_000007.14:g.55181314G>A | UniProt,dbSNP |
VAR_069503 | p.Val769Met | missense variant | - | NC_000007.14:g.55181314G>A | UniProt |
rs147149347 | p.Val769Met | missense variant | - | NC_000007.14:g.55181314G>A | ESP,ExAC,TOPMed,gnomAD |
rs147149347 | p.Val769Leu | missense variant | - | NC_000007.14:g.55181314G>C | ESP,ExAC,TOPMed,gnomAD |
RCV000038411 | p.Val769Leu | missense variant | - | NC_000007.14:g.55181314G>T | ClinVar |
rs147149347 | p.Val769Leu | missense variant | - | NC_000007.14:g.55181314G>T | ESP,ExAC,TOPMed,gnomAD |
RCV000150623 | p.Asp770Ter | frameshift | - | NC_000007.14:g.55181317_55181319delinsTGGG | ClinVar |
COSM48921 | p.Asp770GlyLeu | insertion | Variant assessed as Somatic; MODERATE impact. | NC_000007.14:g.55181319_55181320insGGGTTA | NCI-TCGA Cosmic |
rs727503020 | p.Asn771Asp | missense variant | - | NC_000007.14:g.55181320A>G | - |
RCV000038413 | p.Asn771GlyLeu | insertion | Non-small cell lung cancer (NSCLC) | NC_000007.14:g.55181319_55181320insGGGTTG | ClinVar |
RCV000150625 | p.Asn771Asp | missense variant | - | NC_000007.14:g.55181320A>G | ClinVar |
RCV000150626 | p.Pro772Val | insertion | - | NC_000007.14:g.55181321_55181322insTGT | ClinVar |
rs746677478 | p.Pro772Ala | missense variant | - | NC_000007.14:g.55181323C>G | ExAC,gnomAD |
RCV000038414 | p.Pro772His | insertion | Non-small cell lung cancer (NSCLC) | NC_000007.14:g.55181321_55181323dup | ClinVar |
RCV000420488 | p.His773Arg | missense variant | Non-small cell lung cancer (NSCLC) | NC_000007.14:g.55181327A>G | ClinVar |
RCV000154617 | p.His773ProAsnPro | insertion | - | NC_000007.14:g.55181326_55181327insCGAACCCCC | ClinVar |
rs768468531 | p.His773Gln | missense variant | - | NC_000007.14:g.55181328C>G | ExAC,TOPMed,gnomAD |
rs121913432 | p.His773Arg | missense variant | - | NC_000007.14:g.55181327A>G | - |
RCV000038416 | p.Val774AlaHis | insertion | Non-small cell lung cancer (NSCLC) | NC_000007.14:g.55181324_55181329dup | ClinVar |
rs567477136 | p.Val774Leu | missense variant | - | NC_000007.14:g.55181329G>C | 1000Genomes,TOPMed,gnomAD |
RCV000038419 | p.Val774GlyHis | insertion | Non-small cell lung cancer (NSCLC) | NC_000007.14:g.55181329_55181330insGCCACG | ClinVar |
rs567477136 | p.Val774Met | missense variant | - | NC_000007.14:g.55181329G>A | 1000Genomes,TOPMed,gnomAD |
rs483352806 | p.Arg776His | missense variant | - | NC_000007.14:g.55181336G>A | gnomAD |
RCV000150627 | p.Arg776His | missense variant | Non-small cell lung cancer (NSCLC) | NC_000007.14:g.55181336G>A | ClinVar |
rs1275022697 | p.Arg776Cys | missense variant | - | NC_000007.14:g.55181335C>T | TOPMed |
RCV000038423 | p.Gly779Val | missense variant | - | NC_000007.14:g.55181345G>T | ClinVar |
rs397517120 | p.Gly779Val | missense variant | - | NC_000007.14:g.55181345G>T | - |
RCV000038422 | p.Gly779Cys | missense variant | - | NC_000007.14:g.55181344G>T | ClinVar |
rs397517119 | p.Gly779Cys | missense variant | - | NC_000007.14:g.55181344G>T | - |
NCI-TCGA novel | p.Leu782Phe | missense variant | - | NC_000007.14:g.55181353C>T | NCI-TCGA |
rs1424329195 | p.Ser784Cys | missense variant | - | NC_000007.14:g.55181360C>G | gnomAD |
rs1424329195 | p.Ser784Phe | missense variant | - | NC_000007.14:g.55181360C>T | gnomAD |
rs762672864 | p.Val786Met | missense variant | - | NC_000007.14:g.55181365G>A | ExAC,TOPMed,gnomAD |
rs762672864 | p.Val786Leu | missense variant | - | NC_000007.14:g.55181365G>C | ExAC,TOPMed,gnomAD |
rs1050171 | p.Gln787His | missense variant | - | NC_000007.14:g.55181370G>C | 1000Genomes,ESP,ExAC,TOPMed,gnomAD |
rs1458440474 | p.Gln787Pro | missense variant | - | NC_000007.14:g.55181369A>C | gnomAD |
VAR_026097 | p.Gln787Arg | Missense | - | - | UniProt |
rs767674013 | p.Ile789Leu | missense variant | - | NC_000007.14:g.55181374A>C | ExAC,gnomAD |
COSM4826400 | p.Ile789Met | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000007.14:g.55181376C>G | NCI-TCGA Cosmic |
RCV000154233 | p.Thr790Met | missense variant | Non-small cell lung cancer (NSCLC) | NC_000007.14:g.55181378C>T | ClinVar |
rs121434569 | p.Thr790Met | missense variant | - | NC_000007.14:g.55181378C>T | ExAC,TOPMed,gnomAD |
rs121434569 | p.Thr790Met | missense variant | - | NC_000007.14:g.55181378C>T | UniProt,dbSNP |
VAR_026098 | p.Thr790Met | missense variant | - | NC_000007.14:g.55181378C>T | UniProt |
rs1413493019 | p.Gln791His | missense variant | - | NC_000007.14:g.55181382G>T | gnomAD |
rs370289230 | p.Pro794Thr | missense variant | - | NC_000007.14:g.55181389C>A | ESP,TOPMed |
rs754426793 | p.Gly796Ser | missense variant | - | NC_000007.14:g.55181395G>A | ExAC,TOPMed,gnomAD |
RCV000440892 | p.Cys797Ser | missense variant | Non-small cell lung cancer (NSCLC) | NC_000007.14:g.55181398T>A | ClinVar |
rs1057519861 | p.Cys797Ser | missense variant | - | NC_000007.14:g.55181398T>A | - |
rs483352807 | p.Leu798His | missense variant | - | NC_000007.14:g.55181402T>A | - |
RCV000114408 | p.Leu798His | missense variant | Squamous cell carcinoma of the head and neck (HNSCC) | NC_000007.14:g.55181402T>A | ClinVar |
NCI-TCGA novel | p.Asp800Gly | missense variant | - | NC_000007.14:g.55181408A>G | NCI-TCGA |
rs779394350 | p.Tyr801Cys | missense variant | - | NC_000007.14:g.55181411A>G | ExAC,gnomAD |
NCI-TCGA novel | p.Tyr801LeuPheSerTerUnkUnk | frameshift | - | NC_000007.14:g.55181409_55181410insCT | NCI-TCGA |
rs757642107 | p.Tyr801His | missense variant | - | NC_000007.14:g.55181410T>C | ExAC,gnomAD |
rs1351046105 | p.Val802Phe | missense variant | - | NC_000007.14:g.55181413G>T | TOPMed,gnomAD |
rs1351046105 | p.Val802Ile | missense variant | - | NC_000007.14:g.55181413G>A | TOPMed,gnomAD |
rs1215679186 | p.Arg803Trp | missense variant | - | NC_000007.14:g.55181416C>T | TOPMed,gnomAD |
rs1263602634 | p.Arg803Gln | missense variant | - | NC_000007.14:g.55181417G>A | TOPMed,gnomAD |
RCV000709012 | p.Arg803Trp | missense variant | Hereditary cancer | NC_000007.14:g.55181416C>T | ClinVar |
rs552733360 | p.Glu804Lys | missense variant | - | NC_000007.14:g.55181419G>A | 1000Genomes,gnomAD |
COSM485464 | p.His805Arg | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000007.14:g.55181423A>G | NCI-TCGA Cosmic |
rs754652044 | p.Lys806Glu | missense variant | - | NC_000007.14:g.55181425A>G | ExAC,gnomAD |
RCV000444211 | p.Gly810Ser | missense variant | Squamous cell carcinoma | NC_000007.14:g.55181437G>A | ClinVar |
RCV000425650 | p.Gly810Asp | missense variant | Squamous cell carcinoma | NC_000007.14:g.55181438G>A | ClinVar |
rs121913230 | p.Gly810Ser | missense variant | - | NC_000007.14:g.55181437G>A | - |
rs121913431 | p.Gly810Asp | missense variant | - | NC_000007.14:g.55181438G>A | - |
rs1378775962 | p.Ser811Cys | missense variant | - | NC_000007.14:g.55181441C>G | gnomAD |
rs1278942267 | p.Leu815Phe | missense variant | - | NC_000007.14:g.55181452C>T | TOPMed |
rs1418675303 | p.Asn816Asp | missense variant | - | NC_000007.14:g.55181455A>G | gnomAD |
rs367859869 | p.Ile821Met | missense variant | - | NC_000007.14:g.55181472C>G | ESP,ExAC,TOPMed,gnomAD |
RCV000038431 | p.Ala822Thr | missense variant | - | NC_000007.14:g.55181473G>A | ClinVar |
rs397517125 | p.Ala822Thr | missense variant | - | NC_000007.14:g.55181473G>A | ExAC,TOPMed,gnomAD |
rs483352808 | p.Gly824Asp | missense variant | - | NC_000007.14:g.55191720G>A | ExAC,gnomAD |
RCV000114406 | p.Gly824Asp | missense variant | Squamous cell carcinoma of the head and neck (HNSCC) | NC_000007.14:g.55191720G>A | ClinVar |
rs1474170437 | p.Met825Ile | missense variant | - | NC_000007.14:g.55191724G>T | TOPMed |
rs150749913 | p.Tyr827Phe | missense variant | - | NC_000007.14:g.55191729A>T | ESP |
COSM1090890 | p.Tyr827Ter | stop gained | Variant assessed as Somatic; HIGH impact. | NC_000007.14:g.55191730C>A | NCI-TCGA Cosmic |
rs1256743514 | p.Tyr827His | missense variant | - | NC_000007.14:g.55191728T>C | TOPMed |
rs1489158055 | p.Glu829Gln | missense variant | - | NC_000007.14:g.55191734G>C | TOPMed |
RCV000709013 | p.Glu829Gln | missense variant | Hereditary cancer | NC_000007.14:g.55191734G>C | ClinVar |
RCV000677878 | p.Arg831His | missense variant | Lung adenocarcinoma | NC_000007.14:g.55191741G>A | ClinVar |
rs371228501 | p.Arg831Cys | missense variant | - | NC_000007.14:g.55191740C>T | 1000Genomes,ESP,ExAC,TOPMed,gnomAD |
rs150036236 | p.Arg831His | missense variant | - | NC_000007.14:g.55191741G>A | ESP,ExAC,TOPMed,gnomAD |
RCV000677875 | p.Arg831His | missense variant | Squamous cell lung carcinoma | NC_000007.14:g.55191741G>A | ClinVar |
RCV000038432 | p.Arg831Cys | missense variant | - | NC_000007.14:g.55191740C>T | ClinVar |
rs772091823 | p.Arg832His | missense variant | - | NC_000007.14:g.55191744G>A | ExAC,gnomAD |
rs772091823 | p.Arg832Leu | missense variant | - | NC_000007.14:g.55191744G>T | ExAC,gnomAD |
rs745812480 | p.Arg832Cys | missense variant | - | NC_000007.14:g.55191743C>T | ExAC,gnomAD |
RCV000038433 | p.Leu833Val | missense variant | - | NC_000007.14:g.55191746T>G | ClinVar |
COSM219794 | p.Leu833Phe | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000007.14:g.55191748G>T | NCI-TCGA Cosmic |
rs397517126 | p.Leu833Val | missense variant | - | NC_000007.14:g.55191746T>G | UniProt,dbSNP |
VAR_026099 | p.Leu833Val | missense variant | - | NC_000007.14:g.55191746T>G | UniProt |
rs397517126 | p.Leu833Val | missense variant | - | NC_000007.14:g.55191746T>G | - |
RCV000038435 | p.Val834Leu | missense variant | Non-small cell lung cancer (NSCLC) | NC_000007.14:g.55191749G>T | ClinVar |
RCV000038434 | p.Val834Leu | missense variant | - | NC_000007.14:g.55191749G>C | ClinVar |
rs397517127 | p.Val834Leu | missense variant | - | NC_000007.14:g.55191749G>T | UniProt,dbSNP |
VAR_026100 | p.Val834Leu | missense variant | - | NC_000007.14:g.55191749G>T | UniProt |
rs397517127 | p.Val834Leu | missense variant | - | NC_000007.14:g.55191749G>T | - |
RCV000206918 | p.His835Leu | missense variant | Lung cancer | NC_000007.14:g.55191753A>T | ClinVar |
NCI-TCGA novel | p.His835SerPheSerTerUnkUnk | frameshift | - | NC_000007.14:g.55191751_55191752insAGCCTAACTCTCCCTTT | NCI-TCGA |
RCV000038436 | p.His835Leu | missense variant | - | NC_000007.14:g.55191753A>T | ClinVar |
RCV000150628 | p.His835Ter | frameshift | - | NC_000007.14:g.55191753_55191840del | ClinVar |
rs397517128 | p.His835Leu | missense variant | - | NC_000007.14:g.55191753A>T | UniProt,dbSNP |
VAR_069504 | p.His835Leu | missense variant | - | NC_000007.14:g.55191753A>T | UniProt |
rs397517128 | p.His835Leu | missense variant | - | NC_000007.14:g.55191753A>T | - |
rs374952732 | p.Arg836Cys | missense variant | - | NC_000007.14:g.55191755C>T | ESP,ExAC,TOPMed,gnomAD |
rs146121458 | p.Arg836His | missense variant | - | NC_000007.14:g.55191756G>A | ESP,ExAC,TOPMed,gnomAD |
rs1402174871 | p.Asp837Val | missense variant | - | NC_000007.14:g.55191759A>T | TOPMed |
rs761920220 | p.Asp837Asn | missense variant | - | NC_000007.14:g.55191758G>A | ExAC,TOPMed,gnomAD |
RCV000206923 | p.Leu838Val | missense variant | Lung cancer | NC_000007.14:g.55191761C>G | ClinVar |
rs864621996 | p.Leu838Val | missense variant | - | NC_000007.14:g.55191761C>G | - |
rs143884981 | p.Ala840Thr | missense variant | - | NC_000007.14:g.55191767G>A | ESP,ExAC,TOPMed,gnomAD |
rs773720036 | p.Arg841Ser | missense variant | - | NC_000007.14:g.55191772G>C | ExAC,gnomAD |
rs146795390 | p.Val843Ile | missense variant | - | NC_000007.14:g.55191776G>A | ESP,gnomAD |
COSM747424 | p.Val843Leu | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000007.14:g.55191776G>T | NCI-TCGA Cosmic |
RCV000426205 | p.Val843Ile | missense variant | Head and Neck Neoplasms | NC_000007.14:g.55191776G>A | ClinVar |
NCI-TCGA novel | p.Thr847Lys | missense variant | - | NC_000007.14:g.55191789C>A | NCI-TCGA |
rs148934350 | p.Pro848Leu | missense variant | - | NC_000007.14:g.55191792C>T | ESP,ExAC,TOPMed,gnomAD |
rs148934350 | p.Pro848Gln | missense variant | - | NC_000007.14:g.55191792C>A | ESP,ExAC,TOPMed,gnomAD |
RCV000038438 | p.Pro848Leu | missense variant | - | NC_000007.14:g.55191792C>T | ClinVar |
rs1433831615 | p.Gln849His | missense variant | - | NC_000007.14:g.55191796G>T | gnomAD |
rs1292517709 | p.Lys852Arg | missense variant | - | NC_000007.14:g.55191804A>G | TOPMed,gnomAD |
NCI-TCGA novel | p.Lys852Thr | missense variant | - | NC_000007.14:g.55191804A>C | NCI-TCGA |
RCV000709015 | p.Lys852Arg | missense variant | Hereditary cancer | NC_000007.14:g.55191804A>G | ClinVar |
RCV000150629 | p.Leu858Arg | missense variant | - | NC_000007.14:g.55191822T>G | ClinVar |
RCV000431153 | p.Leu858Met | missense variant | Non-small cell lung cancer (NSCLC) | NC_000007.14:g.55191821C>A | ClinVar |
RCV000211410 | p.Leu858Arg | missense variant | - | NC_000007.14:g.55191822T>G | ClinVar |
RCV000018083 | p.Leu858Arg | missense variant | Nonsmall cell lung cancer, response to tyrosine kinase inhibitor in, somatic | NC_000007.14:g.55191822T>G | ClinVar |
rs1057519847 | p.Leu858Arg | missense variant | - | NC_000007.14:g.55191821_55191822inv | - |
rs1057519848 | p.Leu858Arg | missense variant | - | NC_000007.14:g.55191822_55191823delinsGT | - |
rs121434568 | p.Leu858Arg | missense variant | - | NC_000007.14:g.55191822T>G | UniProt,dbSNP |
VAR_019298 | p.Leu858Arg | missense variant | - | NC_000007.14:g.55191822T>G | UniProt |
RCV000419082 | p.Leu858Gln | missense variant | Non-small cell lung cancer (NSCLC) | NC_000007.14:g.55191822T>A | ClinVar |
RCV000018084 | p.Leu858Arg | missense variant | Adenocarcinoma of lung, response to tyrosine kinase inhibitor in, somatic | NC_000007.14:g.55191822T>G | ClinVar |
RCV000211323 | p.Leu858Arg | missense variant | - | NC_000007.14:g.55191822T>G | ClinVar |
RCV000211235 | p.Leu858Arg | missense variant | - | NC_000007.14:g.55191822T>G | ClinVar |
RCV000425876 | p.Leu858Arg | missense variant | Non-small cell lung cancer (NSCLC) | NC_000007.14:g.55191822_55191823delinsGT | ClinVar |
RCV000435887 | p.Leu858Arg | missense variant | Non-small cell lung cancer (NSCLC) | NC_000007.14:g.55191821_55191822inv | ClinVar |
rs121913443 | p.Leu858Met | missense variant | - | NC_000007.14:g.55191821C>A | UniProt,dbSNP |
VAR_026101 | p.Leu858Met | missense variant | - | NC_000007.14:g.55191821C>A | UniProt |
rs763666690 | p.Ala859Val | missense variant | - | NC_000007.14:g.55191825C>T | ExAC,gnomAD |
RCV000038442 | p.Lys860Asn | missense variant | - | NC_000007.14:g.55191829A>T | ClinVar |
rs397517130 | p.Lys860Asn | missense variant | - | NC_000007.14:g.55191829A>T | - |
rs121913444 | p.Leu861Gln | missense variant | - | NC_000007.14:g.55191831T>A | UniProt,dbSNP |
VAR_026102 | p.Leu861Gln | missense variant | - | NC_000007.14:g.55191831T>A | UniProt |
RCV000427689 | p.Leu861Pro | missense variant | Squamous cell lung carcinoma | NC_000007.14:g.55191831T>C | ClinVar |
RCV000150630 | p.Leu861Gln | missense variant | - | NC_000007.14:g.55191831T>A | ClinVar |
RCV000038443 | p.Leu861Arg | missense variant | - | NC_000007.14:g.55191831T>G | ClinVar |
rs909797662 | p.Gly863Asp | missense variant | - | NC_000007.14:g.55191837G>A | TOPMed |
rs1171287261 | p.Ala864Thr | missense variant | - | NC_000007.14:g.55191839G>A | TOPMed |
COSM219795 | p.Ala864Val | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000007.14:g.55191840C>T | NCI-TCGA Cosmic |
RCV000038445 | p.Glu866Val | missense variant | - | NC_000007.14:g.55191846A>T | ClinVar |
rs397517132 | p.Glu866Val | missense variant | - | NC_000007.14:g.55191846A>T | - |
rs756703787 | p.Glu866Lys | missense variant | - | NC_000007.14:g.55191845G>A | ExAC,gnomAD |
RCV000119351 | p.Glu868Lys | missense variant | Familial cancer of breast | NC_000007.14:g.55191851G>A | ClinVar |
rs104886013 | p.Glu868Lys | missense variant | - | NC_000007.14:g.55191851G>A | gnomAD |
rs104886013 | p.Glu868Gln | missense variant | - | NC_000007.14:g.55191851G>C | gnomAD |
rs1440961719 | p.Tyr869Cys | missense variant | - | NC_000007.14:g.55191855A>G | gnomAD |
rs397517134 | p.Ala871Gly | missense variant | - | NC_000007.14:g.55191861C>G | - |
RCV000038447 | p.Ala871Gly | missense variant | - | NC_000007.14:g.55191861C>G | ClinVar |
COSM53290 | p.Glu872Gly | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000007.14:g.55191864A>G | NCI-TCGA Cosmic |
VAR_026103 | p.Gly873Glu | Missense | - | - | UniProt |
rs766161581 | p.Lys879Asn | missense variant | - | NC_000007.14:g.55192777G>C | ExAC,gnomAD |
COSM3929122 | p.Trp880Ter | stop gained | Variant assessed as Somatic; HIGH impact. | NC_000007.14:g.55192780G>A | NCI-TCGA Cosmic |
rs956455215 | p.Met881Val | missense variant | - | NC_000007.14:g.55192781A>G | TOPMed |
rs397517136 | p.Met881Thr | missense variant | - | NC_000007.14:g.55192782T>C | - |
RCV000038449 | p.Met881Thr | missense variant | - | NC_000007.14:g.55192782T>C | ClinVar |
rs751549547 | p.Met881Ile | missense variant | - | NC_000007.14:g.55192783G>T | ExAC,gnomAD |
rs754772262 | p.Glu884Gly | missense variant | - | NC_000007.14:g.55192791A>G | ExAC,gnomAD |
NCI-TCGA novel | p.Ser885Ter | stop gained | - | NC_000007.14:g.55192794C>G | NCI-TCGA |
RCV000038450 | p.Ser885Leu | missense variant | - | NC_000007.14:g.55192794C>T | ClinVar |
rs397517137 | p.Ser885Leu | missense variant | - | NC_000007.14:g.55192794C>T | - |
rs756403828 | p.His888Gln | missense variant | - | NC_000007.14:g.55192804C>G | ExAC,gnomAD |
rs748000023 | p.His888Arg | missense variant | - | NC_000007.14:g.55192803A>G | ExAC,gnomAD |
rs987884612 | p.Tyr891Cys | missense variant | - | NC_000007.14:g.55192812A>G | TOPMed |
rs151064287 | p.Thr892Ile | missense variant | - | NC_000007.14:g.55192815C>T | ESP,ExAC,gnomAD |
rs1468532072 | p.Thr892Ala | missense variant | - | NC_000007.14:g.55192814A>G | TOPMed |
COSM1451615 | p.His893Tyr | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000007.14:g.55192817C>T | NCI-TCGA Cosmic |
rs749270913 | p.Gln894His | missense variant | - | NC_000007.14:g.55192822G>T | ExAC,gnomAD |
rs1238258563 | p.Val897Ile | missense variant | - | NC_000007.14:g.55192829G>A | gnomAD |
rs1334821010 | p.Val897Ala | missense variant | - | NC_000007.14:g.55192830T>C | TOPMed |
rs1009023863 | p.Gly901Ala | missense variant | - | NC_000007.14:g.55198717G>C | TOPMed,gnomAD |
COSM6178050 | p.Gly901Val | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000007.14:g.55198717G>T | NCI-TCGA Cosmic |
rs1399582136 | p.Gly901Arg | missense variant | - | NC_000007.14:g.55192841G>C | gnomAD |
rs779015469 | p.Val902Leu | missense variant | - | NC_000007.14:g.55198719G>T | ExAC,gnomAD |
rs1375731369 | p.Thr903Ser | missense variant | - | NC_000007.14:g.55198723C>G | gnomAD |
rs538497054 | p.Val904Ile | missense variant | - | NC_000007.14:g.55198725G>A | 1000Genomes,ExAC,TOPMed,gnomAD |
rs1218871031 | p.Leu907Met | missense variant | - | NC_000007.14:g.55198734T>A | TOPMed |
rs1431327306 | p.Met908Thr | missense variant | - | NC_000007.14:g.55198738T>C | TOPMed,gnomAD |
rs1011342626 | p.Ser912Tyr | missense variant | - | NC_000007.14:g.55198750C>A | gnomAD |
rs1275784384 | p.Tyr915Ter | stop gained | - | NC_000007.14:g.55198760T>A | TOPMed |
rs376822837 | p.Asp916Asn | missense variant | - | NC_000007.14:g.55198761G>A | ESP,ExAC,TOPMed,gnomAD |
rs1203302510 | p.Asp916Gly | missense variant | - | NC_000007.14:g.55198762A>G | gnomAD |
rs775695605 | p.Gly917Arg | missense variant | - | NC_000007.14:g.55198764G>A | ExAC,TOPMed,gnomAD |
COSM1090893 | p.Gly917Ala | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000007.14:g.55198765G>C | NCI-TCGA Cosmic |
rs1321754240 | p.Ile918Phe | missense variant | - | NC_000007.14:g.55198767A>T | gnomAD |
rs1390478413 | p.Pro919Thr | missense variant | - | NC_000007.14:g.55198770C>A | TOPMed |
NCI-TCGA novel | p.Ala920Ser | missense variant | - | NC_000007.14:g.55198773G>T | NCI-TCGA |
rs770529788 | p.Ser921Arg | missense variant | - | NC_000007.14:g.55198778C>A | ExAC,TOPMed,gnomAD |
rs773998239 | p.Glu922Val | missense variant | - | NC_000007.14:g.55198780A>T | ExAC,gnomAD |
rs961150162 | p.Glu922Gln | missense variant | - | NC_000007.14:g.55198779G>C | TOPMed,gnomAD |
rs961150162 | p.Glu922Lys | missense variant | - | NC_000007.14:g.55198779G>A | TOPMed,gnomAD |
rs1421825015 | p.Ser924Phe | missense variant | - | NC_000007.14:g.55198786C>T | TOPMed |
rs767507216 | p.Ile926Thr | missense variant | - | NC_000007.14:g.55198792T>C | ExAC,TOPMed,gnomAD |
rs759179459 | p.Ile926Leu | missense variant | - | NC_000007.14:g.55198791A>C | ExAC,gnomAD |
rs767507216 | p.Ile926Asn | missense variant | - | NC_000007.14:g.55198792T>A | ExAC,TOPMed,gnomAD |
NCI-TCGA novel | p.Glu928Val | missense variant | - | NC_000007.14:g.55198798A>T | NCI-TCGA |
rs1247205023 | p.Lys929Arg | missense variant | - | NC_000007.14:g.55198801A>G | TOPMed |
rs1223694747 | p.Arg932Cys | missense variant | - | NC_000007.14:g.55198809C>T | TOPMed |
rs575565383 | p.Pro934Ser | missense variant | - | NC_000007.14:g.55198815C>T | 1000Genomes,ExAC,TOPMed,gnomAD |
COSM3881829 | p.Pro937Leu | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000007.14:g.55198825C>T | NCI-TCGA Cosmic |
rs763924711 | p.Ile938Met | missense variant | - | NC_000007.14:g.55198829A>G | ExAC,gnomAD |
rs753612121 | p.Thr940Ala | missense variant | - | NC_000007.14:g.55198833A>G | ExAC,gnomAD |
rs757493321 | p.Ile941Met | missense variant | - | NC_000007.14:g.55198838C>G | ExAC,gnomAD |
rs1271051562 | p.Asp942Ala | missense variant | - | NC_000007.14:g.55198840A>C | gnomAD |
rs967910623 | p.Asp942His | missense variant | - | NC_000007.14:g.55198839G>C | TOPMed,gnomAD |
rs967910623 | p.Asp942Asn | missense variant | - | NC_000007.14:g.55198839G>A | TOPMed,gnomAD |
rs1375457410 | p.Val943Asp | missense variant | - | NC_000007.14:g.55198843T>A | gnomAD |
rs779164024 | p.Met945Val | missense variant | - | NC_000007.14:g.55198848A>G | ExAC,gnomAD |
rs1169803481 | p.Ile946Val | missense variant | - | NC_000007.14:g.55198851A>G | gnomAD |
rs368698152 | p.Met947Leu | missense variant | - | NC_000007.14:g.55198854A>C | ESP,ExAC,TOPMed,gnomAD |
rs368698152 | p.Met947Val | missense variant | - | NC_000007.14:g.55198854A>G | ESP,ExAC,TOPMed,gnomAD |
rs542967903 | p.Val948Ile | missense variant | - | NC_000007.14:g.55198857G>A | 1000Genomes,ExAC,TOPMed,gnomAD |
NCI-TCGA novel | p.Cys950Ter | stop gained | - | NC_000007.14:g.55200317C>A | NCI-TCGA |
rs773001497 | p.MetIleAspAla952MetIleAspGlyTerThrUnk | stop gained | - | NC_000007.14:g.55200323_55200330dup | ExAC,gnomAD |
rs201830126 | p.Ala955Thr | missense variant | - | NC_000007.14:g.55200330G>A | 1000Genomes,ESP,ExAC,TOPMed,gnomAD |
rs104886026 | p.Asp956Asn | missense variant | - | NC_000007.14:g.55200333G>A | - |
rs1185470008 | p.Asp956Val | missense variant | - | NC_000007.14:g.55200334A>T | TOPMed,gnomAD |
RCV000119366 | p.Asp956Asn | missense variant | Endometrial carcinoma | NC_000007.14:g.55200333G>A | ClinVar |
COSM3923815 | p.Arg958Cys | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000007.14:g.55200339C>T | NCI-TCGA Cosmic |
rs1368179445 | p.Arg958His | missense variant | - | NC_000007.14:g.55200340G>A | TOPMed,gnomAD |
rs1359029869 | p.Lys960Glu | missense variant | - | NC_000007.14:g.55200345A>G | gnomAD |
rs17337451 | p.Arg962Cys | missense variant | - | NC_000007.14:g.55200351C>T | ExAC,TOPMed,gnomAD |
rs17337451 | p.Arg962Gly | missense variant | - | NC_000007.14:g.55200351C>G | ExAC,TOPMed,gnomAD |
rs17337451 | p.Arg962Ser | missense variant | - | NC_000007.14:g.55200351C>A | ExAC,TOPMed,gnomAD |
rs144496976 | p.Arg962His | missense variant | - | NC_000007.14:g.55200352G>A | 1000Genomes,ESP,ExAC,TOPMed,gnomAD |
RCV000120696 | p.Arg962His | missense variant | - | NC_000007.14:g.55200352G>A | ClinVar |
rs751632602 | p.Glu963Gly | missense variant | - | NC_000007.14:g.55200355A>G | ExAC,TOPMed,gnomAD |
rs1383485737 | p.Ile966Val | missense variant | - | NC_000007.14:g.55200363A>G | gnomAD |
NCI-TCGA novel | p.Glu967Ala | missense variant | - | NC_000007.14:g.55200367A>C | NCI-TCGA |
rs755504552 | p.Lys970Arg | missense variant | - | NC_000007.14:g.55200376A>G | ExAC,gnomAD |
rs781609053 | p.Met971Thr | missense variant | - | NC_000007.14:g.55200379T>C | ExAC,gnomAD |
rs748491031 | p.Arg973Gly | missense variant | - | NC_000007.14:g.55200384C>G | ExAC,TOPMed,gnomAD |
rs748491031 | p.Arg973Ter | stop gained | - | NC_000007.14:g.55200384C>T | ExAC,TOPMed,gnomAD |
rs756554871 | p.Arg973Gln | missense variant | - | NC_000007.14:g.55200385G>A | ExAC,TOPMed,gnomAD |
rs1486130926 | p.Asp974Asn | missense variant | - | NC_000007.14:g.55200387G>A | gnomAD |
rs1215599430 | p.Pro975Leu | missense variant | - | NC_000007.14:g.55200391C>T | TOPMed,gnomAD |
rs1486804407 | p.Gln976Glu | missense variant | - | NC_000007.14:g.55200393C>G | gnomAD |
rs745490627 | p.Arg977Pro | missense variant | - | NC_000007.14:g.55200397G>C | ExAC,TOPMed,gnomAD |
rs745490627 | p.Arg977His | missense variant | - | NC_000007.14:g.55200397G>A | ExAC,TOPMed,gnomAD |
rs771888227 | p.Ile981Thr | missense variant | - | NC_000007.14:g.55200409T>C | ExAC,gnomAD |
rs1042344966 | p.Ile981Met | missense variant | - | NC_000007.14:g.55200410T>G | TOPMed |
rs775131364 | p.Gln982Leu | missense variant | - | NC_000007.14:g.55200412A>T | ExAC,gnomAD |
COSM3923816 | p.Gln982Ter | stop gained | Variant assessed as Somatic; HIGH impact. | NC_000007.14:g.55200411C>T | NCI-TCGA Cosmic |
COSM3412205 | p.Gly983Arg | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000007.14:g.55201188G>A | NCI-TCGA Cosmic |
rs750582201 | p.Asp984Tyr | missense variant | - | NC_000007.14:g.55201191G>T | gnomAD |
rs750582201 | p.Asp984Asn | missense variant | - | NC_000007.14:g.55201191G>A | gnomAD |
rs779583988 | p.Arg986Lys | missense variant | - | NC_000007.14:g.55201198G>A | ExAC |
rs17290699 | p.His988Arg | missense variant | - | NC_000007.14:g.55201204A>G | 1000Genomes,ESP,ExAC,TOPMed,gnomAD |
RCV000120698 | p.His988Pro | missense variant | - | NC_000007.14:g.55201204A>C | ClinVar |
rs17290699 | p.His988Pro | missense variant | - | NC_000007.14:g.55201204A>C | 1000Genomes,ESP,ExAC,TOPMed,gnomAD |
rs781134348 | p.Pro990Ser | missense variant | - | NC_000007.14:g.55201209C>T | ExAC,gnomAD |
rs748011710 | p.Ser991Gly | missense variant | - | NC_000007.14:g.55201212A>G | ExAC,gnomAD |
rs748011710 | p.Ser991Arg | missense variant | - | NC_000007.14:g.55201212A>C | ExAC,gnomAD |
rs587778251 | p.AspSer994GlyAla | missense variant | - | NC_000007.14:g.55201222_55201224delinsGTG | - |
RCV000120697 | p.Asp994GlyAla | missense variant | - | NC_000007.14:g.55201222_55201224delinsGTG | ClinVar |
rs771085105 | p.Asn996Lys | missense variant | - | NC_000007.14:g.55201229C>A | ExAC,TOPMed,gnomAD |
rs762795214 | p.Asn996Ser | missense variant | - | NC_000007.14:g.55201228A>G | ExAC,gnomAD |
COSM5415932 | p.Phe997Val | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000007.14:g.55201230T>G | NCI-TCGA Cosmic |
rs1289194907 | p.Tyr998Cys | missense variant | - | NC_000007.14:g.55201234A>G | TOPMed |
rs149248025 | p.Arg999His | missense variant | - | NC_000007.14:g.55201237G>A | ESP,ExAC,TOPMed,gnomAD |
rs149248025 | p.Arg999Leu | missense variant | - | NC_000007.14:g.55201237G>T | ESP,ExAC,TOPMed,gnomAD |
rs866928399 | p.Arg999Cys | missense variant | - | NC_000007.14:g.55201236C>T | gnomAD |
RCV000381625 | p.Arg999Leu | missense variant | Lung cancer | NC_000007.14:g.55201237G>T | ClinVar |
NCI-TCGA novel | p.Ala1000Val | missense variant | - | NC_000007.14:g.55201240C>T | NCI-TCGA |
NCI-TCGA novel | p.Leu1001Pro | insertion | - | NC_000007.14:g.55201244_55201245insCCT | NCI-TCGA |
rs1319486482 | p.Met1002Thr | missense variant | - | NC_000007.14:g.55201246T>C | TOPMed |
rs1225496600 | p.Met1002Val | missense variant | - | NC_000007.14:g.55201245A>G | gnomAD |
rs1256257325 | p.Asp1003Asn | missense variant | - | NC_000007.14:g.55201248G>A | gnomAD |
rs752859687 | p.Asp1006Ala | missense variant | - | NC_000007.14:g.55201258A>C | ExAC,TOPMed,gnomAD |
NCI-TCGA novel | p.Asp1006Asn | missense variant | - | NC_000007.14:g.55201257G>A | NCI-TCGA |
rs747143752 | p.Asp1008Glu | missense variant | - | NC_000007.14:g.55201265C>G | ExAC,TOPMed,gnomAD |
rs747143752 | p.Asp1008Glu | missense variant | - | NC_000007.14:g.55201265C>A | ExAC,TOPMed,gnomAD |
rs1487738928 | p.Asp1008Gly | missense variant | - | NC_000007.14:g.55201264A>G | gnomAD |
rs1162232225 | p.Asp1008Asn | missense variant | - | NC_000007.14:g.55201263G>A | TOPMed |
rs148019583 | p.Asp1009Asn | missense variant | - | NC_000007.14:g.55201266G>A | ESP,ExAC,TOPMed,gnomAD |
rs757699239 | p.Val1010Leu | missense variant | - | NC_000007.14:g.55201269G>C | ExAC,TOPMed,gnomAD |
NCI-TCGA novel | p.Val1010AspPheSerTerUnkUnk | frameshift | - | NC_000007.14:g.55201269_55201270insATAGATCAGAAGACTACAAAAATGAAGC | NCI-TCGA |
rs757699239 | p.Val1010Met | missense variant | - | NC_000007.14:g.55201269G>A | ExAC,TOPMed,gnomAD |
rs1226829354 | p.Val1011Leu | missense variant | - | NC_000007.14:g.55201272G>C | TOPMed,gnomAD |
NCI-TCGA novel | p.Val1011Glu | missense variant | - | NC_000007.14:g.55201273T>A | NCI-TCGA |
rs995022327 | p.Asp1012Glu | missense variant | - | NC_000007.14:g.55201277T>A | TOPMed |
rs1420841957 | p.Asp1012His | missense variant | - | NC_000007.14:g.55201275G>C | gnomAD |
rs779716935 | p.Ala1013Thr | missense variant | - | NC_000007.14:g.55201278G>A | ExAC,gnomAD |
rs751192280 | p.Asp1014Asn | missense variant | - | NC_000007.14:g.55201281G>A | ExAC,TOPMed,gnomAD |
rs1302295057 | p.Glu1015Lys | missense variant | - | NC_000007.14:g.55201284G>A | TOPMed,gnomAD |
NCI-TCGA novel | p.Tyr1016Ter | stop gained | - | NC_000007.14:g.55201289C>A | NCI-TCGA |
rs1345851089 | p.Leu1017Phe | missense variant | - | NC_000007.14:g.55201290C>T | gnomAD |
rs1362774341 | p.Ile1018Val | missense variant | - | NC_000007.14:g.55201293A>G | TOPMed |
RCV000786033 | p.Pro1019Thr | missense variant | Glioblastoma multiforme, somatic | NC_000007.14:g.55201296C>A | ClinVar |
COSM747423 | p.Pro1019Leu | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000007.14:g.55201297C>T | NCI-TCGA Cosmic |
RCV000786032 | p.Pro1019Gln | missense variant | Glioblastoma multiforme, somatic | NC_000007.14:g.55201297C>A | ClinVar |
rs1276184054 | p.Gly1022Ser | missense variant | - | NC_000007.14:g.55201305G>A | gnomAD |
rs747726185 | p.Gly1022Asp | missense variant | - | NC_000007.14:g.55201306G>A | ExAC,gnomAD |
rs777701385 | p.Ser1025Arg | missense variant | - | NC_000007.14:g.55201316C>G | ExAC,gnomAD |
rs1275431248 | p.Ser1025Cys | missense variant | - | NC_000007.14:g.55201314A>T | gnomAD |
rs1296356016 | p.Thr1029Ala | missense variant | - | NC_000007.14:g.55201326A>G | TOPMed |
rs182857647 | p.Thr1029Lys | missense variant | - | NC_000007.14:g.55201327C>A | 1000Genomes,ExAC,TOPMed,gnomAD |
rs182857647 | p.Thr1029Met | missense variant | - | NC_000007.14:g.55201327C>T | 1000Genomes,ExAC,TOPMed,gnomAD |
rs1490923813 | p.Arg1031Gly | missense variant | - | NC_000007.14:g.55201332C>G | TOPMed,gnomAD |
rs1490923813 | p.Arg1031Trp | missense variant | - | NC_000007.14:g.55201332C>T | TOPMed,gnomAD |
rs570295933 | p.Arg1031Gln | missense variant | - | NC_000007.14:g.55201333G>A | 1000Genomes,ExAC,TOPMed,gnomAD |
rs775415330 | p.Thr1032Ala | missense variant | - | NC_000007.14:g.55201335A>G | ExAC,TOPMed,gnomAD |
COSM1451618 | p.Thr1032Ser | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000007.14:g.55201335A>T | NCI-TCGA Cosmic |
rs764626121 | p.Leu1034Ile | missense variant | - | NC_000007.14:g.55201341C>A | ExAC,gnomAD |
rs34352568 | p.Leu1034Pro | missense variant | - | NC_000007.14:g.55201342T>C | ExAC,gnomAD |
rs34352568 | p.Leu1034Arg | missense variant | - | NC_000007.14:g.55201342T>G | ExAC,gnomAD |
rs34352568 | p.Leu1034Arg | missense variant | - | NC_000007.14:g.55201342T>G | UniProt,dbSNP |
VAR_042095 | p.Leu1034Arg | missense variant | - | NC_000007.14:g.55201342T>G | UniProt |
rs762218653 | p.Ser1037Thr | missense variant | - | NC_000007.14:g.55201350T>A | ExAC,gnomAD |
rs765496858 | p.Ser1037Tyr | missense variant | - | NC_000007.14:g.55201351C>A | ExAC,gnomAD |
rs1420042114 | p.Thr1041Ala | missense variant | - | NC_000007.14:g.55201741A>G | gnomAD |
rs1161802556 | p.Ser1042Asn | missense variant | - | NC_000007.14:g.55201745G>A | gnomAD |
rs375035197 | p.Asn1043Ser | missense variant | - | NC_000007.14:g.55201748A>G | ESP,ExAC,gnomAD |
rs1364225726 | p.Ser1045Pro | missense variant | - | NC_000007.14:g.55201753T>C | gnomAD |
rs773437153 | p.Thr1046Asn | missense variant | - | NC_000007.14:g.55201757C>A | ExAC,gnomAD |
rs142442994 | p.Val1047Met | missense variant | - | NC_000007.14:g.55201759G>A | ESP,ExAC,TOPMed,gnomAD |
rs1367552759 | p.Val1047Gly | missense variant | - | NC_000007.14:g.55201760T>G | gnomAD |
RCV000332908 | p.Val1047Met | missense variant | Lung cancer | NC_000007.14:g.55201759G>A | ClinVar |
rs78244461 | p.Ala1048Val | missense variant | - | NC_000007.14:g.55201763C>T | 1000Genomes,ExAC,TOPMed,gnomAD |
rs1186558284 | p.Ala1048Pro | missense variant | - | NC_000007.14:g.55201762G>C | TOPMed |
rs1462369239 | p.Ile1050Phe | missense variant | - | NC_000007.14:g.55201768A>T | gnomAD |
rs529174941 | p.Ile1050Ser | missense variant | - | NC_000007.14:g.55201769T>G | 1000Genomes,ExAC,gnomAD |
rs529174941 | p.Ile1050Thr | missense variant | - | NC_000007.14:g.55201769T>C | 1000Genomes,ExAC,gnomAD |
rs755574890 | p.Asp1051Ala | missense variant | - | NC_000007.14:g.55201772A>C | ExAC,TOPMed,gnomAD |
rs755574890 | p.Asp1051Gly | missense variant | - | NC_000007.14:g.55201772A>G | ExAC,TOPMed,gnomAD |
COSM3833029 | p.Asp1051Asn | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000007.14:g.55201771G>A | NCI-TCGA Cosmic |
COSM6178048 | p.Arg1052Ile | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000007.14:g.55201775G>T | NCI-TCGA Cosmic |
rs758314765 | p.Gln1056His | missense variant | - | NC_000007.14:g.55202522A>C | ExAC,TOPMed,gnomAD |
rs751466686 | p.Ser1057Asn | missense variant | - | NC_000007.14:g.55202524G>A | ExAC,TOPMed,gnomAD |
rs1321975678 | p.Cys1058Ser | missense variant | - | NC_000007.14:g.55202527G>C | gnomAD |
rs1406092971 | p.Pro1059Leu | missense variant | - | NC_000007.14:g.55202530C>T | gnomAD |
rs755238987 | p.Pro1059Ser | missense variant | - | NC_000007.14:g.55202529C>T | ExAC,gnomAD |
rs748111724 | p.Lys1061Gln | missense variant | - | NC_000007.14:g.55202535A>C | ExAC,gnomAD |
rs1224584642 | p.Asp1063Gly | missense variant | - | NC_000007.14:g.55202542A>G | TOPMed,gnomAD |
rs1339648899 | p.Ser1064Ile | missense variant | - | NC_000007.14:g.55202545G>T | gnomAD |
rs1250448734 | p.Ser1064Gly | missense variant | - | NC_000007.14:g.55202544A>G | gnomAD |
rs769949680 | p.Phe1065Ile | missense variant | - | NC_000007.14:g.55202547T>A | ExAC,gnomAD |
rs778095401 | p.Gln1067Lys | missense variant | - | NC_000007.14:g.55202553C>A | ExAC,TOPMed,gnomAD |
rs374501041 | p.Arg1068Gln | missense variant | - | NC_000007.14:g.55202557G>A | ESP,gnomAD |
rs749783044 | p.Arg1068Ter | stop gained | - | NC_000007.14:g.55202556C>T | ExAC,TOPMed,gnomAD |
rs374501041 | p.Arg1068Pro | missense variant | - | NC_000007.14:g.55202557G>C | ESP,gnomAD |
rs771471723 | p.Ser1070Thr | missense variant | - | NC_000007.14:g.55202563G>C | ExAC,gnomAD |
rs771471723 | p.Ser1070Asn | missense variant | - | NC_000007.14:g.55202563G>A | ExAC,gnomAD |
rs887824842 | p.Asp1072Gly | missense variant | - | NC_000007.14:g.55202569A>G | TOPMed,gnomAD |
rs768226783 | p.Pro1073Thr | missense variant | - | NC_000007.14:g.55202571C>A | ExAC,gnomAD |
rs1161834426 | p.Gly1075Asp | missense variant | - | NC_000007.14:g.55202578G>A | gnomAD |
rs776375114 | p.Gly1075Ser | missense variant | - | NC_000007.14:g.55202577G>A | ExAC,gnomAD |
rs755868272 | p.Ala1076Val | missense variant | - | NC_000007.14:g.55202581C>T | ExAC,TOPMed,gnomAD |
rs764780987 | p.Ala1076Pro | missense variant | - | NC_000007.14:g.55202580G>C | ExAC,TOPMed,gnomAD |
rs764780987 | p.Ala1076Thr | missense variant | - | NC_000007.14:g.55202580G>A | ExAC,TOPMed,gnomAD |
rs1164785061 | p.Leu1077Ser | missense variant | - | NC_000007.14:g.55202584T>C | gnomAD |
rs751342391 | p.Thr1078Ser | missense variant | - | NC_000007.14:g.55202586A>T | ExAC,gnomAD |
rs751342391 | p.Thr1078Ala | missense variant | - | NC_000007.14:g.55202586A>G | ExAC,gnomAD |
rs184614596 | p.Glu1079Asp | missense variant | - | NC_000007.14:g.55202591G>C | 1000Genomes,ExAC,TOPMed,gnomAD |
COSM3778506 | p.Glu1079Lys | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000007.14:g.55202589G>A | NCI-TCGA Cosmic |
rs1023185448 | p.Asp1080Asn | missense variant | - | NC_000007.14:g.55202592G>A | TOPMed,gnomAD |
rs371229748 | p.Ile1082Leu | missense variant | - | NC_000007.14:g.55202598A>T | ESP,ExAC,gnomAD |
rs371229748 | p.Ile1082Val | missense variant | - | NC_000007.14:g.55202598A>G | ESP,ExAC,gnomAD |
rs1051476261 | p.Ile1082Arg | missense variant | - | NC_000007.14:g.55202599T>G | TOPMed,gnomAD |
NCI-TCGA novel | p.Asp1083GluPheSerTerUnkUnk | frameshift | - | NC_000007.14:g.55202603C>- | NCI-TCGA |
rs373990043 | p.Asp1083Glu | missense variant | - | NC_000007.14:g.55202603C>A | ESP,ExAC,TOPMed,gnomAD |
rs535060253 | p.Asp1084Asn | missense variant | - | NC_000007.14:g.55202604G>A | TOPMed,gnomAD |
rs1032201502 | p.Phe1086Ile | missense variant | - | NC_000007.14:g.55202610T>A | TOPMed |
rs749400221 | p.Leu1087Arg | missense variant | - | NC_000007.14:g.55202614T>G | ExAC,gnomAD |
rs771418435 | p.Pro1088Leu | missense variant | - | NC_000007.14:g.55202617C>T | ExAC,gnomAD |
rs367870311 | p.Pro1090Ser | missense variant | - | NC_000007.14:g.55202622C>T | ESP,TOPMed,gnomAD |
rs1328333567 | p.Glu1091Lys | missense variant | - | NC_000007.14:g.55202625G>A | TOPMed,gnomAD |
NCI-TCGA novel | p.Asn1094Ser | missense variant | - | NC_000007.14:g.55205265A>G | NCI-TCGA |
COSM1451619 | p.Ser1096Phe | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000007.14:g.55205271C>T | NCI-TCGA Cosmic |
rs775345513 | p.Val1097Ile | missense variant | - | NC_000007.14:g.55205273G>A | ExAC,TOPMed,gnomAD |
rs775345513 | p.Val1097Leu | missense variant | - | NC_000007.14:g.55205273G>C | ExAC,TOPMed,gnomAD |
rs760404029 | p.Lys1099Thr | missense variant | - | NC_000007.14:g.55205280A>C | ExAC,gnomAD |
rs764332519 | p.Pro1101Leu | missense variant | - | NC_000007.14:g.55205286C>T | ExAC,TOPMed,gnomAD |
rs764332519 | p.Pro1101Arg | missense variant | - | NC_000007.14:g.55205286C>G | ExAC,TOPMed,gnomAD |
rs1268506326 | p.Ala1102Ser | missense variant | - | NC_000007.14:g.55205288G>T | gnomAD |
rs1370192881 | p.Gly1103Asp | missense variant | - | NC_000007.14:g.55205292G>A | TOPMed |
rs139388758 | p.Gly1103Ser | missense variant | - | NC_000007.14:g.55205291G>A | ESP,ExAC,gnomAD |
rs376598259 | p.Ser1104Pro | missense variant | - | NC_000007.14:g.55205294T>C | ESP,ExAC,TOPMed,gnomAD |
rs780439043 | p.Gln1106Arg | missense variant | - | NC_000007.14:g.55205301A>G | ExAC,gnomAD |
rs1055315772 | p.Val1109Leu | missense variant | - | NC_000007.14:g.55205309G>C | TOPMed,gnomAD |
rs1055315772 | p.Val1109Ile | missense variant | - | NC_000007.14:g.55205309G>A | TOPMed,gnomAD |
rs369498625 | p.Asn1112His | missense variant | - | NC_000007.14:g.55205318A>C | ESP,ExAC,TOPMed,gnomAD |
rs755330584 | p.Asn1112Ser | missense variant | - | NC_000007.14:g.55205319A>G | ExAC,TOPMed,gnomAD |
rs1186762640 | p.Asn1116Lys | missense variant | - | NC_000007.14:g.55205332C>A | gnomAD |
rs1485236403 | p.Asn1116Asp | missense variant | - | NC_000007.14:g.55205330A>G | gnomAD |
rs777435609 | p.Pro1117Thr | missense variant | - | NC_000007.14:g.55205333C>A | ExAC,gnomAD |
rs777435609 | p.Pro1117Ala | missense variant | - | NC_000007.14:g.55205333C>G | ExAC,gnomAD |
rs1442620290 | p.Pro1117His | missense variant | - | NC_000007.14:g.55205334C>A | TOPMed,gnomAD |
rs1442620290 | p.Pro1117Arg | missense variant | - | NC_000007.14:g.55205334C>G | TOPMed,gnomAD |
rs773996588 | p.Ala1118Val | missense variant | - | NC_000007.14:g.55205337C>T | ExAC,TOPMed,gnomAD |
rs770749711 | p.Ala1118Thr | missense variant | - | NC_000007.14:g.55205336G>A | ExAC,TOPMed,gnomAD |
rs868454218 | p.Pro1119Ser | missense variant | - | NC_000007.14:g.55205339C>T | TOPMed |
rs902672760 | p.Pro1119Arg | missense variant | - | NC_000007.14:g.55205340C>G | TOPMed,gnomAD |
rs775317295 | p.Pro1123Leu | missense variant | - | NC_000007.14:g.55205352C>T | ExAC,TOPMed,gnomAD |
NCI-TCGA novel | p.Pro1123Ser | missense variant | - | NC_000007.14:g.55205351C>T | NCI-TCGA |
rs1358829599 | p.Ser1130Arg | missense variant | - | NC_000007.14:g.55205374C>A | gnomAD |
rs776448547 | p.Val1133Glu | missense variant | - | NC_000007.14:g.55205382T>A | ExAC,gnomAD |
rs865825533 | p.Gly1134Asp | missense variant | - | NC_000007.14:g.55205385G>A | TOPMed,gnomAD |
rs762016851 | p.Gly1134Ser | missense variant | - | NC_000007.14:g.55205384G>A | ExAC,gnomAD |
rs865825533 | p.Gly1134Val | missense variant | - | NC_000007.14:g.55205385G>T | TOPMed,gnomAD |
rs765499904 | p.Asn1135Lys | missense variant | - | NC_000007.14:g.55205389C>A | ExAC,TOPMed,gnomAD |
rs1445729019 | p.Pro1136Leu | missense variant | - | NC_000007.14:g.55205391C>T | gnomAD |
rs780967013 | p.Glu1137Lys | missense variant | - | NC_000007.14:g.55205393G>A | ExAC,gnomAD |
NCI-TCGA novel | p.Tyr1138Cys | missense variant | - | NC_000007.14:g.55205397A>G | NCI-TCGA |
rs1473630143 | p.Leu1139Phe | missense variant | - | NC_000007.14:g.55205399C>T | gnomAD |
NCI-TCGA novel | p.Thr1141Ser | missense variant | - | NC_000007.14:g.55205406C>G | NCI-TCGA |
rs1403923057 | p.Gln1143His | missense variant | - | NC_000007.14:g.55205413G>T | gnomAD |
rs145189325 | p.Gln1143Glu | missense variant | - | NC_000007.14:g.55205411C>G | ESP,ExAC,TOPMed,gnomAD |
NCI-TCGA novel | p.Gln1143Ter | stop gained | - | NC_000007.14:g.55205411C>T | NCI-TCGA |
rs1452191951 | p.Thr1145Pro | missense variant | - | NC_000007.14:g.55205417A>C | gnomAD |
rs1337590341 | p.Cys1146Tyr | missense variant | - | NC_000007.14:g.55205421G>A | TOPMed,gnomAD |
NCI-TCGA novel | p.Val1147Ala | missense variant | - | NC_000007.14:g.55205424T>C | NCI-TCGA |
rs778725594 | p.Asn1148Lys | missense variant | - | NC_000007.14:g.55205428C>G | ExAC,gnomAD |
rs1476431328 | p.Asn1148Ser | missense variant | - | NC_000007.14:g.55205427A>G | gnomAD |
rs745321541 | p.Thr1150Ile | missense variant | - | NC_000007.14:g.55205433C>T | ExAC,gnomAD |
COSM4934357 | p.Thr1150Ser | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000007.14:g.55205432A>T | NCI-TCGA Cosmic |
NCI-TCGA novel | p.Phe1151Leu | missense variant | - | NC_000007.14:g.55205437C>A | NCI-TCGA |
rs368892932 | p.Asp1152Asn | missense variant | - | NC_000007.14:g.55205438G>A | ESP,ExAC,TOPMed,gnomAD |
rs368892932 | p.Asp1152His | missense variant | - | NC_000007.14:g.55205438G>C | ESP,ExAC,TOPMed,gnomAD |
rs1230715733 | p.Ser1153Cys | missense variant | - | NC_000007.14:g.55205441A>T | gnomAD |
NCI-TCGA novel | p.Ser1153Asn | missense variant | - | NC_000007.14:g.55205442G>A | NCI-TCGA |
rs1320747370 | p.His1156Tyr | missense variant | - | NC_000007.14:g.55205450C>T | gnomAD |
RCV000709022 | p.His1156Pro | missense variant | Hereditary cancer | NC_000007.14:g.55205451A>C | ClinVar |
rs149174093 | p.His1156Pro | missense variant | - | NC_000007.14:g.55205451A>C | 1000Genomes,ESP,ExAC,TOPMed,gnomAD |
rs761608448 | p.Trp1157Cys | missense variant | - | NC_000007.14:g.55205455G>C | ExAC,gnomAD |
rs1433524783 | p.Gln1159Ter | stop gained | - | NC_000007.14:g.55205459C>T | TOPMed |
rs1179392671 | p.Gln1159Arg | missense variant | - | NC_000007.14:g.55205460A>G | TOPMed,gnomAD |
rs773454677 | p.Gly1161Asp | missense variant | - | NC_000007.14:g.55205466G>A | ExAC,gnomAD |
rs41321844 | p.Ser1162Asn | missense variant | - | NC_000007.14:g.55205469G>A | 1000Genomes,ESP,ExAC,TOPMed,gnomAD |
rs766347941 | p.Ser1162Arg | missense variant | - | NC_000007.14:g.55205470C>G | ExAC,TOPMed,gnomAD |
RCV000120700 | p.Ser1162Asn | missense variant | - | NC_000007.14:g.55205469G>A | ClinVar |
NCI-TCGA novel | p.Ser1162Cys | missense variant | - | NC_000007.14:g.55205468A>T | NCI-TCGA |
rs1399981803 | p.His1163Tyr | missense variant | - | NC_000007.14:g.55205471C>T | gnomAD |
rs1318894874 | p.His1163Gln | missense variant | - | NC_000007.14:g.55205473C>A | gnomAD |
COSM70574 | p.Gln1164Arg | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000007.14:g.55205475A>G | NCI-TCGA Cosmic |
rs1469310856 | p.Leu1167Val | missense variant | - | NC_000007.14:g.55205483C>G | gnomAD |
COSM1090895 | p.Leu1167Met | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000007.14:g.55205483C>A | NCI-TCGA Cosmic |
rs751701731 | p.Asn1169Ser | missense variant | - | NC_000007.14:g.55205490A>G | ExAC,gnomAD |
rs1408630981 | p.Pro1170Ala | missense variant | - | NC_000007.14:g.55205492C>G | gnomAD |
rs147896627 | p.Gln1173Arg | missense variant | - | NC_000007.14:g.55205502A>G | ESP,ExAC,gnomAD |
rs147896627 | p.Gln1173Pro | missense variant | - | NC_000007.14:g.55205502A>C | ESP,ExAC,gnomAD |
rs756556775 | p.Phe1177Leu | missense variant | - | NC_000007.14:g.55205515T>A | ExAC,gnomAD |
rs556324078 | p.Phe1177Ser | missense variant | - | NC_000007.14:g.55205514T>C | 1000Genomes,ExAC,TOPMed |
COSM3639760 | p.Pro1178Leu | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000007.14:g.55205517C>T | NCI-TCGA Cosmic |
rs1343156007 | p.Lys1179Asn | missense variant | - | NC_000007.14:g.55205521G>C | gnomAD |
NCI-TCGA novel | p.Glu1180Ter | stop gained | - | NC_000007.14:g.55205522G>T | NCI-TCGA |
rs778656021 | p.Ala1181Thr | missense variant | - | NC_000007.14:g.55205525G>A | ExAC,gnomAD |
rs199661469 | p.Pro1183Ser | missense variant | - | NC_000007.14:g.55205531C>T | 1000Genomes,ExAC,gnomAD |
RCV000293175 | p.Pro1183Thr | missense variant | Lung cancer | NC_000007.14:g.55205531C>A | ClinVar |
rs199661469 | p.Pro1183Thr | missense variant | - | NC_000007.14:g.55205531C>A | 1000Genomes,ExAC,gnomAD |
rs779422878 | p.Asn1184Ser | missense variant | - | NC_000007.14:g.55205535A>G | ExAC,TOPMed,gnomAD |
rs746585833 | p.Gly1185Asp | missense variant | - | NC_000007.14:g.55205538G>A | ExAC,gnomAD |
rs746585833 | p.Gly1185Ala | missense variant | - | NC_000007.14:g.55205538G>C | ExAC,gnomAD |
COSM1131542 | p.Gly1185Val | missense variant | Variant assessed as Somatic; MODERATE impact. | NC_000007.14:g.55205538G>T | NCI-TCGA Cosmic |
rs1255635334 | p.Ile1186Val | missense variant | - | NC_000007.14:g.55205540A>G | TOPMed |
rs1272024430 | p.Phe1187Cys | missense variant | - | NC_000007.14:g.55205544T>G | gnomAD |
rs747600559 | p.Gly1189Ala | missense variant | - | NC_000007.14:g.55205550G>C | ExAC,gnomAD |
rs372948989 | p.Thr1191Ile | missense variant | - | NC_000007.14:g.55205556C>T | ESP,ExAC,TOPMed,gnomAD |
rs1480173156 | p.Ala1192Val | missense variant | - | NC_000007.14:g.55205559C>T | gnomAD |
rs773041247 | p.Ala1192Thr | missense variant | - | NC_000007.14:g.55205558G>A | ExAC,gnomAD |
rs1480173156 | p.Ala1192Gly | missense variant | - | NC_000007.14:g.55205559C>G | gnomAD |
rs749441331 | p.Glu1193Lys | missense variant | - | NC_000007.14:g.55205561G>A | ExAC,gnomAD |
NCI-TCGA novel | p.Ala1195Thr | missense variant | - | NC_000007.14:g.55205567G>A | NCI-TCGA |
rs1379387764 | p.Glu1196Lys | missense variant | - | NC_000007.14:g.55205570G>A | gnomAD |
rs376541336 | p.Tyr1197Ter | stop gained | - | NC_000007.14:g.55205575C>A | ESP,ExAC,TOPMed,gnomAD |
rs142188270 | p.Leu1198Val | missense variant | - | NC_000007.14:g.55205576C>G | 1000Genomes,ESP,ExAC,TOPMed,gnomAD |
rs768074018 | p.Arg1199Thr | missense variant | - | NC_000007.14:g.55205580G>C | ExAC,gnomAD |
rs369585356 | p.Ala1201Thr | missense variant | - | NC_000007.14:g.55205585G>A | ESP,ExAC,TOPMed,gnomAD |
rs201717672 | p.Ala1201Val | missense variant | - | NC_000007.14:g.55205586C>T | 1000Genomes,ExAC,TOPMed,gnomAD |
rs201717672 | p.Ala1201Glu | missense variant | - | NC_000007.14:g.55205586C>A | 1000Genomes,ExAC,TOPMed,gnomAD |
rs1301373415 | p.Phe1207Cys | missense variant | - | NC_000007.14:g.55205604T>G | gnomAD |
rs35918369 | p.Ala1210Val | missense variant | - | NC_000007.14:g.55205613C>T | 1000Genomes,ESP,ExAC,TOPMed,gnomAD |
Disease ID | Disease Name | Disease Type | Source |
---|---|---|---|
C0001418 | Adenocarcinoma | group | BEFREE;CTD_human;LHGDN |
C0001420 | Papillary adenocarcinoma | disease | BEFREE;LHGDN |
C0001430 | Adenoma | group | BEFREE |
C0001442 | Adenosarcoma | disease | BEFREE |
C0001486 | Adenovirus Infections | group | BEFREE |
C0001973 | Alcoholic Intoxication, Chronic | disease | BEFREE;PSYGENET |
C0002170 | Alopecia | disease | BEFREE |
C0002395 | Alzheimer's Disease | disease | BEFREE |
C0002448 | Ameloblastoma | disease | BEFREE |
C0002622 | Amnesia | disease | BEFREE |
C0002726 | Amyloidosis | disease | BEFREE |
C0002736 | Amyotrophic Lateral Sclerosis | disease | BEFREE |
C0002793 | Anaplasia | disease | BEFREE |
C0002871 | Anemia | disease | BEFREE |
C0002893 | Refractory anemias | disease | BEFREE |
C0003850 | Arteriosclerosis | disease | BEFREE |
C0003864 | Arthritis | disease | BEFREE |
C0003865 | Arthritis, Adjuvant-Induced | disease | CTD_human |
C0003873 | Rheumatoid Arthritis | disease | BEFREE |
C0004096 | Asthma | disease | BEFREE;LHGDN;RGD |
C0004114 | Astrocytoma | disease | BEFREE;LHGDN |
C0004135 | Ataxia Telangiectasia | disease | BEFREE |
C0004153 | Atherosclerosis | disease | BEFREE |
C0004364 | Autoimmune Diseases | group | BEFREE |
C0004623 | Bacterial Infections | group | LHGDN |
C0004763 | Barrett Esophagus | disease | BEFREE;LHGDN |
C0004997 | Benign Ovarian Neoplasm | disease | BEFREE |
C0005396 | Bile Duct Neoplasms | group | CTD_human |
C0005411 | Biliary Atresia | disease | BEFREE |
C0005586 | Bipolar Disorder | disease | BEFREE;GWASDB |
C0005684 | Malignant neoplasm of urinary bladder | disease | BEFREE;CTD_human |
C0005695 | Bladder Neoplasm | group | BEFREE;CTD_human;LHGDN |
C0005940 | Bone Diseases | group | BEFREE |
C0005967 | Bone neoplasms | group | BEFREE |
C0006012 | Borderline Personality Disorder | disease | BEFREE |
C0006118 | Brain Neoplasms | group | BEFREE;CGI;CLINVAR;LHGDN |
C0006142 | Malignant neoplasm of breast | disease | BEFREE;CTD_human |
C0006145 | Breast Diseases | group | LHGDN |
C0006160 | Brenner Tumor | disease | BEFREE |
C0006277 | Bronchitis | disease | BEFREE |
C0006287 | Bronchopulmonary Dysplasia | disease | BEFREE |
C0006413 | Burkitt Lymphoma | disease | BEFREE |
C0006625 | Cachexia | phenotype | BEFREE |
C0006826 | Malignant Neoplasms | group | BEFREE;CGI |
C0006840 | Candidiasis | disease | BEFREE |
C0007095 | Carcinoid Tumor | group | BEFREE;LHGDN |
C0007097 | Carcinoma | group | BEFREE;CTD_human |
C0007102 | Malignant tumor of colon | disease | BEFREE;CTD_human |
C0007103 | Malignant neoplasm of endometrium | disease | BEFREE;CGI |
C0007107 | Malignant neoplasm of larynx | disease | BEFREE |
C0007112 | Adenocarcinoma of prostate | disease | BEFREE;CGI |
C0007113 | Rectal Carcinoma | disease | BEFREE;CTD_human |
C0007114 | Malignant neoplasm of skin | disease | BEFREE |
C0007115 | Malignant neoplasm of thyroid | disease | BEFREE |
C0007117 | Basal cell carcinoma | disease | LHGDN |
C0007120 | Bronchioloalveolar Adenocarcinoma | disease | BEFREE;HPO;LHGDN;RGD |
C0007121 | Bronchogenic Carcinoma | disease | BEFREE |
C0007124 | Noninfiltrating Intraductal Carcinoma | disease | BEFREE;LHGDN |
C0007129 | Merkel cell carcinoma | disease | BEFREE |
C0007130 | Mucinous Adenocarcinoma | disease | BEFREE |
C0007131 | Non-Small Cell Lung Carcinoma | disease | BEFREE;CGI;CLINVAR;CTD_human;LHGDN |
C0007134 | Renal Cell Carcinoma | disease | BEFREE;LHGDN |
C0007137 | Squamous cell carcinoma | disease | BEFREE;CLINVAR;CTD_human;LHGDN |
C0007138 | Carcinoma, Transitional Cell | disease | BEFREE |
C0007140 | Carcinosarcoma | disease | BEFREE |
C0007193 | Cardiomyopathy, Dilated | group | BEFREE;CTD_human;RGD |
C0007570 | Celiac Disease | disease | BEFREE |
C0007847 | Malignant tumor of cervix | disease | BEFREE |
C0007868 | Cervical dysplasia | disease | BEFREE |
C0007873 | Uterine Cervical Neoplasm | disease | CTD_human;LHGDN |
C0008073 | Developmental Disabilities | group | BEFREE |
C0008354 | Cholera | disease | BEFREE |
C0008479 | Chondrosarcoma | disease | BEFREE |
C0008487 | Chordoma | disease | BEFREE |
C0008497 | Choriocarcinoma | disease | BEFREE |
C0008626 | Congenital chromosomal disease | group | BEFREE |
C0009319 | Colitis | disease | BEFREE |
C0009324 | Ulcerative Colitis | disease | BEFREE |
C0009375 | Colonic Neoplasms | group | BEFREE;CTD_human;LHGDN |
C0009376 | Colonic Polyps | phenotype | BEFREE |
C0009402 | Colorectal Carcinoma | disease | BEFREE;CTD_human |
C0009404 | Colorectal Neoplasms | group | BEFREE;CLINVAR;CTD_human;LHGDN |
C0010068 | Coronary heart disease | disease | BEFREE |
C0010200 | Coughing | phenotype | BEFREE |
C0010278 | Craniosynostosis | disease | BEFREE |
C0010606 | Adenoid Cystic Carcinoma | disease | BEFREE |
C0010674 | Cystic Fibrosis | disease | BEFREE |
C0010701 | Phyllodes Tumor | disease | BEFREE;LHGDN |
C0010823 | Cytomegalovirus Infections | group | LHGDN |
C0011303 | Demyelinating Diseases | group | BEFREE |
C0011570 | Mental Depression | disease | BEFREE |
C0011581 | Depressive disorder | disease | BEFREE |
C0011603 | Dermatitis | disease | BEFREE;CTD_human |
C0011615 | Dermatitis, Atopic | disease | BEFREE |
C0011644 | Scleroderma | disease | BEFREE |
C0011649 | Dermoid Cyst | disease | BEFREE |
C0011847 | Diabetes | disease | BEFREE |
C0011849 | Diabetes Mellitus | group | BEFREE |
C0011854 | Diabetes Mellitus, Insulin-Dependent | disease | RGD |
C0011860 | Diabetes Mellitus, Non-Insulin-Dependent | disease | BEFREE;CTD_human |
C0011881 | Diabetic Nephropathy | disease | BEFREE |
C0011991 | Diarrhea | phenotype | BEFREE |
C0012546 | Diphtheria | disease | BEFREE |
C0013238 | Dry Eye Syndromes | group | BEFREE |
C0013312 | Dupuytren Contracture | disease | BEFREE |
C0013404 | Dyspnea | phenotype | BEFREE |
C0013449 | Ear Neoplasms | group | BEFREE |
C0013595 | Eczema | disease | BEFREE |
C0014116 | Endocardial Cushion Defects | group | BEFREE |
C0014122 | Subacute Bacterial Endocarditis | disease | BEFREE |
C0014132 | Endocrine Gland Neoplasms | group | BEFREE |
C0014145 | Yolk Sac Tumor | disease | BEFREE |
C0014170 | Endometrial Neoplasms | group | LHGDN |
C0014175 | Endometriosis | disease | BEFREE;CTD_human;LHGDN |
C0014474 | Ependymoma | disease | BEFREE;LHGDN |
C0014818 | Erythroplasia | disease | BEFREE |
C0014859 | Esophageal Neoplasms | group | BEFREE;CGI;CTD_human;LHGDN |
C0014869 | Peptic Esophagitis | disease | RGD |
C0015230 | Exanthema | phenotype | BEFREE |
C0015644 | Muscular fasciculation | phenotype | BEFREE |
C0015695 | Fatty Liver | disease | BEFREE |
C0016034 | Breast Fibrocystic Disease | disease | BEFREE |
C0016057 | Fibrosarcoma | disease | BEFREE |
C0016059 | Fibrosis | phenotype | LHGDN |
C0016978 | gallbladder neoplasm | disease | CTD_human |
C0017150 | Gastrinoma | disease | BEFREE |
C0017152 | Gastritis | disease | BEFREE |
C0017154 | Gastritis, Atrophic | disease | BEFREE |
C0017168 | Gastroesophageal reflux disease | disease | BEFREE |
C0017185 | Gastrointestinal Neoplasms | group | BEFREE |
C0017636 | Glioblastoma | disease | BEFREE;CGI;CLINVAR;CTD_human;LHGDN |
C0017638 | Glioma | disease | BEFREE;CGI;LHGDN |
C0017639 | Gliosis | phenotype | LHGDN |
C0018133 | Graft-vs-Host Disease | disease | BEFREE |
C0018206 | granulosa cell tumor | disease | BEFREE |
C0018552 | Hamartoma | group | BEFREE |
C0018553 | Hamartoma Syndrome, Multiple | disease | BEFREE |
C0018621 | Hay fever | disease | BEFREE;LHGDN |
C0018671 | Head and Neck Neoplasms | group | BEFREE;CGI;CLINVAR;CTD_human;LHGDN |
C0018675 | Head Neoplasms | group | CTD_human |
C0018790 | Cardiac Arrest | disease | BEFREE |
C0018798 | Congenital Heart Defects | group | BEFREE |
C0018799 | Heart Diseases | group | BEFREE |
C0018801 | Heart failure | disease | BEFREE |
C0018802 | Congestive heart failure | disease | BEFREE |
C0018939 | Hematological Disease | group | BEFREE |
C0019163 | Hepatitis B | disease | BEFREE |
C0019196 | Hepatitis C | disease | BEFREE;LHGDN |
C0019348 | Herpes Simplex Infections | group | BEFREE |
C0019562 | Von Hippel-Lindau Syndrome | disease | BEFREE |
C0019693 | HIV Infections | group | BEFREE |
C0020217 | Hydatidiform Mole | disease | BEFREE |
C0020437 | Hypercalcemia | disease | BEFREE |
C0020445 | Hypercholesterolemia, Familial | disease | LHGDN |
C0020502 | Hyperparathyroidism | disease | BEFREE |
C0020507 | Hyperplasia | phenotype | LHGDN |
C0020538 | Hypertensive disease | group | BEFREE;HPO;RGD |
C0020608 | Hypodontia | disease | BEFREE |
C0021051 | Immunologic Deficiency Syndromes | group | BEFREE |
C0021053 | Immune System Diseases | group | BEFREE |
C0021294 | Infant, Premature | phenotype | BEFREE |
C0021390 | Inflammatory Bowel Diseases | group | BEFREE |
C0021400 | Influenza | disease | BEFREE |
C0021655 | Insulin Resistance | phenotype | CTD_human |
C0021841 | Intestinal Neoplasms | group | BEFREE |
C0021846 | Intestinal Polyps | phenotype | BEFREE |
C0022548 | Keloid | phenotype | BEFREE |
C0022602 | Actinic keratosis | disease | BEFREE |
C0022658 | Kidney Diseases | group | BEFREE;LHGDN |
C0022660 | Kidney Failure, Acute | disease | CTD_human;RGD |
C0022665 | Kidney Neoplasm | disease | BEFREE |
C0022876 | Premature Obstetric Labor | phenotype | BEFREE |
C0023051 | Laryngeal Diseases | group | BEFREE |
C0023267 | Fibroid Tumor | group | BEFREE;LHGDN |
C0023418 | leukemia | disease | BEFREE;LHGDN |
C0023434 | Chronic Lymphocytic Leukemia | disease | BEFREE |
C0023440 | Acute Erythroblastic Leukemia | disease | BEFREE |
C0023467 | Leukemia, Myelocytic, Acute | disease | BEFREE |
C0023473 | Myeloid Leukemia, Chronic | disease | BEFREE |
C0023487 | Acute Promyelocytic Leukemia | disease | BEFREE |
C0023531 | Leukoplakia | disease | BEFREE |
C0023532 | Leukoplakia, Oral | disease | BEFREE |
C0023890 | Liver Cirrhosis | disease | BEFREE |
C0023895 | Liver diseases | group | BEFREE |
C0023903 | Liver neoplasms | group | BEFREE |
C0024115 | Lung diseases | group | BEFREE;RGD |
C0024117 | Chronic Obstructive Airway Disease | disease | BEFREE;RGD |
C0024121 | Lung Neoplasms | group | BEFREE;CGI;CTD_human;LHGDN |
C0024131 | Lupus Vulgaris | disease | BEFREE |
C0024138 | Lupus Erythematosus, Discoid | disease | BEFREE |
C0024141 | Lupus Erythematosus, Systemic | disease | BEFREE;LHGDN |
C0024232 | Lymphatic Metastasis | disease | BEFREE |
C0024299 | Lymphoma | group | BEFREE |
C0024523 | Malabsorption Syndrome | group | BEFREE |
C0024623 | Malignant neoplasm of stomach | disease | BEFREE;CTD_human |
C0024667 | Animal Mammary Neoplasms | group | CTD_human |
C0024668 | Mammary Neoplasms, Experimental | group | CTD_human |
C0024809 | Marijuana Abuse | disease | BEFREE;PSYGENET |
C0024814 | Marinesco-Sjogren syndrome | disease | BEFREE |
C0025007 | Measles | disease | BEFREE |
C0025149 | Medulloblastoma | disease | BEFREE |
C0025202 | melanoma | disease | BEFREE;LHGDN |
C0025269 | Multiple Endocrine Neoplasia Type 2b | disease | BEFREE |
C0025286 | Meningioma | disease | BEFREE |
C0025500 | Mesothelioma | disease | BEFREE;CTD_human;LHGDN |
C0025568 | Metaplasia | phenotype | LHGDN |
C0026277 | Mixed Salivary Gland Tumor | disease | BEFREE |
C0026499 | Monosomy | group | BEFREE |
C0026640 | Mouth Neoplasms | group | BEFREE;LHGDN |
C0026764 | Multiple Myeloma | disease | BEFREE |
C0026769 | Multiple Sclerosis | disease | BEFREE |
C0027430 | Nasal Polyps | disease | BEFREE |
C0027439 | Nasopharyngeal Neoplasms | group | CTD_human |
C0027533 | Neck Neoplasms | group | BEFREE;CTD_human |
C0027626 | Neoplasm Invasiveness | phenotype | CTD_human |
C0027627 | Neoplasm Metastasis | phenotype | BEFREE;CTD_human;LHGDN |
C0027643 | Neoplasm Recurrence, Local | phenotype | CTD_human |
C0027651 | Neoplasms | group | BEFREE |
C0027708 | Nephroblastoma | disease | BEFREE |
C0027809 | Neurilemmoma | disease | BEFREE;LHGDN |
C0027819 | Neuroblastoma | group | BEFREE |
C0027830 | neurofibroma | disease | BEFREE |
C0027831 | Neurofibromatosis 1 | disease | BEFREE |
C0027859 | Acoustic Neuroma | disease | BEFREE;LHGDN |
C0027888 | Hereditary Motor and Sensory Neuropathies | group | BEFREE |
C0027960 | Nevus | disease | BEFREE |
C0027962 | Melanocytic nevus | disease | BEFREE |
C0028259 | Nodule | phenotype | BEFREE |
C0028754 | Obesity | disease | BEFREE |
C0028797 | Occupational Diseases | group | BEFREE |
C0028945 | oligodendroglioma | disease | BEFREE;LHGDN |
C0029132 | Disorder of the optic nerve | group | LHGDN |
C0029422 | Osteochondrodysplasias | group | BEFREE |
C0029463 | Osteosarcoma | disease | BEFREE;CTD_human;LHGDN |
C0029925 | Ovarian Carcinoma | disease | BEFREE |
C0029927 | Ovarian Cysts | disease | BEFREE |
C0030193 | Pain | phenotype | BEFREE |
C0030297 | Pancreatic Neoplasm | disease | BEFREE;CTD_human;LHGDN |
C0030354 | Papilloma | disease | BEFREE;CTD_human |
C0030521 | Parathyroid Neoplasms | group | BEFREE |
C0030578 | Paronychia Inflammation | disease | BEFREE |
C0030809 | Pemphigus Vulgaris | disease | BEFREE |
C0030920 | Peptic Ulcer | disease | BEFREE |
C0031039 | Pericardial effusion | disease | BEFREE |
C0031117 | Peripheral Neuropathy | group | BEFREE |
C0031118 | Peripheral Nervous System Neoplasms | group | BEFREE |
C0031269 | Peutz-Jeghers Syndrome | disease | BEFREE |
C0032000 | Pituitary Adenoma | disease | BEFREE |
C0032019 | Pituitary Neoplasms | group | BEFREE;LHGDN |
C0032227 | Pleural effusion disorder | group | BEFREE |
C0032229 | Pleural Neoplasms | group | BEFREE |
C0032308 | Staphylococcal Pneumonia | disease | BEFREE |
C0032320 | Pneumoperitoneum | disease | BEFREE |
C0032460 | Polycystic Ovary Syndrome | disease | BEFREE |
C0032461 | Polycythemia | disease | BEFREE |
C0032580 | Adenomatous Polyposis Coli | disease | BEFREE;CTD_human |
C0032584 | polyps | phenotype | BEFREE |
C0032927 | Precancerous Conditions | group | BEFREE |
C0032962 | Pregnancy Complications | group | BEFREE |
C0033375 | Prolactinoma | disease | BEFREE |
C0033578 | Prostatic Neoplasms | group | BEFREE;CLINVAR;CTD_human;LHGDN |
C0033771 | Prurigo | disease | BEFREE |
C0033774 | Pruritus | phenotype | BEFREE |
C0033860 | Psoriasis | disease | BEFREE |
C0033999 | Pterygium | disease | BEFREE |
C0034069 | Pulmonary Fibrosis | disease | BEFREE;RGD |
C0034341 | Pyruvate Carboxylase Deficiency Disease | disease | BEFREE |
C0034885 | Rectal Neoplasms | group | BEFREE;CTD_human;LHGDN |
C0035078 | Kidney Failure | disease | BEFREE |
C0035335 | Retinoblastoma | disease | BEFREE |
C0035369 | Retroviridae Infections | group | BEFREE |
C0035412 | Rhabdomyosarcoma | disease | BEFREE |
C0035455 | Rhinitis | disease | LHGDN |
C0036323 | Schistosomiasis | disease | BEFREE |
C0036341 | Schizophrenia | disease | BEFREE |
C0036391 | Schwartz-Jampel Syndrome | disease | BEFREE |
C0036421 | Systemic Scleroderma | disease | BEFREE |
C0036631 | Seminoma | disease | BEFREE |
C0037274 | Dermatologic disorders | group | BEFREE |
C0037285 | Skin Manifestations | group | BEFREE |
C0037286 | Skin Neoplasms | group | BEFREE;LHGDN |
C0037579 | Soft Tissue Neoplasms | group | BEFREE |
C0037999 | Splenic Neoplasms | group | BEFREE |
C0038160 | Staphylococcal Infections | group | BEFREE |
C0038271 | Stereotyped Behavior | phenotype | BEFREE |
C0038325 | Stevens-Johnson Syndrome | disease | BEFREE |
C0038356 | Stomach Neoplasms | group | BEFREE;CTD_human;LHGDN |
C0039101 | synovial sarcoma | disease | BEFREE;LHGDN |
C0039445 | Hereditary hemorrhagic telangiectasia | disease | BEFREE |
C0039585 | Androgen-Insensitivity Syndrome | disease | BEFREE |
C0040100 | Thymoma | disease | BEFREE;LHGDN |
C0040136 | Thyroid Neoplasm | disease | BEFREE;LHGDN |
C0040425 | Tonsillitis | disease | BEFREE |
C0040580 | Tracheal Diseases | group | BEFREE |
C0040997 | Trigeminal Neuralgia | disease | BEFREE |
C0041107 | Trisomy | group | BEFREE |
C0041327 | Tuberculosis, Pulmonary | disease | BEFREE |
C0041341 | Tuberous Sclerosis | disease | BEFREE |
C0041696 | Unipolar Depression | disease | BEFREE;PSYGENET |
C0041948 | Uremia | disease | BEFREE |
C0042133 | Uterine Fibroids | group | BEFREE |
C0042138 | Uterine Neoplasms | group | LHGDN |
C0042373 | Vascular Diseases | group | BEFREE |
C0042769 | Virus Diseases | group | BEFREE |
C0042963 | Vomiting | phenotype | BEFREE;HPO |
C0079588 | Ichthyosis, X-Linked | disease | BEFREE |
C0079772 | T-Cell Lymphoma | disease | BEFREE |
C0080032 | Pleural Effusion, Malignant | disease | BEFREE;LHGDN |
C0085136 | Central Nervous System Neoplasms | group | BEFREE |
C0085281 | Addictive Behavior | phenotype | BEFREE |
C0085293 | Hepatitis E | disease | LHGDN |
C0085390 | Li-Fraumeni Syndrome | disease | BEFREE |
C0085413 | Polycystic Kidney, Autosomal Dominant | disease | BEFREE;LHGDN |
C0085548 | Autosomal Recessive Polycystic Kidney Disease | disease | BEFREE;CTD_human |
C0085762 | Alcohol abuse | disease | BEFREE;PSYGENET |
C0085786 | Hamman-Rich syndrome | disease | BEFREE |
C0086132 | Depressive Symptoms | phenotype | BEFREE |
C0086543 | Cataract | disease | BEFREE |
C0149521 | Pancreatitis, Chronic | disease | BEFREE |
C0149630 | Bicuspid aortic valve | disease | BEFREE |
C0149678 | Epstein-Barr Virus Infections | group | BEFREE |
C0149782 | Squamous cell carcinoma of lung | disease | BEFREE;CGI;CLINVAR |
C0149911 | Humoral hypercalcemia of malignancy (disorder) | disease | BEFREE |
C0149925 | Small cell carcinoma of lung | disease | BEFREE;CTD_human;LHGDN |
C0149978 | Adenocarcinoma of rectum | disease | BEFREE |
C0151449 | Primary Sj?gren's syndrome | disease | BEFREE |
C0151546 | Oral Cavity Carcinoma | disease | BEFREE |
C0151650 | Renal fibrosis | disease | BEFREE |
C0152013 | Adenocarcinoma of lung (disorder) | disease | BEFREE;CGI;CLINVAR;CTD_human |
C0152018 | Esophageal carcinoma | disease | BEFREE;CGI;CLINVAR |
C0153381 | Malignant neoplasm of mouth | disease | BEFREE |
C0153382 | Malignant neoplasm of oropharynx | disease | BEFREE |
C0153446 | Malignant neoplasm of anus | disease | BEFREE |
C0153452 | Malignant neoplasm of gallbladder | disease | BEFREE;CTD_human |
C0153567 | Uterine Cancer | disease | BEFREE |
C0153579 | Malignant neoplasm of fallopian tube | group | BEFREE |
C0153601 | Malignant neoplasm of penis | disease | BEFREE |
C0153633 | Malignant neoplasm of brain | disease | BEFREE;CGI |
C0153653 | Malignant tumor of parathyroid gland | disease | BEFREE |
C0153676 | Secondary malignant neoplasm of lung | disease | BEFREE |
C0153690 | Secondary malignant neoplasm of bone | disease | BEFREE |
C0153942 | Benign neoplasm of esophagus | disease | CGI |
C0154059 | Carcinoma in situ of esophagus | disease | CGI |
C0154084 | Stage 0 Breast Carcinoma | disease | BEFREE |
C0162359 | Christ-Siemens-Touraine syndrome | disease | BEFREE |
C0162678 | Neurofibromatoses | group | BEFREE |
C0162820 | Dermatitis, Allergic Contact | disease | BEFREE |
C0175693 | Russell-Silver syndrome | disease | BEFREE |
C0175754 | Agenesis of corpus callosum | disease | BEFREE |
C0178874 | Tumor Progression | phenotype | BEFREE |
C0205641 | Adenocarcinoma, Basal Cell | disease | CTD_human |
C0205642 | Adenocarcinoma, Oxyphilic | disease | CTD_human |
C0205643 | Carcinoma, Cribriform | disease | CTD_human |
C0205644 | Carcinoma, Granular Cell | disease | CTD_human |
C0205645 | Adenocarcinoma, Tubular | disease | BEFREE;CTD_human |
C0205696 | Anaplastic carcinoma | disease | BEFREE;CTD_human |
C0205697 | Carcinoma, Spindle-Cell | disease | BEFREE;CTD_human |
C0205698 | Undifferentiated carcinoma | phenotype | BEFREE;CTD_human |
C0205699 | Carcinomatosis | phenotype | BEFREE;CTD_human |
C0205748 | Dysplastic Nevus | disease | BEFREE |
C0205851 | Germ cell tumor | group | BEFREE |
C0205874 | Papilloma, Squamous Cell | disease | CTD_human |
C0205875 | Papillomatosis | disease | CTD_human |
C0205944 | Sarcoma, Epithelioid | disease | BEFREE |
C0205969 | Thymic Carcinoma | disease | BEFREE |
C0206062 | Lung Diseases, Interstitial | group | BEFREE |
C0206093 | Neuroectodermal Tumors | disease | BEFREE |
C0206139 | Lichen Planus, Oral | disease | BEFREE |
C0206623 | Adenosquamous carcinoma | disease | BEFREE;LHGDN |
C0206624 | Hepatoblastoma | disease | BEFREE |
C0206629 | Pulmonary Blastoma | disease | BEFREE |
C0206633 | Angiomyolipoma | disease | LHGDN |
C0206638 | Giant Cell Tumor of Bone | disease | BEFREE |
C0206651 | Clear Cell Sarcoma of Soft Tissue | disease | BEFREE;LHGDN |
C0206655 | Alveolar rhabdomyosarcoma | disease | BEFREE |
C0206656 | Embryonal Rhabdomyosarcoma | disease | BEFREE |
C0206659 | Embryonal Carcinoma | disease | BEFREE;LHGDN |
C0206663 | Neuroectodermal Tumor, Primitive | disease | BEFREE |
C0206667 | Adrenal Cortical Adenoma | disease | BEFREE |
C0206681 | Adenocarcinoma, Clear Cell | disease | BEFREE |
C0206682 | Follicular thyroid carcinoma | disease | BEFREE |
C0206685 | Acinar Cell Carcinoma | disease | BEFREE |
C0206686 | Adrenocortical carcinoma | disease | BEFREE;CTD_human |
C0206687 | Carcinoma, Endometrioid | disease | BEFREE |
C0206694 | Mucoepidermoid Carcinoma | disease | BEFREE;LHGDN |
C0206695 | Carcinoma, Neuroendocrine | group | BEFREE |
C0206698 | Cholangiocarcinoma | disease | BEFREE;CTD_human;LHGDN |
C0206701 | Cystadenocarcinoma, Serous | disease | BEFREE |
C0206704 | Carcinoma, Large Cell | disease | BEFREE |
C0206706 | Verrucous carcinoma | disease | LHGDN |
C0206708 | Cervical Intraepithelial Neoplasia | disease | BEFREE |
C0206716 | Ganglioglioma | disease | BEFREE |
C0206718 | Ganglioneuroblastoma | disease | BEFREE |
C0206721 | Inverted Papilloma | disease | LHGDN |
C0206726 | gliosarcoma | disease | BEFREE;ORPHANET |
C0206727 | Nerve Sheath Tumors | group | BEFREE;LHGDN |
C0206734 | Hemangioblastoma | disease | BEFREE |
C0206743 | Rhabdoid Tumor | disease | BEFREE |
C0206754 | Neuroendocrine Tumors | group | BEFREE;LHGDN |
C0220611 | Childhood Rhabdomyosarcoma | disease | BEFREE |
C0220613 | Adult Soft Tissue Sarcoma | disease | BEFREE |
C0220615 | Adult Acute Myeloblastic Leukemia | disease | BEFREE |
C0220620 | Gastrointestinal Carcinoid Tumor | disease | BEFREE |
C0220633 | Uveal melanoma | disease | BEFREE |
C0220636 | Malignant neoplasm of salivary gland | disease | BEFREE |
C0220641 | Lip and Oral Cavity Carcinoma | disease | BEFREE |
C0220645 | Childhood Soft Tissue Sarcoma | disease | BEFREE |
C0220650 | Metastatic malignant neoplasm to brain | disease | BEFREE |
C0220654 | Meningeal Carcinomatosis | disease | BEFREE |
C0220656 | Malignant ascites | disease | BEFREE |
C0220668 | Congenital contractural arachnodactyly | disease | BEFREE |
C0221228 | Comedone | disease | BEFREE |
C0221239 | Rapidly progressive glomerulonephritis | disease | BEFREE |
C0221270 | Acanthosis | phenotype | HPO |
C0221353 | Horseshoe Kidney | disease | BEFREE |
C0221406 | Pituitary-dependent Cushing's disease | disease | BEFREE |
C0221505 | Lesion of brain | group | BEFREE |
C0231246 | Failure to gain weight | phenotype | HPO |
C0235593 | Thoracic lymphadenopathy | disease | BEFREE |
C0235653 | Malignant neoplasm of female breast | disease | BEFREE |
C0235782 | Gallbladder Carcinoma | disease | BEFREE |
C0235874 | Disease Exacerbation | phenotype | CTD_human |
C0235974 | Pancreatic carcinoma | disease | BEFREE |
C0238033 | Carcinoma of Male Breast | disease | BEFREE |
C0238122 | Fallopian Tube Carcinoma | disease | BEFREE |
C0238198 | Gastrointestinal Stromal Tumors | group | BEFREE;LHGDN |
C0238258 | Lymphangitis carcinomatosa | disease | BEFREE |
C0238301 | Cancer of Nasopharynx | disease | CTD_human |
C0238348 | Squamous cell carcinoma of penis | disease | BEFREE |
C0238461 | Anaplastic thyroid carcinoma | disease | BEFREE |
C0238462 | Medullary carcinoma of thyroid | disease | BEFREE |
C0238463 | Papillary thyroid carcinoma | disease | BEFREE |
C0238792 | Bone lesion | disease | BEFREE |
C0239946 | Fibrosis, Liver | disease | BEFREE |
C0240164 | Squamous Papilloma of the Larynx | disease | BEFREE |
C0241157 | pustule | phenotype | HPO |
C0242379 | Malignant neoplasm of lung | disease | BEFREE;CGI;CTD_human |
C0242787 | Malignant neoplasm of male breast | disease | BEFREE |
C0243038 | Carcinoma, Lewis Lung | disease | BEFREE |
C0262401 | Carcinoma of ampulla of Vater | disease | BEFREE |
C0262584 | Carcinoma, Small Cell | disease | BEFREE;LHGDN |
C0262929 | Myxoma of the Endocardium | disease | BEFREE |
C0263420 | Hyperkeratosis lenticularis perstans | disease | BEFREE |
C0263454 | Chloracne | disease | BEFREE;CTD_human |
C0263641 | Epithelial hyperplasia of skin | disease | BEFREE |
C0263661 | Disorder of skeletal system | group | BEFREE |
C0265306 | Greig cephalopolysyndactyly syndrome | disease | BEFREE |
C0265344 | Donohue Syndrome | disease | BEFREE |
C0265783 | Congenital hypoplasia of lung | disease | BEFREE |
C0268138 | Xeroderma Pigmentosum, Complementation Group D | disease | BEFREE |
C0268398 | Familial lichen amyloidosis | disease | BEFREE |
C0268621 | Hepatic methionine adenosyltransferase deficiency | disease | BEFREE |
C0268800 | Simple renal cyst | disease | BEFREE |
C0269102 | Endometrioma | disease | BEFREE;CTD_human |
C0271844 | Parathyroid hyperplasia | disease | BEFREE |
C0272138 | Erythroblastosis | disease | BEFREE |
C0276447 | Rhinovirus infection | disease | BEFREE |
C0277527 | Epidemic diarrhea | disease | BEFREE |
C0278480 | Stage III Colon Cancer | disease | BEFREE |
C0278484 | Malignant neoplasm of colon stage IV | disease | BEFREE |
C0278488 | Carcinoma breast stage IV | disease | BEFREE |
C0278493 | Breast cancer recurrent | disease | BEFREE |
C0278498 | Malignant neoplasm of stomach stage IV | disease | BEFREE |
C0278504 | Non-small cell lung cancer stage I | disease | BEFREE |
C0278506 | Non-small cell lung cancer stage III | disease | BEFREE |
C0278510 | Childhood Medulloblastoma | disease | BEFREE |
C0278512 | Metastatic osteosarcoma | disease | BEFREE |
C0278517 | Non-small cell lung cancer recurrent | disease | BEFREE |
C0278556 | Anal cancer recurrent | disease | BEFREE |
C0278583 | Cervical carcinoma stage IIB | disease | BEFREE |
C0278601 | Inflammatory Breast Carcinoma | disease | BEFREE |
C0278688 | Stage IV Ovarian Carcinoma | disease | BEFREE |
C0278701 | Gastric Adenocarcinoma | disease | BEFREE |
C0278726 | Small cell lung cancer extensive stage | disease | BEFREE |
C0278802 | Recurrent Endometrial Cancer | disease | BEFREE |
C0278803 | Adenocarcinoma of small intestine | disease | BEFREE |
C0278838 | Prostate cancer recurrent | disease | BEFREE |
C0278846 | Thymoma malignant invasive | disease | BEFREE |
C0278878 | Adult Glioblastoma | disease | BEFREE |
C0278883 | Metastatic melanoma | disease | BEFREE |
C0278884 | Melanoma recurrent | phenotype | BEFREE |
C0278987 | Non-small cell lung cancer metastatic | disease | BEFREE |
C0278996 | Malignant Head and Neck Neoplasm | disease | BEFREE;CGI;CTD_human |
C0279000 | Liver and Intrahepatic Biliary Tract Carcinoma | disease | BEFREE |
C0279557 | Adenosquamous cell lung cancer | disease | BEFREE |
C0279626 | Squamous cell carcinoma of esophagus | disease | BEFREE;CGI;CLINVAR;CTD_human |
C0279628 | Adenocarcinoma Of Esophagus | disease | BEFREE |
C0279637 | Anal carcinoma | disease | BEFREE |
C0279671 | Cervical Squamous Cell Carcinoma | disease | BEFREE |
C0279672 | Cervical Adenocarcinoma | disease | BEFREE |
C0279680 | Transitional cell carcinoma of bladder | disease | BEFREE |
C0279682 | Bladder Adenocarcinoma | disease | BEFREE |
C0279702 | Conventional (Clear Cell) Renal Cell Carcinoma | disease | BEFREE |
C0279746 | Adenocarcinoma of salivary gland | disease | BEFREE |
C0279763 | endometrial adenoacanthoma | disease | CLINVAR |
C0280089 | Carcinoid tumor of lung | disease | BEFREE |
C0280100 | Solid Neoplasm | phenotype | BEFREE |
C0280217 | stage, non-small cell lung cancer | disease | BEFREE |
C0280222 | stage, pancreatic cancer | phenotype | BEFREE |
C0280313 | Squamous cell carcinoma of oropharynx | disease | BEFREE |
C0280317 | Squamous cell carcinoma of tonsil | disease | BEFREE |
C0280324 | Laryngeal Squamous Cell Carcinoma | disease | BEFREE |
C0280474 | Childhood Glioblastoma | disease | BEFREE |
C0280630 | Uterine Carcinosarcoma | disease | BEFREE |
C0280783 | Juvenile Pilocytic Astrocytoma | disease | BEFREE |
C0280785 | Diffuse Astrocytoma | disease | BEFREE |
C0280856 | Squamous cell carcinoma of vulva | disease | BEFREE |
C0281361 | Adenocarcinoma of pancreas | disease | BEFREE |
C0282160 | Aplasia Cutis Congenita | disease | BEFREE |
C0282612 | Prostatic Intraepithelial Neoplasias | disease | BEFREE;LHGDN |
C0302592 | Cervix carcinoma | disease | BEFREE |
C0314719 | Dryness of eye | phenotype | BEFREE |
C0332563 | Papule | phenotype | HPO |
C0333983 | Hyperplastic Polyp | disease | BEFREE |
C0334233 | Pleomorphic carcinoma | disease | BEFREE |
C0334240 | Combined small cell carcinoma | disease | BEFREE |
C0334246 | Squamous cell carcinoma, metastatic | disease | BEFREE |
C0334254 | Lymphoepithelial carcinoma | disease | BEFREE |
C0334268 | Schneiderian papilloma | disease | BEFREE |
C0334276 | Adenocarcinoma in Situ | phenotype | BEFREE |
C0334279 | Adenocarcinoma, intestinal type | disease | BEFREE |
C0334287 | Fibrolamellar Hepatocellular Carcinoma | disease | BEFREE |
C0334299 | Carcinoid tumor no ICD-O subtype | phenotype | BEFREE |
C0334463 | Malignant Fibrous Histiocytoma | disease | BEFREE |
C0334488 | Clear cell sarcoma of kidney | disease | BEFREE |
C0334520 | Teratoma, Malignant | disease | BEFREE |
C0334529 | Hydatidiform Mole, Partial | disease | BEFREE |
C0334579 | Anaplastic astrocytoma | disease | BEFREE |
C0334583 | Pilocytic Astrocytoma | disease | BEFREE |
C0334586 | Pleomorphic Xanthoastrocytoma | disease | BEFREE |
C0334588 | Giant Cell Glioblastoma | disease | CTD_human;ORPHANET |
C0334590 | Anaplastic Oligodendroglioma | disease | BEFREE |
C0338106 | Adenocarcinoma of colon | disease | BEFREE |
C0343641 | Human papilloma virus infection | disease | BEFREE |
C0343751 | Asymptomatic human immunodeficiency virus infection | disease | BEFREE |
C0344460 | Carcinoma ex pleomorphic adenoma | disease | BEFREE |
C0345904 | Malignant neoplasm of liver | disease | BEFREE |
C0345905 | Intrahepatic Cholangiocarcinoma | disease | BEFREE;CTD_human |
C0345958 | Large cell carcinoma of lung | disease | BEFREE |
C0345960 | Giant cell carcinoma of lung | disease | BEFREE |
C0345967 | Malignant mesothelioma | disease | BEFREE;CTD_human |
C0346109 | Malignant Mesothelioma of Peritoneum | disease | BEFREE |
C0346153 | Breast Cancer, Familial | disease | BEFREE |
C0346154 | Malignant phyllodes tumor of breast | disease | BEFREE |
C0346163 | Endometrioid carcinoma ovary | disease | BEFREE |
C0346191 | Carcinoma in situ of endometrium | disease | CGI |
C0346202 | Cervical Adenosquamous Carcinoma | disease | BEFREE |
C0346300 | Pituitary carcinoma | disease | BEFREE |
C0346429 | Multiple malignancy | phenotype | BEFREE |
C0346629 | Malignant neoplasm of large intestine | disease | BEFREE |
C0346647 | Malignant neoplasm of pancreas | disease | BEFREE;CTD_human |
C0346957 | Disseminated Malignant Neoplasm | phenotype | BEFREE |
C0346990 | Carcinomatosis of peritoneal cavity | disease | BEFREE |
C0348374 | Malignant Central Nervous System Neoplasm | disease | GWASCAT;GWASDB |
C0349530 | Early gastric cancer | disease | BEFREE |
C0349566 | Squamous cell carcinoma of tongue | disease | BEFREE;CGI |
C0375023 | Respiratory syncytial virus (RSV) infection in conditions classified elsewhere and of unspecified site | disease | BEFREE |
C0375071 | Malignant neoplasm of vulva | disease | BEFREE |
C0376358 | Malignant neoplasm of prostate | disease | BEFREE;CTD_human |
C0376545 | Hematologic Neoplasms | group | BEFREE |
C0376634 | Craniofacial Abnormalities | group | CTD_human |
C0392514 | Hereditary hemochromatosis | disease | BEFREE |
C0392784 | Dermatofibrosarcoma Protuberans | disease | BEFREE |
C0393559 | Troyer syndrome | disease | BEFREE |
C0394005 | Ataxic cerebral palsy | disease | BEFREE |
C0398623 | Thrombophilia | disease | BEFREE |
C0398738 | Leukocyte adhesion deficiency type 1 | disease | BEFREE |
C0399440 | Hereditary gingival fibromatosis | disease | BEFREE |
C0399474 | Dysplastic oral leukoplakia | disease | BEFREE |
C0403416 | Idiopathic crescentic glomerulonephritis | disease | BEFREE |
C0403592 | Chronic rejection of renal transplant | disease | BEFREE |
C0406484 | Sebaceous hyperplasia | disease | BEFREE |
C0409974 | Lupus Erythematosus | disease | BEFREE |
C0410207 | Tubular Aggregate Myopathy | disease | BEFREE |
C0410528 | Skeletal dysplasia | disease | BEFREE |
C0424295 | Hyperactive behavior | phenotype | BEFREE |
C0476089 | Endometrial Carcinoma | disease | BEFREE;CGI |
C0476273 | Respiratory distress | phenotype | BEFREE |
C0494165 | Secondary malignant neoplasm of liver | disease | BEFREE |
C0497247 | Increase in blood pressure | phenotype | HPO |
C0520459 | Necrotizing Enterocolitis | disease | BEFREE |
C0520571 | Fibrosis of bile duct | disease | BEFREE |
C0520739 | Hereditary pyropoikilocytosis | disease | BEFREE |
C0521158 | Recurrent tumor | phenotype | BEFREE |
C0521707 | Bilateral cataracts (disorder) | disease | BEFREE |
C0524851 | Neurodegenerative Disorders | group | BEFREE |
C0524910 | Hepatitis C, Chronic | disease | BEFREE |
C0542346 | Pimples | phenotype | HPO |
C0546837 | Malignant neoplasm of esophagus | disease | BEFREE;CGI;CTD_human |
C0549473 | Thyroid carcinoma | disease | BEFREE |
C0553694 | Oropharyngeal disorders | group | BEFREE |
C0553723 | Squamous cell carcinoma of skin | disease | BEFREE |
C0555198 | Malignant Glioma | disease | BEFREE |
C0555278 | Cerebral metastasis | disease | BEFREE |
C0558355 | Tonsillar Carcinoma | disease | BEFREE |
C0566602 | Primary sclerosing cholangitis | disease | BEFREE |
C0574143 | Liver calculus | disease | BEFREE |
C0585362 | Squamous cell carcinoma of mouth | disease | BEFREE |
C0585442 | Osteosarcoma of bone | disease | BEFREE |
C0595989 | Carcinoma of larynx | disease | BEFREE |
C0596263 | Carcinogenesis | phenotype | BEFREE |
C0598766 | Leukemogenesis | disease | BEFREE |
C0598935 | Tumor Initiation | phenotype | BEFREE |
C0600139 | Prostate carcinoma | disease | BEFREE |
C0677055 | CARCINOMA OF VULVA | disease | BEFREE |
C0677865 | Brain Stem Glioma | disease | CLINVAR |
C0677886 | Epithelial ovarian cancer | disease | BEFREE |
C0677898 | invasive cancer | phenotype | BEFREE |
C0677932 | Progressive Neoplastic Disease | phenotype | BEFREE |
C0677936 | Refractory cancer | phenotype | BEFREE |
C0677950 | Stage IV Colorectal Cancer | disease | BEFREE |
C0678213 | Complete hydatidiform mole | disease | BEFREE |
C0678222 | Breast Carcinoma | disease | BEFREE;CTD_human |
C0684249 | Carcinoma of lung | disease | BEFREE;CGI;CLINVAR |
C0684337 | Ewings sarcoma-primitive neuroectodermal tumor (PNET) | disease | BEFREE |
C0685938 | Malignant neoplasm of gastrointestinal tract | disease | BEFREE |
C0686377 | CNS metastases | phenotype | BEFREE |
C0686619 | Secondary malignant neoplasm of lymph node | disease | BEFREE |
C0694550 | Recurrent pneumonia | phenotype | HPO |
C0699790 | Colon Carcinoma | disease | BEFREE |
C0699791 | Stomach Carcinoma | disease | BEFREE |
C0699885 | Carcinoma of bladder | disease | BEFREE |
C0699893 | Skin carcinoma | disease | BEFREE |
C0699949 | airway disease | group | BEFREE |
C0700095 | Central neuroblastoma | disease | BEFREE |
C0730328 | Central Serous Chorioretinopathy | disease | BEFREE |
C0740277 | Bile duct carcinoma | disease | BEFREE;CTD_human |
C0740345 | Germ Cell Cancer | disease | BEFREE |
C0740457 | Malignant neoplasm of kidney | disease | BEFREE |
C0740476 | Biliary carcinoma | disease | BEFREE |
C0742132 | cervical cancer metastasis | disease | BEFREE |
C0742468 | Central nervous system lesion | disease | BEFREE |
C0745730 | Multiple lipomata | disease | GENOMICS_ENGLAND |
C0746787 | Cancer of Neck | disease | CTD_human |
C0747845 | early pregnancy | phenotype | BEFREE |
C0748140 | Multiple pulmonary infections | disease | HPO |
C0750952 | Biliary Tract Cancer | disease | BEFREE |
C0750974 | Brain Tumor, Primary | disease | BEFREE |
C0751177 | Cancer of Head | disease | CTD_human |
C0751295 | Memory Loss | phenotype | BEFREE |
C0751396 | Well Differentiated Oligodendroglioma | disease | BEFREE |
C0751560 | Malignant neoplasm tonsil | disease | BEFREE |
C0751569 | Genitourinary Cancer | disease | BEFREE |
C0751688 | Malignant Squamous Cell Neoplasm | disease | BEFREE |
C0751690 | Malignant Peripheral Nerve Sheath Tumor | disease | BEFREE |
C0795839 | Chromosome 10, monosomy 10q | disease | BEFREE |
C0796070 | MICROPHTHALMIA, SYNDROMIC 7 | disease | BEFREE |
C0812413 | Malignant Pleural Mesothelioma | disease | BEFREE |
C0813148 | Metastatic Endometrial Carcinoma | disease | BEFREE |
C0850666 | Infection caused by Helicobacter pylori | disease | BEFREE |
C0850741 | Smoker's lung | disease | BEFREE |
C0851135 | In situ cancer | phenotype | BEFREE |
C0853105 | Penis carcinoma | disease | BEFREE |
C0853879 | Invasive carcinoma of breast | disease | BEFREE |
C0854178 | Metastases to adrenals | disease | BEFREE |
C0854985 | Adenocarcinoma of lung, stage I | disease | BEFREE |
C0854987 | Adenocarcinoma of lung, stage III | disease | BEFREE |
C0854988 | Adenocarcinoma of lung, stage IV | disease | BEFREE |
C0855002 | Recurrent Lung Carcinoma Cell Type Unspecified | disease | BEFREE |
C0855005 | Stage IV Lung Cancer AJCC v7 | disease | BEFREE |
C0861727 | Pancreatic adenocarcinoma metastatic | disease | BEFREE |
C0862802 | Recurrent lung cancer | disease | BEFREE |
C0862824 | Lung cancer stage I | disease | BEFREE |
C0876973 | Infectious disease of lung | group | HPO |
C0877430 | Asthma chronic | disease | BEFREE |
C0878500 | Intraepithelial Neoplasia | disease | BEFREE |
C0878544 | Cardiomyopathies | group | BEFREE |
C0887900 | Upper Aerodigestive Tract Neoplasms | group | CTD_human |
C0917804 | Arteriovenous Malformations, Cerebral | group | CLINVAR |
C0919267 | ovarian neoplasm | disease | BEFREE;CTD_human;LHGDN |
C0920563 | Insulin Sensitivity | phenotype | CTD_human |
C0936223 | Metastatic Prostate Carcinoma | disease | BEFREE |
C0940937 | precancerous lesions | phenotype | BEFREE |
C0948089 | Acute Coronary Syndrome | disease | LHGDN |
C0948380 | Colorectal cancer metastatic | disease | BEFREE |
C0948750 | Salivary gland carcinoma | disease | BEFREE |
C0949541 | Hurthle Cell Tumor | disease | BEFREE |
C0950121 | Denys-Drash Syndrome | disease | BEFREE |
C0971858 | Arthritis, Collagen-Induced | disease | CTD_human |
C0993582 | Arthritis, Experimental | disease | CTD_human |
C1134719 | Invasive Ductal Breast Carcinoma | disease | BEFREE |
C1135868 | Gestational Trophoblastic Neoplasms | group | BEFREE |
C1140680 | Malignant neoplasm of ovary | disease | BEFREE;CTD_human |
C1145670 | Respiratory Failure | disease | BEFREE |
C1153706 | Endometrial adenocarcinoma | disease | BEFREE;CGI |
C1167791 | Skin toxicity | disease | BEFREE |
C1168327 | High-Grade Prostatic Intraepithelial Neoplasia | disease | BEFREE |
C1168328 | Low Grade Prostatic Intraepithelial Neoplasia | disease | BEFREE |
C1168401 | Squamous cell carcinoma of the head and neck | disease | BEFREE;CGI;CLINVAR |
C1176475 | Ductal Carcinoma | disease | BEFREE |
C1257925 | Mammary Carcinoma, Animal | disease | CTD_human |
C1257931 | Mammary Neoplasms, Human | group | CTD_human |
C1258104 | Diffuse Scleroderma | disease | BEFREE |
C1260325 | Dendritic Cell Sarcoma, Follicular | disease | BEFREE |
C1260873 | Aortic valve disorder | group | MGD |
C1261473 | Sarcoma | group | BEFREE;LHGDN |
C1265996 | Large cell neuroendocrine carcinoma | disease | BEFREE |
C1266002 | Non-small cell carcinoma | disease | BEFREE |
C1266025 | Traditional Serrated Adenoma | disease | BEFREE |
C1266065 | Eccrine porocarcinoma | disease | BEFREE |
C1266088 | Adenocarcinoma with neuroendocrine differentiation | disease | BEFREE |
C1266129 | Atypical Lipoma | disease | BEFREE |
C1266158 | Nongerminomatous Germ Cell Tumor | disease | BEFREE |
C1269683 | Major Depressive Disorder | disease | BEFREE;PSYGENET |
C1275122 | Familial multiple trichoepitheliomata | disease | BEFREE |
C1275155 | Multiple basal cell papillomata | disease | BEFREE |
C1279945 | Acute interstitial pneumonia | disease | BEFREE |
C1282496 | Metastasis from malignant tumor of prostate | disease | BEFREE |
C1290854 | Disorder of skull | group | BEFREE |
C1298180 | Single tumor | phenotype | BEFREE |
C1301034 | Pancreatic intraepithelial neoplasia | disease | BEFREE |
C1301194 | Salivary duct carcinoma | disease | BEFREE |
C1302401 | Adenoma of large intestine | disease | BEFREE |
C1302773 | Low Grade Squamous Intraepithelial Neoplasia | disease | BEFREE |
C1306214 | ACTH-Secreting Pituitary Adenoma | disease | BEFREE |
C1306459 | Primary malignant neoplasm | group | BEFREE |
C1306460 | Primary malignant neoplasm of lung | disease | BEFREE |
C1314694 | Astrocytoma, low grade | disease | BEFREE |
C1319018 | Asthmatic bronchitis | disease | BEFREE |
C1319315 | Adenocarcinoma of large intestine | disease | BEFREE;CGI |
C1319317 | Squamous cell carcinoma of pharynx | disease | BEFREE |
C1321546 | Anaplastic large B-cell lymphoma | disease | BEFREE |
C1322286 | Thymoma, type C | disease | BEFREE |
C1328504 | Hormone refractory prostate cancer | disease | BEFREE |
C1332183 | adult astrocytic tumors | group | BEFREE |
C1332206 | Adult Lymphoma | disease | BEFREE |
C1332460 | Barrett's Adenocarcinoma | disease | BEFREE |
C1332833 | Calcifying Fibrous Pseudotumor | disease | BEFREE |
C1332922 | Cervical Squamous Intraepithelial Neoplasia | disease | BEFREE |
C1332979 | Childhood Lymphoma | disease | BEFREE |
C1333443 | Esophageal Basaloid Carcinoma | disease | BEFREE |
C1333990 | Hereditary Nonpolyposis Colorectal Cancer | disease | BEFREE |
C1334177 | Infiltrating Cervical Carcinoma | disease | BEFREE |
C1334272 | Invasive Apocrine Breast Carcinoma | disease | BEFREE |
C1334274 | Invasive Carcinoma | phenotype | BEFREE |
C1334455 | Pulmonary Sclerosing Hemangioma | disease | BEFREE |
C1334603 | Malignant Mixed Mesodermal (Mullerian) Tumor | disease | BEFREE |
C1334615 | Malignant Phyllodes Tumor of Prostate | disease | BEFREE |
C1334708 | Metaplastic breast carcinoma | disease | BEFREE |
C1334811 | Mucinous neoplasm | disease | BEFREE |
C1335302 | Pancreatic Ductal Adenocarcinoma | disease | BEFREE |
C1335363 | Mucoepidermoid carcinoma of parotid gland | disease | BEFREE |
C1335377 | Periampullary Adenocarcinoma | disease | BEFREE |
C1335409 | Prostate Phyllodes Tumor | disease | BEFREE |
C1335475 | Primary Carcinoma | phenotype | BEFREE |
C1335703 | Recurrent Head and Neck Carcinoma | disease | BEFREE |
C1336084 | Squamous Lung Dysplasia | disease | BEFREE |
C1336536 | Supratentorial Glioblastoma | disease | BEFREE |
C1336538 | Supratentorial Embryonal Tumor, Not Otherwise Specified | disease | BEFREE |
C1337013 | Differentiated Thyroid Gland Carcinoma | disease | BEFREE |
C1367859 | Pineal parenchymal tumor of intermediate differentiation | disease | BEFREE |
C1368404 | Hypopharyngeal Carcinoma | disease | BEFREE |
C1368683 | Epithelioma | disease | BEFREE |
C1368910 | Mature Teratoma | disease | BEFREE |
C1370419 | Ovarian Granulosa Cell Tumor | disease | BEFREE |
C1370889 | Liposarcoma, well differentiated | disease | BEFREE |
C1377610 | Peritoneal Mesothelioma | disease | BEFREE |
C1377913 | Pleural Mesothelioma | disease | BEFREE |
C1378703 | Renal carcinoma | disease | BEFREE |
C1384494 | Metastatic Carcinoma | group | BEFREE |
C1402294 | Primary Lesion | phenotype | BEFREE |
C1412036 | Anal squamous cell carcinoma | disease | BEFREE |
C1449563 | Cardiomyopathy, Familial Idiopathic | disease | BEFREE;CTD_human |
C1456781 | Benign melanocytic nevus | disease | BEFREE |
C1458155 | Mammary Neoplasms | group | BEFREE;CTD_human;LHGDN |
C1510472 | Drug Dependence | phenotype | BEFREE |
C1512127 | HER2 gene amplification | phenotype | BEFREE |
C1512409 | Hepatocarcinogenesis | disease | BEFREE |
C1512981 | Mammary Tumorigenesis | phenotype | BEFREE |
C1514422 | Glioblastoma, IDH-Wildtype | disease | BEFREE |
C1514428 | Primary peritoneal carcinoma | disease | BEFREE |
C1515286 | Testicular Intratubular Germ Cell Neoplasia, Unclassified | disease | BEFREE |
C1516170 | Cancer Cell Growth | phenotype | BEFREE |
C1518869 | Pancreatic Intraductal Papillary-Mucinous Neoplasm | disease | BEFREE |
C1519214 | Glioblastoma, IDH-Mutant | disease | BEFREE |
C1519346 | Skin Carcinogenesis | disease | BEFREE |
C1519666 | Tumor-Associated Vasculature | phenotype | BEFREE |
C1519670 | Tumor Angiogenesis | phenotype | BEFREE |
C1527249 | Colorectal Cancer | disease | BEFREE;CTD_human |
C1527336 | Sjogren's Syndrome | disease | BEFREE |
C1527349 | Ductal Breast Carcinoma | disease | BEFREE |
C1527390 | Neoplasms, Intracranial | group | BEFREE |
C1533161 | Eccrine Poroma | disease | BEFREE |
C1559154 | Rash and Dermatitis Adverse Event Associated with Chemoradiation | disease | BEFREE |
C1561643 | Chronic Kidney Diseases | group | BEFREE |
C1565662 | Acute Kidney Insufficiency | disease | CTD_human |
C1569637 | Adenocarcinoma, Endometrioid | disease | BEFREE |
C1608408 | Malignant transformation | phenotype | BEFREE |
C1611743 | Familial (FPAH) | disease | BEFREE |
C1621958 | Glioblastoma Multiforme | disease | BEFREE;CTD_human;GWASCAT |
C1623038 | Cirrhosis | disease | BEFREE |
C1654637 | androgen independent prostate cancer | disease | BEFREE |
C1704230 | Grade I Astrocytoma | disease | BEFREE |
C1704231 | Metastatic Malignant Neoplasm to the Leptomeninges | disease | BEFREE |
C1704272 | Benign Prostatic Hyperplasia | disease | BEFREE |
C1704376 | Uterine Corpus Carcinosarcoma | disease | BEFREE |
C1708349 | Hereditary Diffuse Gastric Cancer | disease | CTD_human |
C1708550 | Intimal sarcoma | disease | BEFREE |
C1708778 | mucoepidermoid carcinoma of lung | disease | BEFREE |
C1708781 | Lung Sarcomatoid Carcinoma | disease | BEFREE |
C1710096 | Sinonasal undifferentiated carcinoma | disease | BEFREE |
C1711276 | carcinosarcoma of lung | disease | BEFREE |
C1719528 | Other stomatitis and mucositis (ulcerative) | disease | BEFREE |
C1800706 | Idiopathic Pulmonary Fibrosis | disease | BEFREE |
C1832661 | ANOPHTHALMIA AND PULMONARY HYPOPLASIA | disease | BEFREE |
C1833921 | Familial medullary thyroid carcinoma | disease | BEFREE |
C1833929 | THYROID CARCINOMA, SPORADIC MEDULLARY | disease | BEFREE |
C1834582 | MYELOPROLIFERATIVE SYNDROME, TRANSIENT | disease | BEFREE |
C1838254 | RIPPLING MUSCLE DISEASE 1 | disease | BEFREE |
C1840264 | IMMUNE SUPPRESSION | phenotype | BEFREE |
C1847319 | PARAGANGLIOMA AND GASTRIC STROMAL SARCOMA | disease | BEFREE |
C1851584 | Childhood Ependymoma | disease | BEFREE |
C1851585 | MYELOPROLIFERATIVE DISORDER, CHRONIC, WITH EOSINOPHILIA | disease | BEFREE |
C1853698 | Rippling muscle disease | disease | BEFREE |
C1853738 | Long eyelashes | phenotype | HPO |
C1853926 | NONAKA MYOPATHY | disease | BEFREE |
C1855179 | CATARACT, ANTERIOR POLAR | disease | BEFREE |
C1859117 | Recurrent pulmonary infections | phenotype | HPO |
C1859598 | ATAXIA, EARLY-ONSET, WITH OCULOMOTOR APRAXIA AND HYPOALBUMINEMIA | disease | BEFREE |
C1861305 | TARSAL-CARPAL COALITION SYNDROME | disease | BEFREE |
C1862382 | SVEINSSON CHORIORETINAL ATROPHY | disease | BEFREE |
C1862866 | Ankyloblepharon filiforme adnatum and cleft palate | disease | BEFREE |
C1868675 | PARKINSON DISEASE 2, AUTOSOMAL RECESSIVE JUVENILE | disease | RGD |
C1868682 | Paroxysmal kinesigenic choreoathetosis | disease | BEFREE |
C1868683 | B-CELL MALIGNANCY, LOW-GRADE | disease | BEFREE |
C1883486 | Uterine Corpus Cancer | disease | BEFREE |
C1960398 | HER2-positive carcinoma of breast | disease | BEFREE |
C1960546 | Myxoma of heart | disease | BEFREE |
C1960925 | Epidermal growth factor receptor positive non-small cell lung cancer | disease | BEFREE |
C1997217 | Low grade glioma | disease | BEFREE |
C2118460 | Acute colitis | disease | BEFREE |
C2145472 | Urothelial Carcinoma | disease | BEFREE |
C2239176 | Liver carcinoma | disease | BEFREE;CTD_human;LHGDN |
C2315100 | Pediatric failure to thrive | disease | HPO |
C2347126 | Microscopic Polyarteritis | disease | BEFREE |
C2349952 | Oropharyngeal Carcinoma | disease | BEFREE |
C2609414 | Acute kidney injury | disease | CTD_human |
C2674218 | SPHEROCYTOSIS, TYPE 1 (disorder) | disease | BEFREE |
C2698045 | Merkel Cell Polyomavirus Infection | disease | BEFREE |
C2711227 | Steatohepatitis | disease | BEFREE |
C2713442 | Polyposis, Adenomatous Intestinal | disease | CTD_human |
C2713443 | Familial Intestinal Polyposis | disease | CTD_human |
C2717836 | Steroid Sulfatase Deficiency Disease | disease | BEFREE |
C2717981 | Poroma | disease | BEFREE |
C2745900 | Promyelocytic leukemia | disease | BEFREE |
C2828150 | Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma | disease | BEFREE |
C2931019 | Split hand foot deformity 1 | disease | BEFREE |
C2931618 | Gestational trophoblastic disease | disease | BEFREE |
C2931822 | Nasopharyngeal carcinoma | disease | BEFREE |
C2937421 | Prostatic Hyperplasia | disease | LHGDN |
C2939419 | Secondary Neoplasm | group | BEFREE |
C2939420 | Metastatic Neoplasm | phenotype | BEFREE |
C2945759 | aggressive cancer | phenotype | BEFREE |
C2986665 | Early-Stage Breast Carcinoma | disease | BEFREE |
C3146251 | Stage IV Colorectal Cancer AJCC v7 | disease | BEFREE |
C3266123 | Serrated polyp | phenotype | BEFREE |
C3266262 | Multiple Chronic Conditions | disease | BEFREE |
C3495917 | Advanced breast cancer | disease | BEFREE |
C3539781 | Progressive cGVHD | disease | BEFREE |
C3539878 | Triple Negative Breast Neoplasms | disease | BEFREE |
C3549742 | Breast cancer, lobular | disease | BEFREE |
C3642345 | Luminal A Breast Carcinoma | disease | BEFREE |
C3642346 | Luminal B Breast Carcinoma | disease | BEFREE |
C3642347 | Basal-Like Breast Carcinoma | disease | BEFREE |
C3658266 | Prostatic Cancer, Castration-Resistant | disease | BEFREE |
C3665419 | intracranial glioma | disease | BEFREE |
C3693482 | Giant Cell Fibroblastoma | disease | BEFREE |
C3714514 | Infection | group | LHGDN |
C3714644 | Thymus Neoplasms | group | BEFREE;LHGDN |
C3805278 | Extrahepatic Cholangiocarcinoma | disease | BEFREE;CTD_human |
C3809250 | ESTROGEN RESISTANCE | disease | BEFREE |
C3811653 | Experimental Organism Basal Cell Carcinoma | phenotype | BEFREE |
C3854329 | Primary mucoepidermoid carcinoma of lung | disease | BEFREE |
C3873341 | Primary adenocarcinoma of lung | disease | BEFREE |
C3875321 | Inflammatory dermatosis | group | BEFREE |
C3887461 | Head and Neck Carcinoma | disease | BEFREE;CGI |
C3887499 | Renal cyst | phenotype | BEFREE |
C3887678 | Central Nervous System Embryonal Tumor, Not Otherwise Specified | disease | BEFREE |
C3897752 | Recurrent Childhood Glioblastoma | disease | BEFREE |
C3898127 | Non-Metastatic Childhood Soft Tissue Sarcoma | disease | BEFREE |
C3898709 | Intestinal-Type Sinonasal Adenocarcinoma | disease | BEFREE |
C4013426 | Bronchial carcinoid | disease | BEFREE |
C4015130 | INFLAMMATORY SKIN AND BOWEL DISEASE, NEONATAL, 2 | disease | CLINVAR;CTD_human;UNIPROT |
C4015136 | Recurrent bronchiolitis | phenotype | HPO |
C4048305 | Neuroepithelioma | disease | BEFREE |
C4048328 | cervical cancer | disease | BEFREE;CTD_human |
C4082937 | Necrotizing enterocolitis in fetus OR newborn | disease | BEFREE |
C4085370 | Fibromatosis, Palmar | disease | BEFREE |
C4282132 | Malignancy | phenotype | BEFREE |
C4288305 | Recurrent Glioblastoma | disease | BEFREE |
C4509816 | Squamous non-small cell lung cancer | disease | BEFREE |
C4531021 | Undergrowth | phenotype | HPO |
GO ID | GO Term | Evidence |
---|---|---|
GO:0001618 | virus receptor activity | IEA |
GO:0003682 | chromatin binding | IDA |
GO:0003690 | double-stranded DNA binding | NAS |
GO:0004709 | MAP kinase kinase kinase activity | NAS |
GO:0004713 | protein tyrosine kinase activity | IMP |
GO:0004713 | protein tyrosine kinase activity | TAS |
GO:0004713 | protein tyrosine kinase activity | IDA |
GO:0004714 | transmembrane receptor protein tyrosine kinase activity | IBA |
GO:0004714 | transmembrane receptor protein tyrosine kinase activity | TAS |
GO:0004888 | transmembrane signaling receptor activity | IDA |
GO:0005006 | epidermal growth factor-activated receptor activity | IDA |
GO:0005006 | epidermal growth factor-activated receptor activity | IBA |
GO:0005006 | epidermal growth factor-activated receptor activity | IMP |
GO:0005006 | epidermal growth factor-activated receptor activity | NAS |
GO:0005178 | integrin binding | IEA |
GO:0005515 | protein binding | IPI |
GO:0005516 | calmodulin binding | IEA |
GO:0005524 | ATP binding | IEA |
GO:0019899 | enzyme binding | IPI |
GO:0019901 | protein kinase binding | IEA |
GO:0019903 | protein phosphatase binding | IPI |
GO:0031625 | ubiquitin protein ligase binding | IPI |
GO:0042802 | identical protein binding | IPI |
GO:0045296 | cadherin binding | HDA |
GO:0048408 | epidermal growth factor binding | IBA |
GO:0051015 | actin filament binding | IDA |
GO:0051117 | ATPase binding | ISS |
GO:0030235 | nitric-oxide synthase regulator activity | IDA |
GO ID | GO Term | Evidence |
---|---|---|
GO:0000165 | MAPK cascade | TAS |
GO:0000186 | activation of MAPKK activity | IEA |
GO:0001503 | ossification | NAS |
GO:0001892 | embryonic placenta development | IEA |
GO:0001934 | positive regulation of protein phosphorylation | IDA |
GO:0001942 | hair follicle development | IEA |
GO:0006357 | regulation of transcription by RNA polymerase II | TAS |
GO:0006412 | translation | IEA |
GO:0006970 | response to osmotic stress | IEA |
GO:0007165 | signal transduction | IDA |
GO:0007165 | signal transduction | TAS |
GO:0007166 | cell surface receptor signaling pathway | IDA |
GO:0007169 | transmembrane receptor protein tyrosine kinase signaling pathway | IBA |
GO:0007173 | epidermal growth factor receptor signaling pathway | IDA |
GO:0007173 | epidermal growth factor receptor signaling pathway | IMP |
GO:0007173 | epidermal growth factor receptor signaling pathway | TAS |
GO:0007202 | activation of phospholipase C activity | TAS |
GO:0007275 | multicellular organism development | IBA |
GO:0007435 | salivary gland morphogenesis | IEA |
GO:0007494 | midgut development | IEA |
GO:0007611 | learning or memory | ISS |
GO:0007623 | circadian rhythm | IEA |
GO:0008283 | cell population proliferation | IDA |
GO:0008284 | positive regulation of cell population proliferation | IBA |
GO:0008284 | positive regulation of cell population proliferation | IMP |
GO:0008284 | positive regulation of cell population proliferation | IDA |
GO:0010750 | positive regulation of nitric oxide mediated signal transduction | IDA |
GO:0010960 | magnesium ion homeostasis | IEA |
GO:0014066 | regulation of phosphatidylinositol 3-kinase signaling | IMP |
GO:0016101 | diterpenoid metabolic process | IEA |
GO:0018108 | peptidyl-tyrosine phosphorylation | IDA |
GO:0021795 | cerebral cortex cell migration | IEA |
GO:0030154 | cell differentiation | IBA |
GO:0030307 | positive regulation of cell growth | IDA |
GO:0030324 | lung development | IEA |
GO:0030335 | positive regulation of cell migration | IMP |
GO:0032930 | positive regulation of superoxide anion generation | IEA |
GO:0033138 | positive regulation of peptidyl-serine phosphorylation | IMP |
GO:0033590 | response to cobalamin | IEA |
GO:0033594 | response to hydroxyisoflavone | IEA |
GO:0033674 | positive regulation of kinase activity | IBA |
GO:0034614 | cellular response to reactive oxygen species | IMP |
GO:0038083 | peptidyl-tyrosine autophosphorylation | IMP |
GO:0038083 | peptidyl-tyrosine autophosphorylation | TAS |
GO:0038128 | ERBB2 signaling pathway | TAS |
GO:0042059 | negative regulation of epidermal growth factor receptor signaling pathway | TAS |
GO:0042060 | wound healing | IEA |
GO:0042177 | negative regulation of protein catabolic process | IDA |
GO:0042327 | positive regulation of phosphorylation | IDA |
GO:0042698 | ovulation cycle | IEA |
GO:0042743 | hydrogen peroxide metabolic process | IEA |
GO:0043006 | activation of phospholipase A2 activity by calcium-mediated signaling | TAS |
GO:0043066 | negative regulation of apoptotic process | IMP |
GO:0043066 | negative regulation of apoptotic process | IBA |
GO:0043406 | positive regulation of MAP kinase activity | IDA |
GO:0043586 | tongue development | IEA |
GO:0045737 | positive regulation of cyclin-dependent protein serine/threonine kinase activity | IMP |
GO:0045739 | positive regulation of DNA repair | IDA |
GO:0045740 | positive regulation of DNA replication | IDA |
GO:0045746 | negative regulation of Notch signaling pathway | TAS |
GO:0045780 | positive regulation of bone resorption | IEA |
GO:0045893 | positive regulation of transcription, DNA-templated | IMP |
GO:0045907 | positive regulation of vasoconstriction | IEA |
GO:0045930 | negative regulation of mitotic cell cycle | IEA |
GO:0045944 | positive regulation of transcription by RNA polymerase II | IDA |
GO:0046328 | regulation of JNK cascade | IMP |
GO:0046718 | viral entry into host cell | IEA |
GO:0046777 | protein autophosphorylation | IMP |
GO:0048143 | astrocyte activation | IEA |
GO:0048146 | positive regulation of fibroblast proliferation | IEA |
GO:0048546 | digestive tract morphogenesis | IEA |
GO:0048661 | positive regulation of smooth muscle cell proliferation | IEA |
GO:0048812 | neuron projection morphogenesis | IEA |
GO:0050679 | positive regulation of epithelial cell proliferation | IDA |
GO:0050679 | positive regulation of epithelial cell proliferation | IBA |
GO:0050729 | positive regulation of inflammatory response | IEA |
GO:0050730 | regulation of peptidyl-tyrosine phosphorylation | IMP |
GO:0050999 | regulation of nitric-oxide synthase activity | IDA |
GO:0051205 | protein insertion into membrane | TAS |
GO:0051592 | response to calcium ion | IEA |
GO:0051897 | positive regulation of protein kinase B signaling | IMP |
GO:0051897 | positive regulation of protein kinase B signaling | TAS |
GO:0051968 | positive regulation of synaptic transmission, glutamatergic | IEA |
GO:0060571 | morphogenesis of an epithelial fold | IEA |
GO:0061024 | membrane organization | TAS |
GO:0061029 | eyelid development in camera-type eye | IEA |
GO:0070141 | response to UV-A | IDA |
GO:0070372 | regulation of ERK1 and ERK2 cascade | IMP |
GO:0070374 | positive regulation of ERK1 and ERK2 cascade | IDA |
GO:0070374 | positive regulation of ERK1 and ERK2 cascade | IMP |
GO:0071230 | cellular response to amino acid stimulus | IEA |
GO:0071260 | cellular response to mechanical stimulus | IEA |
GO:0071276 | cellular response to cadmium ion | IMP |
GO:0071364 | cellular response to epidermal growth factor stimulus | ISS |
GO:0071392 | cellular response to estradiol stimulus | IDA |
GO:0071549 | cellular response to dexamethasone stimulus | IEA |
GO:0090263 | positive regulation of canonical Wnt signaling pathway | IMP |
GO:0097421 | liver regeneration | IEA |
GO:0097755 | positive regulation of blood vessel diameter | IEA |
GO:0098609 | cell-cell adhesion | IMP |
GO:1900020 | positive regulation of protein kinase C activity | IDA |
GO:1900087 | positive regulation of G1/S transition of mitotic cell cycle | IMP |
GO:1901185 | negative regulation of ERBB signaling pathway | TAS |
GO:1901224 | positive regulation of NIK/NF-kappaB signaling | IMP |
GO:1902722 | positive regulation of prolactin secretion | IEA |
GO:1903078 | positive regulation of protein localization to plasma membrane | IDA |
GO:1903800 | positive regulation of production of miRNAs involved in gene silencing by miRNA | IMP |
GO:1905208 | negative regulation of cardiocyte differentiation | IMP |
GO:2000145 | regulation of cell motility | TAS |
GO ID | GO Term | Evidence |
---|---|---|
GO:0000139 | Golgi membrane | IEA |
GO:0005615 | extracellular space | NAS |
GO:0005634 | nucleus | IDA |
GO:0005737 | cytoplasm | IDA |
GO:0005768 | endosome | IDA |
GO:0005789 | endoplasmic reticulum membrane | IEA |
GO:0005886 | plasma membrane | IDA |
GO:0005886 | plasma membrane | TAS |
GO:0005887 | integral component of plasma membrane | IBA |
GO:0005925 | focal adhesion | HDA |
GO:0009925 | basal plasma membrane | IBA |
GO:0009986 | cell surface | IDA |
GO:0010008 | endosome membrane | IDA |
GO:0016020 | membrane | IDA |
GO:0016323 | basolateral plasma membrane | IDA |
GO:0016324 | apical plasma membrane | IEA |
GO:0030054 | cell junction | IDA |
GO:0030139 | endocytic vesicle | IEA |
GO:0030665 | clathrin-coated vesicle membrane | TAS |
GO:0031901 | early endosome membrane | IDA |
GO:0031965 | nuclear membrane | IEA |
GO:0032991 | protein-containing complex | IDA |
GO:0043235 | receptor complex | IBA |
GO:0043235 | receptor complex | IDA |
GO:0045121 | membrane raft | ISS |
GO:0045121 | membrane raft | IDA |
GO:0045202 | synapse | IEA |
GO:0048471 | perinuclear region of cytoplasm | IMP |
GO:0070435 | Shc-EGFR complex | ISS |
GO:0097489 | multivesicular body, internal vesicle lumen | IDA |
Reactome ID | Reactome Term | Evidence |
---|---|---|
R-HSA-1227986 | Signaling by ERBB2 | TAS |
R-HSA-1227986 | Signaling by ERBB2 | IEA |
R-HSA-1227990 | Signaling by ERBB2 in Cancer | TAS |
R-HSA-1236382 | Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants | TAS |
R-HSA-1236394 | Signaling by ERBB4 | TAS |
R-HSA-1250196 | SHC1 events in ERBB2 signaling | IEA |
R-HSA-1250196 | SHC1 events in ERBB2 signaling | TAS |
R-HSA-1251932 | PLCG1 events in ERBB2 signaling | IEA |
R-HSA-1257604 | PIP3 activates AKT signaling | TAS |
R-HSA-1266738 | Developmental Biology | TAS |
R-HSA-1280215 | Cytokine Signaling in Immune system | TAS |
R-HSA-157118 | Signaling by NOTCH | TAS |
R-HSA-162582 | Signal Transduction | TAS |
R-HSA-162582 | Signal Transduction | IEA |
R-HSA-1643685 | Disease | TAS |
R-HSA-1643713 | Signaling by EGFR in Cancer | TAS |
R-HSA-168256 | Immune System | TAS |
R-HSA-177929 | Signaling by EGFR | TAS |
R-HSA-179812 | GRB2 events in EGFR signaling | TAS |
R-HSA-180292 | GAB1 signalosome | TAS |
R-HSA-180336 | SHC1 events in EGFR signaling | TAS |
R-HSA-182971 | EGFR downregulation | TAS |
R-HSA-1963640 | GRB2 events in ERBB2 signaling | IEA |
R-HSA-1963642 | PI3K events in ERBB2 signaling | TAS |
R-HSA-199418 | Negative regulation of the PI3K/AKT network | TAS |
R-HSA-199991 | Membrane Trafficking | TAS |
R-HSA-212436 | Generic Transcription Pathway | TAS |
R-HSA-212718 | EGFR interacts with phospholipase C-gamma | TAS |
R-HSA-2179392 | EGFR Transactivation by Gastrin | TAS |
R-HSA-2219528 | PI3K/AKT Signaling in Cancer | TAS |
R-HSA-2219530 | Constitutive Signaling by Aberrant PI3K in Cancer | TAS |
R-HSA-372790 | Signaling by GPCR | TAS |
R-HSA-373760 | L1CAM interactions | TAS |
R-HSA-388396 | GPCR downstream signalling | TAS |
R-HSA-416476 | G alpha (q) signalling events | TAS |
R-HSA-422475 | Axon guidance | TAS |
R-HSA-445144 | Signal transduction by L1 | TAS |
R-HSA-5637810 | Constitutive Signaling by EGFRvIII | TAS |
R-HSA-5637812 | Signaling by EGFRvIII in Cancer | TAS |
R-HSA-5637815 | Signaling by Ligand-Responsive EGFR Variants in Cancer | TAS |
R-HSA-5638302 | Signaling by Overexpressed Wild-Type EGFR in Cancer | TAS |
R-HSA-5638303 | Inhibition of Signaling by Overexpressed EGFR | TAS |
R-HSA-5653656 | Vesicle-mediated transport | TAS |
R-HSA-5663202 | Diseases of signal transduction | TAS |
R-HSA-5663205 | Infectious disease | TAS |
R-HSA-5673001 | RAF/MAP kinase cascade | TAS |
R-HSA-5683057 | MAPK family signaling cascades | TAS |
R-HSA-5684996 | MAPK1/MAPK3 signaling | TAS |
R-HSA-6785631 | ERBB2 Regulates Cell Motility | TAS |
R-HSA-6811558 | PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling | TAS |
R-HSA-73857 | RNA Polymerase II Transcription | TAS |
R-HSA-74160 | Gene expression (Transcription) | TAS |
R-HSA-881907 | Gastrin-CREB signalling pathway via PKC and MAPK | TAS |
R-HSA-8847993 | ERBB2 Activates PTK6 Signaling | TAS |
R-HSA-8848021 | Signaling by PTK6 | TAS |
R-HSA-8856825 | Cargo recognition for clathrin-mediated endocytosis | TAS |
R-HSA-8856828 | Clathrin-mediated endocytosis | TAS |
R-HSA-8857538 | PTK6 promotes HIF1A stabilization | TAS |
R-HSA-8863795 | Downregulation of ERBB2 signaling | TAS |
R-HSA-8864260 | Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors | TAS |
R-HSA-8866910 | TFAP2 (AP-2) family regulates transcription of growth factors and their receptors | TAS |
R-HSA-8939211 | ESR-mediated signaling | TAS |
R-HSA-9006925 | Intracellular signaling by second messengers | TAS |
R-HSA-9006927 | Signaling by Non-Receptor Tyrosine Kinases | TAS |
R-HSA-9006931 | Signaling by Nuclear Receptors | TAS |
R-HSA-9006934 | Signaling by Receptor Tyrosine Kinases | TAS |
R-HSA-9006934 | Signaling by Receptor Tyrosine Kinases | IEA |
R-HSA-9009391 | Extra-nuclear estrogen signaling | TAS |
R-HSA-9012852 | Signaling by NOTCH3 | TAS |
R-HSA-9013507 | NOTCH3 Activation and Transmission of Signal to the Nucleus | TAS |
R-HSA-9607240 | FLT3 Signaling | TAS |
R-HSA-9609646 | HCMV Infection | TAS |
R-HSA-9609690 | HCMV Early Events | TAS |
R-HSA-9634638 | Estrogen-dependent nuclear events downstream of ESR-membrane signaling | TAS |
R-HSA-9664565 | Signaling by ERBB2 KD Mutants | TAS |
ID | Drug Name | Action | PubMed |
---|---|---|---|
C521487 | 10-nitro-oleic acid | 10-nitro-oleic acid results in decreased expression of EGFR mRNA | 29158255 |
C046783 | 11,12-epoxy-5,8,14-eicosatrienoic acid | 11,12-epoxy-5,8,14-eicosatrienoic acid inhibits the reaction [Terfenadine analog results in decreased phosphorylation of EGFR protein] | 19289568 |
C046783 | 11,12-epoxy-5,8,14-eicosatrienoic acid | 11,12-epoxy-5,8,14-eicosatrienoic acid results in increased phosphorylation of and results in increased activity of EGFR protein | 20804500 |
C046783 | 11,12-epoxy-5,8,14-eicosatrienoic acid | 14,15-eicosa-5-enoic acid inhibits the reaction [11,12-epoxy-5,8,14-eicosatrienoic acid results in increased phosphorylation of and results in increased activity of EGFR protein] | 20804500 |
C552530 | 1,1-bis(3'-indolyl)-1-(4-hydroxyphenyl)methane | 1,1-bis(3'-indolyl)-1-(4-hydroxyphenyl)methane results in decreased expression of EGFR protein | 26035713 |
C051412 | 1,2,3,4,7,8-hexachlorodibenzofuran | 1,2,3,4,7,8-hexachlorodibenzofuran results in decreased activity of EGFR protein | 2718174 |
C569107 | 1-(2-chlorobenzyl)-5'-phenyl-3'H-spiro(indoline-3,2'-(1,3,4)thiadiazol)-2-one | 1-(2-chlorobenzyl)-5'-phenyl-3'H-spiro(indoline-3,2'-(1,3,4)thiadiazol)-2-one results in decreased expression of EGFR mRNA | 23826121 |
C070046 | 1,2-dioleoyloxy-3-(trimethylammonium)propane | [Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of EGFR mRNA | 22129739 |
C049325 | 1,2-dithiol-3-thione | 1,2-dithiol-3-thione results in decreased expression of EGFR mRNA | 19162173 |
C040756 | 1,2-naphthoquinone | 1,2-naphthoquinone results in increased phosphorylation of and results in increased activity of EGFR protein | 24067727 |
C494022 | 14,15-eicosa-5-enoic acid | 14,15-eicosa-5-enoic acid inhibits the reaction [11,12-epoxy-5,8,14-eicosatrienoic acid results in increased phosphorylation of and results in increased activity of EGFR protein] | 20804500 |
C494022 | 14,15-eicosa-5-enoic acid | 14,15-eicosa-5-enoic acid results in decreased phosphorylation of and results in decreased activity of EGFR protein | 20804500 |
C569670 | 1-(4-((2-(2-aminopyrimidin-5-yl)-7-methyl-4-morpholinothieno(3,2-d)pyrimidin-6-yl)methyl)piperazin-1-yl)-2-hydroxypropan-1-one | EGFR gene mutant form results in increased susceptibility to 1-(4-((2-(2-aminopyrimidin-5-yl)-7-methyl-4-morpholinothieno(3,2-d)pyrimidin-6-yl)methyl)piperazin-1-yl)-2-hydroxypropan-1-one | 23136191 |
C553294 | 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one | 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [EGFR protein mutant form results in increased expression of FOXG1 mRNA] | 26455392 |
C553294 | 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one | 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [EGFR protein mutant form results in increased expression of FOXG1 protein] | 26455392 |
C553294 | 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one | 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [EGFR protein mutant form results in increased expression of SOX9 mRNA] | 26455392 |
C553294 | 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one | 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [EGFR protein mutant form results in increased expression of SOX9 protein] | 26455392 |
C517943 | 1-(4-(6-bromobenzo(1,3)dioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta(c)quinolin-8-yl)ethanone | 1-(4-(6-bromobenzo(1,3)dioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta(c)quinolin-8-yl)ethanone promotes the reaction [SRC protein modified form binds to EGFR protein modified form] | 31468104 |
C517943 | 1-(4-(6-bromobenzo(1,3)dioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta(c)quinolin-8-yl)ethanone | 1-(4-(6-bromobenzo(1,3)dioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta(c)quinolin-8-yl)ethanone results in increased phosphorylation of EGFR protein | 31468104 |
C517943 | 1-(4-(6-bromobenzo(1,3)dioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta(c)quinolin-8-yl)ethanone | 4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-3H-cyclopenta(c)quinoline inhibits the reaction [1-(4-(6-bromobenzo(1,3)dioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta(c)quinolin-8-yl)ethanone results in increased phosphorylation of EGFR protein] | 31468104 |
C517943 | 1-(4-(6-bromobenzo(1,3)dioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta(c)quinolin-8-yl)ethanone | EGFR protein promotes the reaction [1-(4-(6-bromobenzo(1,3)dioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta(c)quinolin-8-yl)ethanone results in increased expression of MIR21 mRNA] | 25969534 |
C517943 | 1-(4-(6-bromobenzo(1,3)dioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta(c)quinolin-8-yl)ethanone | [1-(4-(6-bromobenzo(1,3)dioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta(c)quinolin-8-yl)ethanone binds to and results in increased activity of GPER1 protein] which results in increased phosphorylation of and results in increased activity of EGFR protein | 22645130 |
C028474 | 1,4-bis(2-(3,5-dichloropyridyloxy))benzene | 1,4-bis(2-(3,5-dichloropyridyloxy))benzene results in decreased expression of EGFR mRNA | 22698814 |
C028474 | 1,4-bis(2-(3,5-dichloropyridyloxy))benzene | 1,4-bis(2-(3,5-dichloropyridyloxy))benzene results in decreased expression of EGFR protein | 21705713 |
C028474 | 1,4-bis(2-(3,5-dichloropyridyloxy))benzene | 1,4-bis(2-(3,5-dichloropyridyloxy))benzene results in decreased expression of EGFR protein modified form | 21705713 |
C028474 | 1,4-bis(2-(3,5-dichloropyridyloxy))benzene | CTNNB1 gene mutant form affects the susceptibility to [1,4-bis(2-(3,5-dichloropyridyloxy))benzene affects the expression of EGFR protein] | 21705713 |
D015064 | 16,16-Dimethylprostaglandin E2 | EGFR affects the reaction [16,16-Dimethylprostaglandin E2 results in increased phosphorylation of AKT1 protein] | 15578100 |
C060229 | 1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione | 1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [NTS protein results in increased phosphorylation of and results in increased activity of EGFR protein] | 15177934 |
D020001 | 1-Butanol | 1-Butanol inhibits the reaction [AGT protein results in increased phosphorylation of and results in increased activity of EGFR protein] | 15525798 |
D020001 | 1-Butanol | 1-Butanol inhibits the reaction [EGF protein binds to and results in increased degradation of EGFR protein] | 11134345 |
D020001 | 1-Butanol | 1-Butanol inhibits the reaction [EGF protein binds to and results in increased localization of EGFR protein] | 11134345 |
C051246 | 1-methylanthracene | [1-methylanthracene co-treated with fluoranthene] results in increased expression of EGFR mRNA | 28329830 |
C532162 | 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine | EGFR gene mutant form results in increased susceptibility to 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine | 23136191 |
C417207 | 2,2',4,6,6'-pentachlorobiphenyl | 2,2',4,6,6'-pentachlorobiphenyl results in increased phosphorylation of EGFR protein | 16778083 |
C417207 | 2,2',4,6,6'-pentachlorobiphenyl | WHI P154 inhibits the reaction [2,2',4,6,6'-pentachlorobiphenyl results in increased phosphorylation of EGFR protein] | 16778083 |
C093973 | 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one | 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [EGFR protein binds to GPER1 protein] | 19749156 |
C093973 | 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one | 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Sodium Chloride results in increased phosphorylation of EGFR protein] | 21568938 |
C093973 | 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one | 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one results in decreased expression of EGFR mRNA | 18332871 |
C093973 | 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one | 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one results in decreased expression of EGFR protein | 18332871 |
C404910 | 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane | 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane results in increased phosphorylation of EGFR protein | 28426875 |
C404910 | 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane | 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [FSHB protein affects the expression of EGFR mRNA] | 19414516 |
C120227 | 2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide | 2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide results in decreased phosphorylation of EGFR protein | 16261397 |
C038890 | 2,3,4,7,8-pentachlorodibenzofuran | 2,3,4,7,8-pentachlorodibenzofuran results in decreased activity of EGFR protein | 2718174 |
C013186 | 2,3-pentanedione | 2,3-pentanedione results in increased expression of EGFR mRNA | 25710175 |
C014024 | 2,4,5,2',4',5'-hexachlorobiphenyl | 2,4,5,2',4',5'-hexachlorobiphenyl affects the localization of EGFR protein | 19632255 |
C014024 | 2,4,5,2',4',5'-hexachlorobiphenyl | 2,4,5,2',4',5'-hexachlorobiphenyl binds to EGFR protein | 29329451 |
C014024 | 2,4,5,2',4',5'-hexachlorobiphenyl | 2,4,5,2',4',5'-hexachlorobiphenyl inhibits the reaction [EGF protein binds to EGFR protein] | 29329451 |
C014024 | 2,4,5,2',4',5'-hexachlorobiphenyl | 2,4,5,2',4',5'-hexachlorobiphenyl inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein] | 29329451 |
C014024 | 2,4,5,2',4',5'-hexachlorobiphenyl | 2,4,5,2',4',5'-hexachlorobiphenyl results in increased phosphorylation of EGFR protein | 19632255 |
C085911 | 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one | 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [NTS protein results in increased phosphorylation of and results in increased activity of EGFR protein] | 15177934 |
C408604 | 2-(4-nitrophenyl)-4-(4-fluorophenyl)-5-(4-pyridinyl)-1H-imidazole | 2-(4-nitrophenyl)-4-(4-fluorophenyl)-5-(4-pyridinyl)-1H-imidazole affects the phosphorylation of EGFR protein | 19010935 |
C011269 | 2,5-hexanedione | 2,5-hexanedione results in increased expression of EGFR mRNA | 16141653 |
C023704 | 2-acetamidoethanethiol | 2-acetamidoethanethiol analog results in decreased phosphorylation of EGFR protein | 20058253 |
D015073 | 2-Acetylaminofluorene | 2-Acetylaminofluorene affects the reaction [EGF protein results in increased phosphorylation of EGFR protein] | 10900465 |
D015073 | 2-Acetylaminofluorene | 2-Acetylaminofluorene results in decreased expression of EGFR mRNA | 22213190 |
C049584 | 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine | 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of EGFR mRNA | 8603490 |
C049584 | 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine | [RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [[[2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased phosphorylation of MAPK1 protein] co-treated with [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased phosphorylation of MAPK3 protein]] results in increased phosphorylation of ELK1 protein] | 18056474 |
C484327 | 2'-benzoyloxycinnamaldehyde | 2'-benzoyloxycinnamaldehyde results in increased phosphorylation of EGFR protein | 14660655 |
C484327 | 2'-benzoyloxycinnamaldehyde | Acetylcysteine inhibits the reaction [2'-benzoyloxycinnamaldehyde results in increased phosphorylation of EGFR protein] | 14660655 |
C484327 | 2'-benzoyloxycinnamaldehyde | Glutathione inhibits the reaction [2'-benzoyloxycinnamaldehyde results in increased phosphorylation of EGFR protein] | 14660655 |
C457499 | 2-chloro-5-nitrobenzanilide | 2-chloro-5-nitrobenzanilide inhibits the reaction [bisphenol A results in increased phosphorylation of EGFR protein] | 31075703 |
C585004 | 2-monochloropropanediol | 2-monochloropropanediol results in increased expression of EGFR mRNA | 28522335 |
C029955 | 2-nitrotoluene | 2-nitrotoluene results in decreased expression of EGFR mRNA | 15618236 |
C560905 | 3-(2-(dimethylamino)isopropoxy)-1-hydroxybenzo(b)naphtho(2,3-d)furan-6,11-dione | 3-(2-(dimethylamino)isopropoxy)-1-hydroxybenzo(b)naphtho(2,3-d)furan-6,11-dione results in decreased activity of EGFR protein | 21600193 |
C023035 | 3,4,5,3',4'-pentachlorobiphenyl | 3,4,5,3',4'-pentachlorobiphenyl binds to EGFR protein | 29329451 |
C023035 | 3,4,5,3',4'-pentachlorobiphenyl | 3,4,5,3',4'-pentachlorobiphenyl inhibits the reaction [EGF protein binds to EGFR protein] | 29329451 |
C023035 | 3,4,5,3',4'-pentachlorobiphenyl | 3,4,5,3',4'-pentachlorobiphenyl inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein] | 29329451 |
C472791 | 3-(4'-hydroxy-3'-adamantylbiphenyl-4-yl)acrylic acid | 3-(4'-hydroxy-3'-adamantylbiphenyl-4-yl)acrylic acid results in increased expression of EGFR mRNA | 16788091 |
C500530 | 3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo(b)(1,4)dioxin-6-yl)acrylamide | 3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo(b)(1,4)dioxin-6-yl)acrylamide results in increased expression of EGFR protein | 21349818 |
C500530 | 3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo(b)(1,4)dioxin-6-yl)acrylamide | 3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo(b)(1,4)dioxin-6-yl)acrylamide results in increased expression of and results in increased phosphorylation of EGFR protein | 21349818 |
C495482 | (3-chloro-4-fluoro-phenyl)-(6-(4-diethylaminomethyl-piperidin-1yl)-pyrimido(5,4-d)pyrimidin-4-yl)amine | (3-chloro-4-fluoro-phenyl)-(6-(4-diethylaminomethyl-piperidin-1yl)-pyrimido(5,4-d)pyrimidin-4-yl)amine results in decreased activity of EGFR protein | 22573732 |
C002010 | 4-(2-aminoethyl)benzenesulfonylfluoride | 4-(2-aminoethyl)benzenesulfonylfluoride inhibits the reaction [Cadmium Chloride results in increased phosphorylation of and results in increased activity of EGFR protein] | 23376140 |
C088860 | 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline | 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline inhibits the reaction [[Copper binds to Clioquinol] which results in increased phosphorylation of EGFR protein] | 18346929 |
C088860 | 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline | [4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline results in decreased activity of EGFR protein] results in decreased susceptibility to [Copper binds to Clioquinol] | 18346929 |
C088860 | 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline | 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline results in decreased phosphorylation of and results in decreased activity of EGFR protein | 18346929 |
C088860 | 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline | 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline analog results in decreased activity of EGFR protein | 11822173 |
C088860 | 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline | 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline inhibits the reaction [Asbestos, Crocidolite results in increased phosphorylation of EGFR protein] | 16908449 |
C088860 | 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline | 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline inhibits the reaction [betulinic acid results in increased phosphorylation of EGFR protein] | 16077934 |
C088860 | 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline | 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein] | 12915106; 16908449; |
C088860 | 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline | 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline inhibits the reaction [lead acetate results in increased phosphorylation of EGFR protein] | 19133285 |
C088860 | 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline | 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline inhibits the reaction [NTS protein results in increased phosphorylation of and results in increased activity of EGFR protein] | 15177934 |
C088860 | 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline | 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline inhibits the reaction [Zinc results in increased phosphorylation of EGFR protein] | 12972402; 15980035; 16410015; |
C088860 | 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline | 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline inhibits the reaction [Zinc Sulfate results in increased phosphorylation of EGFR protein] | 16410015 |
C088860 | 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline | 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline results in decreased activity of EGFR protein | 11822173; 15955695; 21649584; 22242139; |
C088860 | 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline | [4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline results in decreased phosphorylation of and results in decreased activity of EGFR protein] inhibits the reaction [[Copper binds to Clioquinol] which results in increased phosphorylation of MAPK1 protein] | 18346929 |
C088860 | 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline | [4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline results in decreased phosphorylation of and results in decreased activity of EGFR protein] inhibits the reaction [[Copper binds to Clioquinol] which results in increased phosphorylation of MAPK3 protein] | 18346929 |
C088860 | 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline | 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline inhibits the reaction [Ozone results in increased phosphorylation of EGFR protein] | 26464147 |
C088860 | 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline | 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline results in decreased activity of EGFR protein | 12839940; 15072578; 15952178; 16077934; 16211241; 22573732; 23143138; |
C583126 | 4-(4-(3-hydroxyphenyl)-3-(4-methylphenyl)-6-oxo-1H,4H,5H,6H-pyrrolo(3,4-c)pyrazol-5-yl)benzoic acid | 4-(4-(3-hydroxyphenyl)-3-(4-methylphenyl)-6-oxo-1H,4H,5H,6H-pyrrolo(3,4-c)pyrazol-5-yl)benzoic acid inhibits the reaction [AM 251 results in increased expression of EGFR protein] | 27423937 |
C583126 | 4-(4-(3-hydroxyphenyl)-3-(4-methylphenyl)-6-oxo-1H,4H,5H,6H-pyrrolo(3,4-c)pyrazol-5-yl)benzoic acid | 4-(4-(3-hydroxyphenyl)-3-(4-methylphenyl)-6-oxo-1H,4H,5H,6H-pyrrolo(3,4-c)pyrazol-5-yl)benzoic acid results in decreased expression of EGFR protein | 27423937 |
C575425 | (4-(4'-chloro-2'-fluoro)phenylamino)-6,7-dimethylquinazoline | (4-(4'-chloro-2'-fluoro)phenylamino)-6,7-dimethylquinazoline results in decreased activity of EGFR protein | 22573732 |
C009505 | 4,4'-diaminodiphenylmethane | 4,4'-diaminodiphenylmethane results in increased expression of EGFR mRNA | 18648102 |
C090942 | 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole | 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [AGT protein results in increased phosphorylation of EGFR protein] | 15525798 |
C583074 | 4,4'-hexafluorisopropylidene diphenol | 4,4'-hexafluorisopropylidene diphenol results in increased expression of EGFR mRNA | 27567155 |
C433938 | 4557 W | 4557 W results in decreased activity of EGFR protein | 17093206 |
C459179 | 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide | [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EGFR mRNA | 27188386 |
C459179 | 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide | [NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EGFR mRNA | 27188386 |
C459179 | 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide | [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EGFR mRNA | 27188386 |
C459179 | 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide | [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EGFR mRNA | 27188386 |
C568862 | 4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-3H-cyclopenta(c)quinoline | 4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-3H-cyclopenta(c)quinoline inhibits the reaction [1-(4-(6-bromobenzo(1,3)dioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta(c)quinolin-8-yl)ethanone results in increased phosphorylation of EGFR protein] | 31468104 |
C568862 | 4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-3H-cyclopenta(c)quinoline | 4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-3H-cyclopenta(c)quinoline inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased phosphorylation of EGFR protein] | 31468104 |
C568862 | 4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-3H-cyclopenta(c)quinoline | 4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-3H-cyclopenta(c)quinoline inhibits the reaction [Estradiol results in increased phosphorylation of EGFR protein] | 31468104 |
C108123 | 4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine | 4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [Arsenic Trioxide results in increased phosphorylation of EGFR protein] | 22532027 |
C108123 | 4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine | 4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein] | 25856345 |
C108123 | 4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine | 4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [[Zinc co-treated with EGFR protein] results in increased activity of RAS protein] | 11983694 |
C108123 | 4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine | 4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [Zinc results in increased phosphorylation of EGFR protein] | 11983694 |
C108123 | 4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine | 4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [tert-Butylhydroperoxide results in increased phosphorylation of EGFR protein] | 17116659 |
C108123 | 4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine | 4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [AGT protein results in increased phosphorylation of and results in increased activity of EGFR protein] | 15849355 |
C000603500 | 4'-methoxy-1-naphthylfenoterol | 4'-methoxy-1-naphthylfenoterol inhibits the reaction [AM 251 results in increased expression of EGFR protein] | 27423937 |
C000603500 | 4'-methoxy-1-naphthylfenoterol | 4'-methoxy-1-naphthylfenoterol results in decreased expression of EGFR protein | 27423937 |
C120195 | 4-nitroquinolone-1-oxide | [Arecoline co-treated with 4-nitroquinolone-1-oxide] results in increased phosphorylation of EGFR protein | 26464283 |
C120195 | 4-nitroquinolone-1-oxide | [helioxanthin co-treated with Arecoline co-treated with 4-nitroquinolone-1-oxide] affects the localization of EGFR protein modified form | 26464283 |
C120195 | 4-nitroquinolone-1-oxide | helioxanthin inhibits the reaction [[Arecoline co-treated with 4-nitroquinolone-1-oxide] results in increased phosphorylation of EGFR protein] | 26464283 |
C017572 | 4-nitrotoluene | 4-nitrotoluene results in decreased expression of EGFR protein | 15618236 |
C016583 | 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone | 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone results in increased phosphorylation of EGFR protein | 16671086 |
C016583 | 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone | Atenolol inhibits the reaction [4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone results in increased phosphorylation of EGFR protein] | 16671086 |
C002202 | 4-oxoretinoic acid | 4-oxoretinoic acid results in decreased expression of EGFR mRNA | 15982314 |
C105260 | 4-tert-octylphenol | 4-tert-octylphenol results in increased expression of EGFR mRNA | 17011747 |
C012606 | 4-vinyl-1-cyclohexene dioxide | 4-vinyl-1-cyclohexene dioxide affects the expression of EGFR mRNA | 20829426 |
C480541 | 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one | 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of EGFR protein | 21266357 |
C480541 | 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one | [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one] inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of EGFR protein] | 21266357 |
C480541 | 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one | TGFA protein inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of EGFR protein] | 21266357 |
C513003 | 5-(4-((6-(allyloxy)-2,5,7,8-tetramethylchroman-2-yl)methoxy)-3-methoxybenzylidene)thiazolidine-2,4-dione | 5-(4-((6-(allyloxy)-2,5,7,8-tetramethylchroman-2-yl)methoxy)-3-methoxybenzylidene)thiazolidine-2,4-dione results in decreased expression of EGFR mRNA | 17409431 |
D015117 | 5,8,11,14-Eicosatetraynoic Acid | 5,8,11,14-Eicosatetraynoic Acid inhibits the reaction [AGT protein results in increased phosphorylation of and results in increased activity of EGFR protein] | 15525798 |
D015117 | 5,8,11,14-Eicosatetraynoic Acid | 5,8,11,14-Eicosatetraynoic Acid inhibits the reaction [Arachidonic Acid results in increased phosphorylation of and results in increased activity of EGFR protein] | 15525798 |
C444919 | 5-methoxy-1,2-dimethyl-3-((4-nitrophenoxy)methyl)indole-4,7-dione | [RTKI cpd results in decreased activity of EGFR protein] which results in decreased susceptibility to 5-methoxy-1,2-dimethyl-3-((4-nitrophenoxy)methyl)indole-4,7-dione | 20433816 |
C546607 | 6,2',4'-trimethoxyflavone | [6,2',4'-trimethoxyflavone co-treated with 7-bromoindirubin-3'-oxime] results in increased expression of EGFR mRNA | 31505164 |
C546607 | 6,2',4'-trimethoxyflavone | [6,2',4'-trimethoxyflavone co-treated with E804 bisindole] results in decreased expression of EGFR mRNA | 31505164 |
C475093 | 6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime | 6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein] | 25625231; 30364229; |
C532429 | 64Cu-DOTA-cetuximab | 64Cu-DOTA-cetuximab binds to EGFR protein | 18454685; 18703609; |
C100101 | 6-chrysenamine | 6-chrysenamine inhibits the reaction [EGF protein binds to EGFR protein] | 6309801 |
C053876 | 6-isopropoxy-9-oxoxanthene-2-carboxylic acid | [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] inhibits the reaction [EGFR protein modified form binds to SRC protein] | 19407222 |
C053876 | 6-isopropoxy-9-oxoxanthene-2-carboxylic acid | [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased phosphorylation of and results in decreased expression of EGFR protein | 19407222 |
C107875 | 6-(methylamino)pyrido(3,4-d)pyrimidine | 6-(methylamino)pyrido(3,4-d)pyrimidine results in decreased activity of EGFR protein | 15572027 |
C107875 | 6-(methylamino)pyrido(3,4-d)pyrimidine | 6-(methylamino)pyrido(3,4-d)pyrimidine results in decreased activity of EGFR protein | 15952178 |
D015123 | 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide | 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in decreased expression of EGFR mRNA | 19150397 |
D015123 | 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide | 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in increased phosphorylation of and results in increased activity of EGFR protein | 22457794 |
D015123 | 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide | EGFR mutant form inhibits the reaction [7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in increased phosphorylation of and results in increased activity of AKT1 protein] | 22457794 |
D015123 | 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide | EGFR mutant form inhibits the reaction [7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in increased phosphorylation of and results in increased activity of MAPK1 protein] | 22457794 |
D015123 | 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide | EGFR mutant form inhibits the reaction [7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in increased phosphorylation of and results in increased activity of MAPK3 protein] | 22457794 |
D015123 | 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide | MUC1 mutant form inhibits the reaction [7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in increased phosphorylation of and results in increased activity of EGFR protein] | 22457794 |
D015123 | 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide | 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide inhibits the reaction [EGF protein binds to EGFR protein] | 6309801 |
C514974 | 7-bromoindirubin-3'-oxime | [6,2',4'-trimethoxyflavone co-treated with 7-bromoindirubin-3'-oxime] results in increased expression of EGFR mRNA | 31505164 |
C514974 | 7-bromoindirubin-3'-oxime | 7-bromoindirubin-3'-oxime results in decreased expression of EGFR mRNA | 31505164 |
C003001 | 7-ketocholesterol | 7-ketocholesterol results in increased phosphorylation of EGFR protein | 20466046 |
D015124 | 8-Bromo Cyclic Adenosine Monophosphate | 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of EGFR mRNA | 22079614 |
C469552 | A 419259 | A 419259 inhibits the reaction [GRP protein results in increased phosphorylation of EGFR protein] | 15342401 |
C496492 | abrine | abrine results in increased expression of EGFR mRNA | 31054353 |
D000082 | Acetaminophen | Acetaminophen results in decreased expression of EGFR mRNA | 21420995 |
D000082 | Acetaminophen | Acetaminophen results in increased expression of EGFR mRNA | 29067470 |
D000082 | Acetaminophen | Acetaminophen results in increased phosphorylation of and results in increased activity of EGFR protein | 28123000 |
D000082 | Acetaminophen | Acetaminophen affects the localization of EGFR protein | 28123000 |
D000082 | Acetaminophen | [Acetaminophen results in decreased abundance of Glutathione] which results in increased phosphorylation of and results in increased activity of EGFR protein | 28123000 |
D000082 | Acetaminophen | Acetaminophen results in decreased expression of EGFR mRNA | 24126418 |
D000082 | Acetaminophen | Acetaminophen results in decreased expression of EGFR protein | 15618236 |
D000082 | Acetaminophen | Acetylcysteine inhibits the reaction [Acetaminophen results in increased phosphorylation of and results in increased activity of EGFR protein] | 28123000 |
D000082 | Acetaminophen | Canertinib inhibits the reaction [Acetaminophen affects the localization of EGFR protein] | 28123000 |
D000082 | Acetaminophen | Canertinib inhibits the reaction [Acetaminophen results in increased phosphorylation of and results in increased activity of EGFR protein] | 28123000 |
D000082 | Acetaminophen | [Clofibrate co-treated with Acetaminophen] affects the expression of EGFR mRNA | 17585979 |
D000082 | Acetaminophen | PPARA affects the reaction [[Clofibrate co-treated with Acetaminophen] affects the expression of EGFR mRNA] | 17585979 |
C056165 | acetovanillone | acetovanillone inhibits the reaction [Cadmium results in increased phosphorylation of EGFR protein] | 26514923 |
D000111 | Acetylcysteine | Acetylcysteine inhibits the reaction [2'-benzoyloxycinnamaldehyde results in increased phosphorylation of EGFR protein] | 14660655 |
D000111 | Acetylcysteine | Acetylcysteine inhibits the reaction [Cadmium results in increased phosphorylation of EGFR protein] | 26514923 |
D000111 | Acetylcysteine | Acetylcysteine inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of and results in increased activity of EGFR protein] | 10640773 |
D000111 | Acetylcysteine | Acetylcysteine inhibits the reaction [Acetaminophen results in increased phosphorylation of and results in increased activity of EGFR protein] | 28123000 |
D000111 | Acetylcysteine | Acetylcysteine inhibits the reaction [Asbestos, Crocidolite results in increased activity of EGFR protein] | 15520183 |
D000111 | Acetylcysteine | Acetylcysteine inhibits the reaction [Cadmium Chloride results in increased expression of EGFR mRNA] | 23948867 |
D000111 | Acetylcysteine | Acetylcysteine inhibits the reaction [Cadmium Chloride results in increased phosphorylation of EGFR protein] | 23948867 |
D000111 | Acetylcysteine | Acetylcysteine inhibits the reaction [Diethylnitrosamine results in increased phosphorylation of and results in increased activity of EGFR protein] | 17942915 |
D000111 | Acetylcysteine | Acetylcysteine inhibits the reaction [LHB protein results in increased phosphorylation of and results in increased activity of EGFR protein] | 21220312 |
D000111 | Acetylcysteine | Acetylcysteine inhibits the reaction [AGT protein results in increased phosphorylation of and results in increased activity of EGFR protein] | 15849355 |
D000111 | Acetylcysteine | Acetylcysteine inhibits the reaction [Asbestos, Crocidolite results in increased expression of EGFR protein] | 26368632 |
D000111 | Acetylcysteine | Acetylcysteine inhibits the reaction [EDN1 protein results in increased phosphorylation of and results in increased activity of EGFR protein] | 16261333 |
D000171 | Acrolein | Acrolein results in increased activity of EGFR protein | 11329622 |
D000171 | Acrolein | Acrolein results in increased phosphorylation of EGFR protein | 11329622; 15531749; |
D000171 | Acrolein | EGFR protein affects the reaction [Acrolein results in increased expression of MUC5AC mRNA] | 15531749 |
D000171 | Acrolein | RTKI cpd inhibits the reaction [Acrolein results in increased phosphorylation of EGFR protein] | 15531749 |
D000171 | Acrolein | Acrolein results in increased phosphorylation of EGFR protein | 20153347 |
D000171 | Acrolein | Acrolein results in increased phosphorylation of EGFR protein | 20359552 |
D000171 | Acrolein | Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [Acrolein results in increased phosphorylation of EGFR protein]] | 20359552 |
D000171 | Acrolein | Simvastatin inhibits the reaction [Acrolein results in increased phosphorylation of EGFR protein] | 20359552 |
D020106 | Acrylamide | Acrylamide analog affects the phosphorylation of EGFR protein | 11462982 |
D020106 | Acrylamide | Acrylamide analog results in decreased phosphorylation of EGFR protein | 10753475 |
D020106 | Acrylamide | Acrylamide results in increased expression of EGFR protein | 24508477 |
D020106 | Acrylamide | Curcumin inhibits the reaction [Acrylamide results in increased expression of EGFR protein] | 24508477 |
D020106 | Acrylamide | epigallocatechin gallate inhibits the reaction [Acrylamide results in increased expression of EGFR protein] | 24508477 |
C058956 | acteoside | acteoside inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased phosphorylation of EGFR protein] | 21756928 |
C058956 | acteoside | acteoside promotes the reaction [TGFA protein affects the localization of EGFR protein] | 21967610 |
C058956 | acteoside | acteoside promotes the reaction [TGFA protein affects the localization of EGFR protein modified form] | 21967610 |
C058956 | acteoside | acteoside results in decreased phosphorylation of EGFR protein | 21756928; 21967610; |
C058956 | acteoside | [acteoside co-treated with TNF protein] results in decreased phosphorylation of EGFR protein | 23527233 |
C058956 | acteoside | acteoside inhibits the reaction [[TGFA protein co-treated with IFNG protein] results in increased phosphorylation of EGFR protein] | 21967610 |
C058956 | acteoside | acteoside inhibits the reaction [TGFA protein results in increased phosphorylation of EGFR protein] | 21967610 |
C058956 | acteoside | [leptomycin B co-treated with TGFA protein co-treated with acteoside] affects the localization of EGFR protein modified form | 21967610 |
D000255 | Adenosine Triphosphate | Adenosine Triphosphate results in increased phosphorylation of EGFR protein | 26104857 |
D000255 | Adenosine Triphosphate | sodium arsenite promotes the reaction [Adenosine Triphosphate results in increased phosphorylation of EGFR protein] | 26104857 |
C489254 | AEE 788 | AEE 788 results in decreased activity of EGFR protein | 16940797 |
D000077716 | Afatinib | Afatinib results in decreased activity of EGFR protein | 21322567; 22242139; |
D000077716 | Afatinib | Afatinib results in decreased activity of EGFR protein mutant form | 21322567 |
D000077716 | Afatinib | Afatinib results in decreased phosphorylation of EGFR protein | 28787001 |
C016601 | afimoxifene | EGFR protein results in decreased susceptibility to afimoxifene | 18351453 |
C016601 | afimoxifene | EGFR results in decreased susceptibility to afimoxifene | 21233418 |
C412373 | AG 1879 | AG 1879 inhibits the reaction [Sirolimus results in increased phosphorylation of EGFR protein] | 19151764 |
C412373 | AG 1879 | AG 1879 inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]] | 18787115 |
C412373 | AG 1879 | AG 1879 inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]] | 18787115 |
C412373 | AG 1879 | AG 1879 inhibits the reaction [Alprenolol promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]] | 18787115 |
C412373 | AG 1879 | AG 1879 inhibits the reaction [Capsaicin results in increased phosphorylation of EGFR protein] | 20660715 |
C412373 | AG 1879 | AG 1879 inhibits the reaction [Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]] | 18787115 |
C412373 | AG 1879 | AG 1879 inhibits the reaction [Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]] | 18787115 |
C412373 | AG 1879 | AG 1879 inhibits the reaction [Carvedilol promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]] | 18787115 |
C412373 | AG 1879 | AG 1879 inhibits the reaction [[Clioquinol binds to Copper] which results in increased phosphorylation of and results in increased activity of EGFR protein] | 18346929 |
C412373 | AG 1879 | AG 1879 inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]] | 18787115 |
C412373 | AG 1879 | AG 1879 inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]] | 18787115 |
C412373 | AG 1879 | AG 1879 inhibits the reaction [Dobutamine promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]] | 18787115 |
C412373 | AG 1879 | AG 1879 inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein] | 27087131 |
C412373 | AG 1879 | AG 1879 inhibits the reaction [Nicotine results in increased phosphorylation of EGFR protein] | 14569062 |
C412373 | AG 1879 | AG 1879 inhibits the reaction [Ozone results in increased phosphorylation of EGFR protein] | 25303742 |
C412373 | AG 1879 | AG 1879 inhibits the reaction [Particulate Matter results in increased phosphorylation of EGFR protein] | 17028263 |
C412373 | AG 1879 | AG 1879 inhibits the reaction [Vehicle Emissions results in increased phosphorylation of EGFR protein] | 17028263 |
C412373 | AG 1879 | AG 1879 inhibits the reaction [Zinc results in increased phosphorylation of EGFR protein] | 12915106; 15980035; |
C412373 | AG 1879 | [AG 1879 results in decreased activity of SRC protein] inhibits the reaction [Hexachlorobenzene results in increased phosphorylation of EGFR protein] | 21205633 |
C412373 | AG 1879 | AG 1879 inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein] | 14737115 |
C412373 | AG 1879 | AG 1879 inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of EGFR protein] | 14737115 |
C412373 | AG 1879 | AG 1879 inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Capsaicin] results in increased phosphorylation of EGFR protein] | 20660715 |
C412373 | AG 1879 | AG 1879 inhibits the reaction [SRC protein promotes the reaction [Hexachlorobenzene results in increased phosphorylation of EGFR protein]] | 18295415 |
C430898 | AGN 194204 | AGN 194204 inhibits the reaction [CREBBP protein binds to EGFR promoter] | 21080969 |
C430898 | AGN 194204 | AGN 194204 inhibits the reaction [NCOA1 protein binds to EGFR promoter] | 21080969 |
C430898 | AGN 194204 | AGN 194204 results in decreased expression of EGFR protein | 15318936; 21080969; |
C430898 | AGN 194204 | CREBBP protein inhibits the reaction [AGN 194204 results in decreased expression of EGFR protein] | 21080969 |
C430898 | AGN 194204 | NCOA1 protein inhibits the reaction [AGN 194204 results in decreased expression of EGFR protein] | 21080969 |
C430898 | AGN 194204 | AGN 194204 results in decreased expression of EGFR mRNA | 15302862 |
C046926 | AH 23848 | [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] inhibits the reaction [EGFR protein modified form binds to SRC protein] | 19407222 |
C046926 | AH 23848 | [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased phosphorylation of and results in decreased expression of EGFR protein | 19407222 |
C031143 | AICA ribonucleotide | AICA ribonucleotide inhibits the reaction [EGFR protein results in increased import of Deoxyglucose] | 19625624 |
D000450 | Aldosterone | Aldosterone results in increased expression of EGFR mRNA | 11507004 |
D000077556 | Alitretinoin | Alitretinoin results in decreased expression of EGFR mRNA | 15982314 |
D000517 | alpha-Chlorohydrin | alpha-Chlorohydrin results in increased expression of EGFR mRNA | 28522335 |
C095512 | alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide | alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide inhibits the reaction [Bile Acids and Salts results in increased expression of EGFR protein] | 21127259 |
C095512 | alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide | alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein] | 18995957 |
C011512 | alpha-naphthoflavone | alpha-naphthoflavone inhibits the reaction [Tetrachlorodibenzodioxin results in increased phosphorylation of and results in increased activity of EGFR protein] | 17934341 |
C005277 | alpha-naphthyl thiourea | alpha-naphthyl thiourea results in increased expression of EGFR mRNA | 10755703 |
D000526 | Alprenolol | AG 1879 inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]] | 18787115 |
D000526 | Alprenolol | AG 1879 inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]] | 18787115 |
D000526 | Alprenolol | AG 1879 inhibits the reaction [Alprenolol promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]] | 18787115 |
D000526 | Alprenolol | Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein] | 18787115 |
D000526 | Alprenolol | Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein] | 18787115 |
D000526 | Alprenolol | Alprenolol promotes the reaction [ADRB1 protein results in increased phosphorylation of and results in increased uptake of EGFR protein] | 18787115 |
D000526 | Alprenolol | [Alprenolol results in increased phosphorylation of ADRB1 protein] which results in increased phosphorylation of EGFR protein | 18787115 |
D000526 | Alprenolol | ARRB1 protein promotes the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]] | 18787115 |
D000526 | Alprenolol | ARRB1 protein promotes the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]] | 18787115 |
D000526 | Alprenolol | ARRB2 protein promotes the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]] | 18787115 |
D000526 | Alprenolol | ARRB2 protein promotes the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]] | 18787115 |
D000526 | Alprenolol | HBEGF protein inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]] | 18787115 |
D000526 | Alprenolol | HBEGF protein inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]] | 18787115 |
D000526 | Alprenolol | HBEGF protein promotes the reaction [Alprenolol promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]] | 18787115 |
D000526 | Alprenolol | N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]] | 18787115 |
D000526 | Alprenolol | N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]] | 18787115 |
D000526 | Alprenolol | N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Alprenolol promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]] | 18787115 |
D000526 | Alprenolol | Propranolol inhibits the reaction [Alprenolol promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]] | 18787115 |
D000526 | Alprenolol | Propranolol inhibits the reaction [Alprenolol promotes the reaction [ADRB1 protein results in increased uptake of EGFR protein]] | 18787115 |
D000526 | Alprenolol | RTKI cpd inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]] | 18787115 |
D000526 | Alprenolol | RTKI cpd inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]] | 18787115 |
D000526 | Alprenolol | RTKI cpd inhibits the reaction [Alprenolol promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]] | 18787115 |
D000537 | Aluminum Oxide | Aluminum Oxide results in increased expression of EGFR mRNA | 19464052 |
D000538 | Aluminum Silicates | Aluminum Silicates results in increased expression of EGFR protein | 16335828 |
C103505 | AM 251 | 4-(4-(3-hydroxyphenyl)-3-(4-methylphenyl)-6-oxo-1H,4H,5H,6H-pyrrolo(3,4-c)pyrazol-5-yl)benzoic acid inhibits the reaction [AM 251 results in increased expression of EGFR protein] | 27423937 |
C103505 | AM 251 | 4'-methoxy-1-naphthylfenoterol inhibits the reaction [AM 251 results in increased expression of EGFR protein] | 27423937 |
C103505 | AM 251 | AM 251 results in increased expression of EGFR protein | 27423937 |
D000638 | Amiodarone | Amiodarone results in decreased expression of EGFR mRNA | 24535564 |
D000643 | Ammonium Chloride | Ammonium Chloride affects the expression of EGFR mRNA | 16483693 |
D000643 | Ammonium Chloride | Ammonium Chloride results in decreased expression of EGFR protein | 16483693 |
D000880 | Anthraquinones | Anthraquinones analog results in decreased activity of EGFR protein | 27473261 |
D000903 | Antibiotics, Antineoplastic | EGFR protein affects the susceptibility to Antibiotics, Antineoplastic | 15981280 |
C061374 | antimonite | antimonite results in increased expression of EGFR protein | 17400267 |
D000970 | Antineoplastic Agents | Antineoplastic Agents results in decreased expression of EGFR protein | 23125191 |
D000970 | Antineoplastic Agents | Antineoplastic Agents results in decreased expression of EGFR protein modified form | 23125191 |
D018501 | Antirheumatic Agents | Antirheumatic Agents results in decreased expression of EGFR mRNA | 24449571 |
D016718 | Arachidonic Acid | 5,8,11,14-Eicosatetraynoic Acid inhibits the reaction [Arachidonic Acid results in increased phosphorylation of and results in increased activity of EGFR protein] | 15525798 |
D001115 | Arecoline | [Arecoline co-treated with 4-nitroquinolone-1-oxide] results in increased phosphorylation of EGFR protein | 26464283 |
D001115 | Arecoline | [helioxanthin co-treated with Arecoline co-treated with 4-nitroquinolone-1-oxide] affects the localization of EGFR protein modified form | 26464283 |
D001115 | Arecoline | helioxanthin inhibits the reaction [[Arecoline co-treated with 4-nitroquinolone-1-oxide] results in increased phosphorylation of EGFR protein] | 26464283 |
D001151 | Arsenic | Arsenic results in increased expression of EGFR mRNA | 19945496 |
D001151 | Arsenic | Arsenic results in increased expression of EGFR protein alternative form | 17453740 |
C025657 | arsenic acid | arsenic acid results in increased phosphorylation of EGFR protein | 14674888 |
C025657 | arsenic acid | EGFR protein affects the reaction [arsenic acid results in increased activity of MAPK1 protein] | 14674888 |
C025657 | arsenic acid | EGFR protein affects the reaction [arsenic acid results in increased activity of MAPK3 protein] | 14674888 |
D000077237 | Arsenic Trioxide | 4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [Arsenic Trioxide results in increased phosphorylation of EGFR protein] | 22532027 |
D000077237 | Arsenic Trioxide | Arsenic Trioxide promotes the reaction [EGFR protein mutant form binds to SQSTM1 protein] | 30237564 |
D000077237 | Arsenic Trioxide | Arsenic Trioxide results in decreased expression of and results in decreased phosphorylation of EGFR protein | 30237564 |
D000077237 | Arsenic Trioxide | Arsenic Trioxide results in decreased expression of EGFR mRNA | 20435036 |
D000077237 | Arsenic Trioxide | Arsenic Trioxide results in decreased expression of EGFR protein | 20435036; 23029451; 30237564; |
D000077237 | Arsenic Trioxide | Arsenic Trioxide results in increased expression of EGFR mRNA | 22521957; 29274334; |
D000077237 | Arsenic Trioxide | Arsenic Trioxide results in increased phosphorylation of and results in increased activity of EGFR protein | 15961274; 23548265; |
D000077237 | Arsenic Trioxide | Arsenic Trioxide results in increased phosphorylation of EGFR protein | 22532027 |
D000077237 | Arsenic Trioxide | bafilomycin A1 inhibits the reaction [Arsenic Trioxide results in decreased expression of EGFR protein] | 30237564 |
D000077237 | Arsenic Trioxide | Cycloheximide promotes the reaction [Arsenic Trioxide results in decreased expression of EGFR protein] | 30237564 |
D000077237 | Arsenic Trioxide | EGFR protein affects the susceptibility to Arsenic Trioxide | 29535630 |
D000077237 | Arsenic Trioxide | EGFR protein mutant form affects the susceptibility to Arsenic Trioxide | 30237564 |
D000077237 | Arsenic Trioxide | Erlotinib Hydrochloride inhibits the reaction [Arsenic Trioxide results in increased phosphorylation of and results in increased activity of EGFR protein] | 23548265 |
D000077237 | Arsenic Trioxide | NCF2 mutant form inhibits the reaction [Arsenic Trioxide results in increased phosphorylation of EGFR protein] | 22532027 |
D000077237 | Arsenic Trioxide | SQSTM1 protein affects the reaction [Arsenic Trioxide results in decreased expression of EGFR protein] | 30237564 |
D000077237 | Arsenic Trioxide | SQSTM1 protein inhibits the reaction [Arsenic Trioxide results in decreased expression of EGFR protein] | 30237564 |
D000077237 | Arsenic Trioxide | [Arsenic Trioxide co-treated with huachansu] results in decreased expression of EGFR protein | 21434348 |
D000077237 | Arsenic Trioxide | Arsenic Trioxide results in decreased expression of EGFR protein | 23029451 |
C015001 | arsenite | arsenite results in decreased degradation of EGFR protein | 17400267 |
C015001 | arsenite | arsenite results in increased expression of EGFR protein | 17400267 |
C015001 | arsenite | arsenite results in increased methylation of EGFR promoter | 23974009 |
C015001 | arsenite | arsenite results in increased phosphorylation of EGFR protein | 14674888; 17400267; |
C015001 | arsenite | EGFR protein affects the reaction [arsenite results in increased activity of MAPK1 protein] | 14674888 |
C015001 | arsenite | EGFR protein affects the reaction [arsenite results in increased activity of MAPK3 protein] | 14674888 |
D001194 | Asbestos | Asbestos results in increased phosphorylation of EGFR protein | 26368632 |
D017639 | Asbestos, Amosite | Asbestos, Amosite results in decreased phosphorylation of EGFR protein | 15626777 |
D017639 | Asbestos, Amosite | Asbestos, Amosite results in increased expression of EGFR mRNA | 22251266 |
D017636 | Asbestos, Amphibole | Asbestos, Amphibole results in increased expression of EGFR mRNA | 22251266 |
D017638 | Asbestos, Crocidolite | 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline inhibits the reaction [Asbestos, Crocidolite results in increased phosphorylation of EGFR protein] | 16908449 |
D017638 | Asbestos, Crocidolite | Asbestos, Crocidolite binds to EGFR protein | 23672436 |
D017638 | Asbestos, Crocidolite | Asbestos, Crocidolite results in decreased activity of and results in decreased phosphorylation of EGFR protein | 15626777 |
D017638 | Asbestos, Crocidolite | Asbestos, Crocidolite results in increased activity of EGFR protein | 21762757 |
D017638 | Asbestos, Crocidolite | Asbestos, Crocidolite results in increased expression of EGFR protein | 21570478 |
D017638 | Asbestos, Crocidolite | Asbestos, Crocidolite results in increased phosphorylation of EGFR protein | 16908449 |
D017638 | Asbestos, Crocidolite | CAT protein inhibits the reaction [Asbestos, Crocidolite results in increased phosphorylation of EGFR protein] | 16908449 |
D017638 | Asbestos, Crocidolite | Cytochalasin B inhibits the reaction [Asbestos, Crocidolite results in decreased phosphorylation of EGFR protein] | 15626777 |
D017638 | Asbestos, Crocidolite | Cytochalasin D inhibits the reaction [Asbestos, Crocidolite results in decreased phosphorylation of EGFR protein] | 15626777 |
D017638 | Asbestos, Crocidolite | Deferoxamine inhibits the reaction [Asbestos, Crocidolite results in decreased activity of and results in decreased phosphorylation of EGFR protein] | 15626777 |
D017638 | Asbestos, Crocidolite | EGFR protein affects the reaction [Asbestos, Crocidolite results in increased phosphorylation of MAPK1 protein] | 16908449 |
D017638 | Asbestos, Crocidolite | EGFR protein affects the reaction [Asbestos, Crocidolite results in increased phosphorylation of MAPK3 protein] | 16908449 |
D017638 | Asbestos, Crocidolite | Phytic Acid inhibits the reaction [Asbestos, Crocidolite results in decreased phosphorylation of EGFR protein] | 15626777 |
D017638 | Asbestos, Crocidolite | SOD1 protein inhibits the reaction [Asbestos, Crocidolite results in increased phosphorylation of EGFR protein] | 16908449 |
D017638 | Asbestos, Crocidolite | Acetylcysteine inhibits the reaction [Asbestos, Crocidolite results in increased activity of EGFR protein] | 15520183 |
D017638 | Asbestos, Crocidolite | Asbestos, Crocidolite results in increased activity of EGFR protein | 15520183 |
D017638 | Asbestos, Crocidolite | Asbestos, Crocidolite results in increased phosphorylation of EGFR protein | 14737115 |
D017638 | Asbestos, Crocidolite | EGFR protein promotes the reaction [Asbestos, Crocidolite results in increased expression of FOS mRNA] | 12154012 |
D017638 | Asbestos, Crocidolite | EGFR protein promotes the reaction [Asbestos, Crocidolite results in increased expression of JUN mRNA] | 12154012 |
D017638 | Asbestos, Crocidolite | Acetylcysteine inhibits the reaction [Asbestos, Crocidolite results in increased expression of EGFR protein] | 26368632 |
D017638 | Asbestos, Crocidolite | Asbestos, Crocidolite results in increased expression of EGFR mRNA | 10783328 |
D017638 | Asbestos, Crocidolite | Asbestos, Crocidolite results in increased expression of EGFR protein | 26368632 |
D017638 | Asbestos, Crocidolite | Cycloheximide inhibits the reaction [Asbestos, Crocidolite results in increased expression of EGFR protein] | 26368632 |
D017632 | Asbestos, Serpentine | Asbestos, Serpentine results in decreased phosphorylation of EGFR protein | 15626777 |
D017632 | Asbestos, Serpentine | Asbestos, Serpentine results in increased activity of EGFR protein | 16571779 |
D017632 | Asbestos, Serpentine | N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Asbestos, Serpentine results in increased activity of EGFR protein] | 16571779 |
D001205 | Ascorbic Acid | Ascorbic Acid results in decreased expression of EGFR mRNA | 21919647 |
D001241 | Aspirin | Aspirin results in increased expression of EGFR mRNA | 15456535 |
D001262 | Atenolol | Atenolol inhibits the reaction [4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone results in increased phosphorylation of EGFR protein] | 16671086 |
D000069059 | Atorvastatin | Atorvastatin inhibits the reaction [Phenylephrine results in increased expression of and results in increased phosphorylation of and results in increased activity of EGFR protein] | 18360054 |
D001280 | Atrazine | Atrazine inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein] | 29329451 |
D001280 | Atrazine | Atrazine results in increased expression of EGFR mRNA | 22378314 |
D001285 | Atropine | Atropine inhibits the reaction [Parathion results in increased expression of EGFR protein] | 17390078 |
C049935 | avobenzone | avobenzone results in increased expression of EGFR mRNA | 31016361 |
C040929 | bafilomycin A1 | bafilomycin A1 inhibits the reaction [Arsenic Trioxide results in decreased expression of EGFR protein] | 30237564 |
C006680 | baicalein | baicalein inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein] | 25625231 |
C038044 | baicalin | baicalin inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein] | 25625231 |
C060988 | baohuoside I | baohuoside I inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein] | 25119583 |
C060988 | baohuoside I | baohuoside I results in decreased phosphorylation of EGFR protein | 25119583 |
D001507 | Beclomethasone | Beclomethasone results in increased activity of EGFR protein | 22573732 |
C030935 | benz(a)anthracene | AHR protein affects the reaction [benz(a)anthracene inhibits the reaction [EGF protein binds to EGFR protein]] | 6309801 |
C030935 | benz(a)anthracene | benz(a)anthracene inhibits the reaction [EGF protein binds to EGFR protein] | 6309801 |
C037689 | benzamide | benzamide analog results in decreased activity of EGFR protein | 15186837 |
C032157 | benzamidine | benzamidine analog results in decreased activity of EGFR protein | 15186837 |
D001554 | Benzene | Benzene results in decreased expression of EGFR mRNA | 17905399 |
D001564 | Benzo(a)pyrene | Benzo(a)pyrene results in increased expression of EGFR mRNA | 19181443 |
D001564 | Benzo(a)pyrene | Benzo(a)pyrene results in increased phosphorylation of EGFR protein | 19181443 |
D001564 | Benzo(a)pyrene | EGFR protein results in increased susceptibility to Benzo(a)pyrene | 8608954 |
D001564 | Benzo(a)pyrene | AHR protein affects the reaction [Benzo(a)pyrene inhibits the reaction [EGF protein binds to EGFR protein]] | 6309801 |
D001564 | Benzo(a)pyrene | Benzo(a)pyrene inhibits the reaction [EGF protein binds to EGFR protein] | 6309801 |
D001564 | Benzo(a)pyrene | Benzo(a)pyrene results in decreased expression of EGFR mRNA | 19770486; 21803694; |
C030233 | benzo(a)pyrene-1,6-quinone | benzo(a)pyrene-1,6-quinone results in increased phosphorylation of EGFR protein | 19166869 |
C018003 | benzo(a)pyrene-3,6-quinone | benzo(a)pyrene-3,6-quinone results in increased phosphorylation of EGFR protein | 19166869 |
C006703 | benzo(b)fluoranthene | benzo(b)fluoranthene affects the localization of and results in increased expression of EGFR protein | 21776270 |
C006703 | benzo(b)fluoranthene | benzo(b)fluoranthene results in decreased expression of EGFR mRNA | 26377693 |
D019817 | Benzoic Acid | Benzoic Acid analog inhibits the reaction [EGF protein promotes the reaction [STAT3 protein binds to EGFR protein]] | 26088127 |
C072553 | benzyloxycarbonylleucyl-leucyl-leucine aldehyde | benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [gemcitabine results in increased phosphorylation of and results in increased degradation of EGFR protein] | 17146438 |
C072553 | benzyloxycarbonylleucyl-leucyl-leucine aldehyde | benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [MUC1 affects the expression of EGFR protein] | 22457794 |
C072553 | benzyloxycarbonylleucyl-leucyl-leucine aldehyde | benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [platycodin D results in decreased expression of EGFR protein] | 28711525 |
C072553 | benzyloxycarbonylleucyl-leucyl-leucine aldehyde | benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [sulindac sulfide results in decreased expression of EGFR protein] | 20332299 |
C072553 | benzyloxycarbonylleucyl-leucyl-leucine aldehyde | benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [sulindac sulfone results in decreased expression of EGFR protein] | 20332299 |
C072553 | benzyloxycarbonylleucyl-leucyl-leucine aldehyde | benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of EGFR protein | 20332299 |
C002503 | betulin | betulin results in decreased phosphorylation of EGFR protein | 27447558 |
C002503 | betulin | [Gefitinib co-treated with betulin] results in decreased expression of and results in decreased phosphorylation of EGFR protein | 27447558 |
C002070 | betulinic acid | 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline inhibits the reaction [betulinic acid results in increased phosphorylation of EGFR protein] | 16077934 |
C002070 | betulinic acid | betulinic acid promotes the reaction [Gefitinib results in decreased expression of EGFR protein modified form] | 30136359 |
C002070 | betulinic acid | betulinic acid results in increased phosphorylation of EGFR protein | 16077934 |
C053541 | bicalutamide | bicalutamide inhibits the reaction [bisphenol A promotes the reaction [EGFR protein binds to AR protein]] | 29383186 |
C053541 | bicalutamide | bicalutamide inhibits the reaction [bisphenol A promotes the reaction [EGFR protein binds to ESR2 protein]] | 29383186 |
C053541 | bicalutamide | bicalutamide inhibits the reaction [bisphenol A results in increased phosphorylation of EGFR protein] | 29383186 |
D001647 | Bile Acids and Salts | alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide inhibits the reaction [Bile Acids and Salts results in increased expression of EGFR protein] | 21127259 |
D001647 | Bile Acids and Salts | Bile Acids and Salts results in increased expression of EGFR protein | 21127259 |
D001688 | Biological Products | Biological Products results in decreased phosphorylation of EGFR protein | 30465897 |
C543008 | bis(4-hydroxyphenyl)sulfone | bis(4-hydroxyphenyl)sulfone results in increased expression of EGFR mRNA | 30951980 |
C088060 | bisindolylmaleimide | bisindolylmaleimide inhibits the reaction [NTS protein results in increased phosphorylation of and results in increased activity of EGFR protein] | 15177934 |
C070515 | bisindolylmaleimide I | bisindolylmaleimide I inhibits the reaction [Irinotecan metabolite results in increased phosphorylation of EGFR protein] | 15723263 |
C070515 | bisindolylmaleimide I | bisindolylmaleimide I inhibits the reaction [Irinotecan results in increased phosphorylation of EGFR protein] | 15723263 |
C006780 | bisphenol A | 2-chloro-5-nitrobenzanilide inhibits the reaction [bisphenol A results in increased phosphorylation of EGFR protein] | 31075703 |
C006780 | bisphenol A | bicalutamide inhibits the reaction [bisphenol A promotes the reaction [EGFR protein binds to AR protein]] | 29383186 |
C006780 | bisphenol A | bicalutamide inhibits the reaction [bisphenol A promotes the reaction [EGFR protein binds to ESR2 protein]] | 29383186 |
C006780 | bisphenol A | bicalutamide inhibits the reaction [bisphenol A results in increased phosphorylation of EGFR protein] | 29383186 |
C006780 | bisphenol A | bisphenol A promotes the reaction [EGFR protein binds to AR protein] | 29383186 |
C006780 | bisphenol A | bisphenol A promotes the reaction [EGFR protein binds to ESR2 protein] | 29383186 |
C006780 | bisphenol A | bisphenol A promotes the reaction [EGFR protein modified form binds to SRC protein modified form] | 30615907 |
C006780 | bisphenol A | bisphenol A results in decreased expression of EGFR mRNA | 20678512 |
C006780 | bisphenol A | bisphenol A results in increased expression of EGFR mRNA | 29275510; 30022450; 31016847; |
C006780 | bisphenol A | bisphenol A results in increased expression of EGFR protein | 31016847 |
C006780 | bisphenol A | bisphenol A results in increased phosphorylation of and affects the localization of EGFR protein | 30615907 |
C006780 | bisphenol A | bisphenol A results in increased phosphorylation of EGFR protein | 28426875; 29383186; 31075703; |
C006780 | bisphenol A | ESR1 protein affects the reaction [bisphenol A promotes the reaction [EGFR protein modified form binds to SRC protein modified form]] | 30615907 |
C006780 | bisphenol A | ESR1 protein affects the reaction [bisphenol A results in increased phosphorylation of and affects the localization of EGFR protein] | 30615907 |
C006780 | bisphenol A | Fulvestrant inhibits the reaction [bisphenol A promotes the reaction [EGFR protein binds to AR protein]] | 29383186 |
C006780 | bisphenol A | Fulvestrant inhibits the reaction [bisphenol A promotes the reaction [EGFR protein binds to ESR2 protein]] | 29383186 |
C006780 | bisphenol A | Fulvestrant inhibits the reaction [bisphenol A results in increased phosphorylation of EGFR protein] | 29383186 |
C006780 | bisphenol A | Gefitinib inhibits the reaction [bisphenol A promotes the reaction [EGFR protein binds to AR protein]] | 29383186 |
C006780 | bisphenol A | Gefitinib inhibits the reaction [bisphenol A promotes the reaction [EGFR protein binds to ESR2 protein]] | 29383186 |
C006780 | bisphenol A | Gefitinib inhibits the reaction [bisphenol A results in increased phosphorylation of EGFR protein] | 29383186 |
C006780 | bisphenol A | GW 583340 inhibits the reaction [bisphenol A results in increased phosphorylation of EGFR protein] | 28426875 |
C006780 | bisphenol A | bisphenol A results in decreased expression of EGFR mRNA | 26063408 |
C006780 | bisphenol A | bisphenol A results in increased expression of EGFR mRNA | 30951980 |
C006780 | bisphenol A | bisphenol A results in decreased expression of EGFR mRNA | 30816183 |
C006780 | bisphenol A | bisphenol A results in increased expression of EGFR mRNA | 25181051 |
C006780 | bisphenol A | bisphenol A results in increased methylation of EGFR gene | 28505145 |
C000611646 | bisphenol F | [bisphenol F co-treated with Tretinoin] results in decreased expression of EGFR mRNA | 30951980 |
C000611646 | bisphenol F | bisphenol F results in increased expression of EGFR mRNA | 30951980 |
C471992 | bosutinib | bosutinib results in decreased activity of EGFR protein | 18385429 |
C000595192 | BP-1-102 | BP-1-102 analog inhibits the reaction [EGF protein promotes the reaction [STAT3 protein binds to EGFR protein]] | 26088127 |
C048491 | butaprost | [RTKI cpd results in decreased activity of EGFR protein] which results in decreased susceptibility to butaprost | 21268125 |
D002083 | Butylated Hydroxyanisole | Butylated Hydroxyanisole inhibits the reaction [Particulate Matter results in increased phosphorylation of EGFR protein] | 17028263 |
D002083 | Butylated Hydroxyanisole | Butylated Hydroxyanisole inhibits the reaction [Vehicle Emissions results in increased phosphorylation of EGFR protein] | 17028263 |
D002083 | Butylated Hydroxyanisole | Butylated Hydroxyanisole inhibits the reaction [LHB protein results in increased phosphorylation of and results in increased activity of EGFR protein] | 21220312 |
C027561 | butylbenzyl phthalate | butylbenzyl phthalate results in increased phosphorylation of EGFR protein | 22552774 |
C027561 | butylbenzyl phthalate | Fulvestrant inhibits the reaction [butylbenzyl phthalate results in increased phosphorylation of EGFR protein] | 22552774 |
D002101 | Cacodylic Acid | Cacodylic Acid results in increased expression of EGFR mRNA | 16122865 |
D002104 | Cadmium | 4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-3H-cyclopenta(c)quinoline inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased phosphorylation of EGFR protein] | 31468104 |
D002104 | Cadmium | acetovanillone inhibits the reaction [Cadmium results in increased phosphorylation of EGFR protein] | 26514923 |
D002104 | Cadmium | Acetylcysteine inhibits the reaction [Cadmium results in increased phosphorylation of EGFR protein] | 26514923 |
D002104 | Cadmium | [Cadmium Chloride results in increased abundance of Cadmium] promotes the reaction [SRC protein modified form binds to EGFR protein modified form] | 31468104 |
D002104 | Cadmium | [Cadmium Chloride results in increased abundance of Cadmium] which results in increased phosphorylation of EGFR protein | 31468104 |
D002104 | Cadmium | Cadmium results in increased activity of EGFR protein | 25343777 |
D002104 | Cadmium | Cadmium results in increased phosphorylation of EGFR protein | 26514923 |
D002104 | Cadmium | diphenyleneiodonium inhibits the reaction [Cadmium results in increased phosphorylation of EGFR protein] | 26514923 |
D002104 | Cadmium | EGFR mutant form inhibits the reaction [Cadmium results in increased phosphorylation of MAPK1 protein] | 26006730 |
D002104 | Cadmium | EGFR mutant form inhibits the reaction [Cadmium results in increased phosphorylation of MAPK3 protein] | 26006730 |
D002104 | Cadmium | GPER1 protein affects the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased phosphorylation of EGFR protein] | 31468104 |
D002104 | Cadmium | RTKI cpd inhibits the reaction [Cadmium results in increased activity of EGFR protein] | 25343777 |
D002104 | Cadmium | RTKI cpd inhibits the reaction [Cadmium results in increased phosphorylation of EGFR protein] | 26514923 |
D002104 | Cadmium | Cadmium results in decreased expression of EGFR mRNA | 22666406 |
D019256 | Cadmium Chloride | 4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-3H-cyclopenta(c)quinoline inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased phosphorylation of EGFR protein] | 31468104 |
D019256 | Cadmium Chloride | [Cadmium Chloride results in increased abundance of Cadmium] promotes the reaction [SRC protein modified form binds to EGFR protein modified form] | 31468104 |
D019256 | Cadmium Chloride | [Cadmium Chloride results in increased abundance of Cadmium] which results in increased phosphorylation of EGFR protein | 31468104 |
D019256 | Cadmium Chloride | Cadmium Chloride results in increased expression of EGFR | 21605009 |
D019256 | Cadmium Chloride | Cadmium Chloride results in increased expression of EGFR mRNA | 18560533; 26472689; 26525392; |
D019256 | Cadmium Chloride | Cadmium Chloride results in increased phosphorylation of EGFR protein | 25118938; 26385184; |
D019256 | Cadmium Chloride | EGFR mutant form inhibits the reaction [Cadmium Chloride results in increased phosphorylation of MAPK1 protein] | 25744307 |
D019256 | Cadmium Chloride | EGFR mutant form inhibits the reaction [Cadmium Chloride results in increased phosphorylation of MAPK3 protein] | 25744307 |
D019256 | Cadmium Chloride | EGFR protein promotes the reaction [Cadmium Chloride results in increased phosphorylation of EGFR protein] | 26385184 |
D019256 | Cadmium Chloride | EGFR protein promotes the reaction [Cadmium Chloride results in increased phosphorylation of MAPK1 protein] | 26385184 |
D019256 | Cadmium Chloride | EGFR protein promotes the reaction [Cadmium Chloride results in increased phosphorylation of MAPK3 protein] | 26385184 |
D019256 | Cadmium Chloride | GPER1 protein affects the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased phosphorylation of EGFR protein] | 31468104 |
D019256 | Cadmium Chloride | NOTCH1 mutant form inhibits the reaction [Cadmium Chloride results in increased phosphorylation of EGFR protein] | 25118938 |
D019256 | Cadmium Chloride | RTKI cpd inhibits the reaction [Cadmium Chloride results in increased phosphorylation of EGFR protein] | 26385184 |
D019256 | Cadmium Chloride | [RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [Cadmium Chloride results in increased phosphorylation of FOXO3 protein] | 23673518 |
D019256 | Cadmium Chloride | 4-(2-aminoethyl)benzenesulfonylfluoride inhibits the reaction [Cadmium Chloride results in increased phosphorylation of and results in increased activity of EGFR protein] | 23376140 |
D019256 | Cadmium Chloride | Acetylcysteine inhibits the reaction [Cadmium Chloride results in increased expression of EGFR mRNA] | 23948867 |
D019256 | Cadmium Chloride | Acetylcysteine inhibits the reaction [Cadmium Chloride results in increased phosphorylation of EGFR protein] | 23948867 |
D019256 | Cadmium Chloride | Cadmium Chloride promotes the reaction [EGFR protein binds to SRC protein] | 23376140 |
D019256 | Cadmium Chloride | Cadmium Chloride promotes the reaction [EGFR protein binds to STAT3 protein] | 23376140 |
D019256 | Cadmium Chloride | [[Cadmium Chloride results in increased abundance of Reactive Oxygen Species] which results in increased activity of SRC protein] which results in increased activity of EGFR protein | 23376140 |
D019256 | Cadmium Chloride | [[[Cadmium Chloride results in increased abundance of Reactive Oxygen Species] which results in increased activity of SRC protein] which results in increased activity of EGFR protein] which results in increased activity of STAT3 protein | 23376140 |
D019256 | Cadmium Chloride | [[[[Cadmium Chloride results in increased abundance of Reactive Oxygen Species] which results in increased activity of SRC protein] which results in increased activity of EGFR protein] which results in increased activity of STAT3 protein] promotes the reaction [STAT3 protein binds to STAT3 protein] | 23376140 |
D019256 | Cadmium Chloride | Cadmium Chloride results in increased expression of EGFR mRNA | 23948867 |
D019256 | Cadmium Chloride | Cadmium Chloride results in increased phosphorylation of and results in increased activity of EGFR protein | 23376140 |
D019256 | Cadmium Chloride | Cadmium Chloride results in increased phosphorylation of EGFR protein | 23948867 |
D019256 | Cadmium Chloride | Gefitinib inhibits the reaction [Cadmium Chloride results in increased phosphorylation of EGFR protein] | 23948867 |
D019256 | Cadmium Chloride | [[RTKI cpd results in decreased activity of EGFR protein] co-treated with [SU 6656 results in decreased activity of SRC protein]] inhibits the reaction [Cadmium Chloride results in increased phosphorylation of and results in increased activity of STAT3 protein] | 23376140 |
D019256 | Cadmium Chloride | [RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [Cadmium Chloride results in increased expression of MT2 protein] | 23376140 |
D019256 | Cadmium Chloride | [RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [Cadmium Chloride results in increased phosphorylation of and results in increased activity of MAPK1 protein] | 23376140 |
D019256 | Cadmium Chloride | [RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [Cadmium Chloride results in increased phosphorylation of and results in increased activity of MAPK3 protein] | 23376140 |
D019256 | Cadmium Chloride | [SU 6656 results in decreased activity of SRC protein] inhibits the reaction [Cadmium Chloride results in increased phosphorylation of and results in increased activity of EGFR protein] | 23376140 |
D019256 | Cadmium Chloride | Cadmium Chloride results in increased phosphorylation of EGFR protein | 19233221 |
D019256 | Cadmium Chloride | KN 93 inhibits the reaction [Cadmium Chloride results in increased phosphorylation of EGFR protein] | 19233221 |
D019256 | Cadmium Chloride | RTKI cpd inhibits the reaction [Cadmium Chloride results in increased phosphorylation of EGFR protein] | 19233221 |
D002117 | Calcitriol | Calcitriol results in increased expression of EGFR mRNA | 21592394 |
D002117 | Calcitriol | [Testosterone co-treated with Calcitriol] results in increased expression of EGFR mRNA | 21592394 |
D002117 | Calcitriol | Calcitriol results in increased expression of and binds to EGFR protein | 3498716 |
D002118 | Calcium | Calcium affects the phosphorylation of and affects the expression of EGFR protein | 8393775 |
C031293 | calcium silicate | calcium silicate results in increased activity of EGFR protein | 21762757 |
C420268 | Canertinib | Canertinib inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein] | 18927496 |
C420268 | Canertinib | Canertinib results in decreased activity of EGFR protein | 21322567 |
C420268 | Canertinib | Canertinib results in decreased activity of EGFR protein mutant form | 21322567 |
C420268 | Canertinib | Canertinib results in decreased phosphorylation of EGFR protein | 15956251 |
C420268 | Canertinib | Canertinib inhibits the reaction [Acetaminophen affects the localization of EGFR protein] | 28123000 |
C420268 | Canertinib | Canertinib inhibits the reaction [Acetaminophen results in increased phosphorylation of and results in increased activity of EGFR protein] | 28123000 |
D002211 | Capsaicin | AG 1879 inhibits the reaction [Capsaicin results in increased phosphorylation of EGFR protein] | 20660715 |
D002211 | Capsaicin | Capsaicin inhibits the reaction [EGF results in increased phosphorylation of EGFR protein] | 21462327 |
D002211 | Capsaicin | Capsaicin results in decreased expression of EGFR protein | 19855437 |
D002211 | Capsaicin | Capsaicin results in increased phosphorylation of EGFR protein | 20619260; 20660715; |
D002211 | Capsaicin | N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Capsaicin results in increased phosphorylation of EGFR protein] | 20660715 |
D002211 | Capsaicin | RTKI cpd inhibits the reaction [Capsaicin results in increased phosphorylation of EGFR protein] | 20619260; 20660715; |
D002211 | Capsaicin | AG 1879 inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Capsaicin] results in increased phosphorylation of EGFR protein] | 20660715 |
D002211 | Capsaicin | EGFR gene mutant form inhibits the reaction [Capsaicin promotes the reaction [Tetradecanoylphorbol Acetate results in increased expression of PTGS2 mRNA]] | 20660715 |
D002211 | Capsaicin | EGFR gene mutant form inhibits the reaction [Capsaicin promotes the reaction [Tetradecanoylphorbol Acetate results in increased expression of PTGS2 protein]] | 20660715 |
D002211 | Capsaicin | EGFR gene mutant form inhibits the reaction [Capsaicin results in increased expression of PTGS2 protein] | 20660715 |
D002211 | Capsaicin | EGFR gene mutant form inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Capsaicin] results in increased expression of AREG mRNA] | 20660715 |
D002211 | Capsaicin | EGFR gene mutant form inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Capsaicin] results in increased phosphorylation of AKT1 protein] | 20660715 |
D002211 | Capsaicin | EGFR gene mutant form inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Capsaicin] results in increased phosphorylation of MAPK1 protein] | 20660715 |
D002211 | Capsaicin | EGFR gene mutant form inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Capsaicin] results in increased phosphorylation of MAPK3 protein] | 20660715 |
D002211 | Capsaicin | RTKI cpd inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Capsaicin] results in increased phosphorylation of EGFR protein] | 20660715 |
D002211 | Capsaicin | [Tetradecanoylphorbol Acetate co-treated with Capsaicin] results in increased phosphorylation of EGFR protein | 20660715 |
D002211 | Capsaicin | Capsaicin results in decreased expression of EGFR protein | 14521749 |
D002251 | Carbon Tetrachloride | Carbon Tetrachloride results in decreased expression of EGFR mRNA | 29987408 |
D002251 | Carbon Tetrachloride | Carbon Tetrachloride results in increased expression of EGFR mRNA | 17484886; 27477297; |
D002251 | Carbon Tetrachloride | Carbon Tetrachloride results in increased expression of EGFR protein | 27477297 |
D002251 | Carbon Tetrachloride | NFE2L2 protein promotes the reaction [tetramethylpyrazine inhibits the reaction [Carbon Tetrachloride results in increased expression of EGFR mRNA]] | 27477297 |
D002251 | Carbon Tetrachloride | NFE2L2 protein promotes the reaction [tetramethylpyrazine inhibits the reaction [Carbon Tetrachloride results in increased expression of EGFR protein]] | 27477297 |
D002251 | Carbon Tetrachloride | tetramethylpyrazine inhibits the reaction [Carbon Tetrachloride results in increased expression of EGFR mRNA] | 27477297 |
D002251 | Carbon Tetrachloride | tetramethylpyrazine inhibits the reaction [Carbon Tetrachloride results in increased expression of EGFR protein] | 27477297 |
D002251 | Carbon Tetrachloride | Carbon Tetrachloride results in increased expression of EGFR mRNA | 16644059; 18006644; |
D002251 | Carbon Tetrachloride | Curcumin inhibits the reaction [Carbon Tetrachloride results in increased expression of EGFR mRNA] | 18006644 |
D002251 | Carbon Tetrachloride | [Diethylnitrosamine co-treated with Carbon Tetrachloride] results in increased phosphorylation of EGFR protein | 29923357 |
D002251 | Carbon Tetrachloride | Plant Extracts inhibits the reaction [[Diethylnitrosamine co-treated with Carbon Tetrachloride] results in increased phosphorylation of EGFR protein] | 29923357 |
D000077261 | Carvedilol | AG 1879 inhibits the reaction [Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]] | 18787115 |
D000077261 | Carvedilol | AG 1879 inhibits the reaction [Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]] | 18787115 |
D000077261 | Carvedilol | AG 1879 inhibits the reaction [Carvedilol promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]] | 18787115 |
D000077261 | Carvedilol | ARRB1 protein promotes the reaction [Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]] | 18787115 |
D000077261 | Carvedilol | ARRB1 protein promotes the reaction [Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]] | 18787115 |
D000077261 | Carvedilol | ARRB2 protein promotes the reaction [Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]] | 18787115 |
D000077261 | Carvedilol | ARRB2 protein promotes the reaction [Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]] | 18787115 |
D000077261 | Carvedilol | Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein] | 18787115 |
D000077261 | Carvedilol | Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein] | 18787115 |
D000077261 | Carvedilol | Carvedilol promotes the reaction [ADRB1 protein results in increased phosphorylation of and results in increased uptake of EGFR protein] | 18787115 |
D000077261 | Carvedilol | [Carvedilol results in increased phosphorylation of ADRB1 protein] which results in increased phosphorylation of EGFR protein | 18787115 |
D000077261 | Carvedilol | HBEGF protein inhibits the reaction [Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]] | 18787115 |
D000077261 | Carvedilol | HBEGF protein inhibits the reaction [Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]] | 18787115 |
D000077261 | Carvedilol | HBEGF protein promotes the reaction [Carvedilol promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]] | 18787115 |
D000077261 | Carvedilol | N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]] | 18787115 |
D000077261 | Carvedilol | N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]] | 18787115 |
D000077261 | Carvedilol | N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Carvedilol promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]] | 18787115 |
D000077261 | Carvedilol | Propranolol inhibits the reaction [Carvedilol promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]] | 18787115 |
D000077261 | Carvedilol | Propranolol inhibits the reaction [Carvedilol promotes the reaction [ADRB1 protein results in increased uptake of EGFR protein]] | 18787115 |
D000077261 | Carvedilol | RTKI cpd inhibits the reaction [Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]] | 18787115 |
D000077261 | Carvedilol | RTKI cpd inhibits the reaction [Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]] | 18787115 |
D000077261 | Carvedilol | RTKI cpd inhibits the reaction [Carvedilol promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]] | 18787115 |
C054133 | casticin | casticin results in decreased expression of EGFR protein | 28444820 |
D000068579 | Celecoxib | [Celecoxib co-treated with sulindac sulfone] results in decreased expression of EGFR protein | 17908994 |
D000068579 | Celecoxib | [Celecoxib co-treated with sulindac sulfone] results in decreased expression of EGFR protein modified form | 17908994 |
D000068579 | Celecoxib | Celecoxib promotes the reaction [Hydrochloric Acid results in increased expression of EGFR protein] | 15309881 |
D002706 | Chlordan | Chlordan inhibits the reaction [EGF protein binds to EGFR protein] | 29329451 |
D002706 | Chlordan | Chlordan inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein] | 29329451 |
D002734 | Chlorophyll | Chlorophyll inhibits the reaction [dibenzo(a,l)pyrene results in increased expression of EGFR mRNA] | 22079312 |
D002737 | Chloroprene | Chloroprene results in increased expression of EGFR mRNA | 23125180 |
D002738 | Chloroquine | Chloroquine inhibits the reaction [EGF protein results in decreased expression of EGFR protein] | 20332299 |
D002738 | Chloroquine | Chloroquine inhibits the reaction [MUC1 affects the expression of EGFR protein] | 22457794 |
D002738 | Chloroquine | Chloroquine inhibits the reaction [sulindac sulfide results in decreased expression of EGFR protein] | 20332299 |
D002738 | Chloroquine | Chloroquine inhibits the reaction [sulindac sulfone results in decreased expression of EGFR protein] | 20332299 |
D002738 | Chloroquine | Chloroquine results in decreased expression of EGFR protein | 20332299 |
D004390 | Chlorpyrifos | Chlorpyrifos results in increased phosphorylation of EGFR protein | 26514924 |
D002784 | Cholesterol | [Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of EGFR mRNA | 22129739 |
C002415 | cholesterol alpha-oxide | cholesterol alpha-oxide results in increased phosphorylation of EGFR protein | 20466046 |
C074702 | chromium hexavalent ion | chromium hexavalent ion results in decreased expression of EGFR mRNA | 18053681 |
C074702 | chromium hexavalent ion | chromium hexavalent ion results in increased expression of EGFR mRNA | 19616015 |
C074702 | chromium hexavalent ion | chromium hexavalent ion results in increased phosphorylation of EGFR protein | 25477514 |
C043561 | chrysin | chrysin inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein] | 25625231 |
C039671 | ciglitazone | ciglitazone inhibits the reaction [CREBBP protein binds to EGFR promoter] | 21080969 |
C039671 | ciglitazone | ciglitazone inhibits the reaction [NCOA1 protein binds to EGFR promoter] | 21080969 |
C039671 | ciglitazone | ciglitazone results in decreased expression of EGFR protein | 21080969 |
C039671 | ciglitazone | CREBBP protein inhibits the reaction [ciglitazone results in decreased expression of EGFR protein] | 21080969 |
C039671 | ciglitazone | NCOA1 protein inhibits the reaction [ciglitazone results in decreased expression of EGFR protein] | 21080969 |
C039671 | ciglitazone | EGFR affects the reaction [ciglitazone results in increased activity of MAPK1] | 16616945 |
C039671 | ciglitazone | EGFR affects the reaction [ciglitazone results in increased activity of MAPK3] | 16616945 |
D002922 | Ciguatoxins | Ciguatoxins affects the expression of EGFR mRNA | 18353800 |
D002927 | Cimetidine | Cimetidine inhibits the reaction [EGFR protein results in increased phosphorylation of EGFR protein] | 17295779 |
D002927 | Cimetidine | [Cimetidine results in decreased abundance of Cyclic AMP] inhibits the reaction [EGFR protein results in increased phosphorylation of EGFR protein] | 17295779 |
D002927 | Cimetidine | Cimetidine inhibits the reaction [EGF protein promotes the reaction [EGFR protein results in increased phosphorylation of EGFR protein]] | 17295779 |
D002927 | Cimetidine | Cyclic AMP analog inhibits the reaction [Cimetidine inhibits the reaction [EGFR protein results in increased phosphorylation of EGFR protein]] | 17295779 |
C019304 | ciprofibrate | ciprofibrate results in decreased expression of EGFR protein | 2404574 |
D002945 | Cisplatin | [Cisplatin co-treated with Fluorouracil] results in decreased expression of EGFR mRNA | 15737843 |
D002945 | Cisplatin | [Cisplatin co-treated with Quercetin] results in increased expression of EGFR mRNA | 27514524 |
D002945 | Cisplatin | Cisplatin promotes the reaction [HER3 protein binds to EGFR protein] | 20726858 |
D002945 | Cisplatin | Cisplatin results in increased phosphorylation of and results in increased uptake of EGFR protein | 21431282 |
D002945 | Cisplatin | Cisplatin results in increased phosphorylation of EGFR protein | 20726858 |
D002945 | Cisplatin | EGFR gene mutant form results in increased susceptibility to [gemcitabine co-treated with Cisplatin co-treated with Erlotinib Hydrochloride] | 21541241 |
D002945 | Cisplatin | EGFR mRNA results in decreased susceptibility to Cisplatin | 18337622 |
D002945 | Cisplatin | EGFR protein affects the susceptibility to Cisplatin | 21431282 |
D002945 | Cisplatin | EGFR protein results in increased susceptibility to Cisplatin | 21324906 |
D002945 | Cisplatin | EGFR results in decreased susceptibility to Cisplatin | 21849418; 21909139; |
D002945 | Cisplatin | EGFR results in increased susceptibility to [Cisplatin co-treated with Docetaxel co-treated with Fluorouracil] | 21947696 |
D002945 | Cisplatin | [ITGB1 protein results in increased activity of EGFR protein] which results in decreased susceptibility to Cisplatin | 21478906 |
D002945 | Cisplatin | LRIG1 protein inhibits the reaction [Cisplatin results in increased phosphorylation of and affects the localization of EGFR protein] | 21431282 |
D002945 | Cisplatin | [TNFSF10 protein co-treated with Cisplatin] results in decreased expression of EGFR protein | 21252285 |
D002945 | Cisplatin | Cisplatin promotes the reaction [PRKDC protein binds to EGFR protein] | 21266349 |
D007464 | Clioquinol | 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline inhibits the reaction [[Copper binds to Clioquinol] which results in increased phosphorylation of EGFR protein] | 18346929 |
D007464 | Clioquinol | [4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline results in decreased activity of EGFR protein] results in decreased susceptibility to [Copper binds to Clioquinol] | 18346929 |
D007464 | Clioquinol | [Clioquinol binds to Copper] which results in decreased expression of EGFR protein | 18346929 |
D007464 | Clioquinol | [4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline results in decreased phosphorylation of and results in decreased activity of EGFR protein] inhibits the reaction [[Copper binds to Clioquinol] which results in increased phosphorylation of MAPK1 protein] | 18346929 |
D007464 | Clioquinol | [4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline results in decreased phosphorylation of and results in decreased activity of EGFR protein] inhibits the reaction [[Copper binds to Clioquinol] which results in increased phosphorylation of MAPK3 protein] | 18346929 |
D007464 | Clioquinol | AG 1879 inhibits the reaction [[Clioquinol binds to Copper] which results in increased phosphorylation of and results in increased activity of EGFR protein] | 18346929 |
D007464 | Clioquinol | [[Clioquinol binds to Copper] which results in increased activity of SRC protein] which results in increased phosphorylation of and results in increased activity of EGFR protein | 18346929 |
D007464 | Clioquinol | [Clioquinol binds to Copper] which results in increased phosphorylation of EGFR protein | 18346929 |
D007464 | Clioquinol | [FN1 protein co-treated with [Clioquinol binds to Copper]] results in increased expression of EGFR protein | 18346929 |
D007464 | Clioquinol | FN1 protein promotes the reaction [[Clioquinol binds to Copper] which results in increased phosphorylation of EGFR protein] | 18346929 |
D007464 | Clioquinol | ITGA2 protein promotes the reaction [[Clioquinol binds to Copper] which results in increased phosphorylation of EGFR protein] | 18346929 |
D007464 | Clioquinol | ITGA5 protein promotes the reaction [[Clioquinol binds to Copper] which results in increased phosphorylation of EGFR protein] | 18346929 |
D002994 | Clofibrate | Clofibrate inhibits the reaction [CREBBP protein binds to EGFR promoter] | 21080969 |
D002994 | Clofibrate | Clofibrate inhibits the reaction [NCOA1 protein binds to EGFR promoter] | 21080969 |
D002994 | Clofibrate | Clofibrate results in decreased expression of EGFR protein | 21080969 |
D002994 | Clofibrate | CREBBP protein inhibits the reaction [Clofibrate results in decreased expression of EGFR protein] | 21080969 |
D002994 | Clofibrate | NCOA1 protein inhibits the reaction [Clofibrate results in decreased expression of EGFR protein] | 21080969 |
D002994 | Clofibrate | [Clofibrate co-treated with Acetaminophen] affects the expression of EGFR mRNA | 17585979 |
D002994 | Clofibrate | Clofibrate results in decreased expression of EGFR mRNA | 17585979 |
D002994 | Clofibrate | PPARA affects the reaction [[Clofibrate co-treated with Acetaminophen] affects the expression of EGFR mRNA] | 17585979 |
D002994 | Clofibrate | Clofibrate results in decreased expression of EGFR protein | 2404574 |
C034456 | CMF regimen | EGFR protein affects the susceptibility to [Epirubicin co-treated with CMF regimen] | 18768436 |
C018021 | cobaltous chloride | cobaltous chloride results in increased expression of EGFR mRNA | 19376846 |
C018021 | cobaltous chloride | cobaltous chloride results in decreased expression of EGFR mRNA | 24386269 |
D003042 | Cocaine | Cocaine results in decreased expression of EGFR mRNA | 18000554 |
D003300 | Copper | 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline inhibits the reaction [[Copper binds to Clioquinol] which results in increased phosphorylation of EGFR protein] | 18346929 |
D003300 | Copper | [4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline results in decreased activity of EGFR protein] results in decreased susceptibility to [Copper binds to Clioquinol] | 18346929 |
D003300 | Copper | [Clioquinol binds to Copper] which results in decreased expression of EGFR protein | 18346929 |
D003300 | Copper | [4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline results in decreased phosphorylation of and results in decreased activity of EGFR protein] inhibits the reaction [[Copper binds to Clioquinol] which results in increased phosphorylation of MAPK1 protein] | 18346929 |
D003300 | Copper | [4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline results in decreased phosphorylation of and results in decreased activity of EGFR protein] inhibits the reaction [[Copper binds to Clioquinol] which results in increased phosphorylation of MAPK3 protein] | 18346929 |
D003300 | Copper | AG 1879 inhibits the reaction [[Clioquinol binds to Copper] which results in increased phosphorylation of and results in increased activity of EGFR protein] | 18346929 |
D003300 | Copper | [[Clioquinol binds to Copper] which results in increased activity of SRC protein] which results in increased phosphorylation of and results in increased activity of EGFR protein | 18346929 |
D003300 | Copper | [Clioquinol binds to Copper] which results in increased phosphorylation of EGFR protein | 18346929 |
D003300 | Copper | [Copper binds to neocuproine] which results in increased phosphorylation of EGFR protein | 18346929 |
D003300 | Copper | [Copper binds to Oxyquinoline] which results in increased phosphorylation of EGFR protein | 18346929 |
D003300 | Copper | [Copper binds to pyrrolidine dithiocarbamic acid] which results in increased phosphorylation of EGFR protein | 18346929 |
D003300 | Copper | [FN1 protein co-treated with [Clioquinol binds to Copper]] results in increased expression of EGFR protein | 18346929 |
D003300 | Copper | FN1 protein promotes the reaction [[Clioquinol binds to Copper] which results in increased phosphorylation of EGFR protein] | 18346929 |
D003300 | Copper | ITGA2 protein promotes the reaction [[Clioquinol binds to Copper] which results in increased phosphorylation of EGFR protein] | 18346929 |
D003300 | Copper | ITGA5 protein promotes the reaction [[Clioquinol binds to Copper] which results in increased phosphorylation of EGFR protein] | 18346929 |
D003300 | Copper | [NSC 689534 binds to Copper] which results in increased expression of EGFR mRNA | 20971185 |
D003300 | Copper | [Thiosemicarbazones binds to Copper] which results in increased phosphorylation of EGFR protein | 20931265 |
D003300 | Copper | Copper results in decreased expression of EGFR mRNA | 17205981 |
D019327 | Copper Sulfate | Copper Sulfate results in increased phosphorylation of EGFR protein | 10564177 |
D000077547 | Crizotinib | EGFR protein mutant form results in decreased susceptibility to Crizotinib | 22235099 |
D000077547 | Crizotinib | EGFR protein promotes the reaction [EGF protein results in decreased susceptibility to Crizotinib] | 22553343 |
D000077547 | Crizotinib | EGFR protein promotes the reaction [HBEGF protein results in decreased susceptibility to Crizotinib] | 22553343 |
D000077547 | Crizotinib | EGFR protein promotes the reaction [TGFA protein results in decreased susceptibility to Crizotinib] | 22553343 |
D000077547 | Crizotinib | EGFR protein results in decreased susceptibility to Crizotinib | 21791641 |
D000077547 | Crizotinib | [EGFR protein results in increased phosphorylation of EGFR protein] which results in decreased susceptibility to Crizotinib | 22277784 |
C037886 | cryptotanshinone | cryptotanshinone inhibits the reaction [Dinoprostone results in increased expression of EGFR protein modified form] | 30208247 |
C557526 | cucurbitacin IIa | cucurbitacin IIa results in decreased activity of and results in increased phosphorylation of EGFR protein | 31265865 |
D003471 | Cuprizone | Cuprizone results in increased expression of EGFR mRNA | 26577399 |
D003474 | Curcumin | Curcumin analog results in decreased expression of EGFR mRNA | 26409325 |
D003474 | Curcumin | Curcumin inhibits the reaction [Acrylamide results in increased expression of EGFR protein] | 24508477 |
D003474 | Curcumin | Curcumin inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein] | 10851300; 15129424; 18214481; |
D003474 | Curcumin | Curcumin promotes the reaction [Folfox protocol results in decreased expression of EGFR protein] | 17918158 |
D003474 | Curcumin | Curcumin promotes the reaction [Folfox protocol results in decreased phosphorylation of and results in decreased activity of EGFR protein] | 17918158 |
D003474 | Curcumin | Curcumin results in decreased expression of and results in decreased activity of EGFR protein | 10851300 |
D003474 | Curcumin | Curcumin results in decreased expression of EGFR mRNA | 15486348; 18719366; |
D003474 | Curcumin | Curcumin results in decreased expression of EGFR protein | 17918158; 18719366; |
D003474 | Curcumin | Curcumin results in decreased phosphorylation of and results in decreased activity of EGFR protein | 17918158 |
D003474 | Curcumin | Curcumin results in decreased phosphorylation of EGFR protein | 15486348 |
D003474 | Curcumin | Fluorouracil promotes the reaction [Curcumin results in decreased expression of EGFR protein] | 17918158 |
D003474 | Curcumin | Fluorouracil promotes the reaction [Curcumin results in decreased phosphorylation of and results in decreased activity of EGFR protein] | 17918158 |
D003474 | Curcumin | Curcumin inhibits the reaction [Carbon Tetrachloride results in increased expression of EGFR mRNA] | 18006644 |
D003474 | Curcumin | Curcumin results in decreased expression of EGFR mRNA | 18332871 |
D003474 | Curcumin | Curcumin results in decreased expression of EGFR protein | 18332871 |
D003474 | Curcumin | Curcumin results in decreased phosphorylation of EGFR protein | 17372590; 18332871; |
D003474 | Curcumin | Curcumin results in decreased expression of EGFR | 18462866 |
C057862 | cyanoginosin LR | cyanoginosin LR results in decreased methylation of EGFR gene | 29518473 |
C057862 | cyanoginosin LR | cyanoginosin LR results in increased expression of EGFR mRNA | 29518473 |
D000242 | Cyclic AMP | [Cimetidine results in decreased abundance of Cyclic AMP] inhibits the reaction [EGFR protein results in increased phosphorylation of EGFR protein] | 17295779 |
D000242 | Cyclic AMP | Cyclic AMP analog inhibits the reaction [Cimetidine inhibits the reaction [EGFR protein results in increased phosphorylation of EGFR protein]] | 17295779 |
D003513 | Cycloheximide | Cycloheximide promotes the reaction [Arsenic Trioxide results in decreased expression of EGFR protein] | 30237564 |
D003513 | Cycloheximide | Cycloheximide results in increased expression of EGFR mRNA | 15228094 |
D003513 | Cycloheximide | Cycloheximide inhibits the reaction [Asbestos, Crocidolite results in increased expression of EGFR protein] | 26368632 |
D003520 | Cyclophosphamide | EGFR protein affects the susceptibility to [Cyclophosphamide co-treated with Doxorubicin co-treated with Fluorouracil] | 15981280 |
D016572 | Cyclosporine | Cyclosporine results in increased expression of EGFR mRNA | 20106945 |
D016572 | Cyclosporine | Cyclosporine results in decreased expression of EGFR mRNA | 19770486 |
C017160 | cypermethrin | cypermethrin binds to EGFR protein | 22048644 |
C017160 | cypermethrin | cypermethrin results in decreased expression of EGFR mRNA | 22048644 |
C017160 | cypermethrin | cypermethrin results in decreased expression of EGFR protein | 22048644 |
C017160 | cypermethrin | cypermethrin results in decreased phosphorylation of EGFR protein | 22048644 |
D003571 | Cytochalasin B | Cytochalasin B inhibits the reaction [Asbestos, Crocidolite results in decreased phosphorylation of EGFR protein] | 15626777 |
D015638 | Cytochalasin D | Cytochalasin D inhibits the reaction [Asbestos, Crocidolite results in decreased phosphorylation of EGFR protein] | 15626777 |
C525726 | dacomitinib | dacomitinib inhibits the reaction [EGFR protein results in increased phosphorylation of EGFR protein] | 27491023 |
D003609 | Dactinomycin | Dactinomycin inhibits the reaction [Estradiol results in increased expression of EGFR protein] | 8888411 |
D003609 | Dactinomycin | Dactinomycin inhibits the reaction [Methoxychlor results in increased expression of EGFR protein] | 8888411 |
C004742 | daidzein | [daidzein co-treated with ESR1 protein] results in decreased expression of EGFR mRNA | 19347870 |
C004742 | daidzein | [daidzein co-treated with ESR1 protein] results in decreased expression of EGFR protein | 19347870 |
C004742 | daidzein | [daidzein co-treated with ESR2 protein] results in decreased expression of EGFR mRNA | 19347870 |
C004742 | daidzein | [daidzein co-treated with ESR2 protein] results in decreased expression of EGFR protein | 19347870 |
D000069439 | Dasatinib | Dasatinib inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein] | 20664932 |
D000069439 | Dasatinib | Dasatinib results in decreased phosphorylation of EGFR protein | 19398150 |
D000069439 | Dasatinib | EGFR gene mutant form results in increased susceptibility to Dasatinib | 16740687 |
D000069439 | Dasatinib | [EGFR gene mutant form results in increased susceptibility to Dasatinib] which results in decreased phosphorylation of STAT3 protein | 16740687 |
D000077209 | Decitabine | Decitabine results in increased expression of EGFR mRNA | 19151715 |
D003676 | Deferoxamine | Deferoxamine inhibits the reaction [Asbestos, Crocidolite results in decreased activity of and results in decreased phosphorylation of EGFR protein] | 15626777 |
C107676 | deguelin | deguelin metabolite results in decreased expression of EGFR protein | 19139008 |
C107676 | deguelin | deguelin results in decreased expression of EGFR protein | 19139008 |
D003687 | Dehydroepiandrosterone | EGFR protein promotes the reaction [Dehydroepiandrosterone results in increased expression of MIR21 mRNA] | 25969534 |
C017185 | delphinidin | delphinidin results in decreased phosphorylation of EGFR protein | 18618485 |
D003840 | Deoxycholic Acid | Deoxycholic Acid results in decreased glycosylation of and results in decreased expression of EGFR protein | 22223758 |
D003840 | Deoxycholic Acid | Deoxycholic Acid results in increased activity of EGFR protein | 16213893 |
D003840 | Deoxycholic Acid | Deoxycholic Acid results in increased phosphorylation of EGFR protein | 14747693 |
D003840 | Deoxycholic Acid | EGFR protein results in decreased susceptibility to Deoxycholic Acid | 12507930 |
D003840 | Deoxycholic Acid | Erlotinib Hydrochloride promotes the reaction [Deoxycholic Acid results in decreased glycosylation of and results in decreased expression of EGFR protein] | 22223758 |
D003840 | Deoxycholic Acid | Ursodeoxycholic Acid inhibits the reaction [Deoxycholic Acid results in increased phosphorylation of EGFR protein] | 14747693 |
D003840 | Deoxycholic Acid | Deoxycholic Acid results in increased activity of EGFR protein | 14747693 |
D003847 | Deoxyglucose | AICA ribonucleotide inhibits the reaction [EGFR protein results in increased import of Deoxyglucose] | 19625624 |
D003847 | Deoxyglucose | EGFR protein mutant form results in increased import of Deoxyglucose | 19625624 |
C559662 | Derp2 allergen, Dermatophagoides pteronyssinus | Derp2 allergen, Dermatophagoides pteronyssinus results in increased phosphorylation of EGFR protein | 30623574 |
C559662 | Derp2 allergen, Dermatophagoides pteronyssinus | Erlotinib Hydrochloride inhibits the reaction [Derp2 allergen, Dermatophagoides pteronyssinus results in increased phosphorylation of EGFR protein] | 30623574 |
C559662 | Derp2 allergen, Dermatophagoides pteronyssinus | osimertinib promotes the reaction [Derp2 allergen, Dermatophagoides pteronyssinus results in increased phosphorylation of EGFR protein] | 30623574 |
D003907 | Dexamethasone | Dexamethasone inhibits the reaction [EGF protein promotes the reaction [EGFR protein binds to ARAF protein]] | 10807665 |
D003907 | Dexamethasone | Dexamethasone inhibits the reaction [EGF protein promotes the reaction [EGFR protein binds to GRB2 protein]] | 10807665 |
D003907 | Dexamethasone | Dexamethasone inhibits the reaction [EGF protein promotes the reaction [EGFR protein binds to HRAS protein]] | 10807665 |
D003907 | Dexamethasone | Dexamethasone promotes the reaction [EGFR protein binds to ANXA1 protein modified form] | 10807665 |
D003907 | Dexamethasone | Mifepristone inhibits the reaction [Dexamethasone inhibits the reaction [EGF protein promotes the reaction [EGFR protein binds to ARAF protein]]] | 10807665 |
D003907 | Dexamethasone | Mifepristone inhibits the reaction [Dexamethasone inhibits the reaction [EGF protein promotes the reaction [EGFR protein binds to GRB2 protein]]] | 10807665 |
D003907 | Dexamethasone | Mifepristone inhibits the reaction [Dexamethasone inhibits the reaction [EGF protein promotes the reaction [EGFR protein binds to HRAS protein]]] | 10807665 |
D003907 | Dexamethasone | Mifepristone inhibits the reaction [Dexamethasone promotes the reaction [EGFR protein binds to ANXA1 protein modified form]] | 10807665 |
D003907 | Dexamethasone | Dexamethasone results in decreased phosphorylation of and results in decreased activity of EGFR protein | 15556944 |
D003931 | Diacetyl | Diacetyl results in increased phosphorylation of EGFR protein | 30851105 |
D003931 | Diacetyl | N-((2-(hydroxyaminocarbonyl)methyl)-4-methylpentanoyl)-3-(2'-naphthyl)alanylalanine, 2-aminoethylamide inhibits the reaction [Diacetyl results in increased phosphorylation of EGFR protein] | 30851105 |
C042577 | diallyl trisulfide | diallyl trisulfide results in decreased expression of EGFR protein | 23754639 |
D003976 | Diazinon | Diazinon affects the expression of EGFR mRNA | 22546817 |
C041517 | dibenzo(a,l)pyrene | Chlorophyll inhibits the reaction [dibenzo(a,l)pyrene results in increased expression of EGFR mRNA] | 22079312 |
C041517 | dibenzo(a,l)pyrene | dibenzo(a,l)pyrene results in increased expression of EGFR mRNA | 22079312 |
D003993 | Dibutyl Phthalate | Dibutyl Phthalate results in increased phosphorylation of EGFR protein | 22552774 |
D003993 | Dibutyl Phthalate | Fulvestrant inhibits the reaction [Dibutyl Phthalate results in increased phosphorylation of EGFR protein] | 22552774 |
D003993 | Dibutyl Phthalate | [Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of EGFR mRNA | 25607892 |
D003633 | Dichlorodiphenyl Dichloroethylene | [Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of EGFR mRNA | 25607892 |
D004008 | Diclofenac | Diclofenac results in increased expression of EGFR mRNA | 26934552 |
C000944 | dicrotophos | dicrotophos results in increased expression of EGFR mRNA | 28302478 |
D004026 | Dieldrin | Dieldrin affects the expression of EGFR mRNA | 22546817 |
D004041 | Dietary Fats | Dietary Fats results in decreased expression of EGFR mRNA | 15238619; 22609946; |
D004051 | Diethylhexyl Phthalate | Diethylhexyl Phthalate results in increased expression of EGFR mRNA | 31163220 |
D004051 | Diethylhexyl Phthalate | [Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of EGFR mRNA | 25607892 |
D004051 | Diethylhexyl Phthalate | Diethylhexyl Phthalate results in decreased expression of EGFR protein | 2404574 |
D004052 | Diethylnitrosamine | Acetylcysteine inhibits the reaction [Diethylnitrosamine results in increased phosphorylation of and results in increased activity of EGFR protein] | 17942915 |
D004052 | Diethylnitrosamine | CTNNB1 protein promotes the reaction [Diethylnitrosamine results in decreased expression of EGFR protein] | 20583210 |
D004052 | Diethylnitrosamine | [Diethylnitrosamine co-treated with Piperonyl Butoxide] results in decreased expression of EGFR mRNA | 20101389 |
D004052 | Diethylnitrosamine | Diethylnitrosamine results in decreased expression of EGFR protein | 20583210 |
D004052 | Diethylnitrosamine | Diethylnitrosamine results in increased expression of EGFR mRNA | 27058323 |
D004052 | Diethylnitrosamine | Diethylnitrosamine results in increased phosphorylation of and results in increased activity of EGFR protein | 17942915 |
D004052 | Diethylnitrosamine | epigallocatechin gallate inhibits the reaction [Diethylnitrosamine results in increased expression of EGFR mRNA] | 27058323 |
D004052 | Diethylnitrosamine | MET protein inhibits the reaction [Diethylnitrosamine results in increased phosphorylation of and results in increased activity of EGFR protein] | 17942915 |
D004052 | Diethylnitrosamine | theaflavin inhibits the reaction [Diethylnitrosamine results in increased expression of EGFR mRNA] | 27058323 |
D004052 | Diethylnitrosamine | [Diethylnitrosamine co-treated with Carbon Tetrachloride] results in increased phosphorylation of EGFR protein | 29923357 |
D004052 | Diethylnitrosamine | [Diethylnitrosamine co-treated with Tetrachlorodibenzodioxin] results in decreased expression of EGFR protein | 8403215 |
D004052 | Diethylnitrosamine | [Diethylnitrosamine co-treated with Thioacetamide] results in decreased expression of EGFR mRNA | 28943392 |
D004052 | Diethylnitrosamine | Diethylnitrosamine results in decreased expression of EGFR mRNA | 15660382; 19638242; |
D004052 | Diethylnitrosamine | Diethylnitrosamine results in decreased expression of EGFR protein | 15660382 |
D004052 | Diethylnitrosamine | Plant Extracts inhibits the reaction [[Diethylnitrosamine co-treated with Carbon Tetrachloride] results in increased phosphorylation of EGFR protein] | 29923357 |
D004054 | Diethylstilbestrol | Diethylstilbestrol results in increased expression of EGFR mRNA | 17011747 |
D013196 | Dihydrotestosterone | Dihydrotestosterone results in increased expression of EGFR mRNA | 29581250 |
D015232 | Dinoprostone | cryptotanshinone inhibits the reaction [Dinoprostone results in increased expression of EGFR protein modified form] | 30208247 |
D015232 | Dinoprostone | Dinoprostone results in increased expression of EGFR protein modified form | 30208247 |
D015232 | Dinoprostone | Dinoprostone results in increased phosphorylation of EGFR protein | 17805209 |
D015232 | Dinoprostone | EGFR mutant form affects the reaction [[lead nitrate results in increased expression of PLA2G4A mRNA] which results in increased secretion of Dinoprostone] | 20850495 |
D015232 | Dinoprostone | EGFR mutant form affects the reaction [lead nitrate results in increased secretion of Dinoprostone] | 20850495 |
D015232 | Dinoprostone | EGFR protein results in increased secretion of Dinoprostone | 16213893 |
C007517 | diphenyleneiodonium | diphenyleneiodonium inhibits the reaction [Cadmium results in increased phosphorylation of EGFR protein] | 26514923 |
C007517 | diphenyleneiodonium | diphenyleneiodonium inhibits the reaction [EDN1 protein results in increased phosphorylation of and results in increased activity of EGFR protein] | 16391241 |
C031291 | diphenyliodonium | diphenyliodonium inhibits the reaction [EDN1 protein results in increased phosphorylation of and results in increased activity of EGFR protein] | 16261333 |
D004177 | Dipyrone | Dipyrone promotes the reaction [Hydrochloric Acid results in increased expression of EGFR protein] | 15309881 |
D004280 | Dobutamine | AG 1879 inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]] | 18787115 |
D004280 | Dobutamine | AG 1879 inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]] | 18787115 |
D004280 | Dobutamine | AG 1879 inhibits the reaction [Dobutamine promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]] | 18787115 |
D004280 | Dobutamine | ARRB1 protein promotes the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]] | 18787115 |
D004280 | Dobutamine | ARRB1 protein promotes the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]] | 18787115 |
D004280 | Dobutamine | ARRB2 protein promotes the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]] | 18787115 |
D004280 | Dobutamine | ARRB2 protein promotes the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]] | 18787115 |
D004280 | Dobutamine | Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein] | 18787115 |
D004280 | Dobutamine | Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein] | 18787115 |
D004280 | Dobutamine | Dobutamine promotes the reaction [ADRB1 protein results in increased phosphorylation of and results in increased uptake of EGFR protein] | 18787115 |
D004280 | Dobutamine | HBEGF protein inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]] | 18787115 |
D004280 | Dobutamine | HBEGF protein inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]] | 18787115 |
D004280 | Dobutamine | HBEGF protein promotes the reaction [Dobutamine promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]] | 18787115 |
D004280 | Dobutamine | N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]] | 18787115 |
D004280 | Dobutamine | N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]] | 18787115 |
D004280 | Dobutamine | N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Dobutamine promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]] | 18787115 |
D004280 | Dobutamine | Propranolol inhibits the reaction [Dobutamine promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]] | 18787115 |
D004280 | Dobutamine | Propranolol inhibits the reaction [Dobutamine promotes the reaction [ADRB1 protein results in increased uptake of EGFR protein]] | 18787115 |
D004280 | Dobutamine | RTKI cpd inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]] | 18787115 |
D004280 | Dobutamine | RTKI cpd inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]] | 18787115 |
D004280 | Dobutamine | RTKI cpd inhibits the reaction [Dobutamine promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]] | 18787115 |
D004280 | Dobutamine | EGFR gene mutant form results in decreased susceptibility to Dobutamine | 18599591 |
D000077143 | Docetaxel | ABCB1 protein affects the reaction [EGFR protein results in decreased susceptibility to Docetaxel] | 24888374 |
D000077143 | Docetaxel | EGFR protein results in decreased susceptibility to Docetaxel | 24888374 |
D000077143 | Docetaxel | EGFR results in increased susceptibility to [Cisplatin co-treated with Docetaxel co-treated with Fluorouracil] | 21947696 |
D000077143 | Docetaxel | EGFR results in increased susceptibility to Docetaxel | 21681119 |
D000077143 | Docetaxel | Gefitinib inhibits the reaction [EGFR protein results in decreased susceptibility to Docetaxel] | 24888374 |
C516138 | dorsomorphin | [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EGFR mRNA | 27188386 |
C516138 | dorsomorphin | [NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EGFR mRNA | 27188386 |
C516138 | dorsomorphin | [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EGFR mRNA | 27188386 |
C516138 | dorsomorphin | [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EGFR mRNA | 27188386 |
D004317 | Doxorubicin | Doxorubicin results in decreased expression of EGFR mRNA | 29803840 |
D004317 | Doxorubicin | Doxorubicin results in increased expression of EGFR mRNA | 30031762 |
D004317 | Doxorubicin | Doxorubicin results in increased phosphorylation of EGFR protein | 17974986 |
D004317 | Doxorubicin | EGFR protein affects the susceptibility to [Cyclophosphamide co-treated with Doxorubicin co-treated with Fluorouracil] | 15981280 |
D004317 | Doxorubicin | [[Gefitinib results in decreased activity of EGFR protein] which affects the localization of ABCG2 protein] which results in decreased export of Doxorubicin | 17938326 |
D004317 | Doxorubicin | Doxorubicin results in increased expression of EGFR mRNA | 25896364 |
D004317 | Doxorubicin | Doxorubicin results in increased phosphorylation of and results in increased activity of EGFR protein | 15843167 |
D060766 | Drinking Water | Drinking Water results in increased expression of EGFR mRNA | 19444861 |
D004365 | Drugs, Chinese Herbal | Drugs, Chinese Herbal inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein] | 25856345 |
D004365 | Drugs, Chinese Herbal | Drugs, Chinese Herbal results in decreased activity of EGFR protein | 25856345 |
C509867 | E804 bisindole | [6,2',4'-trimethoxyflavone co-treated with E804 bisindole] results in decreased expression of EGFR mRNA | 31505164 |
C509867 | E804 bisindole | E804 bisindole results in decreased expression of EGFR mRNA | 31505164 |
C058249 | ebastine | ebastine results in increased activity of EGFR protein | 22573732 |
C413879 | EKB 569 | EKB 569 results in decreased activity of EGFR protein | 21322567; 22242139; |
C413879 | EKB 569 | EKB 569 results in decreased activity of EGFR protein mutant form | 21322567 |
C045651 | epigallocatechin gallate | epigallocatechin gallate inhibits the reaction [Acrylamide results in increased expression of EGFR protein] | 24508477 |
C045651 | epigallocatechin gallate | epigallocatechin gallate inhibits the reaction [EGF protein binds to EGFR protein] | 17616711 |
C045651 | epigallocatechin gallate | epigallocatechin gallate inhibits the reaction [EGF protein promotes the reaction [EGFR protein binds to EGFR protein]] | 17616711 |
C045651 | epigallocatechin gallate | epigallocatechin gallate inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein] | 17616711 |
C045651 | epigallocatechin gallate | epigallocatechin gallate results in increased expression of EGFR mRNA | 22079256 |
C045651 | epigallocatechin gallate | [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of EGFR mRNA | 22079256 |
C045651 | epigallocatechin gallate | [Raloxifene Hydrochloride co-treated with epigallocatechin gallate] results in decreased phosphorylation of EGFR protein | 18371987 |
C045651 | epigallocatechin gallate | epigallocatechin gallate inhibits the reaction [Diethylnitrosamine results in increased expression of EGFR mRNA] | 27058323 |
D015251 | Epirubicin | EGFR protein affects the susceptibility to [Epirubicin co-treated with CMF regimen] | 18768436 |
C109476 | epoxiconazole | [Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of EGFR mRNA | 25607892 |
D060754 | Equol | [RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [Equol results in increased chemical synthesis of Oxygen] | 21300668 |
D060754 | Equol | [RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [Equol results in increased phosphorylation of and results in increased activity of NOS3 protein] | 21300668 |
D060754 | Equol | [RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [Equol results in increased phosphorylation of MAPK1 protein] | 21300668 |
D060754 | Equol | [RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [Equol results in increased phosphorylation of MAPK3 protein] | 21300668 |
C083174 | erionite | erionite results in increased expression of EGFR protein | 26368632 |
D000069347 | Erlotinib Hydrochloride | EGFR gene mutant form results in increased susceptibility to [gemcitabine co-treated with Cisplatin co-treated with Erlotinib Hydrochloride] | 21541241 |
D000069347 | Erlotinib Hydrochloride | EGFR protein affects the susceptibility to Erlotinib Hydrochloride | 21080748 |
D000069347 | Erlotinib Hydrochloride | EGFR protein mutant form affects the susceptibility to Erlotinib Hydrochloride | 21080748 |
D000069347 | Erlotinib Hydrochloride | EGFR protein mutant form results in decreased susceptibility to Erlotinib Hydrochloride | 16407879 |
D000069347 | Erlotinib Hydrochloride | Erlotinib Hydrochloride inhibits the reaction [Arsenic Trioxide results in increased phosphorylation of and results in increased activity of EGFR protein] | 23548265 |
D000069347 | Erlotinib Hydrochloride | Erlotinib Hydrochloride inhibits the reaction [Derp2 allergen, Dermatophagoides pteronyssinus results in increased phosphorylation of EGFR protein] | 30623574 |
D000069347 | Erlotinib Hydrochloride | Erlotinib Hydrochloride inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein] | 25625231; 30364229; |
D000069347 | Erlotinib Hydrochloride | Erlotinib Hydrochloride inhibits the reaction [EGFR protein mutant form results in increased expression of FOXG1 mRNA] | 26455392 |
D000069347 | Erlotinib Hydrochloride | Erlotinib Hydrochloride inhibits the reaction [EGFR protein mutant form results in increased expression of FOXG1 protein] | 26455392 |
D000069347 | Erlotinib Hydrochloride | Erlotinib Hydrochloride inhibits the reaction [EGFR protein mutant form results in increased expression of SOX9 mRNA] | 26455392 |
D000069347 | Erlotinib Hydrochloride | Erlotinib Hydrochloride inhibits the reaction [EGFR protein mutant form results in increased expression of SOX9 protein] | 26455392 |
D000069347 | Erlotinib Hydrochloride | Erlotinib Hydrochloride inhibits the reaction [Particulate Matter analog results in increased phosphorylation of EGFR protein] | 28101945 |
D000069347 | Erlotinib Hydrochloride | Erlotinib Hydrochloride inhibits the reaction [sodium arsenite results in increased phosphorylation of EGFR protein] | 19168569 |
D000069347 | Erlotinib Hydrochloride | Erlotinib Hydrochloride promotes the reaction [Deoxycholic Acid results in decreased glycosylation of and results in decreased expression of EGFR protein] | 22223758 |
D000069347 | Erlotinib Hydrochloride | Erlotinib Hydrochloride promotes the reaction [EGF protein binds to EGFR protein] | 21787763 |
D000069347 | Erlotinib Hydrochloride | Erlotinib Hydrochloride results in decreased activity of and results in decreased phosphorylation of EGFR protein | 23548265 |
D000069347 | Erlotinib Hydrochloride | Erlotinib Hydrochloride results in decreased activity of EGFR protein | 12907618; 21080748; 22751098; 23440206; |
D000069347 | Erlotinib Hydrochloride | [Erlotinib Hydrochloride results in decreased activity of EGFR protein] which results in decreased expression of RAD50 protein | 23548265 |
D000069347 | Erlotinib Hydrochloride | [Erlotinib Hydrochloride results in decreased activity of EGFR protein] which results in decreased expression of RAD51 protein | 23548265 |
D000069347 | Erlotinib Hydrochloride | [Erlotinib Hydrochloride results in decreased activity of EGFR protein] which results in decreased phosphorylation of BRCA1 protein | 23548265 |
D000069347 | Erlotinib Hydrochloride | Erlotinib Hydrochloride results in decreased expression of EGFR protein modified form | 30136359 |
D000069347 | Erlotinib Hydrochloride | Erlotinib Hydrochloride results in decreased glycosylation of and results in decreased expression of EGFR protein | 22223758 |
D000069347 | Erlotinib Hydrochloride | Erlotinib Hydrochloride results in decreased phosphorylation of EGFR protein | 16891461; 23099361; 23894143; |
D000069347 | Erlotinib Hydrochloride | Erlotinib Hydrochloride binds to EGFR protein | 22048644 |
D000069347 | Erlotinib Hydrochloride | Erlotinib Hydrochloride results in decreased activity of EGFR protein | 16891461; 18980991; 21613822; 21655094; 22553343; 22573732; |
D004958 | Estradiol | 4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-3H-cyclopenta(c)quinoline inhibits the reaction [Estradiol results in increased phosphorylation of EGFR protein] | 31468104 |
D004958 | Estradiol | [AREG protein co-treated with Estradiol] results in increased phosphorylation of EGFR protein | 21185374 |
D004958 | Estradiol | EGF protein inhibits the reaction [[Estradiol co-treated with EGFR protein] results in increased expression of SIAH2 mRNA] | 18629630 |
D004958 | Estradiol | EGF protein inhibits the reaction [[Estradiol co-treated with EGFR protein] results in increased expression of SIAH2 protein] | 18629630 |
D004958 | Estradiol | EGF protein promotes the reaction [Estradiol results in increased phosphorylation of EGFR protein] | 20005069 |
D004958 | Estradiol | [Estradiol co-treated with EGFR protein] results in increased expression of SIAH2 mRNA | 18629630 |
D004958 | Estradiol | [Estradiol co-treated with EGFR protein] results in increased expression of SIAH2 protein | 18629630 |
D004958 | Estradiol | [Estradiol co-treated with ESR1 protein] results in decreased expression of EGFR mRNA | 19347870 |
D004958 | Estradiol | [Estradiol co-treated with ESR1 protein] results in decreased expression of EGFR protein | 19347870 |
D004958 | Estradiol | [Estradiol co-treated with ESR2 protein] results in decreased expression of EGFR mRNA | 19347870 |
D004958 | Estradiol | [Estradiol co-treated with ESR2 protein] results in decreased expression of EGFR protein | 19347870 |
D004958 | Estradiol | [Estradiol co-treated with IGF1R mutant form] results in increased expression of EGFR mRNA | 23094148 |
D004958 | Estradiol | [Estradiol co-treated with Tetrachlorodibenzodioxin] results in decreased expression of EGFR mRNA | 19619570 |
D004958 | Estradiol | Estradiol promotes the reaction [EGF protein results in increased phosphorylation of EGFR protein] | 21185374 |
D004958 | Estradiol | Estradiol promotes the reaction [SRC protein modified form binds to EGFR protein modified form] | 31468104 |
D004958 | Estradiol | Estradiol results in decreased expression of EGFR mRNA | 20005069 |
D004958 | Estradiol | Estradiol results in decreased expression of EGFR protein | 20005069 |
D004958 | Estradiol | Estradiol results in increased activity of EGFR protein | 15802018 |
D004958 | Estradiol | Estradiol results in increased expression of EGFR mRNA | 19619570 |
D004958 | Estradiol | Estradiol results in increased phosphorylation of EGFR protein | 20005069; 21185374; 31468104; |
D004958 | Estradiol | GPER1 protein affects the reaction [Estradiol results in increased phosphorylation of EGFR protein] | 31468104 |
D004958 | Estradiol | ICI 164384 inhibits the reaction [[Estradiol co-treated with EGFR protein] results in increased expression of SIAH2 mRNA] | 18629630 |
D004958 | Estradiol | [Parathion co-treated with Estradiol] results in increased expression of EGFR protein | 17622325 |
D004958 | Estradiol | [Progesterone co-treated with Estradiol] results in increased expression of EGFR mRNA | 18692832 |
D004958 | Estradiol | RTKI cpd inhibits the reaction [[AREG protein co-treated with Estradiol] results in increased phosphorylation of EGFR protein] | 21185374 |
D004958 | Estradiol | RTKI cpd inhibits the reaction [Estradiol promotes the reaction [EGF protein results in increased phosphorylation of EGFR protein]] | 21185374 |
D004958 | Estradiol | RTKI cpd inhibits the reaction [Estradiol results in increased phosphorylation of EGFR protein] | 21185374 |
D004958 | Estradiol | ESR1 protein promotes the reaction [Estradiol results in increased expression of EGFR mRNA] | 25210133 |
D004958 | Estradiol | Estradiol inhibits the reaction [perfluorooctanoic acid results in decreased expression of EGFR protein] | 22414604 |
D004958 | Estradiol | Estradiol promotes the reaction [Progesterone inhibits the reaction [perfluorooctanoic acid results in decreased expression of EGFR protein]] | 22414604 |
D004958 | Estradiol | Estradiol results in increased expression of EGFR mRNA | 25210133 |
D004958 | Estradiol | Progesterone promotes the reaction [Estradiol inhibits the reaction [perfluorooctanoic acid results in decreased expression of EGFR protein]] | 22414604 |
D004958 | Estradiol | Dactinomycin inhibits the reaction [Estradiol results in increased expression of EGFR protein] | 8888411 |
D004958 | Estradiol | Estradiol results in decreased expression of EGFR mRNA | 20068009; 31119341; |
D004958 | Estradiol | Estradiol results in increased expression of EGFR protein | 8888411 |
C025483 | estradiol-17 beta-glucuronide | EGFR protein promotes the reaction [estradiol-17 beta-glucuronide affects the localization of and results in decreased activity of ABCC2 protein] | 25813982 |
C025483 | estradiol-17 beta-glucuronide | estradiol-17 beta-glucuronide results in increased phosphorylation of and results in increased activity of EGFR protein | 25813982 |
C025483 | estradiol-17 beta-glucuronide | RTKI cpd inhibits the reaction [estradiol-17 beta-glucuronide results in increased phosphorylation of and results in increased activity of EGFR protein] | 25813982 |
C074283 | estradiol 3-benzoate | estradiol 3-benzoate results in increased expression of EGFR protein | 15778002 |
D004967 | Estrogens | Estrogens results in increased expression of EGFR mRNA | 14647453 |
D004967 | Estrogens | [Estrogens co-treated with Progesterone] results in increased expression of EGFR mRNA | 21258428 |
D004967 | Estrogens | [Estrogens co-treated with Progesterone] results in increased expression of EGFR protein | 21258428 |
D004967 | Estrogens | Estrogens results in increased expression of EGFR mRNA | 21258428 |
D004967 | Estrogens | Estrogens results in increased expression of EGFR protein | 21258428 |
D004970 | Estrone | Estrone inhibits the reaction [LEPR gene mutant form inhibits the reaction [EGFR protein results in increased phosphorylation of EGFR protein]] | 1753381 |
D004970 | Estrone | Estrone inhibits the reaction [LEPR gene mutant form results in decreased expression of EGFR mRNA] | 1753381 |
D000431 | Ethanol | [Ethanol co-treated with CYP2E1 protein] results in increased phosphorylation of EGFR protein | 22222162 |
D000431 | Ethanol | Ethanol results in decreased expression of EGFR mRNA | 19167417 |
D000431 | Ethanol | Ethanol results in increased expression of EGFR mRNA | 30319688 |
D000431 | Ethanol | Ethanol results in increased expression of EGFR mRNA | 15353170 |
D004997 | Ethinyl Estradiol | Ethinyl Estradiol affects the expression of EGFR mRNA | 17555576 |
D004997 | Ethinyl Estradiol | Ethinyl Estradiol results in increased expression of EGFR mRNA | 17942748 |
D004997 | Ethinyl Estradiol | Ethinyl Estradiol results in increased expression of EGFR protein | 2197011; 2786453; |
D004997 | Ethinyl Estradiol | Ethinyl Estradiol results in increased stability of EGFR protein | 2197011 |
C024565 | ethylene dichloride | ethylene dichloride results in decreased expression of EGFR mRNA | 28189721 |
D005038 | Ethylnitrosourea | Ethylnitrosourea results in increased mutagenesis of EGFR gene | 15366372; 16724327; |
D005047 | Etoposide | Etoposide results in decreased expression of EGFR mRNA | 15228094 |
D005047 | Etoposide | Etoposide results in decreased expression of EGFR protein | 15228094 |
D005054 | Eugenol | Eugenol results in decreased expression of EGFR protein | 15618236 |
D005054 | Eugenol | Eugenol results in increased expression of EGFR mRNA | 15618236 |
D000068338 | Everolimus | Everolimus results in increased expression of EGFR mRNA | 28711525 |
D000068338 | Everolimus | Everolimus results in increased expression of EGFR protein | 28711525 |
D000068338 | Everolimus | platycodin D inhibits the reaction [Everolimus results in increased expression of EGFR protein] | 28711525 |
C049639 | evodiamine | EGFR mutant form inhibits the reaction [evodiamine results in increased phosphorylation of MAPK1 protein] | 19854188 |
C049639 | evodiamine | EGFR mutant form inhibits the reaction [evodiamine results in increased phosphorylation of MAPK3 protein] | 19854188 |
C049639 | evodiamine | EGFR mutant form inhibits the reaction [evodiamine results in increased phosphorylation of PLCG1 protein] | 19854188 |
C049639 | evodiamine | EGFR mutant form inhibits the reaction [evodiamine results in increased phosphorylation of PRKCA protein] | 19854188 |
C049639 | evodiamine | evodiamine results in increased phosphorylation of EGFR protein | 19854188 |
C049639 | evodiamine | RTKI cpd inhibits the reaction [evodiamine results in increased phosphorylation of EGFR protein] | 19854188 |
C471268 | FD137 nitrosourea | [FD137 nitrosourea inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]] which results in decreased expression of FOS mRNA | 14991862 |
C471268 | FD137 nitrosourea | [FD137 nitrosourea metabolite inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]] which results in decreased expression of FOS mRNA | 14991862 |
C471268 | FD137 nitrosourea | FD137 nitrosourea results in decreased activity of EGFR protein | 14991862 |
C540355 | fenamidone | fenamidone results in increased expression of EGFR mRNA | 27029645 |
D011345 | Fenofibrate | Fenofibrate results in decreased expression of EGFR mRNA | 11798191 |
D017313 | Fenretinide | Fenretinide results in increased expression of EGFR mRNA | 16570282 |
D017313 | Fenretinide | Fenretinide results in decreased expression of EGFR mRNA | 28973697 |
C000499 | ferric oxide | ferric oxide analog results in increased phosphorylation of EGFR protein | 24068039 |
C007738 | fluoranthene | [1-methylanthracene co-treated with fluoranthene] results in increased expression of EGFR mRNA | 28329830 |
D005472 | Fluorouracil | [Cisplatin co-treated with Fluorouracil] results in decreased expression of EGFR mRNA | 15737843 |
D005472 | Fluorouracil | EGFR gene polymorphism affects the susceptibility to [Oxaliplatin co-treated with Fluorouracil] | 16098254 |
D005472 | Fluorouracil | EGFR gene polymorphism results in decreased susceptibility to Fluorouracil | 19217205 |
D005472 | Fluorouracil | EGFR protein affects the susceptibility to [Cyclophosphamide co-treated with Doxorubicin co-treated with Fluorouracil] | 15981280 |
D005472 | Fluorouracil | EGFR protein affects the susceptibility to Fluorouracil | 16836928; 17169374; |
D005472 | Fluorouracil | EGFR results in increased susceptibility to [Cisplatin co-treated with Docetaxel co-treated with Fluorouracil] | 21947696 |
D005472 | Fluorouracil | Fluorouracil promotes the reaction [Curcumin results in decreased expression of EGFR protein] | 17918158 |
D005472 | Fluorouracil | Fluorouracil promotes the reaction [Curcumin results in decreased phosphorylation of and results in decreased activity of EGFR protein] | 17918158 |
D005472 | Fluorouracil | Fluorouracil results in decreased expression of EGFR protein | 17918158; 17982676; |
D005472 | Fluorouracil | Fluorouracil results in decreased phosphorylation of and results in decreased activity of EGFR protein | 17918158 |
D005472 | Fluorouracil | Fluorouracil results in increased phosphorylation of EGFR protein | 18794807 |
D005472 | Fluorouracil | TP53 protein affects the reaction [Fluorouracil results in decreased expression of EGFR protein] | 17982676 |
D005473 | Fluoxetine | [Fluoxetine binds to and results in increased activity of HTR2C protein] which results in increased phosphorylation of and results in increased activity of EGFR protein | 19662385 |
D005473 | Fluoxetine | [[Fluoxetine binds to and results in increased activity of HTR2C protein] which results in increased phosphorylation of and results in increased activity of EGFR protein] which results in increased phosphorylation of and results in increased activity of MAPK1 protein | 19662385 |
D005473 | Fluoxetine | [[Fluoxetine binds to and results in increased activity of HTR2C protein] which results in increased phosphorylation of and results in increased activity of EGFR protein] which results in increased phosphorylation of and results in increased activity of MAPK3 protein | 19662385 |
D005473 | Fluoxetine | Fluoxetine results in increased phosphorylation of EGFR protein | 18758753 |
D005473 | Fluoxetine | N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Fluoxetine results in increased phosphorylation of EGFR protein] | 18758753 |
D005473 | Fluoxetine | RTKI cpd inhibits the reaction [Fluoxetine results in increased phosphorylation of EGFR protein] | 18758753 |
D005478 | Flurandrenolone | Flurandrenolone results in increased activity of EGFR protein | 22573732 |
D005485 | Flutamide | Flutamide results in decreased expression of EGFR mRNA | 24136188 |
C410216 | Folfox protocol | Curcumin promotes the reaction [Folfox protocol results in decreased expression of EGFR protein] | 17918158 |
C410216 | Folfox protocol | Curcumin promotes the reaction [Folfox protocol results in decreased phosphorylation of and results in decreased activity of EGFR protein] | 17918158 |
C410216 | Folfox protocol | Folfox protocol results in decreased expression of EGFR protein | 17918158 |
C410216 | Folfox protocol | Folfox protocol results in decreased phosphorylation of and results in decreased activity of EGFR protein | 17918158 |
D005620 | Freund's Adjuvant | [Urethane co-treated with Freund's Adjuvant] results in increased expression of EGFR mRNA | 12400877 |
D000077267 | Fulvestrant | Fulvestrant inhibits the reaction [bisphenol A promotes the reaction [EGFR protein binds to AR protein]] | 29383186 |
D000077267 | Fulvestrant | Fulvestrant inhibits the reaction [bisphenol A promotes the reaction [EGFR protein binds to ESR2 protein]] | 29383186 |
D000077267 | Fulvestrant | Fulvestrant inhibits the reaction [bisphenol A results in increased phosphorylation of EGFR protein] | 29383186 |
D000077267 | Fulvestrant | Fulvestrant inhibits the reaction [butylbenzyl phthalate results in increased phosphorylation of EGFR protein] | 22552774 |
D000077267 | Fulvestrant | Fulvestrant inhibits the reaction [Dibutyl Phthalate results in increased phosphorylation of EGFR protein] | 22552774 |
C039281 | furan | furan results in decreased expression of EGFR mRNA | 25539665 |
C037032 | galangin | galangin inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein] | 25625231 |
D005707 | Gallic Acid | [Gallic Acid binds to Gold] inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein] | 27634460 |
D005707 | Gallic Acid | Gallic Acid inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein] | 27087131; 27634460; |
D005707 | Gallic Acid | SRC protein modified form affects the reaction [Gallic Acid inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]] | 27087131 |
D005707 | Gallic Acid | SRC protein modified form inhibits the reaction [Gallic Acid inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]] | 27087131 |
C106014 | gedunin | gedunin results in decreased expression of EGFR protein | 17010675 |
D000077156 | Gefitinib | betulinic acid promotes the reaction [Gefitinib results in decreased expression of EGFR protein modified form] | 30136359 |
D000077156 | Gefitinib | EGFR gene mutant form affects the susceptibility to Gefitinib | 18271929 |
D000077156 | Gefitinib | EGFR gene mutant form promotes the reaction [Gefitinib results in decreased expression of SQSTM1 protein] | 27639429 |
D000077156 | Gefitinib | EGFR gene mutant form promotes the reaction [Gefitinib results in increased cleavage of and results in increased activity of CASP3 protein] | 27639429 |
D000077156 | Gefitinib | EGFR gene mutant form results in decreased susceptibility to Gefitinib | 16740687 |
D000077156 | Gefitinib | EGFR gene mutant form results in increased susceptibility to Gefitinib | 16115929; 27639429; |
D000077156 | Gefitinib | EGFR gene polymorphism results in increased susceptibility to Gefitinib | 18625569 |
D000077156 | Gefitinib | EGFR protein affects the susceptibility to Gefitinib | 15976335; 16243822; 18771084; 20846305; 28739874; |
D000077156 | Gefitinib | EGFR protein mutant form affects the susceptibility to Gefitinib | 30237564 |
D000077156 | Gefitinib | EGFR protein mutant form results in decreased susceptibility to Gefitinib | 17290066; 30993382; |
D000077156 | Gefitinib | EGFR protein mutant form results in increased susceptibility to Gefitinib | 16824645; 17270025; |
D000077156 | Gefitinib | [Gefitinib co-treated with betulin] results in decreased expression of and results in decreased phosphorylation of EGFR protein | 27447558 |
D000077156 | Gefitinib | [Gefitinib co-treated with Oxaliplatin] results in decreased phosphorylation of EGFR protein | 13680161 |
D000077156 | Gefitinib | Gefitinib inhibits the reaction [bisphenol A promotes the reaction [EGFR protein binds to AR protein]] | 29383186 |
D000077156 | Gefitinib | Gefitinib inhibits the reaction [bisphenol A promotes the reaction [EGFR protein binds to ESR2 protein]] | 29383186 |
D000077156 | Gefitinib | Gefitinib inhibits the reaction [bisphenol A results in increased phosphorylation of EGFR protein] | 29383186 |
D000077156 | Gefitinib | Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of and results in increased activity of EGFR protein] | 17898861 |
D000077156 | Gefitinib | Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein] | 16243822; 18927496; 19318490; 27087131; |
D000077156 | Gefitinib | Gefitinib inhibits the reaction [EGF results in increased phosphorylation of and results in increased activity of EGFR protein] | 21787763 |
D000077156 | Gefitinib | Gefitinib inhibits the reaction [EGF results in increased phosphorylation of EGFR protein] | 21787763 |
D000077156 | Gefitinib | Gefitinib inhibits the reaction [EGFR protein results in decreased susceptibility to Docetaxel] | 24888374 |
D000077156 | Gefitinib | Gefitinib inhibits the reaction [gemcitabine results in increased phosphorylation of and results in increased degradation of EGFR protein] | 17146438 |
D000077156 | Gefitinib | Gefitinib inhibits the reaction [Irinotecan metabolite results in increased phosphorylation of and results in increased activity of EGFR protein] | 15723263 |
D000077156 | Gefitinib | Gefitinib inhibits the reaction [Irinotecan results in increased phosphorylation of and results in increased activity of EGFR protein] | 15723263 |
D000077156 | Gefitinib | Gefitinib inhibits the reaction [Tobacco Smoke Pollution results in increased phosphorylation of EGFR protein] | 21544845 |
D000077156 | Gefitinib | Gefitinib promotes the reaction [EGF protein binds to EGFR protein] | 21787763 |
D000077156 | Gefitinib | Gefitinib promotes the reaction [EGFR protein binds to EGFR protein] | 21787763 |
D000077156 | Gefitinib | [Gefitinib promotes the reaction [EGFR protein binds to EGFR protein]] which results in decreased activity of EGFR protein | 21787763 |
D000077156 | Gefitinib | Gefitinib promotes the reaction [IGF1R protein binds to EGFR protein] | 17473213 |
D000077156 | Gefitinib | Gefitinib results in decreased activity of EGFR protein | 17938326; 20549698; 21258428; |
D000077156 | Gefitinib | Gefitinib results in decreased activity of [EGFR protein binds to EGFR protein] | 17898861 |
D000077156 | Gefitinib | Gefitinib results in decreased activity of [EGFR protein binds to ERBB2 protein] | 17898861 |
D000077156 | Gefitinib | [Gefitinib results in decreased activity of EGFR protein] which affects the localization of ABCG2 protein | 17938326 |
D000077156 | Gefitinib | [[Gefitinib results in decreased activity of EGFR protein] which affects the localization of ABCG2 protein] which results in decreased export of Doxorubicin | 17938326 |
D000077156 | Gefitinib | Gefitinib results in decreased expression of and results in decreased phosphorylation of EGFR protein | 27447558; 30237564; 30993382; |
D000077156 | Gefitinib | Gefitinib results in decreased expression of EGFR protein modified form | 19288272; 30136359; |
D000077156 | Gefitinib | Gefitinib results in decreased phosphorylation of EGFR protein | 13680161; 14679152; 17145836; 17236550; 17473213; 28942004; 29383186; 30549224; |
D000077156 | Gefitinib | [ITGB1 protein results in increased activity of EGFR protein] which results in decreased susceptibility to Gefitinib | 21478906 |
D000077156 | Gefitinib | KRAS protein affects the reaction [EGFR protein affects the susceptibility to Gefitinib] | 28739874 |
D000077156 | Gefitinib | osimertinib inhibits the reaction [EGFR protein mutant form results in decreased susceptibility to Gefitinib] | 30993382 |
D000077156 | Gefitinib | Gefitinib inhibits the reaction [Cadmium Chloride results in increased phosphorylation of EGFR protein] | 23948867 |
D000077156 | Gefitinib | Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein] | 15841081 |
D000077156 | Gefitinib | [Gefitinib results in decreased activity of EGFR protein] which results in increased susceptibility to naphthalene | 20935109 |
D000077156 | Gefitinib | Gefitinib results in decreased phosphorylation of and results in decreased activity of EGFR protein | 20935109 |
D000077156 | Gefitinib | Gefitinib inhibits the reaction [HBEGF protein inhibits the reaction [sodium arsenite results in decreased phosphorylation of and results in decreased activity of EGFR protein]] | 29228391 |
D000077156 | Gefitinib | Gefitinib results in decreased activity of EGFR protein | 29228391 |
D000077156 | Gefitinib | Gefitinib results in decreased expression of EGFR protein modified form | 15660382 |
D000077156 | Gefitinib | Gefitinib results in decreased phosphorylation of EGFR protein | 18375820 |
D000077156 | Gefitinib | Gefitinib affects the activity of EGFR protein | 23061908 |
D000077156 | Gefitinib | Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein] | 15202007 |
D000077156 | Gefitinib | Gefitinib results in decreased activity of EGFR protein | 12906920; 14639003; 14679152; 14747693; 15604279; 15651060; 15735670; 15841081; 16261397; 17094457; 17236550; 17473213; 18089711; 18980991; 19803472; 21655094; 22573732; |
C001277 | geldanamycin | geldanamycin promotes the reaction [Sulfasalazine results in decreased expression of EGFR protein] | 20007406 |
C001277 | geldanamycin | geldanamycin results in decreased expression of EGFR protein | 20007406 |
C001277 | geldanamycin | geldanamycin inhibits the reaction [Tetrachlorodibenzodioxin inhibits the reaction [EGF protein binds to EGFR protein]] | 9664232 |
C001277 | geldanamycin | geldanamycin inhibits the reaction [Tetrachlorodibenzodioxin inhibits the reaction [EGF protein binds to EGFR protein]] | 9605431 |
C056507 | gemcitabine | benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [gemcitabine results in increased phosphorylation of and results in increased degradation of EGFR protein] | 17146438 |
C056507 | gemcitabine | EGFR gene mutant form results in increased susceptibility to [gemcitabine co-treated with Cisplatin co-treated with Erlotinib Hydrochloride] | 21541241 |
C056507 | gemcitabine | Gefitinib inhibits the reaction [gemcitabine results in increased phosphorylation of and results in increased degradation of EGFR protein] | 17146438 |
C056507 | gemcitabine | gemcitabine promotes the reaction [HER3 protein binds to EGFR protein] | 20726858 |
C056507 | gemcitabine | gemcitabine results in decreased expression of EGFR mRNA | 20103597 |
C056507 | gemcitabine | gemcitabine results in decreased expression of EGFR protein | 17146438 |
C056507 | gemcitabine | gemcitabine results in increased degradation of EGFR protein | 17146438 |
C056507 | gemcitabine | gemcitabine results in increased expression of EGFR mRNA | 17146438 |
C056507 | gemcitabine | gemcitabine results in increased phosphorylation of EGFR protein | 17146438; 20726858; |
D019833 | Genistein | [Genistein co-treated with ESR1 protein] results in decreased expression of EGFR mRNA | 19347870 |
D019833 | Genistein | [Genistein co-treated with ESR1 protein] results in decreased expression of EGFR protein | 19347870 |
D019833 | Genistein | [Genistein co-treated with ESR2 protein] results in decreased expression of EGFR mRNA | 19347870 |
D019833 | Genistein | [Genistein co-treated with ESR2 protein] results in decreased expression of EGFR protein | 19347870 |
D019833 | Genistein | Genistein results in decreased expression of EGFR mRNA | 15257099 |
D019833 | Genistein | Genistein results in decreased expression of EGFR mRNA | 11880592 |
D019833 | Genistein | Genistein results in increased expression of EGFR protein | 15781664 |
D019833 | Genistein | [RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [Genistein results in increased secretion of Testosterone] | 19059320 |
D005839 | Gentamicins | Gentamicins results in increased expression of EGFR mRNA | 22061828 |
C063170 | Ginkgo biloba extract | Ginkgo biloba extract affects the methylation of EGFR promoter | 31278416 |
C097367 | ginsenoside Rg3 | EGF protein promotes the reaction [ginsenoside Rg3 affects the phosphorylation of EGFR protein] | 25824408 |
C097367 | ginsenoside Rg3 | ginsenoside Rg3 affects the phosphorylation of EGFR protein | 25824408 |
C097367 | ginsenoside Rg3 | ginsenoside Rg3 inhibits the reaction [EGF protein promotes the reaction [EGFR protein binds to EGFR protein]] | 25824408 |
C097367 | ginsenoside Rg3 | ginsenoside Rg3 results in decreased expression of and affects the localization of EGFR protein | 25824408 |
D005897 | Glafenine | Glafenine results in decreased expression of EGFR mRNA | 24136188 |
D005978 | Glutathione | Glutathione inhibits the reaction [2'-benzoyloxycinnamaldehyde results in increased phosphorylation of EGFR protein] | 14660655 |
D005978 | Glutathione | [Acetaminophen results in decreased abundance of Glutathione] which results in increased phosphorylation of and results in increased activity of EGFR protein | 28123000 |
D005978 | Glutathione | [phorone results in decreased abundance of Glutathione] which results in increased phosphorylation of and results in increased activity of EGFR protein | 28123000 |
C081021 | Go 6976 | Go 6976 inhibits the reaction [Irinotecan metabolite results in increased phosphorylation of EGFR protein] | 15723263 |
C081021 | Go 6976 | Go 6976 inhibits the reaction [Irinotecan results in increased phosphorylation of EGFR protein] | 15723263 |
C081021 | Go 6976 | Go 6976 inhibits the reaction [EGF protein binds to and results in increased localization of EGFR protein] | 11134345 |
D006046 | Gold | [Gallic Acid binds to Gold] inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein] | 27634460 |
D017612 | Gold Compounds | Gold Compounds results in decreased expression of and results in decreased phosphorylation of EGFR protein | 20209498 |
C551538 | GW 583340 | GW 583340 inhibits the reaction [bisphenol A results in increased phosphorylation of EGFR protein] | 28426875 |
C551538 | GW 583340 | GW 583340 results in decreased phosphorylation of EGFR protein | 28426875 |
C505802 | helioxanthin | [helioxanthin co-treated with Arecoline co-treated with 4-nitroquinolone-1-oxide] affects the localization of EGFR protein modified form | 26464283 |
C505802 | helioxanthin | helioxanthin inhibits the reaction [[Arecoline co-treated with 4-nitroquinolone-1-oxide] results in increased phosphorylation of EGFR protein] | 26464283 |
D006493 | Heparin | Heparin results in decreased expression of EGFR mRNA | 16475731 |
D006493 | Heparin | Heparin results in decreased expression of EGFR protein | 16475731 |
D006493 | Heparin | Heparin results in increased phosphorylation of EGFR protein | 16556679 |
C089796 | hexabromocyclododecane | hexabromocyclododecane results in increased phosphorylation of EGFR protein | 26718265 |
C089796 | hexabromocyclododecane | [hexabromocyclododecane co-treated with FSHB protein] results in increased phosphorylation of EGFR protein | 24071787 |
D006581 | Hexachlorobenzene | [AG 1879 results in decreased activity of SRC protein] inhibits the reaction [Hexachlorobenzene results in increased phosphorylation of EGFR protein] | 21205633 |
D006581 | Hexachlorobenzene | Hexachlorobenzene results in increased phosphorylation of and results in increased expression of EGFR protein | 23462309 |
D006581 | Hexachlorobenzene | Hexachlorobenzene results in increased phosphorylation of EGFR protein | 21205633 |
D006581 | Hexachlorobenzene | [RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [Hexachlorobenzene results in increased phosphorylation of and results in increased activity of MAPK1 protein] | 21205633 |
D006581 | Hexachlorobenzene | [RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [Hexachlorobenzene results in increased phosphorylation of and results in increased activity of MAPK3 protein] | 21205633 |
D006581 | Hexachlorobenzene | [RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [Hexachlorobenzene results in increased phosphorylation of and results in increased activity of STAT5B protein] | 21205633 |
D006581 | Hexachlorobenzene | [RTKI cpd results in decreased activity of EGFR protein] which results in decreased susceptibility to Hexachlorobenzene | 21205633 |
D006581 | Hexachlorobenzene | Hexachlorobenzene affects the reaction [AHR protein affects the expression of EGFR mRNA] | 28923513 |
D006581 | Hexachlorobenzene | Hexachlorobenzene results in increased expression of EGFR mRNA | 28923513 |
D006581 | Hexachlorobenzene | AG 1879 inhibits the reaction [SRC protein promotes the reaction [Hexachlorobenzene results in increased phosphorylation of EGFR protein]] | 18295415 |
D006581 | Hexachlorobenzene | Hexachlorobenzene promotes the reaction [EGFR protein binds to SRC protein] | 18295415; 22245120; |
D006581 | Hexachlorobenzene | Hexachlorobenzene promotes the reaction [Methylnitrosourea promotes the reaction [EGFR protein binds to SRC protein]] | 22245120 |
D006581 | Hexachlorobenzene | Hexachlorobenzene promotes the reaction [Methylnitrosourea results in increased phosphorylation of EGFR protein] | 22245120 |
D006581 | Hexachlorobenzene | Hexachlorobenzene results in increased phosphorylation of and results in decreased expression of EGFR protein | 22245120 |
D006581 | Hexachlorobenzene | Hexachlorobenzene results in increased phosphorylation of EGFR protein | 18295415 |
D006581 | Hexachlorobenzene | Methylnitrosourea promotes the reaction [Hexachlorobenzene promotes the reaction [EGFR protein binds to SRC protein]] | 22245120 |
D006581 | Hexachlorobenzene | Methylnitrosourea promotes the reaction [Hexachlorobenzene results in increased phosphorylation of EGFR protein] | 22245120 |
D006581 | Hexachlorobenzene | SRC protein promotes the reaction [Hexachlorobenzene results in increased phosphorylation of EGFR protein] | 18295415 |
D006632 | Histamine | EGFR protein affects the reaction [Histamine results in increased secretion of MMP1 protein] | 17656145 |
C545813 | huachansu | [Arsenic Trioxide co-treated with huachansu] results in decreased expression of EGFR protein | 21434348 |
D006820 | Hyaluronic Acid | [RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [FSHB protein results in increased chemical synthesis of Hyaluronic Acid] | 21520325 |
D006820 | Hyaluronic Acid | EGFR protein affects the chemical synthesis of and affects the localization of Hyaluronic Acid | 21520325 |
D006820 | Hyaluronic Acid | [RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [EGF protein results in increased chemical synthesis of Hyaluronic Acid] | 21520325 |
D006851 | Hydrochloric Acid | Celecoxib promotes the reaction [Hydrochloric Acid results in increased expression of EGFR protein] | 15309881 |
D006851 | Hydrochloric Acid | Dipyrone promotes the reaction [Hydrochloric Acid results in increased expression of EGFR protein] | 15309881 |
D006851 | Hydrochloric Acid | Hydrochloric Acid results in increased expression of EGFR protein | 15309881 |
D006851 | Hydrochloric Acid | Piroxicam promotes the reaction [Hydrochloric Acid results in increased expression of EGFR protein] | 15309881 |
D006861 | Hydrogen Peroxide | Hydrogen Peroxide results in increased expression of EGFR mRNA | 26846883 |
D006861 | Hydrogen Peroxide | Acetylcysteine inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of and results in increased activity of EGFR protein] | 10640773 |
D006861 | Hydrogen Peroxide | EGFR mutant form inhibits the reaction [Hydrogen Peroxide results in increased expression of MMP9 mRNA] | 26514923 |
D006861 | Hydrogen Peroxide | Hydrogen Peroxide affects the expression of EGFR protein | 21179406 |
D006861 | Hydrogen Peroxide | Hydrogen Peroxide results in increased phosphorylation of and results in increased activity of EGFR protein | 10640773 |
D006861 | Hydrogen Peroxide | AG 1879 inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of EGFR protein] | 14737115 |
D006861 | Hydrogen Peroxide | Hydrogen Peroxide results in increased phosphorylation of EGFR protein | 14737115 |
D006861 | Hydrogen Peroxide | Hydrogen Peroxide results in increased phosphorylation of EGFR protein | 19885844 |
D006877 | Hydroxamic Acids | Hydroxamic Acids analog inhibits the reaction [EGF protein promotes the reaction [STAT3 protein binds to EGFR protein]] | 26088127 |
D006997 | Hypochlorous Acid | Hypochlorous Acid results in increased phosphorylation of and results in increased activity of EGFR protein | 18156441 |
C051781 | ICI 164384 | ICI 164384 inhibits the reaction [[Estradiol co-treated with EGFR protein] results in increased expression of SIAH2 mRNA] | 18629630 |
C531470 | icotinib | EGFR gene mutant form promotes the reaction [icotinib results in decreased expression of SQSTM1 protein] | 27639429 |
C531470 | icotinib | EGFR gene mutant form promotes the reaction [icotinib results in increased cleavage of and results in increased activity of CASP3 protein] | 27639429 |
C531470 | icotinib | EGFR gene mutant form results in increased susceptibility to icotinib | 27639429 |
D007155 | Immunologic Factors | Immunologic Factors results in decreased expression of EGFR protein modified form | 29974605 |
C016517 | indole-3-carbinol | indole-3-carbinol results in decreased expression of EGFR protein | 18025290 |
D007213 | Indomethacin | Indomethacin results in increased expression of EGFR protein | 17977527 |
D007213 | Indomethacin | malabaricone B promotes the reaction [Indomethacin results in increased expression of EGFR protein] | 17977527 |
D007213 | Indomethacin | malabaricone C promotes the reaction [Indomethacin results in increased expression of EGFR protein] | 17977527 |
D007213 | Indomethacin | Indomethacin results in increased expression of EGFR mRNA | 29523851 |
D007213 | Indomethacin | Irbesartan inhibits the reaction [Indomethacin results in increased expression of EGFR mRNA] | 29523851 |
D007213 | Indomethacin | Ranitidine inhibits the reaction [Indomethacin results in increased expression of EGFR mRNA] | 29523851 |
C070690 | insulin, Asp(B10)- | insulin, Asp(B10)- results in increased expression of EGFR protein modified form | 20936651 |
D000077405 | Irbesartan | Irbesartan inhibits the reaction [Indomethacin results in increased expression of EGFR mRNA] | 29523851 |
D000077146 | Irinotecan | bisindolylmaleimide I inhibits the reaction [Irinotecan metabolite results in increased phosphorylation of EGFR protein] | 15723263 |
D000077146 | Irinotecan | bisindolylmaleimide I inhibits the reaction [Irinotecan results in increased phosphorylation of EGFR protein] | 15723263 |
D000077146 | Irinotecan | Gefitinib inhibits the reaction [Irinotecan metabolite results in increased phosphorylation of and results in increased activity of EGFR protein] | 15723263 |
D000077146 | Irinotecan | Gefitinib inhibits the reaction [Irinotecan results in increased phosphorylation of and results in increased activity of EGFR protein] | 15723263 |
D000077146 | Irinotecan | Go 6976 inhibits the reaction [Irinotecan metabolite results in increased phosphorylation of EGFR protein] | 15723263 |
D000077146 | Irinotecan | Go 6976 inhibits the reaction [Irinotecan results in increased phosphorylation of EGFR protein] | 15723263 |
D000077146 | Irinotecan | Irinotecan metabolite results in increased phosphorylation of and results in increased activity of EGFR protein | 15723263 |
D000077146 | Irinotecan | Irinotecan results in increased phosphorylation of and results in increased activity of EGFR protein | 15723263 |
D000077146 | Irinotecan | rottlerin inhibits the reaction [Irinotecan metabolite results in increased phosphorylation of EGFR protein] | 15723263 |
D000077146 | Irinotecan | rottlerin inhibits the reaction [Irinotecan results in increased phosphorylation of EGFR protein] | 15723263 |
D000077146 | Irinotecan | Irinotecan metabolite results in decreased activity of EGFR protein | 15723263 |
D000077146 | Irinotecan | Irinotecan results in decreased activity of EGFR protein | 15723263 |
D007545 | Isoproterenol | Isoproterenol promotes the reaction [ADRB1 protein results in increased uptake of EGFR protein] | 18787115 |
D007545 | Isoproterenol | Isoproterenol results in increased expression of EGFR mRNA | 20003209 |
C016527 | isoquercitrin | isoquercitrin inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein] | 26109002 |
D015474 | Isotretinoin | Isotretinoin results in decreased expression of EGFR mRNA | 15982314 |
C561695 | (+)-JQ1 compound | [EGFR gene mutant form results in increased susceptibility to (+)-JQ1 compound] which results in decreased expression of MYC protein | 26455392 |
C561695 | (+)-JQ1 compound | [EGFR gene mutant form results in increased susceptibility to (+)-JQ1 compound] which results in increased activity of CASP3 protein | 26455392 |
C561695 | (+)-JQ1 compound | [EGFR gene mutant form results in increased susceptibility to (+)-JQ1 compound] which results in increased activity of CASP7 protein | 26455392 |
C471998 | JTE 013 | JTE 013 inhibits the reaction [sphingosine 1-phosphate results in increased phosphorylation of EGFR protein] | 26518876 |
C471998 | JTE 013 | JTE 013 inhibits the reaction [Taurocholic Acid results in increased phosphorylation of EGFR protein] | 26518876 |
C107086 | KB R7785 | KB R7785 inhibits the reaction [CXCL8 protein results in increased phosphorylation of and results in increased activity of EGFR protein] | 15300588 |
C107086 | KB R7785 | KB R7785 inhibits the reaction [IL1B protein results in increased phosphorylation of and results in increased activity of EGFR protein] | 15300588 |
C107086 | KB R7785 | KB R7785 results in decreased phosphorylation of EGFR protein | 16240219 |
D007654 | Ketoconazole | Ketoconazole inhibits the reaction [EGF protein results in increased uptake of and results in increased degradation of EGFR protein] | 23125191 |
C072105 | KN 93 | KN 93 inhibits the reaction [Cadmium Chloride results in increased phosphorylation of EGFR protein] | 19233221 |
D019344 | Lactic Acid | Lactic Acid results in decreased expression of EGFR mRNA | 30851411 |
D064747 | Lansoprazole | Lansoprazole results in increased expression of EGFR protein | 9881512 |
D000077341 | Lapatinib | EGFR protein affects the susceptibility to Lapatinib | 28739874 |
D000077341 | Lapatinib | KRAS protein affects the reaction [EGFR protein affects the susceptibility to Lapatinib] | 28739874 |
D000077341 | Lapatinib | Lapatinib inhibits the reaction [EGFR protein binds to MAPK12 protein] | 28739874 |
D000077341 | Lapatinib | Lapatinib inhibits the reaction [EGFR protein binds to PTPN3 protein] | 28739874 |
D000077341 | Lapatinib | Lapatinib promotes the reaction [pirfenidone inhibits the reaction [EGFR protein binds to MAPK12 protein]] | 28739874 |
D000077341 | Lapatinib | Lapatinib promotes the reaction [pirfenidone inhibits the reaction [EGFR protein binds to PTPN3 protein]] | 28739874 |
D000077341 | Lapatinib | Lapatinib results in decreased activity of EGFR protein | 15665275; 17192538; 19509167; 20549698; |
D000077341 | Lapatinib | pirfenidone promotes the reaction [Lapatinib inhibits the reaction [EGFR protein binds to MAPK12 protein]] | 28739874 |
D000077341 | Lapatinib | pirfenidone promotes the reaction [Lapatinib inhibits the reaction [EGFR protein binds to PTPN3 protein]] | 28739874 |
D000077341 | Lapatinib | Lapatinib results in decreased activity of EGFR protein | 16091755; 21794976; |
D000077341 | Lapatinib | [Lapatinib results in decreased activity of EGFR protein] which results in decreased susceptibility to EGF protein | 21794976 |
D007854 | Lead | Lead results in decreased expression of EGFR protein | 17298174 |
C008261 | lead acetate | 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline inhibits the reaction [lead acetate results in increased phosphorylation of EGFR protein] | 19133285 |
C008261 | lead acetate | EGFR mutant form inhibits the reaction [lead acetate results in increased activity of PRKCA protein] | 19133285 |
C008261 | lead acetate | EGFR mutant form inhibits the reaction [lead acetate results in increased phosphorylation of SRC protein] | 19133285 |
C008261 | lead acetate | lead acetate results in increased phosphorylation of EGFR protein | 19133285 |
C008261 | lead acetate | RTKI cpd inhibits the reaction [lead acetate results in increased phosphorylation of EGFR protein] | 19133285 |
C008261 | lead acetate | lead acetate results in decreased expression of EGFR protein | 17298174 |
C017461 | lead nitrate | EGFR mutant form affects the reaction [lead nitrate results in increased expression of PLA2G4A mRNA] | 20850495 |
C017461 | lead nitrate | EGFR mutant form affects the reaction [[lead nitrate results in increased expression of PLA2G4A mRNA] which results in increased secretion of Dinoprostone] | 20850495 |
C017461 | lead nitrate | EGFR mutant form affects the reaction [lead nitrate results in increased secretion of Dinoprostone] | 20850495 |
C017461 | lead nitrate | EGFR promotes the reaction [lead nitrate results in increased expression of PLA2G4A mRNA] | 20850495 |
C017461 | lead nitrate | lead nitrate results in increased phosphorylation of EGFR protein | 20850495 |
C017461 | lead nitrate | RTKI cpd inhibits the reaction [lead nitrate results in increased phosphorylation of EGFR protein] | 20850495 |
D000077339 | Leflunomide | Leflunomide inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein] | 30364229 |
D000077339 | Leflunomide | Leflunomide results in increased expression of EGFR mRNA | 28988120 |
C038753 | leptomycin B | [leptomycin B co-treated with TGFA protein co-treated with acteoside] affects the localization of EGFR protein modified form | 21967610 |
C038753 | leptomycin B | [leptomycin B co-treated with TGFA protein co-treated with polydatin] affects the localization of EGFR protein modified form | 21967610 |
C038753 | leptomycin B | [leptomycin B co-treated with TGFA protein co-treated with Quercetin] affects the localization of EGFR protein | 21967610 |
C038753 | leptomycin B | [leptomycin B co-treated with TGFA protein co-treated with Quercetin] affects the localization of EGFR protein modified form | 21967610 |
C038753 | leptomycin B | [leptomycin B co-treated with TGFA protein co-treated with Resveratrol] affects the localization of EGFR protein modified form | 21967610 |
C038753 | leptomycin B | [leptomycin B co-treated with TGFA protein co-treated with Rutin] affects the localization of EGFR protein modified form | 21967610 |
C038753 | leptomycin B | leptomycin B promotes the reaction [TGFA protein affects the localization of EGFR protein] | 21967610 |
D017997 | Leukotriene C4 | Leukotriene C4 results in increased expression of EGFR mRNA | 12388339 |
C018584 | linalool | linalool results in increased expression of EGFR mRNA | 19922762 |
D008044 | Linuron | [Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of EGFR mRNA | 25607892 |
D008044 | Linuron | Linuron results in decreased expression of EGFR mRNA | 12730624 |
C482199 | lipopolysaccharide, E coli O55-B5 | lipopolysaccharide, E coli O55-B5 results in increased expression of EGFR mRNA | 24972896 |
C482199 | lipopolysaccharide, E coli O55-B5 | [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of EGFR mRNA | 18930950 |
D008070 | Lipopolysaccharides | Lipopolysaccharides results in increased phosphorylation of EGFR protein | 21874253; 23099361; |
D008070 | Lipopolysaccharides | Quercetin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of EGFR protein] | 23099361 |
D008070 | Lipopolysaccharides | TLR4 mutant form promotes the reaction [Lipopolysaccharides results in increased phosphorylation of EGFR protein] | 21874253 |
D018021 | Lithium Chloride | [Lithium Chloride results in decreased activity of and results in increased phosphorylation of GSK3B protein] which results in increased expression of EGFR mRNA | 22493441 |
D018021 | Lithium Chloride | [Lithium Chloride results in decreased activity of and results in increased phosphorylation of GSK3B protein] which results in increased expression of EGFR protein | 22493441 |
D018021 | Lithium Chloride | Lithium Chloride results in increased expression of EGFR mRNA | 22493441 |
D018021 | Lithium Chloride | Lithium Chloride results in increased expression of EGFR protein | 22493441 |
D018021 | Lithium Chloride | N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Lithium Chloride results in increased expression of EGFR mRNA] | 22493441 |
D008148 | Lovastatin | Lovastatin inhibits the reaction [EGF protein promotes the reaction [EGFR protein results in increased phosphorylation of EGFR protein]] | 12942316 |
D008148 | Lovastatin | Lovastatin inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein] | 19760159 |
D047311 | Luteolin | EGF protein inhibits the reaction [Luteolin results in decreased phosphorylation of EGFR protein] | 12168845 |
D047311 | Luteolin | EGFR protein affects the susceptibility to Luteolin | 12168845 |
D047311 | Luteolin | Luteolin affects the activity of and results in decreased phosphorylation of EGFR protein | 12168845 |
D047311 | Luteolin | Luteolin inhibits the reaction [EGF protein results in increased phosphorylation of and results in increased activity of EGFR protein] | 15135307 |
D047311 | Luteolin | Luteolin inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein] | 10556937; 22926442; |
D047311 | Luteolin | Luteolin results in decreased expression of EGFR mRNA | 22926442 |
D047311 | Luteolin | Luteolin results in decreased phosphorylation of and results in increased activity of EGFR protein | 15135307 |
C032881 | lysophosphatidic acid | GNA13 mutant form inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of EGFR protein] | 23127547 |
C032881 | lysophosphatidic acid | lysophosphatidic acid results in increased phosphorylation of EGFR protein | 23127547 |
C032881 | lysophosphatidic acid | Pertussis Toxin inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of EGFR protein] | 23127547 |
C032881 | lysophosphatidic acid | Resveratrol inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of EGFR protein] | 23127547 |
D008274 | Magnesium | Magnesium inhibits the reaction [Ofloxacin results in increased phosphorylation of EGFR protein] | 23274517 |
D015636 | Magnesium Chloride | [Magnesium Chloride co-treated with EGF protein] results in increased activity of EGFR protein | 2354210 |
D058185 | Magnetite Nanoparticles | [Succimer co-treated with Magnetite Nanoparticles] results in decreased expression of EGFR mRNA | 26378955 |
C071788 | malabaricone B | malabaricone B promotes the reaction [Indomethacin results in increased expression of EGFR protein] | 17977527 |
C071787 | malabaricone C | malabaricone C promotes the reaction [Indomethacin results in increased expression of EGFR protein] | 17977527 |
C025340 | manganese chloride | [manganese chloride co-treated with EGF protein] results in increased activity of EGFR protein | 2354210 |
C025340 | manganese chloride | manganese chloride results in increased activity of EGFR protein | 2354210 |
C025340 | manganese chloride | manganese chloride results in increased expression of EGFR mRNA | 28801915 |
D008555 | Melitten | Melitten results in increased activity of EGFR protein | 22613720 |
D008627 | Mercuric Chloride | Mercuric Chloride results in increased expression of EGFR mRNA | 10901180 |
D008701 | Methapyrilene | Methapyrilene results in decreased expression of EGFR mRNA | 30467583 |
D008727 | Methotrexate | EGFR mRNA results in decreased susceptibility to Methotrexate | 16918715 |
D008727 | Methotrexate | Methotrexate results in increased expression of EGFR mRNA | 18803016 |
D008731 | Methoxychlor | Methoxychlor results in increased phosphorylation of EGFR protein | 28426875 |
D008731 | Methoxychlor | Dactinomycin inhibits the reaction [Methoxychlor results in increased expression of EGFR protein] | 8888411 |
D008731 | Methoxychlor | Methoxychlor results in increased expression of EGFR protein | 8888411 |
D008746 | Methylazoxymethanol Acetate | Methylazoxymethanol Acetate results in increased expression of EGFR mRNA | 28349193 |
D008748 | Methylcholanthrene | Methylcholanthrene results in decreased expression of EGFR mRNA | 29094188 |
C005223 | methyleugenol | methyleugenol results in decreased expression of EGFR protein | 15618236 |
C002950 | methylformamide | methylformamide analog results in decreased expression of EGFR mRNA | 17040096 |
C002950 | methylformamide | methylformamide results in decreased expression of EGFR mRNA | 17040096 |
C004925 | methylmercuric chloride | methylmercuric chloride results in increased expression of EGFR mRNA | 28001369 |
C004925 | methylmercuric chloride | methylmercuric chloride results in increased phosphorylation of EGFR protein | 28958600 |
D008767 | Methylmercury Compounds | Methylmercury Compounds results in decreased expression of EGFR protein | 17298174 |
D008769 | Methylnitronitrosoguanidine | Methylnitronitrosoguanidine affects the localization of EGFR protein | 15708576 |
D008769 | Methylnitronitrosoguanidine | Methylnitronitrosoguanidine inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein] | 15708576 |
D008770 | Methylnitrosourea | Hexachlorobenzene promotes the reaction [Methylnitrosourea promotes the reaction [EGFR protein binds to SRC protein]] | 22245120 |
D008770 | Methylnitrosourea | Hexachlorobenzene promotes the reaction [Methylnitrosourea results in increased phosphorylation of EGFR protein] | 22245120 |
D008770 | Methylnitrosourea | [Methylnitrosourea co-treated with Testosterone] results in increased expression of and results in increased phosphorylation of EGFR protein | 25164625 |
D008770 | Methylnitrosourea | Methylnitrosourea promotes the reaction [EGFR protein binds to SRC protein] | 22245120 |
D008770 | Methylnitrosourea | Methylnitrosourea promotes the reaction [Hexachlorobenzene promotes the reaction [EGFR protein binds to SRC protein]] | 22245120 |
D008770 | Methylnitrosourea | Methylnitrosourea promotes the reaction [Hexachlorobenzene results in increased phosphorylation of EGFR protein] | 22245120 |
D008770 | Methylnitrosourea | Methylnitrosourea results in increased phosphorylation of and results in decreased expression of EGFR protein | 22245120 |
D008770 | Methylnitrosourea | Quercetin inhibits the reaction [[Methylnitrosourea co-treated with Testosterone] results in increased expression of and results in increased phosphorylation of EGFR protein] | 25164625 |
D015741 | Metribolone | Metribolone results in increased phosphorylation of and results in increased activity of EGFR protein | 17272394 |
D008798 | Mevalonic Acid | Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [Acrolein results in increased phosphorylation of EGFR protein]] | 20359552 |
D015735 | Mifepristone | Mifepristone inhibits the reaction [Dexamethasone inhibits the reaction [EGF protein promotes the reaction [EGFR protein binds to ARAF protein]]] | 10807665 |
D015735 | Mifepristone | Mifepristone inhibits the reaction [Dexamethasone inhibits the reaction [EGF protein promotes the reaction [EGFR protein binds to GRB2 protein]]] | 10807665 |
D015735 | Mifepristone | Mifepristone inhibits the reaction [Dexamethasone inhibits the reaction [EGF protein promotes the reaction [EGFR protein binds to HRAS protein]]] | 10807665 |
D015735 | Mifepristone | Mifepristone inhibits the reaction [Dexamethasone promotes the reaction [EGFR protein binds to ANXA1 protein modified form]] | 10807665 |
D015735 | Mifepristone | Mifepristone results in decreased expression of EGFR mRNA | 18591650; 25972201; |
C548887 | MK 2206 | MK 2206 results in increased expression of EGFR protein | 27897231 |
C548887 | MK 2206 | platycodin D inhibits the reaction [MK 2206 results in increased expression of EGFR protein] | 27897231 |
C575143 | Mn(III) meso-tetrakis(N-n-butoxyethylpyridinium-2-yl)porphyrin | Mn(III) meso-tetrakis(N-n-butoxyethylpyridinium-2-yl)porphyrin results in decreased phosphorylation of EGFR protein | 24635018 |
C016599 | mono-(2-ethylhexyl)phthalate | mono-(2-ethylhexyl)phthalate results in decreased expression of EGFR mRNA | 31059758 |
C406082 | monomethylarsonous acid | EGFR protein affects the reaction [monomethylarsonous acid results in increased expression of PTGS2 protein] | 17093206 |
C406082 | monomethylarsonous acid | monomethylarsonous acid results in decreased expression of EGFR mRNA | 20886546 |
C406082 | monomethylarsonous acid | monomethylarsonous acid results in increased expression of EGFR mRNA | 19945496 |
C406082 | monomethylarsonous acid | monomethylarsonous acid results in increased expression of EGFR protein | 17093206 |
C040015 | myricetin | myricetin promotes the reaction [EGF protein results in increased phosphorylation of EGFR protein] | 18995957 |
C040015 | myricetin | myricetin results in decreased phosphorylation of EGFR protein | 18995957 |
C570404 | N-(2-(4-((3-chloro-4-(3-(trifluoromethyl)phenoxy)phenyl)amino)-5H-pyrrolo(3,2-d)pyrimidin-5-yl)ethyl)-3-hydroxy-3-methylbutanamide | N-(2-(4-((3-chloro-4-(3-(trifluoromethyl)phenoxy)phenyl)amino)-5H-pyrrolo(3,2-d)pyrimidin-5-yl)ethyl)-3-hydroxy-3-methylbutanamide results in decreased activity of EGFR protein | 22003817 |
C063509 | N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide | N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Lithium Chloride results in increased expression of EGFR mRNA] | 22493441 |
C092152 | N-((2-(hydroxyaminocarbonyl)methyl)-4-methylpentanoyl)-3-(2'-naphthyl)alanylalanine, 2-aminoethylamide | N-((2-(hydroxyaminocarbonyl)methyl)-4-methylpentanoyl)-3-(2'-naphthyl)alanylalanine, 2-aminoethylamide inhibits the reaction [Diacetyl results in increased phosphorylation of EGFR protein] | 30851105 |
C092152 | N-((2-(hydroxyaminocarbonyl)methyl)-4-methylpentanoyl)-3-(2'-naphthyl)alanylalanine, 2-aminoethylamide | N-((2-(hydroxyaminocarbonyl)methyl)-4-methylpentanoyl)-3-(2'-naphthyl)alanylalanine, 2-aminoethylamide inhibits the reaction [ELANE protein results in increased phosphorylation of EGFR protein] | 17456367 |
C078131 | N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide | N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]] | 18787115 |
C078131 | N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide | N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]] | 18787115 |
C078131 | N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide | N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Alprenolol promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]] | 18787115 |
C078131 | N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide | N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Capsaicin results in increased phosphorylation of EGFR protein] | 20660715 |
C078131 | N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide | N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]] | 18787115 |
C078131 | N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide | N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]] | 18787115 |
C078131 | N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide | N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Carvedilol promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]] | 18787115 |
C078131 | N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide | N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]] | 18787115 |
C078131 | N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide | N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]] | 18787115 |
C078131 | N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide | N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Dobutamine promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]] | 18787115 |
C078131 | N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide | N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Zinc results in increased phosphorylation of EGFR protein] | 12972402 |
C078131 | N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide | N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Asbestos, Serpentine results in increased activity of EGFR protein] | 16571779 |
C078131 | N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide | N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Fluoxetine results in increased phosphorylation of EGFR protein] | 18758753 |
C078131 | N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide | N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Sodium Chloride results in increased phosphorylation of EGFR protein] | 21568938 |
C078131 | N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide | N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide affects the reaction [PTPN11 protein affects the reaction [EDN1 protein results in increased phosphorylation of and results in increased activity of EGFR protein]] | 16261333 |
C415243 | N-(4-(3-chloro-4-fluorophenylamino)quinazolin-6-yl)acrylamide | N-(4-(3-chloro-4-fluorophenylamino)quinazolin-6-yl)acrylamide results in decreased phosphorylation of EGFR protein | 10987266 |
C465666 | N-(4-((4,5-dichloro-2-fluorophenyl)amino)quinazolin-6-yl)acrylamide | N-(4-((4,5-dichloro-2-fluorophenyl)amino)quinazolin-6-yl)acrylamide binds to and results in decreased phosphorylation of EGFR protein | 12209961 |
C465666 | N-(4-((4,5-dichloro-2-fluorophenyl)amino)quinazolin-6-yl)acrylamide | N-(4-((4,5-dichloro-2-fluorophenyl)amino)quinazolin-6-yl)acrylamide results in decreased phosphorylation of EGFR protein | 12573320 |
C452423 | N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine | EGFR affects the susceptibility to N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine | 15604279 |
C452423 | N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine | N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine results in decreased activity of EGFR protein | 15596048 |
C452423 | N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine | N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine results in decreased phosphorylation of EGFR protein | 21350000 |
C452423 | N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine | N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine results in decreased activity of EGFR protein | 15604279; 16940797; 17431108; |
D037742 | Nanotubes, Carbon | Nanotubes, Carbon affects the expression of EGFR mRNA | 23845593 |
D037742 | Nanotubes, Carbon | Nanotubes, Carbon analog results in increased expression of EGFR mRNA | 25620056 |
D037742 | Nanotubes, Carbon | Nanotubes, Carbon results in increased expression of EGFR mRNA | 25554681; 25620056; |
C031721 | naphthalene | [Gefitinib results in decreased activity of EGFR protein] which results in increased susceptibility to naphthalene | 20935109 |
C073873 | naphtho(1,2-b)furan-4,5-dione | naphtho(1,2-b)furan-4,5-dione inhibits the reaction [EGF protein binds to and results in increased activity of EGFR protein] | 23064031 |
C073873 | naphtho(1,2-b)furan-4,5-dione | [naphtho(1,2-b)furan-4,5-dione inhibits the reaction [EGF protein binds to and results in increased activity of EGFR protein]] which results in decreased expression of MMP9 | 23064031 |
C073873 | naphtho(1,2-b)furan-4,5-dione | naphtho(1,2-b)furan-4,5-dione inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein] | 23064031 |
C005273 | naringenin | naringenin inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of EGFR protein] | 25866363 |
C005274 | naringin | naringin inhibits the reaction [EGF protein results in increased expression of and results in increased phosphorylation of EGFR protein] | 22766066 |
C051752 | nefazodone | nefazodone results in decreased expression of EGFR mRNA | 24136188 |
C002701 | neocuproine | [Copper binds to neocuproine] which results in increased phosphorylation of EGFR protein | 18346929 |
C487932 | neratinib | neratinib results in decreased activity of EGFR protein | 21322567; 22242139; |
C487932 | neratinib | neratinib results in decreased activity of EGFR protein mutant form | 21322567 |
D019829 | Nevirapine | Nevirapine results in decreased expression of EGFR mRNA | 19152342 |
C119536 | nickel acetate | MUC1 mutant form inhibits the reaction [nickel acetate results in increased phosphorylation of EGFR protein] | 25053108 |
C119536 | nickel acetate | nickel acetate results in decreased expression of and results in decreased phosphorylation of EGFR protein | 22210268 |
C119536 | nickel acetate | nickel acetate results in decreased expression of EGFR mRNA | 22210268 |
C119536 | nickel acetate | nickel acetate results in increased phosphorylation of EGFR protein | 25053108 |
C022838 | nickel chloride | nickel chloride results in increased expression of EGFR protein | 26026961 |
C022838 | nickel chloride | RECK protein inhibits the reaction [nickel chloride results in increased expression of EGFR protein] | 26026961 |
C022838 | nickel chloride | nickel chloride affects the expression of EGFR mRNA | 22546817 |
C017557 | nickel subsulfide | nickel subsulfide results in increased expression of EGFR mRNA | 21086188 |
C029938 | nickel sulfate | [TGFA protein binds to and affects the activity of EGFR protein] which results in decreased susceptibility to nickel sulfate | 19131640 |
D009534 | Niclosamide | Niclosamide analog results in decreased expression of EGFR protein | 28284560 |
D009534 | Niclosamide | Niclosamide results in decreased expression of EGFR protein | 28284560 |
D009534 | Niclosamide | Niclosamide results in decreased phosphorylation of EGFR protein | 28426875 |
D009538 | Nicotine | AG 1879 inhibits the reaction [Nicotine results in increased phosphorylation of EGFR protein] | 14569062 |
D009538 | Nicotine | Nicotine results in increased phosphorylation of EGFR protein | 14569062 |
D009538 | Nicotine | Nicotine results in decreased expression of EGFR mRNA | 11478936 |
C500716 | N-isobutyl-N-(4-methoxyphenylsulfonyl)glycylhydroxamic acid | N-isobutyl-N-(4-methoxyphenylsulfonyl)glycylhydroxamic acid inhibits the reaction [Zinc results in increased phosphorylation of EGFR protein] | 12972402 |
C562238 | N-methyl-3-(1-(4-(piperazin-1-yl)phenyl)-5-(4'-(trifluoromethyl)-(1,1'-biphenyl)-4-yl)-1H-pyrazol-3-yl)propanamide | ILK protein inhibits the reaction [N-methyl-3-(1-(4-(piperazin-1-yl)phenyl)-5-(4'-(trifluoromethyl)-(1,1'-biphenyl)-4-yl)-1H-pyrazol-3-yl)propanamide results in decreased expression of EGFR mRNA] | 21823616 |
C562238 | N-methyl-3-(1-(4-(piperazin-1-yl)phenyl)-5-(4'-(trifluoromethyl)-(1,1'-biphenyl)-4-yl)-1H-pyrazol-3-yl)propanamide | ILK protein inhibits the reaction [N-methyl-3-(1-(4-(piperazin-1-yl)phenyl)-5-(4'-(trifluoromethyl)-(1,1'-biphenyl)-4-yl)-1H-pyrazol-3-yl)propanamide results in decreased expression of EGFR protein] | 21823616 |
C562238 | N-methyl-3-(1-(4-(piperazin-1-yl)phenyl)-5-(4'-(trifluoromethyl)-(1,1'-biphenyl)-4-yl)-1H-pyrazol-3-yl)propanamide | N-methyl-3-(1-(4-(piperazin-1-yl)phenyl)-5-(4'-(trifluoromethyl)-(1,1'-biphenyl)-4-yl)-1H-pyrazol-3-yl)propanamide results in decreased expression of EGFR mRNA | 21823616 |
C562238 | N-methyl-3-(1-(4-(piperazin-1-yl)phenyl)-5-(4'-(trifluoromethyl)-(1,1'-biphenyl)-4-yl)-1H-pyrazol-3-yl)propanamide | N-methyl-3-(1-(4-(piperazin-1-yl)phenyl)-5-(4'-(trifluoromethyl)-(1,1'-biphenyl)-4-yl)-1H-pyrazol-3-yl)propanamide results in decreased expression of EGFR protein | 21823616 |
C001870 | nonachlor | nonachlor binds to EGFR protein | 29329451 |
C001870 | nonachlor | nonachlor inhibits the reaction [EGF protein binds to EGFR protein] | 29329451 |
C001870 | nonachlor | nonachlor inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein] | 29329451 |
C510003 | nordy | nordy inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein] | 17377739 |
D009638 | Norepinephrine | EGFR protein inhibits the reaction [Norepinephrine results in increased phosphorylation of SHC1 protein alternative form] | 19168439 |
C558013 | NSC 689534 | [NSC 689534 binds to Copper] which results in increased expression of EGFR mRNA | 20971185 |
C501177 | NVP-AEW541 | NVP-AEW541 inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein] | 20664932 |
C516714 | NVP-TAE684 | [EGF protein results in increased phosphorylation of and results in increased activity of EGFR protein] which results in decreased susceptibility to NVP-TAE684 | 22843788 |
C516714 | NVP-TAE684 | EGFR protein results in decreased susceptibility to NVP-TAE684 | 21791641 |
C025589 | ochratoxin A | ochratoxin A results in increased phosphorylation of EGFR protein | 23172667 |
D015242 | Ofloxacin | CYBB protein affects the reaction [Ofloxacin results in increased phosphorylation of EGFR protein] | 23274517 |
D015242 | Ofloxacin | Magnesium inhibits the reaction [Ofloxacin results in increased phosphorylation of EGFR protein] | 23274517 |
D015242 | Ofloxacin | Ofloxacin results in increased phosphorylation of EGFR protein | 23274517 |
D015242 | Ofloxacin | RAC1 protein affects the reaction [Ofloxacin results in increased phosphorylation of EGFR protein] | 23274517 |
D019301 | Oleic Acid | Oleic Acid results in increased phosphorylation of EGFR protein | 27447558 |
D019301 | Oleic Acid | [Palmitic Acid co-treated with Oleic Acid] affects the expression of EGFR mRNA | 30547786 |
D000069463 | Olive Oil | Olive Oil analog affects the expression of EGFR mRNA | 17349074 |
C000596361 | osimertinib | osimertinib affects the reaction [EGF protein results in increased phosphorylation of EGFR protein] | 30623574 |
C000596361 | osimertinib | osimertinib inhibits the reaction [EGFR protein mutant form results in decreased susceptibility to Gefitinib] | 30993382 |
C000596361 | osimertinib | osimertinib promotes the reaction [Derp2 allergen, Dermatophagoides pteronyssinus results in increased phosphorylation of EGFR protein] | 30623574 |
C000596361 | osimertinib | osimertinib results in decreased activity of EGFR protein | 28237877 |
C000596361 | osimertinib | osimertinib results in decreased expression of and results in decreased phosphorylation of EGFR protein | 30993382 |
D010042 | Ouabain | Ouabain results in decreased phosphorylation of EGFR protein | 28795476 |
D010047 | Ovalbumin | Ovalbumin results in increased expression of EGFR mRNA | 12388339 |
D000077150 | Oxaliplatin | EGFR gene polymorphism affects the susceptibility to [Oxaliplatin co-treated with Fluorouracil] | 16098254 |
D000077150 | Oxaliplatin | [Gefitinib co-treated with Oxaliplatin] results in decreased phosphorylation of EGFR protein | 13680161 |
D000077150 | Oxaliplatin | Oxaliplatin results in increased phosphorylation of EGFR protein | 16243822 |
D000077150 | Oxaliplatin | [Oxaliplatin co-treated with Topotecan] results in increased expression of EGFR mRNA | 25729387 |
D010076 | Oxazepam | Oxazepam results in decreased expression of EGFR mRNA | 15618236 |
D010076 | Oxazepam | Oxazepam results in decreased expression of EGFR protein | 15618236 |
C029341 | oxophenylarsine | oxophenylarsine inhibits the reaction [EGF protein binds to and affects the localization of EGFR protein] | 12093727 |
D010100 | Oxygen | [RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [Equol results in increased chemical synthesis of Oxygen] | 21300668 |
D015125 | Oxyquinoline | [Copper binds to Oxyquinoline] which results in increased phosphorylation of EGFR protein | 18346929 |
D010121 | Oxytocin | Oxytocin results in increased expression of EGFR protein modified form | 23707249 |
D010126 | Ozone | AG 1879 inhibits the reaction [Ozone results in increased phosphorylation of EGFR protein] | 25303742 |
D010126 | Ozone | AHR protein affects the reaction [Ozone results in increased phosphorylation of EGFR protein] | 19536146 |
D010126 | Ozone | Ozone results in increased phosphorylation of EGFR protein | 19536146; 25303742; |
D010126 | Ozone | Protein Kinase Inhibitors inhibits the reaction [Ozone results in increased phosphorylation of EGFR protein] | 25303742 |
D010126 | Ozone | 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline inhibits the reaction [Ozone results in increased phosphorylation of EGFR protein] | 26464147 |
D010126 | Ozone | Ozone results in increased phosphorylation of EGFR protein | 26464147 |
D017239 | Paclitaxel | Paclitaxel promotes the reaction [HER3 protein binds to EGFR protein] | 20726858 |
D017239 | Paclitaxel | Paclitaxel results in decreased expression of EGFR mRNA | 18058816 |
D017239 | Paclitaxel | Paclitaxel results in increased phosphorylation of EGFR protein | 16211241; 20726858; |
D017239 | Paclitaxel | [PD168393 co-treated with Paclitaxel] results in decreased phosphorylation of EGFR protein | 16413505 |
D019308 | Palmitic Acid | [Palmitic Acid co-treated with Oleic Acid] affects the expression of EGFR mRNA | 30547786 |
D010269 | Paraquat | Paraquat results in decreased expression of EGFR protein | 17298174 |
D010278 | Parathion | Atropine inhibits the reaction [Parathion results in increased expression of EGFR protein] | 17390078 |
D010278 | Parathion | [Parathion co-treated with Estradiol] results in increased expression of EGFR protein | 17622325 |
D010278 | Parathion | Parathion results in increased expression of EGFR protein | 17390078; 17622325; |
D017374 | Paroxetine | [Paroxetine binds to and results in increased activity of HTR2C protein] which results in increased phosphorylation of and results in increased activity of EGFR protein | 19662385 |
D017374 | Paroxetine | [[Paroxetine binds to and results in increased activity of HTR2C protein] which results in increased phosphorylation of and results in increased activity of EGFR protein] which results in increased phosphorylation of and results in increased activity of MAPK1 protein | 19662385 |
D017374 | Paroxetine | [[Paroxetine binds to and results in increased activity of HTR2C protein] which results in increased phosphorylation of and results in increased activity of EGFR protein] which results in increased phosphorylation of and results in increased activity of MAPK3 protein | 19662385 |
D052638 | Particulate Matter | AG 1879 inhibits the reaction [Particulate Matter results in increased phosphorylation of EGFR protein] | 17028263 |
D052638 | Particulate Matter | Butylated Hydroxyanisole inhibits the reaction [Particulate Matter results in increased phosphorylation of EGFR protein] | 17028263 |
D052638 | Particulate Matter | EGFR protein affects the reaction [Particulate Matter results in increased secretion of AR protein] | 24555532 |
D052638 | Particulate Matter | EGFR protein affects the reaction [Particulate Matter results in increased secretion of CXCL8 protein] | 24555532 |
D052638 | Particulate Matter | EGFR protein affects the reaction [Particulate Matter results in increased secretion of TGFA protein] | 24555532 |
D052638 | Particulate Matter | Erlotinib Hydrochloride inhibits the reaction [Particulate Matter analog results in increased phosphorylation of EGFR protein] | 28101945 |
D052638 | Particulate Matter | Particulate Matter analog results in increased expression of EGFR mRNA | 24910982 |
D052638 | Particulate Matter | Particulate Matter analog results in increased phosphorylation of EGFR protein | 28101945 |
D052638 | Particulate Matter | Particulate Matter results in decreased expression of EGFR mRNA | 24769257 |
D052638 | Particulate Matter | Particulate Matter results in increased phosphorylation of EGFR protein | 17028263; 18926838; |
D052638 | Particulate Matter | Particulate Matter results in increased phosphorylation of EGFR protein | 27158778; 27377055; |
C000610380 | p-carboxymethylphenyl 1,1-bis(3'-indolyl)-1-(p-carboxymethylphenyl)methane | p-carboxymethylphenyl 1,1-bis(3'-indolyl)-1-(p-carboxymethylphenyl)methane results in decreased expression of EGFR protein | 26035713 |
D020245 | p-Chloromercuribenzoic Acid | [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EGFR mRNA | 27188386 |
D020245 | p-Chloromercuribenzoic Acid | p-Chloromercuribenzoic Acid results in decreased expression of EGFR mRNA | 26272509 |
C509204 | PD168393 | PD168393 affects the localization of EGFR protein | 21967610 |
C509204 | PD168393 | PD168393 affects the localization of EGFR protein modified form | 21967610 |
C509204 | PD168393 | [PD168393 co-treated with Paclitaxel] results in decreased phosphorylation of EGFR protein | 16413505 |
C509204 | PD168393 | PD168393 inhibits the reaction [Resveratrol results in increased phosphorylation of EGFR protein] | 23527233 |
C509204 | PD168393 | PD168393 inhibits the reaction [TGFA protein affects the localization of EGFR protein] | 21967610 |
C509204 | PD168393 | PD168393 inhibits the reaction [TGFA protein affects the localization of EGFR protein modified form] | 21967610 |
C509204 | PD168393 | PD168393 results in decreased phosphorylation of EGFR protein | 21967610; 23527233; |
C509204 | PD168393 | PD168393 inhibits the reaction [AGT protein results in increased phosphorylation of EGFR protein] | 25398788 |
C509204 | PD168393 | PD168393 inhibits the reaction [[Resveratrol co-treated with TNF protein] results in increased phosphorylation of EGFR protein] | 23527233 |
C509204 | PD168393 | PD168393 results in decreased activity of EGFR protein | 21967610 |
C509204 | PD168393 | [PD168393 results in decreased activity of EGFR protein] which results in decreased susceptibility to TGFA protein | 21967610 |
C086401 | pentabromodiphenyl ether | pentabromodiphenyl ether results in increased phosphorylation of EGFR protein | 24184330 |
C000622612 | peracetylated N-azidoacetylmannosamine | peracetylated N-azidoacetylmannosamine results in decreased expression of EGFR mRNA | 30181604 |
C076994 | perfluorooctane sulfonic acid | perfluorooctane sulfonic acid results in increased phosphorylation of EGFR protein | 28288859 |
C076994 | perfluorooctane sulfonic acid | perfluorooctane sulfonic acid results in increased expression of EGFR mRNA | 21251948 |
C076994 | perfluorooctane sulfonic acid | perfluorooctane sulfonic acid results in increased expression of EGFR protein | 21251948 |
C023036 | perfluorooctanoic acid | Estradiol inhibits the reaction [perfluorooctanoic acid results in decreased expression of EGFR protein] | 22414604 |
C023036 | perfluorooctanoic acid | Estradiol promotes the reaction [Progesterone inhibits the reaction [perfluorooctanoic acid results in decreased expression of EGFR protein]] | 22414604 |
C023036 | perfluorooctanoic acid | perfluorooctanoic acid results in decreased expression of EGFR protein | 22414604 |
C023036 | perfluorooctanoic acid | perfluorooctanoic acid results in increased expression of EGFR protein | 20118188 |
C023036 | perfluorooctanoic acid | Progesterone inhibits the reaction [perfluorooctanoic acid results in decreased expression of EGFR protein] | 22414604 |
C023036 | perfluorooctanoic acid | Progesterone promotes the reaction [Estradiol inhibits the reaction [perfluorooctanoic acid results in decreased expression of EGFR protein]] | 22414604 |
C023036 | perfluorooctanoic acid | perfluorooctanoic acid results in decreased expression of EGFR mRNA | 16221955 |
D037342 | Pertussis Toxin | Pertussis Toxin inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of EGFR protein] | 23127547 |
C076715 | pervanadate | pervanadate results in increased phosphorylation of EGFR protein | 18926838 |
D010575 | Pesticides | Pesticides results in increased methylation of EGFR gene | 28396702 |
D010634 | Phenobarbital | Phenobarbital inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein] | 25625231; 30364229; |
D010634 | Phenobarbital | NR1I3 protein affects the reaction [Phenobarbital results in decreased expression of EGFR mRNA] | 19482888 |
D010634 | Phenobarbital | Phenobarbital affects the expression of EGFR mRNA | 19136022; 23091169; |
D010634 | Phenobarbital | Phenobarbital inhibits the reaction [EGF protein binds to EGFR protein] | 6309801 |
D010634 | Phenobarbital | Phenobarbital results in decreased expression of EGFR mRNA | 19482888 |
D010634 | Phenobarbital | Phenobarbital inhibits the reaction [EGF protein binds to EGFR protein] | 10828207 |
D010634 | Phenobarbital | Phenobarbital results in decreased expression of EGFR mRNA | 19162173 |
D010634 | Phenobarbital | Phenobarbital binds to and results in decreased activity of EGFR protein | 25949234 |
D010634 | Phenobarbital | [Phenobarbital binds to and results in decreased activity of EGFR protein] which affects the localization of NR1I3 protein | 25949234 |
D010656 | Phenylephrine | Atorvastatin inhibits the reaction [Phenylephrine results in increased expression of and results in increased phosphorylation of and results in increased activity of EGFR protein] | 18360054 |
D010656 | Phenylephrine | Phenylephrine results in increased expression of and results in increased phosphorylation of and results in increased activity of EGFR protein | 18360054 |
D010656 | Phenylephrine | [EGF protein binds to EGFR protein] promotes the reaction [Phenylephrine results in increased phosphorylation of MAPK1 protein] | 16760267 |
D010656 | Phenylephrine | [EGF protein binds to EGFR protein] promotes the reaction [Phenylephrine results in increased phosphorylation of MAPK3 protein] | 16760267 |
D010656 | Phenylephrine | Phenylephrine results in increased phosphorylation of EGFR protein | 14676212 |
C529675 | phenylhydrazonopyrazolone sulfonate 1 | phenylhydrazonopyrazolone sulfonate 1 promotes the reaction [ARSB protein affects the expression of EGFR mRNA] | 29794138 |
C529675 | phenylhydrazonopyrazolone sulfonate 1 | phenylhydrazonopyrazolone sulfonate 1 results in increased expression of EGFR protein | 29794138 |
D010662 | Phenylmercuric Acetate | [NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EGFR mRNA | 27188386 |
D010662 | Phenylmercuric Acetate | Phenylmercuric Acetate results in increased expression of EGFR mRNA | 26272509 |
C018637 | phorone | [phorone results in decreased abundance of Glutathione] which results in increased phosphorylation of and results in increased activity of EGFR protein | 28123000 |
C008890 | phosphoramidon | phosphoramidon inhibits the reaction [NTS protein results in increased phosphorylation of and results in increased activity of EGFR protein] | 15177934 |
D010833 | Phytic Acid | Phytic Acid inhibits the reaction [Asbestos, Crocidolite results in decreased phosphorylation of EGFR protein] | 15626777 |
D010862 | Pilocarpine | Pilocarpine results in decreased expression of EGFR mRNA | 17971868 |
D010882 | Piperonyl Butoxide | [Diethylnitrosamine co-treated with Piperonyl Butoxide] results in decreased expression of EGFR mRNA | 20101389 |
C093844 | pirfenidone | Lapatinib promotes the reaction [pirfenidone inhibits the reaction [EGFR protein binds to MAPK12 protein]] | 28739874 |
C093844 | pirfenidone | Lapatinib promotes the reaction [pirfenidone inhibits the reaction [EGFR protein binds to PTPN3 protein]] | 28739874 |
C093844 | pirfenidone | pirfenidone inhibits the reaction [EGFR protein binds to MAPK12 protein] | 28739874 |
C093844 | pirfenidone | [pirfenidone inhibits the reaction [EGFR protein binds to MAPK12 protein]] which results in decreased phosphorylation of PTPN3 protein | 28739874 |
C093844 | pirfenidone | [pirfenidone inhibits the reaction [EGFR protein binds to MAPK12 protein]] which results in increased phosphorylation of EGFR protein | 28739874 |
C093844 | pirfenidone | pirfenidone inhibits the reaction [EGFR protein binds to PTPN3 protein] | 28739874 |
C093844 | pirfenidone | pirfenidone promotes the reaction [Lapatinib inhibits the reaction [EGFR protein binds to MAPK12 protein]] | 28739874 |
C093844 | pirfenidone | pirfenidone promotes the reaction [Lapatinib inhibits the reaction [EGFR protein binds to PTPN3 protein]] | 28739874 |
C006253 | pirinixic acid | pirinixic acid affects the expression of EGFR mRNA | 19136022 |
C006253 | pirinixic acid | [pirinixic acid binds to and results in increased activity of PPARA protein] which results in decreased expression of EGFR mRNA | 19710929 |
C006253 | pirinixic acid | [pirinixic acid co-treated with PPARA] results in decreased expression of EGFR mRNA | 20813756 |
C006253 | pirinixic acid | pirinixic acid results in decreased expression of EGFR mRNA | 11798191; 15302862; 17426115; 18445702; 20059764; 20813756; 23811191; |
C006253 | pirinixic acid | PPARA protein promotes the reaction [pirinixic acid results in decreased expression of EGFR mRNA] | 20059764 |
C006253 | pirinixic acid | pirinixic acid results in decreased expression of EGFR protein | 2404574 |
D010894 | Piroxicam | Piroxicam results in decreased expression of EGFR mRNA | 21858171 |
D010894 | Piroxicam | Piroxicam promotes the reaction [Hydrochloric Acid results in increased expression of EGFR protein] | 15309881 |
C410026 | PKI 166 | PKI 166 results in decreased activity of and results in decreased phosphorylation of EGFR protein | 12912971 |
D010936 | Plant Extracts | Plant Extracts results in decreased expression of EGFR mRNA | 23557933 |
D010936 | Plant Extracts | Plant Extracts results in increased phosphorylation of EGFR protein | 25051199 |
D010936 | Plant Extracts | Plant Extracts inhibits the reaction [[Diethylnitrosamine co-treated with Carbon Tetrachloride] results in increased phosphorylation of EGFR protein] | 29923357 |
D028321 | Plant Preparations | Plant Preparations results in decreased expression of EGFR mRNA | 24973489 |
C108953 | platycodin D | benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [platycodin D results in decreased expression of EGFR protein] | 28711525 |
C108953 | platycodin D | platycodin D inhibits the reaction [Everolimus results in increased expression of EGFR protein] | 28711525 |
C108953 | platycodin D | platycodin D inhibits the reaction [MK 2206 results in increased expression of EGFR protein] | 27897231 |
C108953 | platycodin D | platycodin D results in decreased expression of EGFR protein | 23867902; 27897231; 28711525; |
C108953 | platycodin D | platycodin D inhibits the reaction [EGF protein results in increased phosphorylation of and results in increased activity of EGFR protein] | 23867902 |
D011078 | Polychlorinated Biphenyls | Polychlorinated Biphenyls results in decreased expression of EGFR mRNA | 31026535 |
D011084 | Polycyclic Aromatic Hydrocarbons | Polycyclic Aromatic Hydrocarbons results in increased expression of EGFR mRNA | 24910982 |
C058229 | polydatin | polydatin inhibits the reaction [TGFA protein affects the localization of EGFR protein] | 21967610 |
C058229 | polydatin | [leptomycin B co-treated with TGFA protein co-treated with polydatin] affects the localization of EGFR protein modified form | 21967610 |
C058229 | polydatin | polydatin inhibits the reaction [EGFR protein affects the expression of CCL2 mRNA] | 21967610 |
C058229 | polydatin | polydatin inhibits the reaction [EGFR protein affects the expression of CCL2 protein] | 21967610 |
C058229 | polydatin | polydatin inhibits the reaction [EGFR protein affects the expression of CXCL10 mRNA] | 21967610 |
C058229 | polydatin | polydatin inhibits the reaction [EGFR protein affects the expression of CXCL10 protein] | 21967610 |
C545373 | ponatinib | ponatinib results in decreased activity of EGFR protein mutant form | 19878872 |
C027373 | potassium chromate(VI) | [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of EGFR mRNA | 22079256 |
C027373 | potassium chromate(VI) | potassium chromate(VI) results in decreased expression of EGFR mRNA | 22079256 |
C009006 | potassium perchlorate | potassium perchlorate results in increased expression of EGFR mRNA | 29673971 |
D011319 | Primaquine | Primaquine inhibits the reaction [EGF protein results in increased uptake of and results in increased degradation of EGFR protein] | 23125191 |
C045362 | prochloraz | [Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of EGFR mRNA | 25607892 |
C035988 | procymidone | [Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of EGFR mRNA | 25607892 |
D011374 | Progesterone | [Progesterone co-treated with Estradiol] results in increased expression of EGFR mRNA | 18692832 |
D011374 | Progesterone | Progesterone promotes the reaction [EGF protein results in increased phosphorylation of EGFR protein] | 16175315 |
D011374 | Progesterone | Progesterone results in increased expression of EGFR protein | 16175315 |
D011374 | Progesterone | [RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [FSHB protein results in increased chemical synthesis of Progesterone] | 21520325 |
D011374 | Progesterone | Estradiol promotes the reaction [Progesterone inhibits the reaction [perfluorooctanoic acid results in decreased expression of EGFR protein]] | 22414604 |
D011374 | Progesterone | Progesterone inhibits the reaction [perfluorooctanoic acid results in decreased expression of EGFR protein] | 22414604 |
D011374 | Progesterone | Progesterone promotes the reaction [Estradiol inhibits the reaction [perfluorooctanoic acid results in decreased expression of EGFR protein]] | 22414604 |
D011374 | Progesterone | [Estrogens co-treated with Progesterone] results in increased expression of EGFR mRNA | 21258428 |
D011374 | Progesterone | [Estrogens co-treated with Progesterone] results in increased expression of EGFR protein | 21258428 |
D011374 | Progesterone | Progesterone results in increased expression of EGFR mRNA | 18591650 |
D011374 | Progesterone | EGFR protein affects the chemical synthesis of Progesterone | 21520325 |
D011433 | Propranolol | Propranolol inhibits the reaction [Alprenolol promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]] | 18787115 |
D011433 | Propranolol | Propranolol inhibits the reaction [Alprenolol promotes the reaction [ADRB1 protein results in increased uptake of EGFR protein]] | 18787115 |
D011433 | Propranolol | Propranolol inhibits the reaction [Carvedilol promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]] | 18787115 |
D011433 | Propranolol | Propranolol inhibits the reaction [Carvedilol promotes the reaction [ADRB1 protein results in increased uptake of EGFR protein]] | 18787115 |
D011433 | Propranolol | Propranolol inhibits the reaction [Dobutamine promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]] | 18787115 |
D011433 | Propranolol | Propranolol inhibits the reaction [Dobutamine promotes the reaction [ADRB1 protein results in increased uptake of EGFR protein]] | 18787115 |
D011441 | Propylthiouracil | Propylthiouracil results in increased expression of EGFR mRNA | 24780913 |
D047428 | Protein Kinase Inhibitors | Protein Kinase Inhibitors inhibits the reaction [Ozone results in increased phosphorylation of EGFR protein] | 25303742 |
C028025 | protoporphyrin IX | protoporphyrin IX results in decreased expression of EGFR protein | 23624237 |
C043680 | ptaquiloside | ptaquiloside results in decreased expression of EGFR mRNA | 23274088 |
C107773 | pterostilbene | pterostilbene inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of EGFR protein] | 19447859 |
D011710 | Pyocyanine | Pyocyanine results in increased phosphorylation of EGFR protein | 24015256 |
C513428 | pyrachlostrobin | pyrachlostrobin results in increased expression of EGFR mRNA | 27029645 |
C432165 | pyrazolanthrone | pyrazolanthrone results in decreased expression of EGFR mRNA | 15923621 |
C432165 | pyrazolanthrone | pyrazolanthrone results in decreased expression of EGFR protein | 15923621 |
C432165 | pyrazolanthrone | pyrazolanthrone results in decreased expression of EGFR mRNA | 18332871 |
C432165 | pyrazolanthrone | pyrazolanthrone results in decreased expression of EGFR protein | 18332871 |
C014175 | pyrazolo(3,4-d)pyrimidine | pyrazolo(3,4-d)pyrimidine analog affects the expression of EGFR mRNA | 21152443 |
C014175 | pyrazolo(3,4-d)pyrimidine | pyrazolo(3,4-d)pyrimidine analog results in decreased expression of EGFR protein | 21152443 |
C020972 | pyrrolidine dithiocarbamic acid | [Copper binds to pyrrolidine dithiocarbamic acid] which results in increased phosphorylation of EGFR protein | 18346929 |
D011794 | Quercetin | [Cisplatin co-treated with Quercetin] results in increased expression of EGFR mRNA | 27514524 |
D011794 | Quercetin | EGF protein inhibits the reaction [Quercetin results in decreased phosphorylation of EGFR protein] | 12168845 |
D011794 | Quercetin | EGFR protein affects the susceptibility to Quercetin | 12168845 |
D011794 | Quercetin | Quercetin affects the activity of and results in decreased phosphorylation of EGFR protein | 12168845 |
D011794 | Quercetin | Quercetin inhibits the reaction [EGF protein results in increased phosphorylation of and results in increased activity of EGFR protein] | 15135307 |
D011794 | Quercetin | Quercetin inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein] | 10556937 |
D011794 | Quercetin | Quercetin inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased phosphorylation of EGFR protein] | 21756928 |
D011794 | Quercetin | Quercetin results in decreased expression of EGFR mRNA | 21308698 |
D011794 | Quercetin | Quercetin results in decreased phosphorylation of and results in increased activity of EGFR protein | 15135307 |
D011794 | Quercetin | Quercetin results in decreased phosphorylation of EGFR protein | 18618485; 21308698; 21756928; 21967610; 23099361; |
D011794 | Quercetin | Quercetin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of EGFR protein] | 23099361 |
D011794 | Quercetin | Quercetin inhibits the reaction [[Methylnitrosourea co-treated with Testosterone] results in increased expression of and results in increased phosphorylation of EGFR protein] | 25164625 |
D011794 | Quercetin | [leptomycin B co-treated with TGFA protein co-treated with Quercetin] affects the localization of EGFR protein | 21967610 |
D011794 | Quercetin | [leptomycin B co-treated with TGFA protein co-treated with Quercetin] affects the localization of EGFR protein modified form | 21967610 |
D011794 | Quercetin | Quercetin inhibits the reaction [[TGFA protein co-treated with IFNG protein] results in increased phosphorylation of EGFR protein] | 21967610 |
D011794 | Quercetin | Quercetin promotes the reaction [TGFA protein affects the localization of EGFR protein] | 21967610 |
D011794 | Quercetin | Quercetin promotes the reaction [TGFA protein affects the localization of EGFR protein modified form] | 21967610 |
D011799 | Quinazolines | Quinazolines analog inhibits the reaction [EGFR protein results in increased activity of MAPK1 protein] | 21075094 |
D011799 | Quinazolines | Quinazolines analog inhibits the reaction [EGFR protein results in increased activity of MAPK3 protein] | 21075094 |
D011799 | Quinazolines | Quinazolines analog results in decreased phosphorylation of EGFR protein | 10753475 |
D020849 | Raloxifene Hydrochloride | [Raloxifene Hydrochloride co-treated with epigallocatechin gallate] results in decreased phosphorylation of EGFR protein | 18371987 |
D020849 | Raloxifene Hydrochloride | Raloxifene Hydrochloride results in increased phosphorylation of EGFR protein | 24782323 |
D011899 | Ranitidine | Ranitidine inhibits the reaction [Indomethacin results in increased expression of EGFR mRNA] | 29523851 |
D017382 | Reactive Oxygen Species | [[Cadmium Chloride results in increased abundance of Reactive Oxygen Species] which results in increased activity of SRC protein] which results in increased activity of EGFR protein | 23376140 |
D017382 | Reactive Oxygen Species | [[[Cadmium Chloride results in increased abundance of Reactive Oxygen Species] which results in increased activity of SRC protein] which results in increased activity of EGFR protein] which results in increased activity of STAT3 protein | 23376140 |
D017382 | Reactive Oxygen Species | [[[[Cadmium Chloride results in increased abundance of Reactive Oxygen Species] which results in increased activity of SRC protein] which results in increased activity of EGFR protein] which results in increased activity of STAT3 protein] promotes the reaction [STAT3 protein binds to STAT3 protein] | 23376140 |
D017382 | Reactive Oxygen Species | EGFR protein affects the reaction [Reactive Oxygen Species affects the phosphorylation of SHC1 protein] | 19168439 |
D017382 | Reactive Oxygen Species | Reactive Oxygen Species results in increased activity of EGFR protein | 24635018 |
D000077185 | Resveratrol | AR protein affects the reaction [[Resveratrol binds to EGFR protein] which results in decreased phosphorylation of EGFR protein] | 20729295 |
D000077185 | Resveratrol | EGF protein inhibits the reaction [Resveratrol results in decreased phosphorylation of EGFR protein] | 20729295 |
D000077185 | Resveratrol | PD168393 inhibits the reaction [Resveratrol results in increased phosphorylation of EGFR protein] | 23527233 |
D000077185 | Resveratrol | Resveratrol affects the localization of EGFR protein | 23527233 |
D000077185 | Resveratrol | Resveratrol affects the localization of EGFR protein modified form | 23527233 |
D000077185 | Resveratrol | Resveratrol binds to EGFR protein | 20729295 |
D000077185 | Resveratrol | [Resveratrol binds to EGFR protein] which results in decreased phosphorylation of EGFR protein | 20729295 |
D000077185 | Resveratrol | Resveratrol inhibits the reaction [EGR protein results in increased phosphorylation of EGFR protein] | 23127547 |
D000077185 | Resveratrol | Resveratrol inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of EGFR protein] | 23127547 |
D000077185 | Resveratrol | Resveratrol inhibits the reaction [TGFA protein affects the localization of EGFR protein] | 21967610 |
D000077185 | Resveratrol | Resveratrol promotes the reaction [EGF protein results in increased phosphorylation of EGFR protein] | 16343977 |
D000077185 | Resveratrol | Resveratrol results in decreased expression of and results in decreased phosphorylation of EGFR protein | 25063218 |
D000077185 | Resveratrol | Resveratrol results in decreased expression of EGFR mRNA | 25667456 |
D000077185 | Resveratrol | Resveratrol results in decreased expression of EGFR protein | 24514079 |
D000077185 | Resveratrol | Resveratrol results in decreased phosphorylation of EGFR protein | 20729295; 23527233; |
D000077185 | Resveratrol | Resveratrol results in increased activity of EGFR protein | 15802018 |
D000077185 | Resveratrol | Resveratrol results in increased degradation of EGFR protein | 23527233 |
D000077185 | Resveratrol | Resveratrol results in increased phosphorylation of EGFR protein | 23527233 |
D000077185 | Resveratrol | Resveratrol inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of EGFR] | 26100520 |
D000077185 | Resveratrol | Resveratrol promotes the reaction [ursolic acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of EGFR]] | 26100520 |
D000077185 | Resveratrol | Resveratrol results in decreased expression of EGFR mRNA | 23525482 |
D000077185 | Resveratrol | ursolic acid promotes the reaction [Resveratrol inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of EGFR]] | 26100520 |
D000077185 | Resveratrol | [leptomycin B co-treated with TGFA protein co-treated with Resveratrol] affects the localization of EGFR protein modified form | 21967610 |
D000077185 | Resveratrol | PD168393 inhibits the reaction [[Resveratrol co-treated with TNF protein] results in increased phosphorylation of EGFR protein] | 23527233 |
D000077185 | Resveratrol | [Resveratrol co-treated with TNF protein] results in increased phosphorylation of EGFR protein | 23527233 |
D000077185 | Resveratrol | Resveratrol inhibits the reaction [EGF protein results in increased expression of and results in increased phosphorylation of EGFR protein] | 21942447 |
D000077185 | Resveratrol | Resveratrol inhibits the reaction [EGFR protein affects the expression of CCL2 mRNA] | 21967610 |
D000077185 | Resveratrol | Resveratrol inhibits the reaction [EGFR protein affects the expression of CCL2 protein] | 21967610 |
D000077185 | Resveratrol | Resveratrol inhibits the reaction [EGFR protein affects the expression of CXCL10 mRNA] | 21967610 |
D000077185 | Resveratrol | Resveratrol inhibits the reaction [EGFR protein affects the expression of CXCL10 protein] | 21967610 |
C000589977 | rociletinib | rociletinib results in decreased activity of EGFR protein | 28237877 |
C087123 | romidepsin | romidepsin results in decreased expression of EGFR protein | 15014036 |
D000077154 | Rosiglitazone | Rosiglitazone results in increased phosphorylation of EGFR protein | 18507034 |
D012402 | Rotenone | Rotenone results in decreased expression of EGFR mRNA | 28374803 |
D012402 | Rotenone | Rotenone results in decreased expression of EGFR protein | 17555550 |
C085746 | rottlerin | rottlerin inhibits the reaction [Irinotecan metabolite results in increased phosphorylation of EGFR protein] | 15723263 |
C085746 | rottlerin | rottlerin inhibits the reaction [Irinotecan results in increased phosphorylation of EGFR protein] | 15723263 |
C085746 | rottlerin | rottlerin inhibits the reaction [NTS protein results in increased phosphorylation of and results in increased activity of EGFR protein] | 15177934 |
C101044 | RTKI cpd | RTKI cpd results in decreased phosphorylation of EGFR protein | 19151764 |
C101044 | RTKI cpd | RTKI cpd inhibits the reaction [Acrolein results in increased phosphorylation of EGFR protein] | 15531749 |
C101044 | RTKI cpd | RTKI cpd inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]] | 18787115 |
C101044 | RTKI cpd | RTKI cpd inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]] | 18787115 |
C101044 | RTKI cpd | RTKI cpd inhibits the reaction [Alprenolol promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]] | 18787115 |
C101044 | RTKI cpd | RTKI cpd inhibits the reaction [[AREG protein co-treated with Estradiol] results in increased phosphorylation of EGFR protein] | 21185374 |
C101044 | RTKI cpd | RTKI cpd inhibits the reaction [Cadmium Chloride results in increased phosphorylation of EGFR protein] | 26385184 |
C101044 | RTKI cpd | RTKI cpd inhibits the reaction [Cadmium results in increased activity of EGFR protein] | 25343777 |
C101044 | RTKI cpd | RTKI cpd inhibits the reaction [Cadmium results in increased phosphorylation of EGFR protein] | 26514923 |
C101044 | RTKI cpd | RTKI cpd inhibits the reaction [Capsaicin results in increased phosphorylation of EGFR protein] | 20619260; 20660715; |
C101044 | RTKI cpd | RTKI cpd inhibits the reaction [Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]] | 18787115 |
C101044 | RTKI cpd | RTKI cpd inhibits the reaction [Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]] | 18787115 |
C101044 | RTKI cpd | RTKI cpd inhibits the reaction [Carvedilol promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]] | 18787115 |
C101044 | RTKI cpd | RTKI cpd inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]] | 18787115 |
C101044 | RTKI cpd | RTKI cpd inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]] | 18787115 |
C101044 | RTKI cpd | RTKI cpd inhibits the reaction [Dobutamine promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]] | 18787115 |
C101044 | RTKI cpd | RTKI cpd inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein] | 16472761; 25856345; 25969534; 26385184; 28974440; |
C101044 | RTKI cpd | RTKI cpd inhibits the reaction [EGFR protein binds to GPER1 protein] | 19749156 |
C101044 | RTKI cpd | RTKI cpd inhibits the reaction [Estradiol promotes the reaction [EGF protein results in increased phosphorylation of EGFR protein]] | 21185374 |
C101044 | RTKI cpd | RTKI cpd inhibits the reaction [Estradiol results in increased phosphorylation of EGFR protein] | 21185374 |
C101044 | RTKI cpd | RTKI cpd inhibits the reaction [lead acetate results in increased phosphorylation of EGFR protein] | 19133285 |
C101044 | RTKI cpd | RTKI cpd inhibits the reaction [lead nitrate results in increased phosphorylation of EGFR protein] | 20850495 |
C101044 | RTKI cpd | RTKI cpd inhibits the reaction [NTS protein results in increased phosphorylation of and results in increased activity of EGFR protein] | 15177934 |
C101044 | RTKI cpd | RTKI cpd inhibits the reaction [sodium arsenite results in increased phosphorylation of and results in increased activity of EGFR protein] | 15504454 |
C101044 | RTKI cpd | RTKI cpd inhibits the reaction [sodium arsenite results in increased phosphorylation of EGFR protein] | 28974440 |
C101044 | RTKI cpd | RTKI cpd inhibits the reaction [Win 55212-2 results in increased phosphorylation of EGFR protein] | 20619260 |
C101044 | RTKI cpd | RTKI cpd results in decreased activity of EGFR protein | 27071941 |
C101044 | RTKI cpd | [RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [Cadmium Chloride results in increased phosphorylation of FOXO3 protein] | 23673518 |
C101044 | RTKI cpd | [RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [Equol results in increased chemical synthesis of Oxygen] | 21300668 |
C101044 | RTKI cpd | [RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [Equol results in increased phosphorylation of and results in increased activity of NOS3 protein] | 21300668 |
C101044 | RTKI cpd | [RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [Equol results in increased phosphorylation of MAPK1 protein] | 21300668 |
C101044 | RTKI cpd | [RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [Equol results in increased phosphorylation of MAPK3 protein] | 21300668 |
C101044 | RTKI cpd | [RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [FSHB protein results in increased chemical synthesis of Hyaluronic Acid] | 21520325 |
C101044 | RTKI cpd | [RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [FSHB protein results in increased chemical synthesis of Progesterone] | 21520325 |
C101044 | RTKI cpd | [RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [Hexachlorobenzene results in increased phosphorylation of and results in increased activity of MAPK1 protein] | 21205633 |
C101044 | RTKI cpd | [RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [Hexachlorobenzene results in increased phosphorylation of and results in increased activity of MAPK3 protein] | 21205633 |
C101044 | RTKI cpd | [RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [Hexachlorobenzene results in increased phosphorylation of and results in increased activity of STAT5B protein] | 21205633 |
C101044 | RTKI cpd | [RTKI cpd results in decreased activity of EGFR protein] which results in decreased susceptibility to 5-methoxy-1,2-dimethyl-3-((4-nitrophenoxy)methyl)indole-4,7-dione | 20433816 |
C101044 | RTKI cpd | [RTKI cpd results in decreased activity of EGFR protein] which results in decreased susceptibility to FSHB protein | 21520325 |
C101044 | RTKI cpd | [RTKI cpd results in decreased activity of EGFR protein] which results in decreased susceptibility to Hexachlorobenzene | 21205633 |
C101044 | RTKI cpd | [RTKI cpd results in decreased activity of EGFR protein] which results in decreased susceptibility to Topotecan | 15923621 |
C101044 | RTKI cpd | RTKI cpd results in decreased expression of EGFR protein modified form | 29974605 |
C101044 | RTKI cpd | RTKI cpd results in decreased phosphorylation of EGFR protein | 15923621; 18618485; 18633435; 23538097; |
C101044 | RTKI cpd | RTKI cpd inhibits the reaction [evodiamine results in increased phosphorylation of EGFR protein] | 19854188 |
C101044 | RTKI cpd | RTKI cpd inhibits the reaction [Fluoxetine results in increased phosphorylation of EGFR protein] | 18758753 |
C101044 | RTKI cpd | RTKI cpd inhibits the reaction [LHB protein results in increased phosphorylation of and results in increased activity of EGFR protein] | 21220312 |
C101044 | RTKI cpd | RTKI cpd inhibits the reaction [Sodium Chloride results in increased phosphorylation of EGFR protein] | 21568938 |
C101044 | RTKI cpd | RTKI cpd inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Capsaicin] results in increased phosphorylation of EGFR protein] | 20660715 |
C101044 | RTKI cpd | RTKI cpd results in decreased activity of EGFR protein | 12794006 |
C101044 | RTKI cpd | [[RTKI cpd results in decreased activity of EGFR protein] co-treated with [SU 6656 results in decreased activity of SRC protein]] inhibits the reaction [Cadmium Chloride results in increased phosphorylation of and results in increased activity of STAT3 protein] | 23376140 |
C101044 | RTKI cpd | [RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [Cadmium Chloride results in increased expression of MT2 protein] | 23376140 |
C101044 | RTKI cpd | [RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [Cadmium Chloride results in increased phosphorylation of and results in increased activity of MAPK1 protein] | 23376140 |
C101044 | RTKI cpd | [RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [Cadmium Chloride results in increased phosphorylation of and results in increased activity of MAPK3 protein] | 23376140 |
C101044 | RTKI cpd | [RTKI cpd results in decreased activity of EGFR protein] which results in decreased expression of BIRC5 protein | 21268125 |
C101044 | RTKI cpd | [RTKI cpd results in decreased activity of EGFR protein] which results in decreased phosphorylation of STAT3 protein | 21268125 |
C101044 | RTKI cpd | [RTKI cpd results in decreased activity of EGFR protein] which results in decreased susceptibility to butaprost | 21268125 |
C101044 | RTKI cpd | RTKI cpd results in decreased phosphorylation of and results in decreased activity of EGFR protein | 21268125 |
C101044 | RTKI cpd | RTKI cpd inhibits the reaction [tert-Butylhydroperoxide results in increased phosphorylation of EGFR protein] | 17116659 |
C101044 | RTKI cpd | RTKI cpd inhibits the reaction [AGT protein results in increased phosphorylation of and results in increased activity of EGFR protein] | 15849355 |
C101044 | RTKI cpd | RTKI cpd inhibits the reaction [AGT protein results in increased phosphorylation of EGFR protein] | 25398788 |
C101044 | RTKI cpd | RTKI cpd inhibits the reaction [Cadmium Chloride results in increased phosphorylation of EGFR protein] | 19233221 |
C101044 | RTKI cpd | RTKI cpd inhibits the reaction [EGFR protein affects the reaction [EDN1 protein results in increased phosphorylation of MAPK1 protein]] | 16261333 |
C101044 | RTKI cpd | RTKI cpd inhibits the reaction [EGFR protein affects the reaction [EDN1 protein results in increased phosphorylation of MAPK3 protein]] | 16261333 |
C101044 | RTKI cpd | RTKI cpd inhibits the reaction [estradiol-17 beta-glucuronide results in increased phosphorylation of and results in increased activity of EGFR protein] | 25813982 |
C101044 | RTKI cpd | RTKI cpd inhibits the reaction [LHB protein results in increased phosphorylation of EGFR protein] | 15459120 |
C101044 | RTKI cpd | RTKI cpd inhibits the reaction [sodium arsenite promotes the reaction [SHC1 protein modified form binds to EGFR protein binds to GRB protein]] | 9710602 |
C101044 | RTKI cpd | RTKI cpd inhibits the reaction [sodium arsenite results in increased phosphorylation of EGFR protein] | 9710602 |
C101044 | RTKI cpd | RTKI cpd results in decreased activity of EGFR protein | 15574683 |
C101044 | RTKI cpd | [RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [Genistein results in increased secretion of Testosterone] | 19059320 |
C101044 | RTKI cpd | RTKI cpd binds to EGFR protein | 22048644 |
C101044 | RTKI cpd | RTKI cpd results in decreased activity of EGFR protein | 12154034; 14569062; 15279711; 15706222; 16373414; 16391241; 19059320; 19168439; 20433816; 20593979; 21205633; 21300668; 21520325; 21568938; 22573732; 22645130; 23064031; 23376140; 23673518; |
C101044 | RTKI cpd | [RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [[[2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased phosphorylation of MAPK1 protein] co-treated with [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased phosphorylation of MAPK3 protein]] results in increased phosphorylation of ELK1 protein] | 18056474 |
C101044 | RTKI cpd | [RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [EGF protein results in increased chemical synthesis of Hyaluronic Acid] | 21520325 |
C101044 | RTKI cpd | [RTKI cpd results in decreased activity of EGFR protein] results in decreased activity of [OXT protein binds to and results in increased activity of OXTR protein] | 12955084 |
C101044 | RTKI cpd | [RTKI cpd results in decreased activity of EGFR protein] which results in decreased susceptibility to EGF protein | 21520325 |
D012431 | Rutin | Rutin inhibits the reaction [TGFA protein affects the localization of EGFR protein] | 21967610 |
D012431 | Rutin | [leptomycin B co-treated with TGFA protein co-treated with Rutin] affects the localization of EGFR protein modified form | 21967610 |
D012431 | Rutin | Rutin promotes the reaction [TGFA protein results in increased phosphorylation of EGFR protein] | 21967610 |
C093642 | SB 203580 | SB 203580 inhibits the reaction [tert-Butylhydroperoxide results in increased phosphorylation of EGFR protein] | 17116659 |
D012601 | Scopolamine | Scopolamine results in decreased expression of EGFR mRNA | 12818353 |
C090142 | secoisolariciresinol diglucoside | secoisolariciresinol diglucoside results in decreased expression of EGFR mRNA | 19904759 |
D012643 | Selenium | Selenium results in decreased expression of EGFR mRNA | 17390030 |
D012645 | Selenomethionine | Selenomethionine results in increased expression of EGFR mRNA | 17205524 |
D020280 | Sertraline | Sertraline results in increased expression of EGFR mRNA | 24865413 |
D012822 | Silicon Dioxide | Silicon Dioxide analog results in increased expression of EGFR mRNA | 25895662 |
D012822 | Silicon Dioxide | Silicon Dioxide analog results in increased phosphorylation of EGFR protein | 24844442 |
D012822 | Silicon Dioxide | Silicon Dioxide results in increased expression of EGFR mRNA | 21540303 |
D012822 | Silicon Dioxide | Silicon Dioxide results in increased expression of EGFR mRNA | 23221170 |
D018030 | Silver Compounds | Silver Compounds results in decreased expression of EGFR mRNA | 29703973 |
D019821 | Simvastatin | Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [Acrolein results in increased phosphorylation of EGFR protein]] | 20359552 |
D019821 | Simvastatin | Simvastatin inhibits the reaction [Acrolein results in increased phosphorylation of EGFR protein] | 20359552 |
D020123 | Sirolimus | AG 1879 inhibits the reaction [Sirolimus results in increased phosphorylation of EGFR protein] | 19151764 |
D020123 | Sirolimus | Sirolimus results in increased phosphorylation of and results in increased activity of EGFR protein | 19151764 |
D020123 | Sirolimus | [Sirolimus results in increased phosphorylation of and results in increased activity of EGFR protein] which results in increased phosphorylation of MAPK1 protein | 19151764 |
D020123 | Sirolimus | [Sirolimus results in increased phosphorylation of and results in increased activity of EGFR protein] which results in increased phosphorylation of MAPK3 protein | 19151764 |
D020123 | Sirolimus | [Sirolimus results in increased phosphorylation of and results in increased activity of SRC protein] which results in increased phosphorylation of EGFR protein | 19151764 |
D012906 | Smoke | Smoke results in decreased expression of EGFR mRNA | 21095227 |
D012906 | Smoke | Smoke results in decreased nitrosation of EGFR protein | 21652289 |
C009277 | sodium arsenate | sodium arsenate results in increased expression of EGFR mRNA | 21795629 |
C017947 | sodium arsenite | EGFR mutant form inhibits the reaction [sodium arsenite results in increased expression of CDKN1A protein] | 15734884 |
C017947 | sodium arsenite | Erlotinib Hydrochloride inhibits the reaction [sodium arsenite results in increased phosphorylation of EGFR protein] | 19168569 |
C017947 | sodium arsenite | RTKI cpd inhibits the reaction [sodium arsenite results in increased phosphorylation of and results in increased activity of EGFR protein] | 15504454 |
C017947 | sodium arsenite | RTKI cpd inhibits the reaction [sodium arsenite results in increased phosphorylation of EGFR protein] | 28974440 |
C017947 | sodium arsenite | sodium arsenite affects the methylation of EGFR gene | 28589171 |
C017947 | sodium arsenite | sodium arsenite promotes the reaction [Adenosine Triphosphate results in increased phosphorylation of EGFR protein] | 26104857 |
C017947 | sodium arsenite | sodium arsenite results in decreased expression of EGFR mRNA | 28595984 |
C017947 | sodium arsenite | sodium arsenite results in increased activity of and results in increased phosphorylation of EGFR protein | 15734884 |
C017947 | sodium arsenite | sodium arsenite results in increased activity of EGFR protein | 19414066 |
C017947 | sodium arsenite | sodium arsenite results in increased expression of EGFR mRNA | 12016162 |
C017947 | sodium arsenite | sodium arsenite results in increased expression of EGFR protein | 25907674 |
C017947 | sodium arsenite | [sodium arsenite results in increased expression of EGFR protein] which results in increased phosphorylation of PCNA protein | 25907674 |
C017947 | sodium arsenite | sodium arsenite results in increased phosphorylation of and results in increased activity of EGFR protein | 11723127; 15504454; 19168569; |
C017947 | sodium arsenite | sodium arsenite results in increased phosphorylation of EGFR protein | 10564177; 11943669; 20043101; 28974440; |
C017947 | sodium arsenite | SU 6656 inhibits the reaction [sodium arsenite results in increased phosphorylation of and results in increased activity of EGFR protein] | 15504454 |
C017947 | sodium arsenite | sodium arsenite affects the expression of EGFR mRNA | 16507464 |
C017947 | sodium arsenite | sodium arsenite promotes the reaction [SRC protein binds to EGFR protein] | 11723127 |
C017947 | sodium arsenite | sodium arsenite results in decreased expression of EGFR mRNA | 19822182 |
C017947 | sodium arsenite | sodium arsenite results in decreased expression of EGFR protein | 16507464 |
C017947 | sodium arsenite | sodium arsenite results in increased expression of EGFR mRNA | 17077188; 9846968; |
C017947 | sodium arsenite | sodium arsenite results in increased phosphorylation of and results in increased activity of EGFR protein | 11723127 |
C017947 | sodium arsenite | [EGF protein results in decreased expression of EGFR protein] inhibits the reaction [sodium arsenite results in increased activity of MAPK1 protein] | 9710602 |
C017947 | sodium arsenite | [EGF protein results in decreased expression of EGFR protein] inhibits the reaction [sodium arsenite results in increased activity of MAPK3 protein] | 9710602 |
C017947 | sodium arsenite | Gefitinib inhibits the reaction [HBEGF protein inhibits the reaction [sodium arsenite results in decreased phosphorylation of and results in decreased activity of EGFR protein]] | 29228391 |
C017947 | sodium arsenite | HBEGF protein inhibits the reaction [sodium arsenite results in decreased phosphorylation of and results in decreased activity of EGFR protein] | 29228391 |
C017947 | sodium arsenite | HBEGF protein inhibits the reaction [sodium arsenite results in decreased phosphorylation of EGFR protein] | 29228391 |
C017947 | sodium arsenite | RTKI cpd inhibits the reaction [sodium arsenite promotes the reaction [SHC1 protein modified form binds to EGFR protein binds to GRB protein]] | 9710602 |
C017947 | sodium arsenite | RTKI cpd inhibits the reaction [sodium arsenite results in increased phosphorylation of EGFR protein] | 9710602 |
C017947 | sodium arsenite | sodium arsenite promotes the reaction [SHC1 protein modified form binds to EGFR protein binds to GRB protein] | 9710602 |
C017947 | sodium arsenite | sodium arsenite results in decreased phosphorylation of and results in decreased activity of EGFR protein | 29228391 |
C017947 | sodium arsenite | sodium arsenite results in decreased phosphorylation of EGFR protein | 29228391 |
C017947 | sodium arsenite | sodium arsenite results in increased phosphorylation of EGFR protein | 9710602 |
C017947 | sodium arsenite | Suramin inhibits the reaction [sodium arsenite results in increased phosphorylation of EGFR protein] | 9710602 |
D012965 | Sodium Chloride | 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Sodium Chloride results in increased phosphorylation of EGFR protein] | 21568938 |
D012965 | Sodium Chloride | N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Sodium Chloride results in increased phosphorylation of EGFR protein] | 21568938 |
D012965 | Sodium Chloride | RTKI cpd inhibits the reaction [Sodium Chloride results in increased phosphorylation of EGFR protein] | 21568938 |
D012965 | Sodium Chloride | Sodium Chloride results in increased phosphorylation of EGFR protein | 21568938 |
D012965 | Sodium Chloride | Wortmannin inhibits the reaction [Sodium Chloride results in increased phosphorylation of EGFR protein] | 21568938 |
D012972 | Sodium Hydroxide | EGFR SNP affects the susceptibility to Sodium Hydroxide | 27206134 |
D018038 | Sodium Selenite | Sodium Selenite results in decreased expression of EGFR mRNA | 23274088 |
D053260 | Soot | Soot results in increased expression of EGFR mRNA | 22461453; 26551751; |
D000077157 | Sorafenib | Sorafenib results in decreased expression of EGFR mRNA | 26409325 |
C060506 | sphingosine 1-phosphate | JTE 013 inhibits the reaction [sphingosine 1-phosphate results in increased phosphorylation of EGFR protein] | 26518876 |
C060506 | sphingosine 1-phosphate | sphingosine 1-phosphate results in increased phosphorylation of EGFR protein | 26518876 |
C106195 | SR 11302 | SR 11302 inhibits the reaction [ARSB protein affects the expression of EGFR mRNA] | 29794138 |
C106195 | SR 11302 | SR 11302 inhibits the reaction [ARSB protein affects the expression of EGFR protein] | 29794138 |
D019311 | Staurosporine | Staurosporine inhibits the reaction [NTS protein results in increased phosphorylation of and results in increased activity of EGFR protein] | 15177934 |
D013267 | Stilbenes | Stilbenes analog results in decreased expression of and results in decreased phosphorylation of EGFR protein | 25063218 |
C416927 | SU 6656 | SU 6656 inhibits the reaction [sodium arsenite results in increased phosphorylation of and results in increased activity of EGFR protein] | 15504454 |
C416927 | SU 6656 | [[RTKI cpd results in decreased activity of EGFR protein] co-treated with [SU 6656 results in decreased activity of SRC protein]] inhibits the reaction [Cadmium Chloride results in increased phosphorylation of and results in increased activity of STAT3 protein] | 23376140 |
C416927 | SU 6656 | [SU 6656 results in decreased activity of SRC protein] inhibits the reaction [Cadmium Chloride results in increased phosphorylation of and results in increased activity of EGFR protein] | 23376140 |
D004113 | Succimer | [Succimer co-treated with Magnetite Nanoparticles] results in decreased expression of EGFR mRNA | 26378955 |
D012460 | Sulfasalazine | geldanamycin promotes the reaction [Sulfasalazine results in decreased expression of EGFR protein] | 20007406 |
D012460 | Sulfasalazine | [Sulfasalazine co-treated with tripterine] affects the expression of EGFR protein | 20007406 |
D012460 | Sulfasalazine | [Sulfasalazine co-treated with tripterine] results in decreased expression of EGFR protein | 20007406 |
C025462 | sulindac sulfide | benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [sulindac sulfide results in decreased expression of EGFR protein] | 20332299 |
C025462 | sulindac sulfide | Chloroquine inhibits the reaction [sulindac sulfide results in decreased expression of EGFR protein] | 20332299 |
C025462 | sulindac sulfide | sulindac sulfide results in decreased expression of EGFR protein | 20332299 |
C025462 | sulindac sulfide | sulindac sulfide results in decreased phosphorylation of EGFR protein | 20332299 |
C025462 | sulindac sulfide | sulindac sulfide results in increased phosphorylation of EGFR protein | 20332299 |
C025462 | sulindac sulfide | sulindac sulfide results in increased ubiquitination of EGFR protein | 20332299 |
C025463 | sulindac sulfone | benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [sulindac sulfone results in decreased expression of EGFR protein] | 20332299 |
C025463 | sulindac sulfone | Chloroquine inhibits the reaction [sulindac sulfone results in decreased expression of EGFR protein] | 20332299 |
C025463 | sulindac sulfone | sulindac sulfone results in decreased expression of EGFR protein | 20332299 |
C025463 | sulindac sulfone | sulindac sulfone results in decreased phosphorylation of EGFR protein | 20332299 |
C025463 | sulindac sulfone | sulindac sulfone results in increased phosphorylation of EGFR protein | 20332299 |
C025463 | sulindac sulfone | sulindac sulfone results in increased ubiquitination of EGFR protein | 20332299 |
C025463 | sulindac sulfone | [Celecoxib co-treated with sulindac sulfone] results in decreased expression of EGFR protein | 17908994 |
C025463 | sulindac sulfone | [Celecoxib co-treated with sulindac sulfone] results in decreased expression of EGFR protein modified form | 17908994 |
D000077210 | Sunitinib | Sunitinib results in decreased expression of EGFR mRNA | 31533062 |
D013498 | Suramin | Suramin inhibits the reaction [sodium arsenite results in increased phosphorylation of EGFR protein] | 9710602 |
C467766 | taiwanin C | taiwanin C results in decreased phosphorylation of EGFR protein | 26537528; 30884126; |
D013629 | Tamoxifen | [EGF protein results in increased activity of EGFR protein] which results in decreased susceptibility to Tamoxifen | 24758408 |
D013629 | Tamoxifen | EGFR mutant form inhibits the reaction [[EGF protein results in increased activity of EGFR protein] which results in decreased susceptibility to Tamoxifen] | 24758408; 24758408; |
D013629 | Tamoxifen | EGFR protein results in decreased susceptibility to Tamoxifen | 15665275; 16000581; |
D013629 | Tamoxifen | [Tamoxifen co-treated with ESR1 protein] results in decreased expression of EGFR mRNA | 19347870 |
D013629 | Tamoxifen | [Tamoxifen co-treated with ESR1 protein] results in decreased expression of EGFR protein | 19347870 |
D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in increased expression of EGFR mRNA | 19347870 |
D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in increased expression of EGFR protein | 19347870 |
D013629 | Tamoxifen | Tamoxifen results in increased expression of EGFR mRNA | 20005069 |
D013629 | Tamoxifen | Tamoxifen results in increased expression of EGFR protein | 20005069 |
D013629 | Tamoxifen | Tamoxifen affects the expression of EGFR mRNA | 17555576 |
C112765 | tanespimycin | tanespimycin results in decreased expression of EGFR protein | 17010675 |
C112765 | tanespimycin | tanespimycin results in increased degradation of and results in decreased expression of EGFR protein | 16061882 |
D013656 | Taurocholic Acid | JTE 013 inhibits the reaction [Taurocholic Acid results in increased phosphorylation of EGFR protein] | 26518876 |
D013656 | Taurocholic Acid | S1PR2 mRNA promotes the reaction [Taurocholic Acid results in increased phosphorylation of EGFR protein] | 26518876 |
D013656 | Taurocholic Acid | Taurocholic Acid results in increased phosphorylation of EGFR protein | 26518876 |
D016593 | Terfenadine | 11,12-epoxy-5,8,14-eicosatrienoic acid inhibits the reaction [Terfenadine analog results in decreased phosphorylation of EGFR protein] | 19289568 |
D016593 | Terfenadine | Terfenadine analog results in decreased phosphorylation of EGFR protein | 19289568 |
C527525 | teriflunomide | teriflunomide inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein] | 30364229 |
D020122 | tert-Butylhydroperoxide | 4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [tert-Butylhydroperoxide results in increased phosphorylation of EGFR protein] | 17116659 |
D020122 | tert-Butylhydroperoxide | RTKI cpd inhibits the reaction [tert-Butylhydroperoxide results in increased phosphorylation of EGFR protein] | 17116659 |
D020122 | tert-Butylhydroperoxide | SB 203580 inhibits the reaction [tert-Butylhydroperoxide results in increased phosphorylation of EGFR protein] | 17116659 |
D020122 | tert-Butylhydroperoxide | tert-Butylhydroperoxide results in increased phosphorylation of EGFR protein | 17116659 |
D013739 | Testosterone | [Testosterone co-treated with Calcitriol] results in increased expression of EGFR mRNA | 21592394 |
D013739 | Testosterone | Testosterone results in increased expression of EGFR mRNA | 21592394 |
D013739 | Testosterone | Testosterone results in increased expression of EGFR mRNA | 21669218 |
D013739 | Testosterone | [Methylnitrosourea co-treated with Testosterone] results in increased expression of and results in increased phosphorylation of EGFR protein | 25164625 |
D013739 | Testosterone | Quercetin inhibits the reaction [[Methylnitrosourea co-treated with Testosterone] results in increased expression of and results in increased phosphorylation of EGFR protein] | 25164625 |
D013739 | Testosterone | [RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [Genistein results in increased secretion of Testosterone] | 19059320 |
D013739 | Testosterone | Testosterone results in increased phosphorylation of and results in increased activity of EGFR protein | 17272394 |
D013739 | Testosterone | Testosterone results in increased phosphorylation of EGFR protein | 21177760 |
D013739 | Testosterone | Testosterone results in increased activity of EGFR protein | 20403869 |
C020806 | tetrabromobisphenol A | tetrabromobisphenol A results in increased phosphorylation of EGFR protein | 26718265 |
D013749 | Tetrachlorodibenzodioxin | alpha-naphthoflavone inhibits the reaction [Tetrachlorodibenzodioxin results in increased phosphorylation of and results in increased activity of EGFR protein] | 17934341 |
D013749 | Tetrachlorodibenzodioxin | EGFR protein affects the susceptibility to Tetrachlorodibenzodioxin | 9163677 |
D013749 | Tetrachlorodibenzodioxin | EGFR protein promotes the reaction [Tetrachlorodibenzodioxin results in increased phosphorylation of and results in increased activity of AKT1 protein] | 11309286 |
D013749 | Tetrachlorodibenzodioxin | EGFR protein promotes the reaction [Tetrachlorodibenzodioxin results in increased phosphorylation of and results in increased activity of MAPK1 protein] | 11309286 |
D013749 | Tetrachlorodibenzodioxin | EGFR protein promotes the reaction [Tetrachlorodibenzodioxin results in increased phosphorylation of and results in increased activity of MAPK3 protein] | 11309286 |
D013749 | Tetrachlorodibenzodioxin | [Estradiol co-treated with Tetrachlorodibenzodioxin] results in decreased expression of EGFR mRNA | 19619570 |
D013749 | Tetrachlorodibenzodioxin | Tetrachlorodibenzodioxin inhibits the reaction [EGF protein binds to EGFR protein] | 2033054 |
D013749 | Tetrachlorodibenzodioxin | Tetrachlorodibenzodioxin results in decreased expression of EGFR | 1336723 |
D013749 | Tetrachlorodibenzodioxin | Tetrachlorodibenzodioxin results in increased expression of EGFR mRNA | 19619570; 9163677; |
D013749 | Tetrachlorodibenzodioxin | Tetrachlorodibenzodioxin results in increased expression of EGFR protein | 9787404 |
D013749 | Tetrachlorodibenzodioxin | Tetrachlorodibenzodioxin results in increased phosphorylation of and results in increased activity of EGFR protein | 17934341 |
D013749 | Tetrachlorodibenzodioxin | Tetrachlorodibenzodioxin results in increased phosphorylation of EGFR protein | 20971882; 26971374; |
D013749 | Tetrachlorodibenzodioxin | Tetrachlorodibenzodioxin results in decreased activity of EGFR protein | 9707505 |
D013749 | Tetrachlorodibenzodioxin | CSK protein promotes the reaction [Tetrachlorodibenzodioxin inhibits the reaction [EGF protein binds to EGFR protein]] | 9664232 |
D013749 | Tetrachlorodibenzodioxin | geldanamycin inhibits the reaction [Tetrachlorodibenzodioxin inhibits the reaction [EGF protein binds to EGFR protein]] | 9664232 |
D013749 | Tetrachlorodibenzodioxin | Tetrachlorodibenzodioxin affects the expression of EGFR mRNA | 21570461; 26377647; |
D013749 | Tetrachlorodibenzodioxin | Tetrachlorodibenzodioxin inhibits the reaction [EGF protein binds to EGFR protein] | 6309801; 9664232; |
D013749 | Tetrachlorodibenzodioxin | Tetrachlorodibenzodioxin results in decreased expression of EGFR mRNA | 14708085; 19770486; 22666406; 26290441; |
D013749 | Tetrachlorodibenzodioxin | Tetrachlorodibenzodioxin results in increased expression of EGFR mRNA | 17942748; 21167638; |
D013749 | Tetrachlorodibenzodioxin | Tetrachlorodibenzodioxin results in increased expression of EGFR protein | 2305375; 9787404; |
D013749 | Tetrachlorodibenzodioxin | Tetrachlorodibenzodioxin inhibits the reaction [EGF protein binds to EGFR protein] | 8430419 |
D013749 | Tetrachlorodibenzodioxin | Tetrachlorodibenzodioxin results in increased phosphorylation of EGFR protein | 8430419; 8470122; |
D013749 | Tetrachlorodibenzodioxin | [Tetrachlorodibenzodioxin results in increased phosphorylation of EGFR protein] inhibits the reaction [EGF protein binds to EGFR protein] | 8430419 |
D013749 | Tetrachlorodibenzodioxin | [Diethylnitrosamine co-treated with Tetrachlorodibenzodioxin] results in decreased expression of EGFR protein | 8403215 |
D013749 | Tetrachlorodibenzodioxin | geldanamycin inhibits the reaction [Tetrachlorodibenzodioxin inhibits the reaction [EGF protein binds to EGFR protein]] | 9605431 |
D013749 | Tetrachlorodibenzodioxin | Tetrachlorodibenzodioxin affects the expression of EGFR mRNA | 22298810 |
D013749 | Tetrachlorodibenzodioxin | Tetrachlorodibenzodioxin inhibits the reaction [EGF protein binds to EGFR protein] | 9605431 |
D013749 | Tetrachlorodibenzodioxin | Tetrachlorodibenzodioxin results in decreased expression of and affects the localization of EGFR protein | 11752688 |
D013749 | Tetrachlorodibenzodioxin | Tetrachlorodibenzodioxin results in decreased expression of EGFR mRNA | 20959002 |
D013749 | Tetrachlorodibenzodioxin | Tetrachlorodibenzodioxin results in decreased expression of EGFR protein | 8403215 |
D013749 | Tetrachlorodibenzodioxin | Tetrachlorodibenzodioxin results in increased phosphorylation of EGFR protein | 10401681; 15592923; |
D013749 | Tetrachlorodibenzodioxin | [EGF protein results in increased activity of EGFR protein] inhibits the reaction [Tetrachlorodibenzodioxin promotes the reaction [[AHR protein binds to CYP1A1 gene] which results in increased expression of CYP1A1 mRNA]] | 21835898 |
D013749 | Tetrachlorodibenzodioxin | [EGF protein results in increased activity of EGFR protein] inhibits the reaction [Tetrachlorodibenzodioxin promotes the reaction [[AHR protein binds to FLG gene] which results in increased expression of FLG mRNA]] | 21835898 |
D013749 | Tetrachlorodibenzodioxin | [EGF protein results in increased activity of EGFR protein] inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of FLG2 mRNA] | 21835898 |
D013749 | Tetrachlorodibenzodioxin | [EGF protein results in increased activity of EGFR protein] inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of FLG mRNA] | 21835898 |
D013749 | Tetrachlorodibenzodioxin | [EGF protein results in increased activity of EGFR protein] inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of FLG protein] | 21835898 |
D013749 | Tetrachlorodibenzodioxin | [EGF protein results in increased activity of EGFR protein] inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of HRNR mRNA] | 21835898 |
D013749 | Tetrachlorodibenzodioxin | [EGF protein results in increased activity of EGFR protein] inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of LCE3A mRNA] | 21835898 |
D013749 | Tetrachlorodibenzodioxin | [EGF protein results in increased activity of EGFR protein] inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of LCE3E mRNA] | 21835898 |
D013749 | Tetrachlorodibenzodioxin | [EGF protein results in increased activity of EGFR protein] inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of RPTN mRNA] | 21835898 |
D013749 | Tetrachlorodibenzodioxin | [EGF protein results in increased activity of EGFR protein] inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of S100A12 mRNA] | 21835898 |
D013749 | Tetrachlorodibenzodioxin | [EGF protein results in increased activity of EGFR protein] inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of S100A7 mRNA] | 21835898 |
D013749 | Tetrachlorodibenzodioxin | [EGF protein results in increased activity of EGFR protein] inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of S100A9 mRNA] | 21835898 |
D013749 | Tetrachlorodibenzodioxin | [EGF protein results in increased activity of EGFR protein] inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of SPRR1A mRNA] | 21835898 |
D013749 | Tetrachlorodibenzodioxin | [EGF protein results in increased activity of EGFR protein] inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of SPRR2A mRNA] | 21835898 |
D013749 | Tetrachlorodibenzodioxin | [EGF protein results in increased activity of EGFR protein] inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of SPRR2B mRNA] | 21835898 |
C005806 | tetrachloroisophthalonitrile | tetrachloroisophthalonitrile results in decreased phosphorylation of EGFR protein | 28426875 |
D013752 | Tetracycline | Tetracycline results in decreased expression of EGFR mRNA | 24489787 |
D013755 | Tetradecanoylphorbol Acetate | naringenin inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of EGFR protein] | 25866363 |
D013755 | Tetradecanoylphorbol Acetate | pterostilbene inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of EGFR protein] | 19447859 |
D013755 | Tetradecanoylphorbol Acetate | Tetradecanoylphorbol Acetate results in increased expression of EGFR protein | 19447859; 25866363; |
D013755 | Tetradecanoylphorbol Acetate | AG 1879 inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Capsaicin] results in increased phosphorylation of EGFR protein] | 20660715 |
D013755 | Tetradecanoylphorbol Acetate | EGFR gene mutant form inhibits the reaction [Capsaicin promotes the reaction [Tetradecanoylphorbol Acetate results in increased expression of PTGS2 mRNA]] | 20660715 |
D013755 | Tetradecanoylphorbol Acetate | EGFR gene mutant form inhibits the reaction [Capsaicin promotes the reaction [Tetradecanoylphorbol Acetate results in increased expression of PTGS2 protein]] | 20660715 |
D013755 | Tetradecanoylphorbol Acetate | EGFR gene mutant form inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Capsaicin] results in increased expression of AREG mRNA] | 20660715 |
D013755 | Tetradecanoylphorbol Acetate | EGFR gene mutant form inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Capsaicin] results in increased phosphorylation of AKT1 protein] | 20660715 |
D013755 | Tetradecanoylphorbol Acetate | EGFR gene mutant form inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Capsaicin] results in increased phosphorylation of MAPK1 protein] | 20660715 |
D013755 | Tetradecanoylphorbol Acetate | EGFR gene mutant form inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Capsaicin] results in increased phosphorylation of MAPK3 protein] | 20660715 |
D013755 | Tetradecanoylphorbol Acetate | Resveratrol inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of EGFR] | 26100520 |
D013755 | Tetradecanoylphorbol Acetate | Resveratrol promotes the reaction [ursolic acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of EGFR]] | 26100520 |
D013755 | Tetradecanoylphorbol Acetate | RTKI cpd inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Capsaicin] results in increased phosphorylation of EGFR protein] | 20660715 |
D013755 | Tetradecanoylphorbol Acetate | [Tetradecanoylphorbol Acetate co-treated with Capsaicin] results in increased phosphorylation of EGFR protein | 20660715 |
D013755 | Tetradecanoylphorbol Acetate | Tetradecanoylphorbol Acetate inhibits the reaction [EGF protein binds to EGFR protein] | 6309801 |
D013755 | Tetradecanoylphorbol Acetate | Tetradecanoylphorbol Acetate results in increased expression of EGFR | 26100520 |
D013755 | Tetradecanoylphorbol Acetate | Tetradecanoylphorbol Acetate results in increased phosphorylation of EGFR protein | 26513295 |
D013755 | Tetradecanoylphorbol Acetate | ursolic acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of EGFR] | 26100520 |
D013755 | Tetradecanoylphorbol Acetate | ursolic acid promotes the reaction [Resveratrol inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of EGFR]] | 26100520 |
C017953 | tetramethylpyrazine | NFE2L2 protein promotes the reaction [tetramethylpyrazine inhibits the reaction [Carbon Tetrachloride results in increased expression of EGFR mRNA]] | 27477297 |
C017953 | tetramethylpyrazine | NFE2L2 protein promotes the reaction [tetramethylpyrazine inhibits the reaction [Carbon Tetrachloride results in increased expression of EGFR protein]] | 27477297 |
C017953 | tetramethylpyrazine | tetramethylpyrazine inhibits the reaction [Carbon Tetrachloride results in increased expression of EGFR mRNA] | 27477297 |
C017953 | tetramethylpyrazine | tetramethylpyrazine inhibits the reaction [Carbon Tetrachloride results in increased expression of EGFR protein] | 27477297 |
C009438 | tetrandrine | tetrandrine results in decreased phosphorylation of EGFR protein | 30549224 |
C020809 | tetrathiomolybdate | tetrathiomolybdate inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein] | 18480265 |
C042172 | thallium nitrate | thallium nitrate affects the reaction [EGF protein results in increased phosphorylation of EGFR protein] | 25534134 |
C042172 | thallium nitrate | thallium nitrate analog affects the reaction [EGF protein results in increased phosphorylation of EGFR protein] | 25534134 |
D019284 | Thapsigargin | Thapsigargin results in increased expression of EGFR protein | 24648495 |
C056068 | theaflavin | theaflavin inhibits the reaction [Diethylnitrosamine results in increased expression of EGFR mRNA] | 27058323 |
D013853 | Thioacetamide | [Diethylnitrosamine co-treated with Thioacetamide] results in decreased expression of EGFR mRNA | 28943392 |
D013853 | Thioacetamide | Thioacetamide results in decreased expression of EGFR mRNA | 23411599 |
D013859 | Thiocarbamates | Thiocarbamates results in decreased expression of and results in decreased phosphorylation of EGFR protein | 20209498 |
D013882 | Thiosemicarbazones | [Thiosemicarbazones binds to Copper] which results in increased phosphorylation of EGFR protein | 20931265 |
D014028 | Tobacco Smoke Pollution | Gefitinib inhibits the reaction [Tobacco Smoke Pollution results in increased phosphorylation of EGFR protein] | 21544845 |
D014028 | Tobacco Smoke Pollution | Tobacco Smoke Pollution affects the expression of EGFR protein | 30291989 |
D014028 | Tobacco Smoke Pollution | Tobacco Smoke Pollution results in decreased expression of EGFR mRNA | 28065790 |
D014028 | Tobacco Smoke Pollution | Tobacco Smoke Pollution results in increased expression of EGFR mRNA | 27865774 |
D014028 | Tobacco Smoke Pollution | Tobacco Smoke Pollution results in increased phosphorylation of and results in increased activity of EGFR protein | 22457794 |
D014028 | Tobacco Smoke Pollution | Tobacco Smoke Pollution results in increased phosphorylation of EGFR protein | 21544845 |
D014028 | Tobacco Smoke Pollution | Tobacco Smoke Pollution results in increased expression of EGFR mRNA | 29545142 |
D014051 | Toluene 2,4-Diisocyanate | EGFR protein affects the reaction [[Toluene 2,4-Diisocyanate binds to ALB protein] which results in increased expression of CCL5 protein] | 16908450 |
D014051 | Toluene 2,4-Diisocyanate | EGFR protein affects the reaction [[Toluene 2,4-Diisocyanate binds to ALB protein] which results in increased expression of CSF2 protein] | 16908450 |
D014051 | Toluene 2,4-Diisocyanate | EGFR protein affects the reaction [[Toluene 2,4-Diisocyanate binds to ALB protein] which results in increased expression of CXCL8 protein] | 16908450 |
D019772 | Topotecan | [RTKI cpd results in decreased activity of EGFR protein] which results in decreased susceptibility to Topotecan | 15923621 |
D019772 | Topotecan | Topotecan results in decreased expression of EGFR mRNA | 15923621 |
D019772 | Topotecan | Topotecan results in decreased expression of EGFR protein | 15923621 |
D019772 | Topotecan | Topotecan results in decreased phosphorylation of EGFR protein | 15923621 |
D019772 | Topotecan | [Oxaliplatin co-treated with Topotecan] results in increased expression of EGFR mRNA | 25729387 |
D014212 | Tretinoin | Tretinoin metabolite results in decreased expression of EGFR mRNA | 15982314 |
D014212 | Tretinoin | Tretinoin results in decreased expression of EGFR protein | 15970678; 16473924; |
D014212 | Tretinoin | Tretinoin results in increased expression of EGFR mRNA | 21934132 |
D014212 | Tretinoin | [bisphenol F co-treated with Tretinoin] results in decreased expression of EGFR mRNA | 30951980 |
D014212 | Tretinoin | HBEGF protein promotes the reaction [Tretinoin results in increased phosphorylation of EGFR protein] | 16357442 |
D014212 | Tretinoin | Tretinoin results in increased expression of EGFR mRNA | 16604517 |
D014212 | Tretinoin | Tretinoin results in increased phosphorylation of EGFR protein | 16357442 |
D014223 | Triamterene | EGFR gene SNP affects the susceptibility to Triamterene | 25622337 |
D014241 | Trichloroethylene | Trichloroethylene results in decreased expression of EGFR mRNA | 15363585; 19448997; 25549359; |
D014241 | Trichloroethylene | Trichloroethylene results in increased methylation of EGFR gene | 27618143 |
C012589 | trichostatin A | [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EGFR mRNA | 27188386 |
C012589 | trichostatin A | trichostatin A results in increased expression of EGFR mRNA | 24935251; 26272509; |
C050414 | tripterine | [Sulfasalazine co-treated with tripterine] affects the expression of EGFR protein | 20007406 |
C050414 | tripterine | [Sulfasalazine co-treated with tripterine] results in decreased expression of EGFR protein | 20007406 |
C050414 | tripterine | tripterine results in decreased expression of EGFR protein | 17010675 |
C016805 | tris(1,3-dichloro-2-propyl)phosphate | tris(1,3-dichloro-2-propyl)phosphate results in decreased expression of EGFR mRNA | 26179874 |
C080163 | trovafloxacin | [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of EGFR mRNA | 18930950 |
C113580 | U 0126 | U 0126 inhibits the reaction [EGFR protein mutant form results in increased expression of FOXG1 mRNA] | 26455392 |
C113580 | U 0126 | U 0126 inhibits the reaction [EGFR protein mutant form results in increased expression of FOXG1 protein] | 26455392 |
C113580 | U 0126 | U 0126 inhibits the reaction [EGFR protein mutant form results in increased expression of SOX9 mRNA] | 26455392 |
C113580 | U 0126 | U 0126 inhibits the reaction [EGFR protein mutant form results in increased expression of SOX9 protein] | 26455392 |
C113580 | U 0126 | U 0126 inhibits the reaction [EGFR protein promotes the reaction [EGF protein results in increased phosphorylation of AKT1 protein]] | 24758408 |
C113580 | U 0126 | U 0126 inhibits the reaction [EGFR protein promotes the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]] | 24758408 |
C113580 | U 0126 | U 0126 inhibits the reaction [EGFR protein promotes the reaction [EGF protein results in increased phosphorylation of MAPK3 protein]] | 24758408 |
C113580 | U 0126 | U 0126 inhibits the reaction [NTS protein results in increased phosphorylation of and results in increased activity of EGFR protein] | 15177934 |
D014520 | Urethane | Urethane results in decreased expression of EGFR mRNA | 28818685 |
D014520 | Urethane | IFNG protein promotes the reaction [Urethane results in increased expression of EGFR mRNA] | 12810352 |
D014520 | Urethane | [Urethane co-treated with Freund's Adjuvant] results in increased expression of EGFR mRNA | 12400877 |
D014520 | Urethane | Urethane results in increased expression of EGFR mRNA | 12400877 |
D014544 | Uridine Triphosphate | Uridine Triphosphate results in increased phosphorylation of EGFR protein | 14676212 |
D014580 | Ursodeoxycholic Acid | Ursodeoxycholic Acid inhibits the reaction [Deoxycholic Acid results in increased phosphorylation of EGFR protein] | 14747693 |
C005466 | ursolic acid | Resveratrol promotes the reaction [ursolic acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of EGFR]] | 26100520 |
C005466 | ursolic acid | ursolic acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of EGFR] | 26100520 |
C005466 | ursolic acid | ursolic acid promotes the reaction [Resveratrol inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of EGFR]] | 26100520 |
C406224 | valdecoxib | valdecoxib results in decreased expression of EGFR mRNA | 24136188 |
D014635 | Valproic Acid | [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EGFR mRNA | 27188386 |
D014635 | Valproic Acid | Valproic Acid results in decreased methylation of EGFR gene | 29154799 |
D014635 | Valproic Acid | Valproic Acid results in increased expression of EGFR mRNA | 23179753; 24383497; 24935251; 26272509; 27188386; 28001369; |
D014635 | Valproic Acid | Valproic Acid results in decreased expression of EGFR mRNA | 24535564 |
C034028 | vanadyl sulfate | vanadyl sulfate results in increased phosphorylation of EGFR protein | 10564177; 11943669; |
D001335 | Vehicle Emissions | AG 1879 inhibits the reaction [Vehicle Emissions results in increased phosphorylation of EGFR protein] | 17028263 |
D001335 | Vehicle Emissions | Butylated Hydroxyanisole inhibits the reaction [Vehicle Emissions results in increased phosphorylation of EGFR protein] | 17028263 |
D001335 | Vehicle Emissions | EGFR protein affects the reaction [Vehicle Emissions results in increased secretion of AR protein] | 24555532 |
D001335 | Vehicle Emissions | EGFR protein affects the reaction [Vehicle Emissions results in increased secretion of CXCL8 protein] | 24555532 |
D001335 | Vehicle Emissions | EGFR protein affects the reaction [Vehicle Emissions results in increased secretion of TGFA protein] | 24555532 |
D001335 | Vehicle Emissions | Vehicle Emissions results in increased phosphorylation of EGFR protein | 17028263; 18926838; |
D001335 | Vehicle Emissions | Vehicle Emissions results in decreased expression of EGFR mRNA | 19165385 |
C521013 | veliparib | EGFR protein results in decreased susceptibility to veliparib | 21912620 |
C521013 | veliparib | veliparib affects the localization of EGFR protein | 21719137 |
C025643 | vinclozolin | [Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of EGFR mRNA | 25607892 |
D014801 | Vitamin A | Vitamin A deficiency results in increased expression of EGFR mRNA | 7519440 |
D014810 | Vitamin E | Vitamin E results in decreased expression of EGFR mRNA | 19244175 |
D024483 | Vitamin K 3 | Vitamin K 3 results in increased phosphorylation of EGFR protein | 15843167 |
D000077337 | Vorinostat | Vorinostat results in decreased phosphorylation of EGFR protein | 20531243 |
D000077337 | Vorinostat | Vorinostat results in decreased expression of EGFR mRNA | 21389970 |
D000077337 | Vorinostat | Vorinostat results in decreased expression of EGFR protein | 21389970 |
D014873 | Water Pollutants | Water Pollutants results in decreased expression of EGFR mRNA | 23591932 |
C113888 | WHI P154 | WHI P154 inhibits the reaction [2,2',4,6,6'-pentachlorobiphenyl results in increased phosphorylation of EGFR protein] | 16778083 |
C113888 | WHI P154 | WHI P154 results in decreased activity of EGFR protein | 11173405 |
C118361 | WHI P180 | WHI P180 results in decreased activity of EGFR protein | 11173405 |
C070417 | Win 55212-2 | RTKI cpd inhibits the reaction [Win 55212-2 results in increased phosphorylation of EGFR protein] | 20619260 |
C070417 | Win 55212-2 | Win 55212-2 results in increased phosphorylation of EGFR protein | 20619260 |
D000077191 | Wortmannin | Wortmannin inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein] | 25856345 |
D000077191 | Wortmannin | Wortmannin inhibits the reaction [NTS protein results in increased phosphorylation of and results in increased activity of EGFR protein] | 15177934 |
D000077191 | Wortmannin | Wortmannin inhibits the reaction [Sodium Chloride results in increased phosphorylation of EGFR protein] | 21568938 |
C571455 | WZ4002 | WZ4002 results in decreased activity of EGFR protein mutant form | 22553343 |
C523798 | YM 155 | EGF protein inhibits the reaction [YM 155 results in decreased phosphorylation of EGFR protein] | 28787001 |
C523798 | YM 155 | YM 155 results in decreased phosphorylation of EGFR protein | 28787001 |
D015032 | Zinc | 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline inhibits the reaction [Zinc results in increased phosphorylation of EGFR protein] | 12972402; 15980035; 16410015; |
D015032 | Zinc | AG 1879 inhibits the reaction [Zinc results in increased phosphorylation of EGFR protein] | 12915106; 15980035; |
D015032 | Zinc | HBEGF protein affects the reaction [Zinc results in increased phosphorylation of EGFR protein] | 12972402 |
D015032 | Zinc | N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Zinc results in increased phosphorylation of EGFR protein] | 12972402 |
D015032 | Zinc | N-isobutyl-N-(4-methoxyphenylsulfonyl)glycylhydroxamic acid inhibits the reaction [Zinc results in increased phosphorylation of EGFR protein] | 12972402 |
D015032 | Zinc | Zinc results in increased phosphorylation of and results in increased activity of EGFR protein | 16410015 |
D015032 | Zinc | Zinc results in increased phosphorylation of EGFR protein | 12915106; 12972402; 15980035; |
D015032 | Zinc | 4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [[Zinc co-treated with EGFR protein] results in increased activity of RAS protein] | 11983694 |
D015032 | Zinc | 4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [Zinc results in increased phosphorylation of EGFR protein] | 11983694 |
D015032 | Zinc | [SRC protein results in increased phosphorylation of EGFR protein] affects the reaction [[Zinc co-treated with EGFR protein] results in increased activity of RAS protein] | 11983694 |
D015032 | Zinc | [Zinc co-treated with EGFR protein] results in increased activity of RAS protein | 11983694 |
D015032 | Zinc | Zinc promotes the reaction [EGFR protein binds to SRC protein] | 11983694 |
D015032 | Zinc | Zinc results in increased phosphorylation of EGFR protein | 11983694 |
D015032 | Zinc | Zinc deficiency results in decreased expression of EGFR mRNA | 12672911 |
C016837 | zinc chloride | zinc chloride results in increased phosphorylation of EGFR protein | 21540303 |
D019287 | Zinc Sulfate | 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline inhibits the reaction [Zinc Sulfate results in increased phosphorylation of EGFR protein] | 16410015 |
D019287 | Zinc Sulfate | Zinc Sulfate results in increased phosphorylation of and results in increased activity of EGFR protein | 16410015 |
D019287 | Zinc Sulfate | Zinc Sulfate results in increased phosphorylation of EGFR protein | 10564177; 11943669; |
D019287 | Zinc Sulfate | Zinc Sulfate results in increased phosphorylation of EGFR protein | 19946718 |
Keyword ID | Keyword Term |
---|---|
KW-0002 | 3D-structure |
KW-0025 | Alternative splicing |
KW-0067 | ATP-binding |
KW-1003 | Cell membrane |
KW-0217 | Developmental protein |
KW-0903 | Direct protein sequencing |
KW-0225 | Disease mutation |
KW-1015 | Disulfide bond |
KW-0256 | Endoplasmic reticulum |
KW-0967 | Endosome |
KW-0325 | Glycoprotein |
KW-0333 | Golgi apparatus |
KW-1183 | Host cell receptor for virus entry |
KW-0945 | Host-virus interaction |
KW-1017 | Isopeptide bond |
KW-0418 | Kinase |
KW-0449 | Lipoprotein |
KW-0472 | Membrane |
KW-0488 | Methylation |
KW-0547 | Nucleotide-binding |
KW-0539 | Nucleus |
KW-0564 | Palmitate |
KW-0597 | Phosphoprotein |
KW-0621 | Polymorphism |
KW-0656 | Proto-oncogene |
KW-0675 | Receptor |
KW-1185 | Reference proteome |
KW-0677 | Repeat |
KW-0964 | Secreted |
KW-0732 | Signal |
KW-0808 | Transferase |
KW-0812 | Transmembrane |
KW-1133 | Transmembrane helix |
KW-0829 | Tyrosine-protein kinase |
KW-0832 | Ubl conjugation |
InterPro ID | InterPro Term |
---|---|
IPR006211 | Furin-like_Cys-rich_dom |
IPR006212 | Furin_repeat |
IPR032778 | GF_recep_IV |
IPR009030 | Growth_fac_rcpt_cys_sf |
IPR011009 | Kinase-like_dom_sf |
IPR000719 | Prot_kinase_dom |
IPR017441 | Protein_kinase_ATP_BS |
IPR000494 | Rcpt_L-dom |
IPR036941 | Rcpt_L-dom_sf |
IPR001245 | Ser-Thr/Tyr_kinase_cat_dom |
IPR008266 | Tyr_kinase_AS |
IPR020635 | Tyr_kinase_cat_dom |
IPR016245 | Tyr_kinase_EGF/ERB/XmrK_rcpt |